
<html lang="en"     class="pb-page"  data-request-id="e3891897-a7fd-4253-b0e7-805d1ad3cbcb"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;issue:issue:10.1021/jmcmar.2018.61.issue-23;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.8b00407;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Lead-like Drugs: A Perspective" /></meta><meta name="dc.Creator" content="Brian  Raymer" /></meta><meta name="dc.Creator" content="Samit K.  Bhattacharya" /></meta><meta name="dc.Description" content="Lead-like drugs, or drugs below molecular weight 300, are an important and sometimes overlooked component of the current pharmacopeia and contemporary medicinal chemistry practice. To examine the r..." /></meta><meta name="Description" content="Lead-like drugs, or drugs below molecular weight 300, are an important and sometimes overlooked component of the current pharmacopeia and contemporary medicinal chemistry practice. To examine the r..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 27, 2018" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b00407" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright Â© 2018 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00407" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b00407" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00407" /></link>
        
    
    

<title>Lead-like Drugs: A Perspective | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b00407" /></meta><meta property="og:title" content="Lead-like Drugs: A Perspective" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b00407/20181207/images/large/jm-2018-00407x_0004.jpeg" /></meta><meta property="og:description" content="Lead-like drugs, or drugs below molecular weight 300, are an important and sometimes overlooked component of the current pharmacopeia and contemporary medicinal chemistry practice. To examine the recent state-of-the-art in lead-like drug discovery, we surveyed recent drug approvals from 2011 to 2017 and top 200 prescribed medications, as well as provide case studies on recently approved lead-like drugs. Many of these recent drugs are close analogs of previously known drugs or natural substrates, with a key focus of their medicinal chemistry optimization being the choice of a low molecular weight starting point and maintaining low molecular weight during the optimization. However, the identification of low molecular weight starting points may be limited by the availability of suitable low molecular weight screening sets. To increase the discovery rate of lead-like drugs, we suggest an increased focus on inclusion and prosecution of lead-like starting points in screening libraries." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b00407"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b00407">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b00407&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b00407&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b00407&amp;href=/doi/10.1021/acs.jmedchem.8b00407" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 23</span><span class="cit-fg-pageRange">, 10375-10384</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/23" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b01922" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.8b00540" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Lead-like Drugs: A Perspective</span></h1><h2 class="article_header-subtitle"><span class="hlFld-SubTitle">Miniperspective</span></h2><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Brian Raymer</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Brian Raymer</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicine Design, Pfizer Worldwide Research and Development, 1 Portland Street, Cambridge, Massachusetts 02139, United States</div></div><span class="conrtib-corresp"><strong>*</strong>B.R.: e-mail: <a href="/cdn-cgi/l/email-protection#3c5e4e555d52124e5d4551594e7c5d5057594e51594f125f5351"><span class="__cf_email__" data-cfemail="99fbebf0f8f7b7ebf8e0f4fcebd9f8f5f2fcebf4fceab7faf6f4">[emailÂ protected]</span></a>. Current Address: Alkermes, Inc. 852 Winter Street, Waltham, Massachusetts 02451.</span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Brian++Raymer">Brian Raymer</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">Â andÂ </span><li><span><span class="hlFld-ContribAuthor">Samit K. Bhattacharya</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Samit K. Bhattacharya</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicine Design, Pfizer Worldwide Research and Development, 1 Portland Street, Cambridge, Massachusetts 02139, United States</div></div><span class="conrtib-corresp"><strong>*</strong>S.K.B.: e-mail: <a href="/cdn-cgi/l/email-protection#7e0d1f13170a5015501c161f0a0a1f1d161f0c071f3e0e1817041b0c501d1113"><span class="__cf_email__" data-cfemail="91e2f0fcf8e5bffabff3f9f0e5e5f0f2f9f0e3e8f0d1e1f7f8ebf4e3bff2fefc">[emailÂ protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Samit+K.++Bhattacharya">Samit K. Bhattacharya</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0948-4254" title="Orcid link">http://orcid.org/0000-0002-0948-4254</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00407&amp;href=/doi/10.1021%2Facs.jmedchem.8b00407" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 23</span><span class="cit-pageRange">, 10375â10384</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">July 27, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>13 March 2018</li><li><span class="item_label"><b>Published</b> online</span>27 July 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 13 December 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b00407" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00407</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D10375%26pageCount%3D10%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DBrian%2BRaymer%252C%2BSamit%2BK.%2BBhattacharya%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D61%26issueNum%3D23%26contentID%3Dacs.jmedchem.8b00407%26title%3DLead-like%2BDrugs%253A%2BA%2BPerspective%26numPages%3D10%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D10384%26publicationDate%3DDecember%2B2018">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b00407"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">10022</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">22</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b00407" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Lead-like Drugs: A Perspective&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Brian&quot;,&quot;last_name&quot;:&quot;Raymer&quot;},{&quot;first_name&quot;:&quot;Samit&quot;,&quot;last_name&quot;:&quot;K. Bhattacharya&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;27&quot;,&quot;issue&quot;:&quot;23&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;10375-10384&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b00407&quot;},&quot;abstract&quot;:&quot;Lead-like drugs, or drugs below molecular weight 300, are an important and sometimes overlooked component of the current pharmacopeia and contemporary medicinal chemistry practice. To examine the recent state-of-the-art in lead-like drug discovery, we surveyed recent drug approvals from 2011 to 2017 and top 200 prescribed medications, as well as provide case studies on recently approved lead-like drugs. Many of these recent drugs are close analogs of previously known drugs or natural substrates, with a key focus of their medicinal chemistry optimization being the choice of a low molecular weight starting point and maintaining low molecular weight during the optimization. However, the identification of low molecular weight starting points may be limited by the availability of suitable low molecular weight screening sets. To increase the discovery rate of lead-like drugs, we suggest an increased focus on inclusion and prosecution of lead-like starting points in screening libraries.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00407&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00407" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00407&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00407" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00407&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00407" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00407&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00407&amp;href=/doi/10.1021/acs.jmedchem.8b00407" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b00407" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b00407" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (1 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b00407%26sid%3Dliteratum%253Aachs%26pmid%3D30052440%26genre%3Darticle%26aulast%3DRaymer%26date%3D2018%26atitle%3DLead-like%2BDrugs%253A%2BA%2BPerspective%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D23%26spage%3D10375%26epage%3D10384%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">Â»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291494" title="Medicinal chemistry">Medicinal chemistry</a>,</li><li><a href="/action/doSearch?ConceptID=292304" title="Optimization">Optimization</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291070" title="Pharmaceuticals">Pharmaceuticals</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/23" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/jmcmar.2018.61.issue-23/20181213/jmcmar.2018.61.issue-23.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b00407/20181207/images/medium/jm-2018-00407x_0004.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b00407/20181207/images/large/jm-2018-00407x_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00407&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Lead-like drugs, or drugs below molecular weight 300, are an important and sometimes overlooked component of the current pharmacopeia and contemporary medicinal chemistry practice. To examine the recent state-of-the-art in lead-like drug discovery, we surveyed recent drug approvals from 2011 to 2017 and top 200 prescribed medications, as well as provide case studies on recently approved lead-like drugs. Many of these recent drugs are close analogs of previously known drugs or natural substrates, with a key focus of their medicinal chemistry optimization being the choice of a low molecular weight starting point and maintaining low molecular weight during the optimization. However, the identification of low molecular weight starting points may be limited by the availability of suitable low molecular weight screening sets. To increase the discovery rate of lead-like drugs, we suggest an increased focus on inclusion and prosecution of lead-like starting points in screening libraries.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="quote"><p class="first last">In small proportions we just beauties see,</p></div><div class="quote"><p class="first">And in short measures life may perfect be.</p><div class="attrib">Ben Jonson. From <i>Underwoods</i> (1640): âTo the Immortal Memory of That Noble Pair, Sir Lucius Cary and Sir Henry Morisonâ</div></div></div><div id="secz" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70745" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70745" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Lead-like drugs, or drugs below molecular weight (MW) 300, are an important and sometimes overlooked component of the current pharmacopeia and contemporary medicinal chemistry practice.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> In 2011, Walters and colleagues collated physicochemical properties of approved drugs across a 50-year span. They found typical molecular weight ranges of approved drugs as 300â360 during the earliest time period (1959â1964), with a trend upward over time to 360â440 for the most recent time period (2005â2009). Taken together, it is reasonable to conclude that on average, the molecular weight of drugs typically falls within the range of 300â440. The molecular weight boundary of 300 for lead-like drugs also conveniently coincides with the molecular weight criteria of the rule-of-three (Ro3), although that value is focused on fragment selection for fragment-based drug discovery.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Given these ranges and trends in molecular weight, we propose that drugs below a molecular weight of 300 can be considered atypical and use this criteria as an upper boundary for lead-like drugs.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a></div><div class="NLM_p">To examine the recent state-of-the-art in lead-like drug discovery, we surveyed drug approvals [by Food and Drug Administration (FDA) and European Medicines Agency (EMA)] between 2011 and 2017 (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>; see <a href="/doi/suppl/10.1021/acs.jmedchem.8b00407/suppl_file/jm8b00407_si_001.csv" class="ext-link">Supporting Information</a> for the full list of drugs), excluding drugs above MW 2000. We also analyzed a list of the top 200 prescribed medications (branded and generic) from 2014 U.S. prescription data.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> The figure highlights the number of lead-like drugs recently approved and, moreover, the long-term success of lead-like drugs based on prescription levels of the top 200 prescribed medications. During 2011â2016, 25 of 146 recent drug approvals (17%) were below the typical molecular weight range of 300â440. As to the top 200 prescribed medications, 57 of the 160 low molecular weight drugs had a molecular weight below 300, accounting for 36% of highly prescribed low molecular weight drugs. Of note, the large proportion of approved drugs above molecular weight 440 from 2011 to 2016 differs from the small proportion of drugs above molecular weight 440 represented in the top 200 prescribed drugs. The relative proportions of approved drugs less than molecular weight 300, molecular weight 300â440, and greater than molecular weight 440 differ considerably when comparing drugs approved in 2011â2016 and the top 200 prescribed drugs. A large proportion of drugs below molecular weight 300 are found in the top 200 prescribed drugs, while a higher proportion of drugs above molecular weight 440 are seen in the distribution of drugs approved between 2011 and 2016. Many of the top 200 prescribed low molecular weight drugs have been on the market for a long period of time; it will be interesting to observe how the molecular weight distribution of highly prescribed drugs evolves over time given the molecular weight distribution of recent approvals. For the year 2017, the recent trend of larger proportion of higher molecular weight drugs continues as 18/28 FDA approved drugs have molecular weight of >440 while 3/28 have molecular weight of <300.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b00407/20181207/images/medium/jm-2018-00407x_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b00407/20181207/images/large/jm-2018-00407x_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Number of new small molecule drug approvals and highly prescribed drugs, binned by molecular weight ranges: top 200 U.S. prescribed drugs in 2014 (red bars); drugs approved from 2011 to 2016 (blue bars); drugs approved in 2017 (green).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b00407/20181207/images/large/jm-2018-00407x_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00407&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">While trends in molecular weight are of interest to the medicinal chemist, the stories behind the discovery of these drugs and application of common principles can be of value when tackling current and future projects. Here, we present case histories of a selection of recently approved lead-like drugs and discuss common themes (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> We identified three types of lead-like drugs: drugs chiefly resulting from lead-like screening efforts; drugs resulting from medicinal chemistry optimization; and drugs resulting from biological and clinical efforts, namely, drug repurposing and drugs derived from metabolites or natural products. ADME and toxicity features of lead-like drugs are discussed using these case studies, as well as recommendations on pursuing lead-like drugs based on these common themes.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Approved Drugs (2011â2017) Selected for Case Studies<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">name</th><th class="colsep0 rowsep0" align="center">MW</th><th class="colsep0 rowsep0" align="center">clogP</th><th class="colsep0 rowsep0" align="center">PSA</th><th class="colsep0 rowsep0" align="center">po dose (mg)</th><th class="colsep0 rowsep0" align="center"><i>K</i><sub>D</sub>, <i>K</i><sub>i</sub>, EC<sub>50</sub>, IC<sub>50</sub>, MIC<sub>50</sub>; (LE)<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center"><i>V</i><sub>d</sub> (L)</th><th class="colsep0 rowsep0" align="center"><i>T</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center">urine excretion (%)<a class="ref internalNav" href="#t1fn6" aria-label="f">f</a></th><th class="colsep0 rowsep0" align="center">target class</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">tavaborole</td><td class="colsep0 rowsep0" align="left">152</td><td class="colsep0 rowsep0" align="left">1.2</td><td class="colsep0 rowsep0" align="left">29.5</td><td class="colsep0 rowsep0" align="left">topical</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub>Â =Â 1Â Î¼M (0.78)</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">enzyme</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left">crisaborole</td><td class="colsep0 rowsep0" align="left">251</td><td class="colsep0 rowsep0" align="left">2.6</td><td class="colsep0 rowsep0" align="left">62.5</td><td class="colsep0 rowsep0" align="left">topical</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> = 0.5 Î¼M (0.47)</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">enzyme</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="left">ataluren</td><td class="colsep0 rowsep0" align="left">284</td><td class="colsep0 rowsep0" align="left">3.7</td><td class="colsep0 rowsep0" align="left">76.2</td><td class="colsep0 rowsep0" align="left">700</td><td class="colsep0 rowsep0" align="left">IC<sub>max</sub> = 3 Î¼M (0.38)</td><td class="colsep0 rowsep0" align="left">low<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">2â6</td><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="left">unknown</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left">vortioxetine</td><td class="colsep0 rowsep0" align="left">298</td><td class="colsep0 rowsep0" align="left">4.9</td><td class="colsep0 rowsep0" align="left">40.6</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left"><i>K</i><sub>i</sub> = 15 nM (0.53)</td><td class="colsep0 rowsep0" align="left">2600</td><td class="colsep0 rowsep0" align="left">66</td><td class="colsep0 rowsep0" align="left">59</td><td class="colsep0 rowsep0" align="left">GPCR</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left">edaravone</td><td class="colsep0 rowsep0" align="left">174</td><td class="colsep0 rowsep0" align="left">1.3</td><td class="colsep0 rowsep0" align="left">32.7</td><td class="colsep0 rowsep0" align="left">60, iv</td><td class="colsep0 rowsep0" align="left">EC<sub>50</sub> = 10 Î¼M (0.56)</td><td class="colsep0 rowsep0" align="left">18.5</td><td class="colsep0 rowsep0" align="left">4.5â6</td><td class="colsep0 rowsep0" align="left">70â90</td><td class="colsep0 rowsep0" align="left">unknown</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">tasimelteon</td><td class="colsep0 rowsep0" align="left">245</td><td class="colsep0 rowsep0" align="left">1.9</td><td class="colsep0 rowsep0" align="left">38.3</td><td class="colsep0 rowsep0" align="left">20</td><td class="colsep0 rowsep0" align="left"><i>K</i><sub>i</sub> = 0.35 nM (0.74)</td><td class="colsep0 rowsep0" align="left">56â126</td><td class="colsep0 rowsep0" align="left">1â4</td><td class="colsep0 rowsep0" align="left">80</td><td class="colsep0 rowsep0" align="left">GPCR</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left">lorcaserin</td><td class="colsep0 rowsep0" align="left">196</td><td class="colsep0 rowsep0" align="left">3.2</td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">EC<sub>50</sub> = 8 nM (0.88)</td><td class="colsep0 rowsep0" align="left">CSF, CNS<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="left">92</td><td class="colsep0 rowsep0" align="left">GPCR</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">brivaracetam</td><td class="colsep0 rowsep0" align="left">212</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">63.4</td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> = 100 nM (0.66)</td><td class="colsep0 rowsep0" align="left">35<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">9</td><td class="colsep0 rowsep0" align="left">95</td><td class="colsep0 rowsep0" align="left">transporter</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="left">tipiracil<a class="ref internalNav" href="#t1fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="left">243</td><td class="colsep0 rowsep0" align="left">â0.2</td><td class="colsep0 rowsep0" align="left">89.1</td><td class="colsep0 rowsep0" align="left">6.14</td><td class="colsep0 rowsep0" align="left"><i>K</i><sub>i</sub> = 20 nM (0.68)</td><td class="colsep0 rowsep0" align="left">333</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">27</td><td class="colsep0 rowsep0" align="left">enzyme</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="left">pomalidomide</td><td class="colsep0 rowsep0" align="left">273</td><td class="colsep0 rowsep0" align="left">â0.2</td><td class="colsep0 rowsep0" align="left">109.6</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> = 3 Î¼M (0.4)</td><td class="colsep0 rowsep0" align="left">62â138</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">73</td><td class="colsep0 rowsep0" align="left">multiple</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left">pitolisant</td><td class="colsep0 rowsep0" align="left">296</td><td class="colsep0 rowsep0" align="left">4.8</td><td class="colsep0 rowsep0" align="left">12.5</td><td class="colsep0 rowsep0" align="left">18</td><td class="colsep0 rowsep0" align="left">EC<sub>50</sub> = 1.5 nM (0.62)</td><td class="colsep0 rowsep0" align="left">low<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">10â12</td><td class="colsep0 rowsep0" align="left">63</td><td class="colsep0 rowsep0" align="left">GPCR</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="left">dimethyl fumarate</td><td class="colsep0 rowsep0" align="left">144</td><td class="colsep0 rowsep0" align="left">0.8</td><td class="colsep0 rowsep0" align="left">52.6</td><td class="colsep0 rowsep0" align="left">120</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> = 10 Î¼M (0.72)</td><td class="colsep0 rowsep0" align="left">53â73</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">unknown</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="left">migalastat</td><td class="colsep0 rowsep0" align="left">163</td><td class="colsep0 rowsep0" align="left">â1.4</td><td class="colsep0 rowsep0" align="left">93</td><td class="colsep0 rowsep0" align="left">123</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> = 830 Î¼M (0.42)</td><td class="colsep0 rowsep0" align="left">77â133</td><td class="colsep0 rowsep0" align="left">3â5</td><td class="colsep0 rowsep0" align="left">77</td><td class="colsep0 rowsep0" align="left">enzyme</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="left">pirfenidone</td><td class="colsep0 rowsep0" align="left">185</td><td class="colsep0 rowsep0" align="left">2.4</td><td class="colsep0 rowsep0" align="left">22</td><td class="colsep0 rowsep0" align="left">267</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> = 1.6 mM (0.30)</td><td class="colsep0 rowsep0" align="left">59â71</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">80</td><td class="colsep0 rowsep0" align="left">enzyme</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="left">teriflunomide</td><td class="colsep0 rowsep0" align="left">270</td><td class="colsep0 rowsep0" align="left">2.1</td><td class="colsep0 rowsep0" align="left">73.1</td><td class="colsep0 rowsep0" align="left">14</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> = 0.3 Î¼M (0.49)</td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="left">18â19Â d</td><td class="colsep0 rowsep0" align="left">23</td><td class="colsep0 rowsep0" align="left">enzyme</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="left">eslicarbazepine<a class="ref internalNav" href="#t1fn8" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="left">296</td><td class="colsep0 rowsep0" align="left">1.5</td><td class="colsep0 rowsep0" align="left">72.6</td><td class="colsep0 rowsep0" align="left">800</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> = 30 Î¼M (0.35)</td><td class="colsep0 rowsep0" align="left">61<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">13â20</td><td class="colsep0 rowsep0" align="left">90</td><td class="colsep0 rowsep0" align="left">ion channel</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">po dose, <i>V</i><sub>d</sub>, <i>T</i><sub>1/2</sub>, and % urine excretion taken from FDA or EMA product labels.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Ligand efficiency (LE) for each drug was calculated using corresponding primary potency data in an in vitro assay described in the literature.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Distribution to CSF and CNS described.</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">Based on 70 kg body weight.</p></div><div class="footnote" id="t1fn5"><sup><sup>e</sup></sup><p class="last">Based on no or moderate distribution to red blood cells and high plasma protein binding.</p></div><div class="footnote" id="t1fn6"><sup><sup>f</sup></sup><p class="last">Percent urine excretion of parent and/or metabolites.</p></div><div class="footnote" id="t1fn7"><sup><sup>g</sup></sup><p class="last">As part of a combination.</p></div><div class="footnote" id="t1fn8"><sup><sup>h</sup></sup><p class="last">Measurements of parent drug.</p></div></div></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Case Studies: Drugs Derived from Lead-like Screening Efforts</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26644" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26644" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Tavaborole (<b>1</b>, Kerydin)</h3><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b00407/20181207/images/medium/jm-2018-00407x_0005.gif" alt="" id="fx1" /></img><div class="NLM_p">Tavaborole is used for topical treatment of toenail onychomycosis and acts via inhibition of fungal cytoplasmic leucyl-transfer ribonucleic acid (tRNA) synthetase.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> The boron-containing compound (<b>1a</b>) was identified by screening boron-containing small molecule libraries in antibacterial assays.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Subsequent medicinal chemistry efforts, essentially addition of a fluorine substituent and modification of the phenyl-boron to a hydroxyl-boron group, led to the identification of tavaborole.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Nail penetration and keratin binding preclinical studies identified tavaborole as a clinical candidate for further evaluation. The tavaborole study highlights the utility of screening lead-like compound libraries in suitable in vitro assays to identify compounds with high efficacy and pursuing a topical approach to avoid systemic safety concerns.</div><div class="NLM_p last">â</div></div><div id="sec2_1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Crisaborole (<b>2</b>, Eucrisa)</h3><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b00407/20181207/images/medium/jm-2018-00407x_0006.gif" alt="" id="fx2" /></img><div class="NLM_p">Boron-containing compounds inhibit the release of cytokines such as TNFÎ± and IFNÎ± from peripheral blood mononuclear cells and were shown to be PDE4 enzyme inhibitors.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Screening of a boron-containing compound library, in analogy to the discovery of tavaborole, and subsequent medicinal chemistry efforts led to the discovery of the development candidate, AN-2728, later named crisaborole. Crisaborole is the first topically applied PDE4 inhibitor approved by the FDA for treatment of atopic dermatitis in patients older than two years of age. It has potent inhibitory activity (IC<sub>50</sub> = 55â340 nM) for various PDE4 isoforms (PDE 4A1A, 4B1, 4B2, 4C1, 4D7) and is less potent against other PDE isozymes. The tetrahedral geometry of the boron atom in crisaborole mimics the phosphate of cAMP and is thought to overlap the cAMP binding site in PDE4.</div><div class="NLM_p last">â</div></div><div id="sec2_1_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Ataluren (<b>3</b>, Translarna)</h3><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b00407/20181207/images/medium/jm-2018-00407x_0007.gif" alt="" id="fx3" /></img><div class="NLM_p">Aminoglycoside antibiotics modify gene expression and suppress stop codons disrupting the normal functioning of the ribosome. However, they tend to be nonspecific leading to serious side effects. The small molecule ataluren is reported to modulate the bacterial ribosome with lower toxicity. Two high-throughput screens (HTS) of specifically low molecular weight compounds identified modulators that promote UGA nonsense suppression. An oxadiazole series was selected from multiple classes of compounds identified through lead optimization. The oxadiazole and benzoic acid portion are essential for activity, and the H-bonding of the carboxylic acid moiety with an amino group in the mRNA has been shown to be an important interaction.<a onclick="showRef(event, 'ref11 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref13">(11â13)</a> Even though ataluren has received conditional approval in EU, the FDA has not approved it in the U.S. and has requested more clinical trials.</div><div class="NLM_p last">â</div></div><div id="sec2_1_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Vortioxetine (<b>4</b>, Trintellix)</h3><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b00407/20181207/images/medium/jm-2018-00407x_0008.gif" alt="" id="fx4" /></img><div class="NLM_p last">Vortioxetine is a serotonin modulator approved for major depressive disorder (MDD). The discovery of vortioxetine has been guided by the desire to identify a new generation of antidepressants with dual activity at the serotonin transporter (SERT) and the 5-HT<sub>1A</sub> receptor.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> A focused screening program identified an arylpiperazine compound, <b>4a</b>, which was eventually transformed to <b>4</b> (vortioxetine). Vortioxetine exhibits polypharmacology, showing activity as antagonist at the 5-HT<sub>3A</sub> and 5-HT<sub>7</sub> receptors, a partial agonist at the 5-HT<sub>1B</sub> receptor, an agonist at the 5-HT<sub>1A</sub> receptor and as SERT inhibitor. This concerted multimodal serotonergic activity profile presumably leads to a more robust antidepressant effect.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">Case Studies: Drugs Derived from Previously Known Lead-like Substrates and Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08455" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08455" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Edaravone (<b>5</b>, Radicava)</h3><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b00407/20181207/images/medium/jm-2018-00407x_0009.gif" alt="" id="fx5" /></img><div class="NLM_p">Edaravone was approved in the U.S. in 2017 for amyotrophic lateral sclerosis (ALS) as an intravenous infusion; it was the first ALS drug approved in 22 years. While the exact mechanism of how edaravone works in ALS is unknown, edaravone has been known since the 1980s as a free radical scavenger and was previously approved in Japan for treatment of acute cerebral infarction.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Edaravone (MCI-186) was shown to prevent both nonenzymatic peroxidation and lipoxygenase activity in vitro and attenuated the ischemic and postischemic brain swelling.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Edaravone is a derivative of phenazone (<b>5a</b>), an analgesic and a nonsteroidal anti-inflammatory drug (NSAID) that was first synthesized in 1887.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Edaravone was shown to have beneficial effects on mice with ALS-like symptoms and eventually tested in the clinic as a treatment for ALS. An oral formulation of the drug is under clinical development.</div><div class="NLM_p last">â</div></div><div id="sec3_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Tasimelteon (<b>6</b>, Hetlioz)</h3><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b00407/20181207/images/medium/jm-2018-00407x_0010.gif" alt="" id="fx6" /></img><div class="NLM_p">Tasimelteon is a selective melatonin receptor agonist with subnanomolar potency at the MT<sub>1</sub> and MT<sub>2</sub> receptors.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> The compound is used to treat non-24-h sleepâwake disorder in blind adults. Tasimelteon is a structural analog of the natural substrate melatonin (<b>6a</b>) and a close analog to another melatonin agonist, ramelteon (<b>6b</b>), that also selectively binds to MT<sub>1</sub> and MT<sub>2</sub> receptors. The pharmacokinetics of tasimelteon is superior to that of melatonin, and it also avoids the formation of kynuric metabolites.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> The discovery of tasimelteon as a lead-like drug was guided by medicinal chemistry optimization of similar drugs related to a natural substrate of a central nervous system aminergic GPCR target.</div><div class="NLM_p last">â</div></div><div id="sec3_1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Lorcaserin (<b>7</b>, Belviq)</h3><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b00407/20181207/images/medium/jm-2018-00407x_0011.gif" alt="" id="fx7" /></img><div class="NLM_p">The appetite reduction and weight loss effects of central serotonergic pathways are well-known.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> In particular, nonselective 5-HT<sub>2C</sub> receptor agonists have positive effects on weight loss but suffer from serious toxicities, including increased cardiac valve defects. To mitigate toxic off-target effects, medicinal chemistry efforts focused on conformational restriction of known serotonergic scaffolds to improve selectivity of the 5-HT<sub>2C</sub> over 5-HT<sub>2A</sub> and 5-HT<sub>2B</sub> receptors.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> On the basis of in vitro selectivity and favorable in vivo pharmacokinetics, pharmacodynamics, and efficacy data, lorcaserin was advanced to clinical trials where it showed an increased durable weight loss in obese patients.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> The optimization of lorcaserin highlights the application of conformational restriction design concept to a lead-like drug to improve selectivity.</div><div class="NLM_p last">â</div></div><div id="sec3_1_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Brivaracetam (<b>8</b>, Briviact)</h3><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b00407/20181207/images/medium/jm-2018-00407x_0012.gif" alt="" id="fx8" /></img><div class="NLM_p">The discovery of brivaracetam arose from a chemical biology effort to identify the target of levetiracetam (<b>8a</b>), an anticonvulsant and antiepileptic drug.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> A photoaffinity probe, UCB 30889 (<b>8b</b>), was used to identify synaptic vesicle glycoprotein 2a (SV2A) as the putative drug target. A subsequent optimization effort resulted in the identification of the C2-propyl derivative of levetiracetam resulting in <b>8</b> as a drug candidate. Brivaracetam showed increased potency and a faster onset of action compared to levetiracetam, resulting in a lower efficacious clinical dose.<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24,25)</a> The discovery of brivaracetam shows the impact of chemical biology and medicinal chemistry to improve upon drugs already in use.</div><div class="NLM_p last">â</div></div><div id="sec3_1_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Tipiracil (<b>9</b>, as Part of Lonsurf)</h3><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b00407/20181207/images/medium/jm-2018-00407x_0013.gif" alt="" id="fx9" /></img><div class="NLM_p">Tipiracil is a thymidine phosphorylase (TPase) inhibitor used to increase the relative concentration of the anticancer drug trifluridine by blocking its metabolism.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> The initial step toward the discovery of tipiracil was the identification of 5-halogenated 6-amino uracils known to inhibit uracil phosphorylase (UPase), a related enzyme to TPase.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Subsequent medicinal chemistry optimization of the uracil derivatives led to the identification of tipiracil, which showed appropriate in vitro enzyme inhibition and in vivo pharmacokinetics and pharmacodynamics to advance to human studies.<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28,29)</a> Subsequent clinical trials confirmed the efficacy of tipiracil in raising trifluridine concentrations, potentiating the efficacy of trifluridine compared to trifluridine alone.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> The discovery of tipiracil highlights the use of selective optimization of activity to afford a drug candidate.</div><div class="NLM_p last">â</div></div><div id="sec3_1_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Pomalidomide (<b>10</b>, Pomalyst)</h3><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b00407/20181207/images/medium/jm-2018-00407x_0014.gif" alt="" id="fx10" /></img><div class="NLM_p">Pomalidomide is a 3-amino analog of thalidomide (<b>10a</b>) indicated for patients with multiple myeloma.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Thalidomide, a synthetic derivative of glutamic acid, is a controversial sedative drug that was withdrawn from the market in the 1960s due to its teratogenic and other side effects. Thalidomide was later shown to have antiangiogenic effects and eventually was approved in 1998 for use against multiple myeloma.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Scientists at Dana-Farber investigated the 3-aminothalidomide analog of thalidomide and showed that it had enhanced TNF-Î± inhibitory activity compared to thalidomide,<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> although the antiangiogenic effect does not correlate with the magnitude of TNF-Î± inhibition. The two drugs differentially regulate various cytokines as well which might be responsible for myeloma cell proliferation. Thalidomide and pomalidomide are sold as racemates, with both enantiomers rapidly interconverting in plasma and in vivo. Both enantiomers of pomalidomide were shown to have similar TNF-Î± synthesis inhibitory activity.</div><div class="NLM_p last">â</div></div><div id="sec3_1_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Pitolisant (<b>11</b>, Wakix)</h3><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b00407/20181207/images/medium/jm-2018-00407x_0015.gif" alt="" id="fx11" /></img><div class="NLM_p last">Histaminergic neurons in the brain play a critical role in the maintenance of wakefulness and enhanced cerebral functions. Blockade of histamine H<sub>3</sub> receptors by drugs like pitolisant increases the activity of histaminergic neurons and the level of histamines in the brain. Pitolisant has its origin in the structure of the natural substrate histamine itself (<b>11a</b>). Thioperamide (<b>11b</b>) and ciproxifan (<b>11c</b>) are additional examples of potent H<sub>3</sub> receptor antagonists that were discovered previously but could not be advanced due to hepatotoxicity. Eventual replacement of the imidazole ring with a piperidine ring yielded pitolisant.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Case Studies: Drugs from Biological and Clinical Efforts (Repurposing, Metabolites or Natural Products)</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55358" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55358" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Dimethyl Fumarate (<b>12</b>, Tecfidera)</h3><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b00407/20181207/images/medium/jm-2018-00407x_0016.gif" alt="" id="fx12" /></img><div class="NLM_p">The use of fumarate to treat inflammatory conditions was first attempted by a German biochemist through self-administration of fumarate to treat his psoriasis, by correcting a perceived fumarate deficiency.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Dimethyl fumarate is the diester precursor of fumarate, a metabolic component of the citric acid cycle. Viewed in this light, dimethyl fumarate is a prodrug of an endogenous human metabolite. Initially, dimethyl fumarate was used for radiation sensitization of cells.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Subsequent testing of fumaric acid ester combinations revealed the utility of dimethyl fumarate in psoriasis and subsequently for multiple sclerosis treatment. As a single agent, dimethyl fumarate significantly reduced multiple sclerosis disease activity in a phase 3 study.<a onclick="showRef(event, 'ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref37 ref38">(37,38)</a> Recent studies have revealed that dimethyl fumarate acts by blocking cytokine production via the inhibition of ubiquitin chain formation.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Given that the structure of dimethyl fumarate was well-known, the drug was commercialized based on formulation and method of use patents. Of note, dimethyl fumarate has also been used as a furniture treatment to prevent mold growth, this application has been discontinued due to risk of contact dermatitis.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> The advancement of dimethyl fumarate as a therapy for multiple sclerosis highlights the possibility of serendipitous drug discovery and drug repurposing.</div><div class="NLM_p last">â</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Migalastat (<b>13</b>, Galafold)</h3><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b00407/20181207/images/medium/jm-2018-00407x_0017.gif" alt="" id="GRAPHIC-d7e1058-autogenerated" /></img><div class="NLM_p">The amino-sugar analog migalastat (galactostatin) was isolated as a fermentation product and is close in structure to nojirimycin (<b>13a</b>) and galactose (<b>13b</b>).<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Because miglustat (<b>13c</b>) was similar to the terminal galactose of the substrate for Î±-galactoside A, globotriasoylceramide, the natural product has been considered as a possible modulator of the enzyme.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> In vitro and in vivo experiments showed that migalastat could serve as a pharmacological chaperone for Î±-galactoside A, preserving the activity of the enzyme and reducing buildup of enzyme substrates;<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43,44)</a> furthermore, similar substrates have been used as enzyme chaperones previously.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> The chaperone approach allowed an oral drug to mimic the efficacy of enzyme replacement therapies Fabrazyme and Replagal in Fabry disease.<a onclick="showRef(event, 'ref46 ref47'); return false;" href="javascript:void(0);" class="ref ref46 ref47">(46,47)</a> Migalastat given at a 150 mg dose every other day increased the Î±-galactoside A activity in patients, decreasing the buildup of globotriasoylceramide.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Taken together, the use of lead-like natural products that mimic substrates in disease has proven to be an effective approach in treating Fabry disease.</div><div class="NLM_p last">â</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Pirfenidone (<b>14</b>, Esbriet)</h3><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b00407/20181207/images/medium/jm-2018-00407x_0018.gif" alt="" id="GRAPHIC-d7e1097-autogenerated" /></img><div class="NLM_p">The antifibrotic compound pirfenidone is used to treat idiopathic pulmonary fibrosis (IPF) by reducing fibroblast proliferation and collagen production.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Pirfenidone was first investigated as an anti-inflammatory treatment in the 1970s and then was pursued as an IPF treatment, after preclinical studies showed positive effects of the compound in lung fibroblasts.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Clinical trials have shown a favorable benefitârisk profile in IPF, and meta-analysis of pirfenidone clinical trials have shown an association of the drug with a reduction of the relative risk of mortality in clinical trials.<a onclick="showRef(event, 'ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref51 ref52">(51,52)</a> Pirfenidone may have multiple uses as an antifibrotic, alone and in combination with angiotensin II type I receptor antagonists.<a onclick="showRef(event, 'ref53 ref54'); return false;" href="javascript:void(0);" class="ref ref53 ref54">(53,54)</a> The advancement of pirfenidone highlights candidate repurposing efforts based on compelling preclinical biology.</div><div class="NLM_p last">â</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Teriflunomide (<b>15</b>, Aubagio)</h3><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b00407/20181207/images/medium/jm-2018-00407x_0019.gif" alt="" id="GRAPHIC-d7e1122-autogenerated" /></img><div class="NLM_p">Teriflunomide is the main active metabolite of leflunomide (<b>15a</b>), a drug for rheumatoid arthritis approved in the U.S. and Europe since 1998 and 1999, respectively. Leflunomide originated as an agricultural fungicide that was later found to be an anti-inflammatory immunomodulator. Upon oral administration, leflunomide is rapidly converted to its active primary metabolite (<b>15</b>).<a onclick="showRef(event, 'ref55 ref56'); return false;" href="javascript:void(0);" class="ref ref55 ref56">(55,56)</a> Teriflunomide has been shown to inhibit the enzyme dihydroorotate dehydrogenase (DHODH) by binding to a narrow hydrophobic channel of DHODH leading to the active site.</div><div class="NLM_p last">â</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Eslicarbazepine Acetate (<b>16</b>, Aptiom)</h3><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b00407/20181207/images/medium/jm-2018-00407x_0020.gif" alt="" id="GRAPHIC-d7e1144-autogenerated" /></img><div class="NLM_p last">Eslicarbazepine is a voltage-gated sodium channel blocker approved for partial-onset seizures epilepsy. It is related to oxcarbazepine (<b>16a</b>) that was introduced in the 1990s as a low molecular weight antiepileptic drug.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> Oxcarbazepine was determined to be rapidly and extensively metabolized in vivo to a racemic mixture of its corresponding reduced alcohols (<b>16b</b>, C10-<i>S</i> and C10-<i>R</i> in a ratio of 4:1). Both alcohols were synthesized separately along with a series of esters designed to act as prodrugs. From this cohort, the <i>S</i>-acetate (<b>16</b>, eslicarbazepine acetate) was shown to have the highest sodium channel inhibitory activity in vitro and in vivo. Although no crystal structure of the human sodium channel receptor has been solved, subtype nonselective sodium channel modulators such as eslicarbazepine (<b>16c</b>) are hypothesized to bind to an intracellular site within the sodium channel pore.</div></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15104" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15104" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Inspection of the of the 28 of 174 lead-like drugs approved between 2011 and 2017 (see <a href="/doi/suppl/10.1021/acs.jmedchem.8b00407/suppl_file/jm8b00407_si_001.csv" class="ext-link">Supporting Information</a>) reveals a property profile that falls between the ârule-of-threeâ and ârule of fiveâ (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). For instance, 21 of 28 drugs below 300 MW have calculated logÂ <i>P</i> values of 3 or less, 20 of 28 have three or less hydrogen bond donors, and 18 of 28 have three or less hydrogen bond acceptors. When viewed through the ârule-of-fiveâ lens, only 1 of 28 drugs is an outlier with six hydrogen bonds.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> Additionally, all the lead-like drugs from 2011 to 2017 have total polar surface areas below 125 Ã and rotatable bond counts below 10, compliant with property ranges preferable for oral bioavailability.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b00407/20181207/images/medium/jm-2018-00407x_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b00407/20181207/images/large/jm-2018-00407x_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Counts of clogP, polar surface area (PSA), nitrogen and oxygen counts (NO), hydrogen bond donor counts (HBD), and rotational bonds for the approved (2011â2017) drugs that have MW â¤ 300.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b00407/20181207/images/large/jm-2018-00407x_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00407&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">There are three common themes that emerge when considering the selected case studies of recently approved drugs below molecular weight 300. First, a portion of the list such as tavaborole, crisaborole, and ataluren originate from screening efforts using lead-like libraries. Second, a large portion of the recently approved drugs are based on medicinal chemistry optimization or derivatization of known lead-like drugs or natural products. For instance, lorcaserin is a conformationally restricted analog of known serotonergic scaffolds, tasimelteon is related to known melatonin receptor agonists, and pomalidomide is a close structural analog of thalidomide. Taken together, the molecular weight of the medicinal chemistry starting point has a strong influence on the molecular weight of the approved drug.<a onclick="showRef(event, 'ref60 ref61'); return false;" href="javascript:void(0);" class="ref ref60 ref61">(60,61)</a> Third, repurposed drugs (dimethyl fumarate, pirfenidone) and active metabolites make up a small but significant portion of the recently approved lead-like drugs. Of note, while the lead-like drugs from the case studies have a range of potency values (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), 11 of 15 have ligand efficiency values above the typical drug (0.45), correlating to high potency for each atom of the drug.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a></div><div id="sec6" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Lead-like ADME and Toxicity</h3><div class="NLM_p">Lead-like drugs do not differ significantly in physicochemical properties of known drugs. In the case studies included, clogP and polar surface areas are typical of successful, orally bioavailable drugs (see <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> As a consequence of low molecular weight, the ligand efficiencies (LE) of these drugs are on the higher end of the range. However, the dose ranges of these drugs are within the ranges of historic drugs.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> To investigate ADME implications of molecular weight further, we analyzed data from a collection of 105 drugs of various molecular weights.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> We found that 76% of drugs with less than 300 MW had human oral bioavailability greater than 90% while only 53% of drugs with 300â440 MW and 42% of drugs with MW above 440 had human oral bioavailability greater than 90%. This trend of increased bioavailability of lead-like compounds may correspond to previously noted relationships of solubility and permeability to molecular weight. Specifically, solubility tends to decrease in relation to increased molecular size, and low molecular weight compounds may have both paracellular and transcellular paths to absorption.<a onclick="showRef(event, 'ref66 ref67 ref68 ref69'); return false;" href="javascript:void(0);" class="ref ref66 ref67 ref68 ref69">(66â69)</a></div><div class="NLM_p">Likewise, an analysis of a diverse set of 47â¯018 compounds by Johnson and colleagues demonstrated the predictive value of molecular weight and logÂ <i>D</i> toward clearance and permeability.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> Compounds with molecular weight below 300 are predicted to tolerate a greater range of lipophilicity values (logÂ <i>D</i> of â2 to 5) while still maintaining preferred permeability and clearance values in vitro. Also, lead-like compounds are more likely to be brain penetrant, as has been noted in many reviews.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> Inspection of the half-life values and volumes of distribution of the case study drugs shows a range of values in line with values typically seen in marketed drugs.<a onclick="showRef(event, 'ref72 ref73'); return false;" href="javascript:void(0);" class="ref ref72 ref73">(72,73)</a> Molecular weights may also influence the excretion pathway of a drug with higher molecular weight correlating with increased biliary excretion and decreased molecular weight favoring renal excretion, possibly due to increased transporter impact on clearance.<a onclick="showRef(event, 'ref74 ref75 ref76'); return false;" href="javascript:void(0);" class="ref ref74 ref75 ref76">(74â76)</a> The case study drugs reflect the likely renal excretion routes of lead-like drugs because of the presence of drug parent or metabolites in urine for many of the drugs highlighted (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><div class="NLM_p last">There appear to be few studies of the overall influence of molecular weight on toxicity. Drugs below molecular weight 300 may show a decreased risk of toxicity based on previous analyses.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> An analysis by Struck, Schmidt, and colleagues correlated toxicity and molecular weight through the compilation and analysis of 50â¯000 small molecule compounds with experimental measures of toxicity.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> Specifically, the percentage of compounds with medium toxicity was significantly lower in the molecular weight 300 and below range when compared to molecular weight 300â400 or 400â500. An internal analysis suggests that most of the approved drugs that have a therapeutic index (TI) of >10 and an unbound efficacious concentration (<i>C</i><sub>eff</sub>) of > 1 Î¼M fall into a property space of MW < 300 and higher polarity (clogP < 2.5).<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a></div></div><div id="sec7" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Recommendations and Considerations</h3><div id="sec7_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> Ensure Use of Screening Sets below MW 300</h4><div class="NLM_p">Lead-like starting points are key to the discovery of lead-like drugs. However, recent analyses of commercially available screening compounds observed a median molecular weight of 387 with a median absolute deviation of 78, indicating that a large portion of commercially available screening sets would not cover chemical space below molecular weight 300.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> This implies that many screening efforts likely may not lead to the identification of hits below molecular weight 300, a range representing approximately half of human drugâtarget pairs. Fortuitously, with the increased focus on fragment-based drug discovery, there are an increasing number of commercially available lead-like starting points.<a onclick="showRef(event, 'ref81 ref82 ref83'); return false;" href="javascript:void(0);" class="ref ref81 ref82 ref83">(81â83)</a> Lead-like starting points have also been used to identify adipocyte differentiation  promoters through phenotypic screening and fragment-based  chemical proteomics, providing lead-like starting points for optimization.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> Related to the discovery of lead-like drugs is the âmedicinal chemistâs eyeâ, discussed in a comparative hit triage across many medicinal chemists.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> Namely, this investigation showed that medicinal chemists are relatively biased and differentiated in their evaluation of hit lists and hit triage. When applied to lead-like drug discovery, there may be a bias at the initial stages of screening that eliminate hits too soon based on molecular weight.</div><div class="NLM_p last">It is reassuring to see that in the 16 examples included in this review, diverse target classes such as enzymes, GPCRs, ion channels, and transporters are represented. Additionally recent investigations of cryptic and secondary pockets<a onclick="showRef(event, 'ref86 ref87 ref88'); return false;" href="javascript:void(0);" class="ref ref86 ref87 ref88">(86â88)</a> may extend the target space of lead-like compounds to less represented target classes through allostery, induced fit, or other mechanisms.</div></div><div id="sec7_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> Emphasize MW-Neutral, MW-Limited Medicinal Chemistry</h4><div class="NLM_p">Molecules at or below molecular weight 300 may typically be viewed as hits that need to be advanced through medicinal chemistry optimization to provide drugs, whether through potency or property optimization. However, a comparison of molecular weight ranges of starting compounds to optimized compounds in the monoamine GPCR family identified a median change in molecular weight of 30 (mean change 50) in optimization of starting compounds below molecular weight 300.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> This implies that optimized compounds can have similar molecular weights compared to their lead-like starting points. The analysis identified ion channels and transporters, in addition to monoamine GPCRs, as protein target classes associated with lower molecular weight ligands. Supporting this, clinical candidates in the ion channel target class have significantly lower molecular mass on average. This implies that starting compounds in certain target classes may be more amenable to optimization efforts toward clinical candidates that retain a low molecular weight.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> Additionally, the identification of binding pockets with lower surface area may also indicate the opportunity for lead-like drug discovery efforts.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a></div><div class="NLM_p last">The implementation of lead-like screening strategies is feasible, and lead-like medicinal chemistry optimization efforts, while challenging, may yield desired results. High concentration fragment screening using biochemical assays has demonstrated utility, providing sensitive hit identification with an acceptable number of artifacts due to the high concentration.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> Fragment-based screening in biochemical assays was shown to be suitable for the identification of serine protease and metalloprotease targets and can reduce protein requirements when compared to SPR and NMR fragment-based screening techniques.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> Keeping molecular weight low during fragment to lead medicinal chemistry efforts can be difficult. An analysis of 2015 and 2016 fragment to lead medicinal chemistry publications by Johnson and colleagues shows that out of 55 publications with hits less than molecular weight 300, only 6 resulted in leads with less than molecular weight 300.<a onclick="showRef(event, 'ref94 ref95'); return false;" href="javascript:void(0);" class="ref ref94 ref95">(94,95)</a> Application of medicinal chemistry strategies such as conformational restriction, heavy atom substitution, and truncation that maintain or reduce molecular weight is advisible to investigate, while strategies such as growth into additional pockets, fragment linking, or appending solubilizing groups may be contraindicated. Further work is needed to determine how and when lead-like screening and medicinal chemistry strategies are deployed.</div></div><div id="sec7_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> Evaluate Biological and Clinical Options</h4><div class="NLM_p last">Finally, sources of drugs without the need of large-scale screening or extensive medicinal chemistry efforts should not be ignored. Metabolites of known drugs, biological investigations of natural products, and clinically driven repurposing of known drugs have all resulted in new drug approvals.</div></div></div></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i29">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18260" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18260" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Compounds below molecular weight 300 represent a fruitful area of drug research with a number of recent drug approvals occurring in this space. Many of these recent drugs are close analogs of previously known drugs or natural substrates, with a key focus of medicinal chemistry optimization being the choice of a low molecular weight starting point and maintaining low molecular weight during the optimization. Advantages of lead-like space may include reduced toxicity and improved absorption and clearance. However, the identification of low molecular weight starting points may be limited by the availability of suitable low molecular weight screening sets. To increase the discovery rate of lead-like drugs, we suggest an increased focus on inclusion of lead-like starting points in screening libraries. While it may not be possible to generate clinical candidates and drugs that are lead-like in all cases, historic and recent drug approvals indicate that this area is ripe for further pursuit.</div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i30"><a href="/doi/suppl/10.1021/acs.jmedchem.8b00407" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34748" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34748" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.8b00407" class="ext-link">10.1021/acs.jmedchem.8b00407</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">List of FDA and EMA approved drugs from 2011 to 2017 with physicochemical properties and Smiles (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00407/suppl_file/jm8b00407_si_001.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00407/suppl_file/jm8b00407_si_001.csv">jm8b00407_si_001.csv (18.25 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.8b00407" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63157" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63157" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brian Raymer</span> - <span class="hlFld-Affiliation affiliation">Medicine Design, Pfizer Worldwide Research and Development, 1 Portland Street, Cambridge, Massachusetts 02139, United States</span>;Â 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#accedec5cdc282decdd5c1c9deeccdc0c7c9dec1c9df82cfc3c1"><span class="__cf_email__" data-cfemail="0567776c646b2b77647c6860774564696e60776860762b666a68">[emailÂ protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Samit K. Bhattacharya</span> - <span class="hlFld-Affiliation affiliation">Medicine Design, Pfizer Worldwide Research and Development, 1 Portland Street, Cambridge, Massachusetts 02139, United States</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0948-4254" title="Orcid link">http://orcid.org/0000-0002-0948-4254</a>;Â 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#7d0e1c1014095316531f151c09091c1e151c0f041c3d0d1b1407180f531e1210"><span class="__cf_email__" data-cfemail="88fbe9e5e1fca6e3a6eae0e9fcfce9ebe0e9faf1e9c8f8eee1f2edfaa6ebe7e5">[emailÂ protected]</span></a></span></div></li></ul></li><li><ul></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81316" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81316" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Brian Raymer</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00407&amp;id=BIO-d7e1415-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Brian Raymer</b> earned a B.A in Chemistry from St. Olaf College (Northfield, MN) and then joined the Process Development group at Pfizer (Groton, CT). He then moved to Harvard University and obtained his Ph.D. with Prof. David A. Evans working on synthetic routes toward a marine toxin, azaspiracid. In 2004, he joined the Global Discovery Chemistry department at Novartis (Cambridge, MA) working on small molecule projects in the diabetes, metabolism, and cardiovascular disease areas as well as peptide, polymer, and antibodyâdrug conjugate projects as part of the Chemical Biology department. In 2013 he moved to Pfizer (Cambridge, MA) as a medicinal chemistry and research project leader in Medicinal Design, contributing to two clinical candidates including a ketohexokinase inhibitor currently in phase 2 clinical trials.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Samit K. Bhattacharya</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00407&amp;id=BIO-d7e1420-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Samit K. Bhattacharya</b> did his undergraduate work in Organic Chemistry at Jadavpur University, Calcutta, India, and earned his Ph.D. at University of Pennsylvania, Philadelphia, PA, under the tutelage of Professor Jeffrey Winkler working on the total synthesis of anticancer drug paclitaxel (Taxol). Thereafter he moved to Columbia University, NY, as a Postdoctoral Fellow with Professor Samuel Danishefsky, working on the total synthesis of anticancer agent eleutherobin and ganglioside GM-1. In 1999, he joined the Oncology group in Pfizer, Groton, CT, as a medicinal chemist and then moved onto the Cardiovascular and Metabolic Diseases group. Samit has contributed to multiple clinical candidates across these two therapeutic areas. Samit is currently in the Inflammation and Immunology group located in Cambridge, MA.</p></figure></div><div class="ack" id="ACK-d7e1345-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i33">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47866" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47866" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors are indebted to Drs. David Price, Markus Boehm, John Litchfield, Fabien Vincent, Phil Carpino, and Manthena Varma for critically reviewing the manuscript and providing invaluable suggestions. The authors also thank the ACS reviewers for their thoughtful suggestions.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">MW</td><td class="NLM_def"><p class="first last">molecular weight</p></td></tr><tr><td class="NLM_term">PSA</td><td class="NLM_def"><p class="first last">polar surface area</p></td></tr><tr><td class="NLM_term">Ro3</td><td class="NLM_def"><p class="first last">rule of three</p></td></tr><tr><td class="NLM_term">LE</td><td class="NLM_def"><p class="first last">ligand efficiency</p></td></tr><tr><td class="NLM_term">DHODH</td><td class="NLM_def"><p class="first last">dihydroorotate dehydrogenase</p></td></tr><tr><td class="NLM_term">NSAID</td><td class="NLM_def"><p class="first last">nonsteroidal anti-inflammatory drug</p></td></tr><tr><td class="NLM_term">HBD</td><td class="NLM_def"><p class="first last">hydrogen bond donor count</p></td></tr><tr><td class="NLM_term">SERT</td><td class="NLM_def"><p class="first last">serotonin transporter</p></td></tr><tr><td class="NLM_term">ALS</td><td class="NLM_def"><p class="first last">amyotrophic lateral sclerosis</p></td></tr><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">absorption, distribution, metabolism and excretion</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i35">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60133" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60133" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 95 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walters, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murcko, M. A.</span></span> <span> </span><span class="NLM_article-title">What Do Medicinal Chemists Actually Make? A 50-Year Retrospective</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">6405</span>â <span class="NLM_lpage">6416</span>, <span class="refDoi">Â DOI: 10.1021/jm200504p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200504p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFWjsr7O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6405-6416&issue=19&author=W.+P.+Waltersauthor=J.+Greenauthor=J.+R.+Weissauthor=M.+A.+Murcko&title=What+Do+Medicinal+Chemists+Actually+Make%3F+A+50-Year+Retrospective&doi=10.1021%2Fjm200504p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">What Do Medicinal Chemists Actually Make? A 50-Year Retrospective</span></div><div class="casAuthors">Walters, W. Patrick; Green, Jeremy; Weiss, Jonathan R.; Murcko, Mark A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6405-6416</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Despite the dramatically increasing costs of pharmaceutical R&D productivity, as measured by the no. of new drugs approved each year, has languished during the past decade.  Many different explanations have been proposed to account for this decline, such as increasing regulatory scrutiny, the inherent inefficiency of very large organizations, the pursuit of highly speculative targets identified from genomics, and more objective decision-making about advancing marginal compds. into latest age clin. trials.  Another factor often cited to help explain low pharmaceutical productivity is that, paradoxically, many compds. synthesized by medicinal chemists are not "druglike", at least as measured by various criteria.  The authors discuss the past, present and perspectives in the development of medicinal chem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqg5xuF4wHqKrVg90H21EOLACvtfcHk0ljxrUI7y4yyUw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFWjsr7O&md5=33109f9d55967be0d34f377f433621e4</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1021%2Fjm200504p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200504p%26sid%3Dliteratum%253Aachs%26aulast%3DWalters%26aufirst%3DW.%2BP.%26aulast%3DGreen%26aufirst%3DJ.%26aulast%3DWeiss%26aufirst%3DJ.%2BR.%26aulast%3DMurcko%26aufirst%3DM.%2BA.%26atitle%3DWhat%2520Do%2520Medicinal%2520Chemists%2520Actually%2520Make%253F%2520A%252050-Year%2520Retrospective%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D19%26spage%3D6405%26epage%3D6416%26doi%3D10.1021%2Fjm200504p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lipinski, C. A.</span></span> <span> </span><span class="NLM_article-title">Lead- and Drug-Like Compounds: The Rule-of-Five Revolution</span>. <i>Drug Discovery Today: Technol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">337</span>â <span class="NLM_lpage">341</span>, <span class="refDoi">Â DOI: 10.1016/j.ddtec.2004.11.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1016%2Fj.ddtec.2004.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=24981612" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlSqsrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2004&pages=337-341&issue=4&author=C.+A.+Lipinski&title=Lead-+and+Drug-Like+Compounds%3A+The+Rule-of-Five+Revolution&doi=10.1016%2Fj.ddtec.2004.11.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Lead- and drug-like compounds: the rule-of-five revolution</span></div><div class="casAuthors">Lipinski, Christopher A.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today: Technologies</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">337-341</span>CODEN:
                <span class="NLM_cas:coden">DDTTB5</span>;
        ISSN:<span class="NLM_cas:issn">1740-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Citations in CAS SciFinder to the rule-of-five (RO5) publication will exceed 1000 by year-end 2004.  Trends in the RO5 literature explosion that can be discerned are the further definitions of drug-like.  This topic is explored in terms of drug-like physicochem. features, drug-like structural features, a comparison of drug-like and non-drug-like in drug discovery and a discussion of how drug-like features relate to clin. success.  Physicochem. features of CNS drugs and features related to CNS blood-brain transporter affinity are briefly reviewed.  Recent literature on features of non-oral drugs is reviewed and how features of lead-like compds. differ from those of drug-like compds. is discussed.  Most recently, partly driven by NIH roadmap initiatives, considerations have arisen as to what tool-like means in the search for chem. tools to probe biol. space.  All these topics frame the scope of this short review/perspective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnjiyP3CY7lLVg90H21EOLACvtfcHk0ljxrUI7y4yyUw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlSqsrg%253D&md5=952c29b47003b884116d790ae9e4721f</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.ddtec.2004.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ddtec.2004.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26atitle%3DLead-%2520and%2520Drug-Like%2520Compounds%253A%2520The%2520Rule-of-Five%2520Revolution%26jtitle%3DDrug%2520Discovery%2520Today%253A%2520Technol.%26date%3D2004%26volume%3D1%26issue%3D4%26spage%3D337%26epage%3D341%26doi%3D10.1016%2Fj.ddtec.2004.11.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Congreve, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jhoti, H.</span></span> <span> </span><span class="NLM_article-title">A âRule of Threeâ for Fragment-Based Lead Discovery?</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">876</span>â <span class="NLM_lpage">877</span>, <span class="refDoi">Â DOI: 10.1016/S1359-6446(03)02831-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1016%2FS1359-6446%2803%2902831-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=14554012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A280%3ADC%252BD3svns1Cnsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2003&pages=876-877&issue=19&author=M.+Congreveauthor=R.+Carrauthor=C.+Murrayauthor=H.+Jhoti&title=A+%E2%80%98Rule+of+Three%E2%80%99+for+Fragment-Based+Lead+Discovery%3F&doi=10.1016%2FS1359-6446%2803%2902831-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">A 'rule of three' for fragment-based lead discovery?</span></div><div class="casAuthors">Congreve Miles; Carr Robin; Murray Chris; Jhoti Harren</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">876-7</span>
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRfFswFSn5vb43yKPtYViAGfW6udTcc2ebnfMhcseJww7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3svns1Cnsw%253D%253D&md5=137886dbb2062f7a3ad39277dd888df3</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2803%2902831-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252803%252902831-9%26sid%3Dliteratum%253Aachs%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DCarr%26aufirst%3DR.%26aulast%3DMurray%26aufirst%3DC.%26aulast%3DJhoti%26aufirst%3DH.%26atitle%3DA%2520%25E2%2580%2598Rule%2520of%2520Three%25E2%2580%2599%2520for%2520Fragment-Based%2520Lead%2520Discovery%253F%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2003%26volume%3D8%26issue%3D19%26spage%3D876%26epage%3D877%26doi%3D10.1016%2FS1359-6446%2803%2902831-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quinton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charruault, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nevers, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volland, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dognon, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creminon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taran, F.</span></span> <span> </span><span class="NLM_article-title">Toward the Limits of Sandwich Immunoassay of Very Low Molecular Weight Molecules</span>. <i>Anal. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>82</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">2536</span>â <span class="NLM_lpage">2540</span>, <span class="refDoi">Â DOI: 10.1021/ac100058f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ac100058f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2010&pages=2536-2540&issue=6&author=J.+Quintonauthor=L.+Charruaultauthor=M.+C.+Neversauthor=H.+Vollandauthor=J.+P.+Dognonauthor=C.+Creminonauthor=F.+Taran&title=Toward+the+Limits+of+Sandwich+Immunoassay+of+Very+Low+Molecular+Weight+Molecules&doi=10.1021%2Fac100058f"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fac100058f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fac100058f%26sid%3Dliteratum%253Aachs%26aulast%3DQuinton%26aufirst%3DJ.%26aulast%3DCharruault%26aufirst%3DL.%26aulast%3DNevers%26aufirst%3DM.%2BC.%26aulast%3DVolland%26aufirst%3DH.%26aulast%3DDognon%26aufirst%3DJ.%2BP.%26aulast%3DCreminon%26aufirst%3DC.%26aulast%3DTaran%26aufirst%3DF.%26atitle%3DToward%2520the%2520Limits%2520of%2520Sandwich%2520Immunoassay%2520of%2520Very%2520Low%2520Molecular%2520Weight%2520Molecules%26jtitle%3DAnal.%2520Chem.%26date%3D2010%26volume%3D82%26issue%3D6%26spage%3D2536%26epage%3D2540%26doi%3D10.1021%2Fac100058f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span>The Top
200 of 2017. <a href="http://clincalc.com/DrugStats/Top200Drugs.aspx" class="extLink">http://clincalc.com/DrugStats/Top200Drugs.aspx</a> (accessed November
17, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=The+Top%0A200+of+2017.+http%3A%2F%2Fclincalc.com%2FDrugStats%2FTop200Drugs.aspx+%28accessed+November%0A17%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverett, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyne, R. E.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâDonnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2014 New Drugs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1937</span>â <span class="NLM_lpage">1980</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2016.03.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1016%2Fj.bmc.2016.03.004" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=1937-1980&issue=9&author=A.+C.+Flickauthor=H.+X.+Dingauthor=C.+A.+Leverettauthor=R.+E.+Kyneauthor=K.+K.+Liuauthor=S.+J.+Finkauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+the+2014+New+Drugs&doi=10.1016%2Fj.bmc.2016.03.004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.03.004%26sid%3Dliteratum%253Aachs%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLeverett%26aufirst%3DC.%2BA.%26aulast%3DKyne%26aufirst%3DR.%2BE.%26aulast%3DLiu%26aufirst%3DK.%2BK.%26aulast%3DFink%26aufirst%3DS.%2BJ.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202014%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26issue%3D9%26spage%3D1937%26epage%3D1980%26doi%3D10.1016%2Fj.bmc.2016.03.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Elewski, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aly, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldwin, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez
Soto, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rich, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisfeld, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiltz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zane, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollak, R.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of Tavaborole Topical Solution, 5%, a Novel Boron-Based Antifungal Agent, for the Treatment of Toenail Onychomycosis: Results from 2 Randomized Phase-III Studies</span>. <i>J. Am. Acad. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>73</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">62</span>â <span class="NLM_lpage">69</span>, <span class="refDoi">Â DOI: 10.1016/j.jaad.2015.04.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1016%2Fj.jaad.2015.04.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=25956661" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnvFSqtrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2015&pages=62-69&issue=1&author=B.+E.+Elewskiauthor=R.+Alyauthor=S.+L.+Baldwinauthor=R.+F.+Gonzalez%0ASotoauthor=P.+Richauthor=M.+Weisfeldauthor=H.+Wiltzauthor=L.+T.+Zaneauthor=R.+Pollak&title=Efficacy+and+Safety+of+Tavaborole+Topical+Solution%2C+5%25%2C+a+Novel+Boron-Based+Antifungal+Agent%2C+for+the+Treatment+of+Toenail+Onychomycosis%3A+Results+from+2+Randomized+Phase-III+Studies&doi=10.1016%2Fj.jaad.2015.04.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: Results from 2 randomized phase-III studies</span></div><div class="casAuthors">Elewski, Boni E.; Aly, Raza; Baldwin, Sheryl L.; Gonzalez Soto, Remigio F.; Rich, Phoebe; Weisfeld, Max; Wiltz, Hector; Zane, Lee T.; Pollak, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Academy of Dermatology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">62-69</span>CODEN:
                <span class="NLM_cas:coden">JAADDB</span>;
        ISSN:<span class="NLM_cas:issn">0190-9622</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Onychomycosis, a fungal nail infection, can impact quality of life.  We sought to evaluate the efficacy and safety of tavaborole topical soln., 5% for treatment of toenail onychomycosis.  In 2 phase-III trials, adults with distal subungual onychomycosis affecting 20% to 60% of a target great toenail were randomized 2:1 to tavaborole or vehicle once daily for 48 wk.  The primary end point was complete cure of the target great toenail (completely clear nail with neg. mycol.) at week 52.  Secondary end points included completely or almost clear nail, neg. mycol., completely or almost clear nail plus neg. mycol., and safety.  Rates of neg. mycol. (31.1%-35.9% vs 7.2%-12.2%) and complete cure (6.5% and 9.1% vs 0.5% and 1.5%) significantly favored tavaborole vs. vehicle (P â¤ .001).  Completely or almost clear nail rates also significantly favored tavaborole vs. vehicle (26.1%-27.5% vs 9.3%-14.6%; P < .001).  Rates of completely or almost clear nail plus neg. mycol. (15.3%-17.9% vs 1.5%-3.9%) were significantly greater for tavaborole vs. vehicle (P < .001).  Application-site reactions with tavaborole included exfoliation (2.7%), erythema (1.6%), and dermatitis (1.3%).  Duration of follow-up is a limitation.  Tavaborole demonstrates a favorable benefit-risk profile in treatment of toenail onychomycosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq57HESc8Cdt7Vg90H21EOLACvtfcHk0ljHZ9Jc5wtLQQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnvFSqtrs%253D&md5=ce2bd25a222bec52157508b38f9971f9</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.jaad.2015.04.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaad.2015.04.010%26sid%3Dliteratum%253Aachs%26aulast%3DElewski%26aufirst%3DB.%2BE.%26aulast%3DAly%26aufirst%3DR.%26aulast%3DBaldwin%26aufirst%3DS.%2BL.%26aulast%3DGonzalez%2BSoto%26aufirst%3DR.%2BF.%26aulast%3DRich%26aufirst%3DP.%26aulast%3DWeisfeld%26aufirst%3DM.%26aulast%3DWiltz%26aufirst%3DH.%26aulast%3DZane%26aufirst%3DL.%2BT.%26aulast%3DPollak%26aufirst%3DR.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Tavaborole%2520Topical%2520Solution%252C%25205%2525%252C%2520a%2520Novel%2520Boron-Based%2520Antifungal%2520Agent%252C%2520for%2520the%2520Treatment%2520of%2520Toenail%2520Onychomycosis%253A%2520Results%2520from%25202%2520Randomized%2520Phase-III%2520Studies%26jtitle%3DJ.%2520Am.%2520Acad.%2520Dermatol.%26date%3D2015%26volume%3D73%26issue%3D1%26spage%3D62%26epage%3D69%26doi%3D10.1016%2Fj.jaad.2015.04.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benkovic, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alley, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baboval, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajagopalan, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahng, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavassoli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, L.</span></span> <span> </span><span class="NLM_article-title">Identification of Borinic Esters as Inhibitors of Bacterial Cell Growth and Bacterial Methyltransferases, Ccrm and Menh</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">7468</span>â <span class="NLM_lpage">7476</span>, <span class="refDoi">Â DOI: 10.1021/jm050676a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm050676a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=7468-7476&issue=23&author=S.+J.+Benkovicauthor=S.+J.+Bakerauthor=M.+R.+Alleyauthor=Y.+H.+Wooauthor=Y.+K.+Zhangauthor=T.+Akamaauthor=W.+Maoauthor=J.+Babovalauthor=P.+T.+Rajagopalanauthor=M.+Wallauthor=L.+S.+Kahngauthor=A.+Tavassoliauthor=L.+Shapiro&title=Identification+of+Borinic+Esters+as+Inhibitors+of+Bacterial+Cell+Growth+and+Bacterial+Methyltransferases%2C+Ccrm+and+Menh&doi=10.1021%2Fjm050676a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Fjm050676a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050676a%26sid%3Dliteratum%253Aachs%26aulast%3DBenkovic%26aufirst%3DS.%2BJ.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DAlley%26aufirst%3DM.%2BR.%26aulast%3DWoo%26aufirst%3DY.%2BH.%26aulast%3DZhang%26aufirst%3DY.%2BK.%26aulast%3DAkama%26aufirst%3DT.%26aulast%3DMao%26aufirst%3DW.%26aulast%3DBaboval%26aufirst%3DJ.%26aulast%3DRajagopalan%26aufirst%3DP.%2BT.%26aulast%3DWall%26aufirst%3DM.%26aulast%3DKahng%26aufirst%3DL.%2BS.%26aulast%3DTavassoli%26aufirst%3DA.%26aulast%3DShapiro%26aufirst%3DL.%26atitle%3DIdentification%2520of%2520Borinic%2520Esters%2520as%2520Inhibitors%2520of%2520Bacterial%2520Cell%2520Growth%2520and%2520Bacterial%2520Methyltransferases%252C%2520Ccrm%2520and%2520Menh%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26issue%3D23%26spage%3D7468%26epage%3D7476%26doi%3D10.1021%2Fjm050676a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alley, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanders, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plattner, J. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of a New Boron-Containing Antifungal Agent, 5-Fluoro-1,3-Dihydro-1-Hydroxy-2,1- Benzoxaborole (AN2690), for the Potential Treatment of Onychomycosis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">4447</span>â <span class="NLM_lpage">4450</span>, <span class="refDoi">Â DOI: 10.1021/jm0603724</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0603724" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BD28Xmt12lsro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=4447-4450&issue=15&author=S.+J.+Bakerauthor=Y.+K.+Zhangauthor=T.+Akamaauthor=A.+Lauauthor=H.+Zhouauthor=V.+Hernandezauthor=W.+Maoauthor=M.+R.+Alleyauthor=V.+Sandersauthor=J.+J.+Plattner&title=Discovery+of+a+New+Boron-Containing+Antifungal+Agent%2C+5-Fluoro-1%2C3-Dihydro-1-Hydroxy-2%2C1-+Benzoxaborole+%28AN2690%29%2C+for+the+Potential+Treatment+of+Onychomycosis&doi=10.1021%2Fjm0603724"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a New Boron-Containing Antifungal Agent, 5-Fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole (AN2690), for the Potential Treatment of Onychomycosis</span></div><div class="casAuthors">Baker, Stephen J.; Zhang, Yong-Kang; Akama, Tsutomu; Lau, Agnes; Zhou, Huchen; Hernandez, Vincent; Mao, Weimin; Alley, M. R. K.; Sanders, Virginia; Plattner, Jacob J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4447-4450</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A structure-activity relationship investigation for a more efficacious therapy to treat onychomycosis, a fungal infection of the toe and fingernails, led to the discovery of a boron-contg. small mol., AN2690 (I), which is currently in clin. trials for onychomycosis topical treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQCA9knQ5nc7Vg90H21EOLACvtfcHk0lhOAb7HSEKqvg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xmt12lsro%253D&md5=c21119d24d45861fefe07d802d9a786e</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fjm0603724&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0603724%26sid%3Dliteratum%253Aachs%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DZhang%26aufirst%3DY.%2BK.%26aulast%3DAkama%26aufirst%3DT.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DHernandez%26aufirst%3DV.%26aulast%3DMao%26aufirst%3DW.%26aulast%3DAlley%26aufirst%3DM.%2BR.%26aulast%3DSanders%26aufirst%3DV.%26aulast%3DPlattner%26aufirst%3DJ.%2BJ.%26atitle%3DDiscovery%2520of%2520a%2520New%2520Boron-Containing%2520Antifungal%2520Agent%252C%25205-Fluoro-1%252C3-Dihydro-1-Hydroxy-2%252C1-%2520Benzoxaborole%2520%2528AN2690%2529%252C%2520for%2520the%2520Potential%2520Treatment%2520of%2520Onychomycosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26issue%3D15%26spage%3D4447%26epage%3D4450%26doi%3D10.1021%2Fjm0603724" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paton, D. M.</span></span> <span> </span><span class="NLM_article-title">Crisaborole: Phosphodiesterase Inhibitor for Treatment of Atopic Dermatitis</span>. <i>Drugs Today</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">239</span>â <span class="NLM_lpage">245</span>, <span class="refDoi">Â DOI: 10.1358/dot.2017.53.4.2604174</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1358%2Fdot.2017.53.4.2604174" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A280%3ADC%252BC1crmtVykug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2017&pages=239-245&issue=4&author=D.+M.+Paton&title=Crisaborole%3A+Phosphodiesterase+Inhibitor+for+Treatment+of+Atopic+Dermatitis&doi=10.1358%2Fdot.2017.53.4.2604174"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Crisaborole: Phosphodiesterase inhibitor for treatment of atopic dermatitis</span></div><div class="casAuthors">Paton D M</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of today (Barcelona, Spain : 1998)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">239-245</span>
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    </div><div class="casAbstract">Atopic dermatitis (AD) is an extremely common condition affecting as many as 10-20% of children and 2-10% of adults.  A particularly distressing symptom of AD is pruritus.  One of the important aspects of AD is inflammation associated with increased activity of phosphodiesterase 4 (PDE4), resulting in decreased intracellular levels of cyclic adenosine monophosphate, which in turn causes increased production of inflammatory cytokines.  Crisaborole was developed as a small-molecule, boron-based, selective PDE4 inhibitor that can be used topically.  Clinical trials have demonstrated its efficacy in treating patients with mild to moderate AD, resulting in significant relief of pruritus.  Unlike PDE4 inhibitors that act systemically, crisaborole does not cause significant gastrointestinal adverse effects.  The most common adverse effect has been temporary stinging and burning in about 4% of patients upon application of the 2% ointment.  To date there is no evidence of atrophy, telangiectasia or hypopigmentation resulting from its use.  Crisaborole is the first topically applied PDE4 inhibitor to be approved by the FDA for use in AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTC3c4rt0Hyh4qdXsLcGTEUfW6udTcc2eYzYt6KHIoLkrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crmtVykug%253D%253D&md5=a854efec1d46127283db4e443c22221f</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1358%2Fdot.2017.53.4.2604174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2017.53.4.2604174%26sid%3Dliteratum%253Aachs%26aulast%3DPaton%26aufirst%3DD.%2BM.%26atitle%3DCrisaborole%253A%2520Phosphodiesterase%2520Inhibitor%2520for%2520Treatment%2520of%2520Atopic%2520Dermatitis%26jtitle%3DDrugs%2520Today%26date%3D2017%26volume%3D53%26issue%3D4%26spage%3D239%26epage%3D245%26doi%3D10.1358%2Fdot.2017.53.4.2604174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pibiri, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lentini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melfi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallucci, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pace, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinello, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barone, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Leonardo, A.</span></span> <span> </span><span class="NLM_article-title">Enhancement of Premature Stop Codon Readthrough in the Cftr Gene by Ataluren (PTC124) Derivatives</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">236</span>â <span class="NLM_lpage">244</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2015.06.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1016%2Fj.ejmech.2015.06.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=26142488" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlCqsbvO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2015&pages=236-244&author=I.+Pibiriauthor=L.+Lentiniauthor=R.+Melfiauthor=G.+Gallucciauthor=A.+Paceauthor=A.+Spinelloauthor=G.+Baroneauthor=A.+Di+Leonardo&title=Enhancement+of+Premature+Stop+Codon+Readthrough+in+the+Cftr+Gene+by+Ataluren+%28PTC124%29+Derivatives&doi=10.1016%2Fj.ejmech.2015.06.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Enhancement of premature stop codon readthrough in the CFTR gene by Ataluren (PTC124) derivatives</span></div><div class="casAuthors">Pibiri, Ivana; Lentini, Laura; Melfi, Raffaella; Gallucci, Giulia; Pace, Andrea; Spinello, Angelo; Barone, Giampaolo; Di Leonardo, Aldo</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">236-244</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Premature stop codons are the result of nonsense mutations occurring within the coding sequence of a gene.  These mutations lead to the synthesis of a truncated protein and are responsible for several genetic diseases.  A potential pharmacol. approach to treat these diseases is to promote the translational readthrough of premature stop codons by small mols. aiming to restore the full-length protein.  The compd. PTC124 (Ataluren) was reported to promote the readthrough of the premature UGA stop codon, although its activity was questioned.  The potential interaction of PTC124 with mutated mRNA was recently suggested by mol. dynamics (MD) studies highlighting the importance of H-bonding and stacking Ï-Ï interactions.  To improve the readthrough activity we changed the fluorine no. and position in the PTC124 fluoroaryl moiety.  The readthrough ability of these PTC124 derivs. was tested in human cells harboring reporter plasmids with premature stop codons in H2BGFP and FLuc genes as well as in cystic fibrosis (CF) IB3.1 cells with a nonsense mutation.  Maintaining low toxicity, three of these mols. showed higher efficacy than PTC124 in the readthrough of the UGA premature stop codon and in recovering the expression of the CFTR protein in IB3.1 cells from cystic fibrosis patient.  Mol. dynamics simulations performed with mutated CFTR mRNA fragments and active or inactive derivs. are in agreement with the suggested interaction of PTC124 with mRNA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQCRNDatyIrbVg90H21EOLACvtfcHk0ljhP1VMdGUxCQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlCqsbvO&md5=98faa152347759ad8d442d2acb0a24b1</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.06.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.06.038%26sid%3Dliteratum%253Aachs%26aulast%3DPibiri%26aufirst%3DI.%26aulast%3DLentini%26aufirst%3DL.%26aulast%3DMelfi%26aufirst%3DR.%26aulast%3DGallucci%26aufirst%3DG.%26aulast%3DPace%26aufirst%3DA.%26aulast%3DSpinello%26aufirst%3DA.%26aulast%3DBarone%26aufirst%3DG.%26aulast%3DDi%2BLeonardo%26aufirst%3DA.%26atitle%3DEnhancement%2520of%2520Premature%2520Stop%2520Codon%2520Readthrough%2520in%2520the%2520Cftr%2520Gene%2520by%2520Ataluren%2520%2528PTC124%2529%2520Derivatives%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D101%26spage%3D236%26epage%3D244%26doi%3D10.1016%2Fj.ejmech.2015.06.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lentini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melfi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Leonardo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinello, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barone, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pace, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palumbo
Piccionello, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pibiri, I.</span></span> <span> </span><span class="NLM_article-title">Toward a Rationale for the Ptc124 (Ataluren) Promoted Readthrough of Premature Stop Codons: A Computational Approach and GFP-Reporter Cell-Based Assay</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">653</span>â <span class="NLM_lpage">664</span>, <span class="refDoi">Â DOI: 10.1021/mp400230s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp400230s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsF2mtrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2014&pages=653-664&issue=3&author=L.+Lentiniauthor=R.+Melfiauthor=A.+Di+Leonardoauthor=A.+Spinelloauthor=G.+Baroneauthor=A.+Paceauthor=A.+Palumbo%0APiccionelloauthor=I.+Pibiri&title=Toward+a+Rationale+for+the+Ptc124+%28Ataluren%29+Promoted+Readthrough+of+Premature+Stop+Codons%3A+A+Computational+Approach+and+GFP-Reporter+Cell-Based+Assay&doi=10.1021%2Fmp400230s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Toward a rationale for the PTC124 (Ataluren) promoted readthrough of premature stop codons: a computational approach and GFP-reporter cell-based assay</span></div><div class="casAuthors">Lentini, Laura; Melfi, Raffaella; Di Leonardo, Aldo; Spinello, Angelo; Barone, Giampaolo; Pace, Andrea; Palumbo Piccionello, Antonio; Pibiri, Ivana</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">653-664</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The presence in the mRNA of premature stop codons (PTCs) results in protein truncation responsible for several inherited (genetic) diseases.  A well-known example of these diseases is cystic fibrosis (CF), where approx. 10% (worldwide) of patients have nonsense mutations in the CF transmembrane regulator (CFTR) gene.  PTC124 (3-(5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl)-benzoic acid), also known as Ataluren, is a small mol. that has been suggested to allow PTC readthrough even though its target has yet to be identified.  In the lack of a general consensus about its mechanism of action, we exptl. tested the ability of PTC124 to promote the readthrough of premature termination codons by using a new reporter.  The reporter vector was based on a plasmid harboring the H2B histone coding sequence fused in frame with the green fluorescent protein (GFP) cDNA, and a TGA stop codon was introduced in the H2B-GFP gene by site-directed mutagenesis.  Addnl., an unprecedented computational study on the putative supramol. interaction between PTC124 and an 11-codon (33-nucleotides) sequence corresponding to a CFTR mRNA fragment contg. a central UGA nonsense mutation showed a specific interaction between PTC124 and the UGA codon.  Altogether, the H2B-GFP-opal based assay and the mol. dynamics (MD) simulation support the hypothesis that PTC124 is able to promote the specific readthrough of internal TGA premature stop codons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoMyq0NCLi-rVg90H21EOLACvtfcHk0ljhP1VMdGUxCQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsF2mtrg%253D&md5=9db7ec531aa57c1e0c376d05612bfd2f</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fmp400230s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp400230s%26sid%3Dliteratum%253Aachs%26aulast%3DLentini%26aufirst%3DL.%26aulast%3DMelfi%26aufirst%3DR.%26aulast%3DDi%2BLeonardo%26aufirst%3DA.%26aulast%3DSpinello%26aufirst%3DA.%26aulast%3DBarone%26aufirst%3DG.%26aulast%3DPace%26aufirst%3DA.%26aulast%3DPalumbo%2BPiccionello%26aufirst%3DA.%26aulast%3DPibiri%26aufirst%3DI.%26atitle%3DToward%2520a%2520Rationale%2520for%2520the%2520Ptc124%2520%2528Ataluren%2529%2520Promoted%2520Readthrough%2520of%2520Premature%2520Stop%2520Codons%253A%2520A%2520Computational%2520Approach%2520and%2520GFP-Reporter%2520Cell-Based%2520Assay%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2014%26volume%3D11%26issue%3D3%26spage%3D653%26epage%3D664%26doi%3D10.1021%2Fmp400230s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karp, G. M.</span>; <span class="NLM_string-name">Hwang, S.</span>; <span class="NLM_string-name">Chen, G.</span>; <span class="NLM_string-name">Almstead, N. G.</span>; <span class="NLM_string-name">Moon, Y.-C.</span></span> <span> </span><span class="NLM_article-title">1,2,4-Oxadiazole Benzoic Acid Compounds and Their Use for Nonsense Suppression and the Treatment of Disease</span>. <span class="NLM_patent">US6992096B2</span>, <span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=G.+M.+Karp&author=S.+Hwang&author=G.+Chen&author=N.+G.+Almstead&author=Y.-C.+Moon&title=1%2C2%2C4-Oxadiazole+Benzoic+Acid+Compounds+and+Their+Use+for+Nonsense+Suppression+and+the+Treatment+of+Disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKarp%26aufirst%3DG.%2BM.%26atitle%3D1%252C2%252C4-Oxadiazole%2520Benzoic%2520Acid%2520Compounds%2520and%2520Their%2520Use%2520for%2520Nonsense%2520Suppression%2520and%2520the%2520Treatment%2520of%2520Disease%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bang-Andersen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruhland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frederiksen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mork, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stensbol, T. B.</span></span> <span> </span><span class="NLM_article-title">Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)Phenyl]Piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">3206</span>â <span class="NLM_lpage">3221</span>, <span class="refDoi">Â DOI: 10.1021/jm101459g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101459g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC3MXksFGgtLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=3206-3221&issue=9&author=B.+Bang-Andersenauthor=T.+Ruhlandauthor=M.+Jorgensenauthor=G.+Smithauthor=K.+Frederiksenauthor=K.+G.+Jensenauthor=H.+Zhongauthor=S.+M.+Nielsenauthor=S.+Hoggauthor=A.+Morkauthor=T.+B.+Stensbol&title=Discovery+of+1-%5B2-%282%2C4-Dimethylphenylsulfanyl%29Phenyl%5DPiperazine+%28Lu+AA21004%29%3A+A+Novel+Multimodal+Compound+for+the+Treatment+of+Major+Depressive+Disorder&doi=10.1021%2Fjm101459g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder</span></div><div class="casAuthors">Bang-Andersen, Benny; Ruhland, Thomas; Jorgensen, Morten; Smith, Garrick; Frederiksen, Kristen; Jensen, Klaus Gjervig; Zhong, Huailing; Nielsen, Soren Moller; Hogg, Sandra; Mork, Arne; Stensbol, Tine Bryan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3206-3221</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis and structure-activity relationship of a novel series of compds. with combined effects on 5-HT3A and 5-HT1A receptors and on the serotonin (5-HT) transporter (SERT) are described.  Compd. 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004) was the lead compd., displaying high affinity for recombinant human 5-HT1A (Ki = 15 nM), 5-HT1B (Ki = 33 nM), 5-HT3A (Ki = 3.7 nM), 5-HT7 (Ki = 19 nM), and noradrenergic Î²1 (Ki = 46 nM) receptors, and SERT (Ki = 1.6 nM).  Lu AA21004 displayed antagonistic properties at 5-HT3A and 5-HT7 receptors, partial agonist properties at 5-HT1B receptors, agonistic properties at 5-HT1A receptors, and potent inhibition of SERT.  In conscious rats, Lu AA21004 significantly increased extracellular 5-HT levels in the brain after acute and 3 days of treatment.  Following the 3-day treatment (5 or 10 (mg/kg)/day) SERT occupancies were only 43% and 57%, resp.  These characteristics indicate that Lu AA21004 is a novel multimodal serotonergic compd., and is currently in clin. development for major depressive disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAspA4Bk8ro7Vg90H21EOLACvtfcHk0ljhP1VMdGUxCQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXksFGgtLs%253D&md5=b9823f8a86f6d4d44d4a17cb510ea903</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm101459g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101459g%26sid%3Dliteratum%253Aachs%26aulast%3DBang-Andersen%26aufirst%3DB.%26aulast%3DRuhland%26aufirst%3DT.%26aulast%3DJorgensen%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DG.%26aulast%3DFrederiksen%26aufirst%3DK.%26aulast%3DJensen%26aufirst%3DK.%2BG.%26aulast%3DZhong%26aufirst%3DH.%26aulast%3DNielsen%26aufirst%3DS.%2BM.%26aulast%3DHogg%26aufirst%3DS.%26aulast%3DMork%26aufirst%3DA.%26aulast%3DStensbol%26aufirst%3DT.%2BB.%26atitle%3DDiscovery%2520of%25201-%255B2-%25282%252C4-Dimethylphenylsulfanyl%2529Phenyl%255DPiperazine%2520%2528Lu%2520AA21004%2529%253A%2520A%2520Novel%2520Multimodal%2520Compound%2520for%2520the%2520Treatment%2520of%2520Major%2520Depressive%2520Disorder%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D9%26spage%3D3206%26epage%3D3221%26doi%3D10.1021%2Fjm101459g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Edaravone
Acute Infarction Study Group.</span> <span> </span><span class="NLM_article-title">Effect of a Novel Free Radical Scavenger, Edaravone (MCI-186), on
Acute Brain Infarction. Randomized, Placebo-Controlled, Double-Blind
Study at Multicenters</span>. <i>Cerebrovasc. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">222</span>â <span class="NLM_lpage">229</span>, <span class="refDoi">Â DOI: 10.1159/000069318</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1159%2F000069318" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=12715790" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2003&pages=222-229&issue=3&author=Edaravone%0AAcute+Infarction+Study+Group.&title=Effect+of+a+Novel+Free+Radical+Scavenger%2C+Edaravone+%28MCI-186%29%2C+on%0AAcute+Brain+Infarction.+Randomized%2C+Placebo-Controlled%2C+Double-Blind%0AStudy+at+Multicenters&doi=10.1159%2F000069318"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1159%2F000069318&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000069318%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DEffect%2520of%2520a%2520Novel%2520Free%2520Radical%2520Scavenger%252C%2520Edaravone%2520%2528MCI-186%2529%252C%2520on%250AAcute%2520Brain%2520Infarction.%2520Randomized%252C%2520Placebo-Controlled%252C%2520Double-Blind%250AStudy%2520at%2520Multicenters%26jtitle%3DCerebrovasc.%2520Dis.%26date%3D2003%26volume%3D15%26issue%3D3%26spage%3D222%26epage%3D229%26doi%3D10.1159%2F000069318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kogure, K.</span></span> <span> </span><span class="NLM_article-title">Strong Attenuation of Ischemic and Postischemic Brain Edema in Rats by a Novel Free Radical Scavenger</span>. <i>Stroke</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">480</span>â <span class="NLM_lpage">485</span>, <span class="refDoi">Â DOI: 10.1161/01.STR.19.4.480</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1161%2F01.STR.19.4.480" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=1988&pages=480-485&issue=4&author=K.+Abeauthor=S.+Yukiauthor=K.+Kogure&title=Strong+Attenuation+of+Ischemic+and+Postischemic+Brain+Edema+in+Rats+by+a+Novel+Free+Radical+Scavenger&doi=10.1161%2F01.STR.19.4.480"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1161%2F01.STR.19.4.480&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.STR.19.4.480%26sid%3Dliteratum%253Aachs%26aulast%3DAbe%26aufirst%3DK.%26aulast%3DYuki%26aufirst%3DS.%26aulast%3DKogure%26aufirst%3DK.%26atitle%3DStrong%2520Attenuation%2520of%2520Ischemic%2520and%2520Postischemic%2520Brain%2520Edema%2520in%2520Rats%2520by%2520a%2520Novel%2520Free%2520Radical%2520Scavenger%26jtitle%3DStroke%26date%3D1988%26volume%3D19%26issue%3D4%26spage%3D480%26epage%3D485%26doi%3D10.1161%2F01.STR.19.4.480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brune, K.</span></span> <span> </span><span class="NLM_article-title">The Early History of Non-Opioid Analgesics</span>. <i>Acute Pain</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">33</span>â <span class="NLM_lpage">40</span>, <span class="refDoi">Â DOI: 10.1016/S1366-0071(97)80033-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1016%2FS1366-0071%2897%2980033-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADyaK1MXns1Srt7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1997&pages=33-40&issue=1&author=K.+Brune&title=The+Early+History+of+Non-Opioid+Analgesics&doi=10.1016%2FS1366-0071%2897%2980033-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">The early history of non-opioid analgesics</span></div><div class="casAuthors">Brune, Kay</div><div class="citationInfo"><span class="NLM_cas:title">Acute Pain</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-40</span>CODEN:
                <span class="NLM_cas:coden">ACPAFS</span>;
        ISSN:<span class="NLM_cas:issn">1366-0071</span>.
    
            (<span class="NLM_cas:orgname">Saldatore Ltd.</span>)
        </div><div class="casAbstract">A review with 14 refs.  The late 19th century gave rise to the discovery of the three prototypes of modern non-opioid antipyretic analgesics: acetaminophen (acetanilide), aspirin and salicylic acid, and phenazone.  At three different sites at almost the same time in Germany the zest for finding substitutes for quinine, ie antipyretic drugs, led to synthetic efforts culminating at Erlangen in the synthesis of phenazone (antipyrine), at Strasbourg of acetanilide (antifebrin), and at Wuppertal of aspirin (acetylsalicylic acid).  The rationales for synthesizing these drugs were not stringent, but proved, nonetheless, successful.  Thereafter chemists concd. their attempts merely on modifying the drugs discovered with the help of the rapidly expanding and improving org. chem.  Although no new principles were discovered, the 'relatives' of the originals, namely aspirin and its modifications, acetaminophen and propyphenazone, as well as dipyrone, still make up for about 50% of the market of the antipyretic analgesics worldwide.  Some of these compds. have attracted new interest recently.  This is particularly the case with dipyrone (metamizole, Novalgin).  After more than 50 yr of clin. use (without major research efforts) state of the art investigation was commenced, and at its 75th birthday this compd. is now thoroughly investigated.  The side effect profile and risks, as well as the pharmacokinetic parameters, are defined and the mode of action has been elucidated.  Although several clin. studies show effectiveness, probably due to the 75 yr-long worldwide experience, modern therapy orientated studies proving usefulness in specific indications, claimed by many physicians and patients (eg after bone marrow transplantation, against migraine, and in osteoarthrosis), are still unavailable.  In this respect, further research efforts and extension of knowledge is required, since this drug lacks gastrointestinal and renal toxicity, blood coagulation is only marginally influenced, and the widely discussed agranulocytosis is extremely rare and nearly never fatal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1yyVaqKrcBLVg90H21EOLACvtfcHk0liVhw7NtgzoDA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXns1Srt7Y%253D&md5=35f2b06edf0b20306808ae2d8c173379</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2FS1366-0071%2897%2980033-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1366-0071%252897%252980033-2%26sid%3Dliteratum%253Aachs%26aulast%3DBrune%26aufirst%3DK.%26atitle%3DThe%2520Early%2520History%2520of%2520Non-Opioid%2520Analgesics%26jtitle%3DAcute%2520Pain%26date%3D1997%26volume%3D1%26issue%3D1%26spage%3D33%26epage%3D40%26doi%3D10.1016%2FS1366-0071%2897%2980033-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hardeland, R.</span></span> <span> </span><span class="NLM_article-title">Investigational Melatonin Receptor Agonists</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">747</span>â <span class="NLM_lpage">764</span>, <span class="refDoi">Â DOI: 10.1517/13543784.2010.482926</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1517%2F13543784.2010.482926" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2010&pages=747-764&issue=6&author=R.+Hardeland&title=Investigational+Melatonin+Receptor+Agonists&doi=10.1517%2F13543784.2010.482926"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1517%2F13543784.2010.482926&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2010.482926%26sid%3Dliteratum%253Aachs%26aulast%3DHardeland%26aufirst%3DR.%26atitle%3DInvestigational%2520Melatonin%2520Receptor%2520Agonists%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2010%26volume%3D19%26issue%3D6%26spage%3D747%26epage%3D764%26doi%3D10.1517%2F13543784.2010.482926" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vachharajani, N. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeleswaram, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulton, D. W.</span></span> <span> </span><span class="NLM_article-title">Preclinical Pharmacokinetics and Metabolism of BMS-214778, a Novel Melatonin Receptor Agonist</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>92</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">760</span>â <span class="NLM_lpage">772</span>, <span class="refDoi">Â DOI: 10.1002/jps.10348</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1002%2Fjps.10348" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2003&pages=760-772&issue=4&author=N.+N.+Vachharajaniauthor=K.+Yeleswaramauthor=D.+W.+Boulton&title=Preclinical+Pharmacokinetics+and+Metabolism+of+BMS-214778%2C+a+Novel+Melatonin+Receptor+Agonist&doi=10.1002%2Fjps.10348"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2Fjps.10348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.10348%26sid%3Dliteratum%253Aachs%26aulast%3DVachharajani%26aufirst%3DN.%2BN.%26aulast%3DYeleswaram%26aufirst%3DK.%26aulast%3DBoulton%26aufirst%3DD.%2BW.%26atitle%3DPreclinical%2520Pharmacokinetics%2520and%2520Metabolism%2520of%2520BMS-214778%252C%2520a%2520Novel%2520Melatonin%2520Receptor%2520Agonist%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2003%26volume%3D92%26issue%3D4%26spage%3D760%26epage%3D772%26doi%3D10.1002%2Fjps.10348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Halford, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrold, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawton, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blundell, J. E.</span></span> <span> </span><span class="NLM_article-title">Serotonin (5-HT) Drugs: Effects on Appetite Expression and Use for the Treatment of Obesity</span>. <i>Curr. Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">201</span>â <span class="NLM_lpage">213</span>, <span class="refDoi">Â DOI: 10.2174/1389450053174550</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.2174%2F1389450053174550" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=15777190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BD2MXisVSqu74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=201-213&issue=2&author=J.+C.+Halfordauthor=J.+A.+Harroldauthor=C.+L.+Lawtonauthor=J.+E.+Blundell&title=Serotonin+%285-HT%29+Drugs%3A+Effects+on+Appetite+Expression+and+Use+for+the+Treatment+of+Obesity&doi=10.2174%2F1389450053174550"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Serotonin (5-HT) drugs: effects on appetite expression and use for the treatment of obesity</span></div><div class="casAuthors">Halford, Jason C. G.; Harrold, Joanne A.; Lawton, Clare L.; Blundell, John E.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">201-213</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The pivotal role of 5-HT in the control of appetite was formally proposed nearly 30 years ago.  In particular endogenous hypothalamic 5-HT was implicated in the processes of within meal satiation and the end state of post meal satiety.  Of the numerous 5-HT receptor subtypes currently identified, 5-HT1B and 5-HT2C receptors are believed to mediate the 5-HT induced satiety.  5-HT drugs such as d-fenfluramine, selective serotoninergic reuptake inhibitor (SSRIs) and 5-HT2C receptor agonists have all been shown to significantly attenuate rodent body wt. gain, an effect strongly assocd. with marked hypophagia.  D-Fenfluramine, sibutramine, fluoxetine and the 5-HT2C receptor agonist mCPP have also all been shown to reduce caloric intake by modifying appetite in both lean and obese humans.  Specifically, 5-HT drugs reduce appetite prior to and after the consumption of fixed caloric loads, and reduce pre meal appetite and caloric intake at ad libitum meals.  Clin. significant wt. loss over a year or more can be produced by both d-fenfluramine and sibutramine treatment, but apparently not by the SSRI fluoxetine.  Treatment with the preferential 5-HT2C receptor agonist mCPP and the serotonin precursor 5-HTP was also shown to produce wt. loss in the obese.  Issues around the actual and possible side effects of these compds., and in the case of d-fenfluramine toxicity, have led to a search for drugs that act selectively on the CNS 5-HT receptors crit. to the satiety response.  Currently, a new generation of 5-HT2C selective agonists were developed (including Ro 60-0175, Org 12962, VER-3323, BVT-933 and YM348) and at least one, ADP356, is currently undergoing clin. trials.  Hopefully, such drugs will be as or even more effective at regulating appetite and controlling body wt., and will also be free of their predecessors' side effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMX0O68S7bxLVg90H21EOLACvtfcHk0liVhw7NtgzoDA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXisVSqu74%253D&md5=ad765430cb2787564d02aad590309068</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.2174%2F1389450053174550&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389450053174550%26sid%3Dliteratum%253Aachs%26aulast%3DHalford%26aufirst%3DJ.%2BC.%26aulast%3DHarrold%26aufirst%3DJ.%2BA.%26aulast%3DLawton%26aufirst%3DC.%2BL.%26aulast%3DBlundell%26aufirst%3DJ.%2BE.%26atitle%3DSerotonin%2520%25285-HT%2529%2520Drugs%253A%2520Effects%2520on%2520Appetite%2520Expression%2520and%2520Use%2520for%2520the%2520Treatment%2520of%2520Obesity%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2005%26volume%3D6%26issue%3D2%26spage%3D201%26epage%3D213%26doi%3D10.2174%2F1389450053174550" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilson, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrada, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prieto, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallardo, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sengupta, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dosa, P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covel, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beeley, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espitia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saldana, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjenning, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whelan, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grottick, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menzaghi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomsen, W. J.</span></span> <span> </span><span class="NLM_article-title">Discovery and Structure-Activity Relationship of (1<i>R</i>)-8-Chloro-2,3,4,5-Tetrahydro-1-Methyl-1h-3-Benzazepine (Lorcaserin), a Selective Serotonin 5-HT2c Receptor Agonist for the Treatment of Obesity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">305</span>â <span class="NLM_lpage">313</span>, <span class="refDoi">Â DOI: 10.1021/jm0709034</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0709034" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=305-313&issue=2&author=B.+M.+Smithauthor=J.+M.+Smithauthor=J.+H.+Tsaiauthor=J.+A.+Schultzauthor=C.+A.+Gilsonauthor=S.+A.+Estradaauthor=R.+R.+Chenauthor=D.+M.+Parkauthor=E.+B.+Prietoauthor=C.+S.+Gallardoauthor=D.+Senguptaauthor=P.+I.+Dosaauthor=J.+A.+Covelauthor=A.+Renauthor=R.+R.+Webbauthor=N.+R.+Beeleyauthor=M.+Martinauthor=M.+Morganauthor=S.+Espitiaauthor=H.+R.+Saldanaauthor=C.+Bjenningauthor=K.+T.+Whelanauthor=A.+J.+Grottickauthor=F.+Menzaghiauthor=W.+J.+Thomsen&title=Discovery+and+Structure-Activity+Relationship+of+%281R%29-8-Chloro-2%2C3%2C4%2C5-Tetrahydro-1-Methyl-1h-3-Benzazepine+%28Lorcaserin%29%2C+a+Selective+Serotonin+5-HT2c+Receptor+Agonist+for+the+Treatment+of+Obesity&doi=10.1021%2Fjm0709034"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm0709034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0709034%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DB.%2BM.%26aulast%3DSmith%26aufirst%3DJ.%2BM.%26aulast%3DTsai%26aufirst%3DJ.%2BH.%26aulast%3DSchultz%26aufirst%3DJ.%2BA.%26aulast%3DGilson%26aufirst%3DC.%2BA.%26aulast%3DEstrada%26aufirst%3DS.%2BA.%26aulast%3DChen%26aufirst%3DR.%2BR.%26aulast%3DPark%26aufirst%3DD.%2BM.%26aulast%3DPrieto%26aufirst%3DE.%2BB.%26aulast%3DGallardo%26aufirst%3DC.%2BS.%26aulast%3DSengupta%26aufirst%3DD.%26aulast%3DDosa%26aufirst%3DP.%2BI.%26aulast%3DCovel%26aufirst%3DJ.%2BA.%26aulast%3DRen%26aufirst%3DA.%26aulast%3DWebb%26aufirst%3DR.%2BR.%26aulast%3DBeeley%26aufirst%3DN.%2BR.%26aulast%3DMartin%26aufirst%3DM.%26aulast%3DMorgan%26aufirst%3DM.%26aulast%3DEspitia%26aufirst%3DS.%26aulast%3DSaldana%26aufirst%3DH.%2BR.%26aulast%3DBjenning%26aufirst%3DC.%26aulast%3DWhelan%26aufirst%3DK.%2BT.%26aulast%3DGrottick%26aufirst%3DA.%2BJ.%26aulast%3DMenzaghi%26aufirst%3DF.%26aulast%3DThomsen%26aufirst%3DW.%2BJ.%26atitle%3DDiscovery%2520and%2520Structure-Activity%2520Relationship%2520of%2520%25281R%2529-8-Chloro-2%252C3%252C4%252C5-Tetrahydro-1-Methyl-1h-3-Benzazepine%2520%2528Lorcaserin%2529%252C%2520a%2520Selective%2520Serotonin%25205-HT2c%2520Receptor%2520Agonist%2520for%2520the%2520Treatment%2520of%2520Obesity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26issue%3D2%26spage%3D305%26epage%3D313%26doi%3D10.1021%2Fjm0709034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brashier, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahiya, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khadka, A.</span></span> <span> </span><span class="NLM_article-title">Lorcaserin: A Novel Antiobesity Drug</span>. <i>J. Pharmacol. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">175</span>â <span class="NLM_lpage">178</span>, <span class="refDoi">Â DOI: 10.4103/0976-500X.130158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.4103%2F0976-500X.130158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=24799830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A280%3ADC%252BC2cnpvVKqtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=175-178&issue=2&author=D.+B.+Brashierauthor=A.+K.+Sharmaauthor=N.+Dahiyaauthor=S.+K.+Singhauthor=A.+Khadka&title=Lorcaserin%3A+A+Novel+Antiobesity+Drug&doi=10.4103%2F0976-500X.130158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Lorcaserin: A novel antiobesity drug</span></div><div class="casAuthors">Brashier Dick B S; Sharma A K; Dahiya Navdeep; Singh S K; Khadka Anjan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of pharmacology & pharmacotherapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">175-8</span>
        ISSN:<span class="NLM_cas:issn">0976-500X</span>.
    </div><div class="casAbstract">Obesity is a major co-morbidity with hypertension and diabetes mellitus.  There are few drugs for treatment of obesity like orlistat and recentlty approved drug lorcaserin.  Lorcaserin has serotonergic properties and acts as an anorectic.  It may cause serious side effects, including serotonin syndrome, particularly when taken with certain medicines that increase serotonin levels or activate serotonin receptors.  Although, mainstay and first line of approach of treatment will always remain in having low calorie diet and increase in physical activity.  Lorcaserin has come as a new hope to achieve success in treating obese patients but still a long road with further extensive research to be undertaken in the treatment of obesity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSGtAc-AGMp0Kx48Rj5GnGofW6udTcc2eZ9d4um5XIikbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cnpvVKqtw%253D%253D&md5=7ec58017a635b51869935df70adb0f97</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.4103%2F0976-500X.130158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F0976-500X.130158%26sid%3Dliteratum%253Aachs%26aulast%3DBrashier%26aufirst%3DD.%2BB.%26aulast%3DSharma%26aufirst%3DA.%2BK.%26aulast%3DDahiya%26aufirst%3DN.%26aulast%3DSingh%26aufirst%3DS.%2BK.%26aulast%3DKhadka%26aufirst%3DA.%26atitle%3DLorcaserin%253A%2520A%2520Novel%2520Antiobesity%2520Drug%26jtitle%3DJ.%2520Pharmacol.%2520Pharmacother.%26date%3D2014%26volume%3D5%26issue%3D2%26spage%3D175%26epage%3D178%26doi%3D10.4103%2F0976-500X.130158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rogawski, M. A.</span></span> <span> </span><span class="NLM_article-title">Brivaracetam: A Rational Drug Discovery Success Story</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>154</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1555</span>â <span class="NLM_lpage">1557</span>, <span class="refDoi">Â DOI: 10.1038/bjp.2008.221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1038%2Fbjp.2008.221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=18552880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BD1cXps1Gru7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2008&pages=1555-1557&issue=8&author=M.+A.+Rogawski&title=Brivaracetam%3A+A+Rational+Drug+Discovery+Success+Story&doi=10.1038%2Fbjp.2008.221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Brivaracetam: a rational drug discovery success story</span></div><div class="casAuthors">Rogawski, M. A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1555-1557</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Levetiracetam, the Î±-Et analog of the nootropic piracetam, is a widely used antiepileptic drug (AED) that provides protection against partial seizures and is also effective in the treatment of primary generalized seizure syndromes including juvenile myoclonic epilepsy.  Levetiracetam was discovered in 1992 through screening in audiogenic seizure susceptible mice and, 3 years later, was reported to exhibit saturable, stereospecific binding in brain to a â¼90 kDa protein, later identified as the ubiquitous synaptic vesicle glycoprotein SV2A.  A large-scale screening effort to optimize binding affinity identified the 4-Pr analog, brivaracetam, as having greater potency and a broadened spectrum of activity in animal seizure models.  Recent phase II clin. trials demonstrating that brivaracetam is efficacious and well tolerated in the treatment of partial onset seizures have validated the strategy of the discovery program.  Brivaracetam is among the first clin. effective AEDs to be discovered by optimization of pharmacodynamic activity at a mol. target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqH0YRbNA1z7Vg90H21EOLACvtfcHk0ljNtu981aC8ew"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXps1Gru7Y%253D&md5=2747db868571f4e48024d6688126f0ce</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fbjp.2008.221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjp.2008.221%26sid%3Dliteratum%253Aachs%26aulast%3DRogawski%26aufirst%3DM.%2BA.%26atitle%3DBrivaracetam%253A%2520A%2520Rational%2520Drug%2520Discovery%2520Success%2520Story%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2008%26volume%3D154%26issue%3D8%26spage%3D1555%26epage%3D1557%26doi%3D10.1038%2Fbjp.2008.221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klitgaard, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matagne, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolas, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamberty, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Ryck, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaminski, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leclercq, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niespodziany, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolff, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannestad, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kervyn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenda, B.</span></span> <span> </span><span class="NLM_article-title">Brivaracetam: Rationale for Discovery and Preclinical Profile of a Selective SV2A Ligand for Epilepsy Treatment</span>. <i>Epilepsia</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">538</span>â <span class="NLM_lpage">548</span>, <span class="refDoi">Â DOI: 10.1111/epi.13340</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1111%2Fepi.13340" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2016&pages=538-548&issue=4&author=H.+Klitgaardauthor=A.+Matagneauthor=J.+M.+Nicolasauthor=M.+Gillardauthor=Y.+Lambertyauthor=M.+De+Ryckauthor=R.+M.+Kaminskiauthor=K.+Leclercqauthor=I.+Niespodzianyauthor=C.+Wolffauthor=M.+Woodauthor=J.+Hannestadauthor=S.+Kervynauthor=B.+Kenda&title=Brivaracetam%3A+Rationale+for+Discovery+and+Preclinical+Profile+of+a+Selective+SV2A+Ligand+for+Epilepsy+Treatment&doi=10.1111%2Fepi.13340"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1111%2Fepi.13340&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fepi.13340%26sid%3Dliteratum%253Aachs%26aulast%3DKlitgaard%26aufirst%3DH.%26aulast%3DMatagne%26aufirst%3DA.%26aulast%3DNicolas%26aufirst%3DJ.%2BM.%26aulast%3DGillard%26aufirst%3DM.%26aulast%3DLamberty%26aufirst%3DY.%26aulast%3DDe%2BRyck%26aufirst%3DM.%26aulast%3DKaminski%26aufirst%3DR.%2BM.%26aulast%3DLeclercq%26aufirst%3DK.%26aulast%3DNiespodziany%26aufirst%3DI.%26aulast%3DWolff%26aufirst%3DC.%26aulast%3DWood%26aufirst%3DM.%26aulast%3DHannestad%26aufirst%3DJ.%26aulast%3DKervyn%26aufirst%3DS.%26aulast%3DKenda%26aufirst%3DB.%26atitle%3DBrivaracetam%253A%2520Rationale%2520for%2520Discovery%2520and%2520Preclinical%2520Profile%2520of%2520a%2520Selective%2520SV2A%2520Ligand%2520for%2520Epilepsy%2520Treatment%26jtitle%3DEpilepsia%26date%3D2016%26volume%3D57%26issue%3D4%26spage%3D538%26epage%3D548%26doi%3D10.1111%2Fepi.13340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Russo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Citraro, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mula, M.</span></span> <span> </span><span class="NLM_article-title">The Preclinical Discovery and Development of Brivaracetam for the Treatment of Focal Epilepsy</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1169</span>â <span class="NLM_lpage">1178</span>, <span class="refDoi">Â DOI: 10.1080/17460441.2017.1366985</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1080%2F17460441.2017.1366985" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=1169-1178&issue=11&author=E.+Russoauthor=R.+Citraroauthor=M.+Mula&title=The+Preclinical+Discovery+and+Development+of+Brivaracetam+for+the+Treatment+of+Focal+Epilepsy&doi=10.1080%2F17460441.2017.1366985"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1080%2F17460441.2017.1366985&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17460441.2017.1366985%26sid%3Dliteratum%253Aachs%26aulast%3DRusso%26aufirst%3DE.%26aulast%3DCitraro%26aufirst%3DR.%26aulast%3DMula%26aufirst%3DM.%26atitle%3DThe%2520Preclinical%2520Discovery%2520and%2520Development%2520of%2520Brivaracetam%2520for%2520the%2520Treatment%2520of%2520Focal%2520Epilepsy%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2017%26volume%3D12%26issue%3D11%26spage%3D1169%26epage%3D1178%26doi%3D10.1080%2F17460441.2017.1366985" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salem, M. E.</span></span> <span> </span><span class="NLM_article-title">Trifluridine/Tipiracil and Regorafenib: New Weapons in the War against Metastatic Colorectal Cancer</span>. <i>Clin Adv. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">630</span>â <span class="NLM_lpage">638</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=27487107" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A280%3ADC%252BC2s3nsFGjsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&pages=630-638&issue=8&author=B.+A.+Weinbergauthor=J.+L.+Marshallauthor=M.+E.+Salem&title=Trifluridine%2FTipiracil+and+Regorafenib%3A+New+Weapons+in+the+War+against+Metastatic+Colorectal+Cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Trifluridine/tipiracil and regorafenib: new weapons in the war against metastatic colorectal cancer</span></div><div class="casAuthors">Weinberg Benjamin A; Marshall John L; Salem Mohamed E</div><div class="citationInfo"><span class="NLM_cas:title">Clinical advances in hematology & oncology : H&O</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">630-8</span>
        ISSN:<span class="NLM_cas:issn">1543-0790</span>.
    </div><div class="casAbstract">Colorectal cancer (CRC) is the second leading cause of cancer-related death in the United States.  Approximately 20% of patients have metastatic disease at diagnosis, and a vast number of these patients die within 5 years.  The advent of modern chemotherapeutics has improved median overall survival for these patients; nonetheless, we must keep striving for better outcomes.  Trifluridine/tipiracil (TAS-102) and regorafenib are agents newly approved by the US Food and Drug Administration that show promise in the treatment of metastatic colorectal cancer.  These drugs have the benefit of being formulated for oral administration and have different side effect profiles.  These differences are important in the selection of the best therapy for each patient, especially if the patient is prone to a side effect that is unique to just one of the treatments.  In this review, we discuss the mechanism of action, side effect profile, and clinical efficacy of trifluridine/tipiracil, and compare them with those of regorafenib.  Future trials will evaluate the use of these drugs in earlier lines of therapy, alone and in combination with other agents.  We now have 2 more agents in the arsenal against metastatic colorectal cancer and the future is looking brighter for patients, although we still have a long way to go.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSZ0YmuRJN9jIqdXsLcGTEUfW6udTcc2ebjoMPEC7Y0Orntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s3nsFGjsA%253D%253D&md5=42869ab762519154b8def8023a512f79</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWeinberg%26aufirst%3DB.%2BA.%26aulast%3DMarshall%26aufirst%3DJ.%2BL.%26aulast%3DSalem%26aufirst%3DM.%2BE.%26atitle%3DTrifluridine%252FTipiracil%2520and%2520Regorafenib%253A%2520New%2520Weapons%2520in%2520the%2520War%2520against%2520Metastatic%2520Colorectal%2520Cancer%26jtitle%3DClin%2520Adv.%2520Hematol.%2520Oncol.%26date%3D2016%26volume%3D14%26issue%3D8%26spage%3D630%26epage%3D638" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fukushima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazuno, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asao, T.</span></span> <span> </span><span class="NLM_article-title">Structure and Activity of Specific Inhibitors of Thymidine Phosphorylase to Potentiate the Function of Antitumor 2â²-Deoxyribonucleosides</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1227</span>â <span class="NLM_lpage">1236</span>, <span class="refDoi">Â DOI: 10.1016/S0006-2952(00)00253-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1016%2FS0006-2952%2800%2900253-7" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2000&pages=1227-1236&issue=10&author=M.+Fukushimaauthor=N.+Suzukiauthor=T.+Emuraauthor=S.+Yanoauthor=H.+Kazunoauthor=Y.+Tadaauthor=Y.+Yamadaauthor=T.+Asao&title=Structure+and+Activity+of+Specific+Inhibitors+of+Thymidine+Phosphorylase+to+Potentiate+the+Function+of+Antitumor+2%E2%80%B2-Deoxyribonucleosides&doi=10.1016%2FS0006-2952%2800%2900253-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2FS0006-2952%2800%2900253-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-2952%252800%252900253-7%26sid%3Dliteratum%253Aachs%26aulast%3DFukushima%26aufirst%3DM.%26aulast%3DSuzuki%26aufirst%3DN.%26aulast%3DEmura%26aufirst%3DT.%26aulast%3DYano%26aufirst%3DS.%26aulast%3DKazuno%26aufirst%3DH.%26aulast%3DTada%26aufirst%3DY.%26aulast%3DYamada%26aufirst%3DY.%26aulast%3DAsao%26aufirst%3DT.%26atitle%3DStructure%2520and%2520Activity%2520of%2520Specific%2520Inhibitors%2520of%2520Thymidine%2520Phosphorylase%2520to%2520Potentiate%2520the%2520Function%2520of%2520Antitumor%25202%25E2%2580%25B2-Deoxyribonucleosides%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2000%26volume%3D59%26issue%3D10%26spage%3D1227%26epage%3D1236%26doi%3D10.1016%2FS0006-2952%2800%2900253-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peters, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Bruin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukushima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Triest, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoekman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinedo, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ackland, S. P.</span></span> <span> </span><span class="NLM_article-title">Thymidine Phosphorylase in Angiogenesis and Drug Resistance. Homology with Platelet-Derived Endothelial Cell Growth Factor</span>. <i>Adv. Exp. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>486</i></span>,  <span class="NLM_fpage">291</span>â <span class="NLM_lpage">294</span>, <span class="refDoi">Â DOI: 10.1007/0-306-46843-3_57</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1007%2F0-306-46843-3_57" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=486&publication_year=2000&pages=291-294&author=G.+J.+Petersauthor=M.+De+Bruinauthor=M.+Fukushimaauthor=B.+Van+Triestauthor=K.+Hoekmanauthor=H.+M.+Pinedoauthor=S.+P.+Ackland&title=Thymidine+Phosphorylase+in+Angiogenesis+and+Drug+Resistance.+Homology+with+Platelet-Derived+Endothelial+Cell+Growth+Factor&doi=10.1007%2F0-306-46843-3_57"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1007%2F0-306-46843-3_57&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F0-306-46843-3_57%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DG.%2BJ.%26aulast%3DDe%2BBruin%26aufirst%3DM.%26aulast%3DFukushima%26aufirst%3DM.%26aulast%3DVan%2BTriest%26aufirst%3DB.%26aulast%3DHoekman%26aufirst%3DK.%26aulast%3DPinedo%26aufirst%3DH.%2BM.%26aulast%3DAckland%26aufirst%3DS.%2BP.%26atitle%3DThymidine%2520Phosphorylase%2520in%2520Angiogenesis%2520and%2520Drug%2520Resistance.%2520Homology%2520with%2520Platelet-Derived%2520Endothelial%2520Cell%2520Growth%2520Factor%26jtitle%3DAdv.%2520Exp.%2520Med.%2520Biol.%26date%3D2000%26volume%3D486%26spage%3D291%26epage%3D294%26doi%3D10.1007%2F0-306-46843-3_57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akiyama, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakajo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitazono, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natsugoe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyadera, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukushima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aikou, T.</span></span> <span> </span><span class="NLM_article-title">Suppression of Metastasis by Thymidine Phosphorylase Inhibitor</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">5345</span>â <span class="NLM_lpage">5348</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2000&pages=5345-5348&issue=19&author=S.+Takaoauthor=S.+I.+Akiyamaauthor=A.+Nakajoauthor=H.+Yohauthor=M.+Kitazonoauthor=S.+Natsugoeauthor=K.+Miyaderaauthor=M.+Fukushimaauthor=Y.+Yamadaauthor=T.+Aikou&title=Suppression+of+Metastasis+by+Thymidine+Phosphorylase+Inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTakao%26aufirst%3DS.%26aulast%3DAkiyama%26aufirst%3DS.%2BI.%26aulast%3DNakajo%26aufirst%3DA.%26aulast%3DYoh%26aufirst%3DH.%26aulast%3DKitazono%26aufirst%3DM.%26aulast%3DNatsugoe%26aufirst%3DS.%26aulast%3DMiyadera%26aufirst%3DK.%26aulast%3DFukushima%26aufirst%3DM.%26aulast%3DYamada%26aufirst%3DY.%26aulast%3DAikou%26aufirst%3DT.%26atitle%3DSuppression%2520of%2520Metastasis%2520by%2520Thymidine%2520Phosphorylase%2520Inhibitor%26jtitle%3DCancer%2520Res.%26date%3D2000%26volume%3D60%26issue%3D19%26spage%3D5345%26epage%3D5348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cleary, J.
M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasco, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, W.</span></span> <span> </span><span class="NLM_article-title">A Phase 1 Study of the Pharmacokinetics of Nucleoside Analog Trifluridine and Thymidine Phosphorylase Inhibitor Tipiracil (Components of TAS-102) Vs Trifluridine Alone</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">189</span>â <span class="NLM_lpage">197</span>, <span class="refDoi">Â DOI: 10.1007/s10637-016-0409-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1007%2Fs10637-016-0409-9" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=189-197&issue=2&author=J.%0AM.+Clearyauthor=L.+S.+Rosenauthor=K.+Yoshidaauthor=D.+Rascoauthor=G.+I.+Shapiroauthor=W.+Sun&title=A+Phase+1+Study+of+the+Pharmacokinetics+of+Nucleoside+Analog+Trifluridine+and+Thymidine+Phosphorylase+Inhibitor+Tipiracil+%28Components+of+TAS-102%29+Vs+Trifluridine+Alone&doi=10.1007%2Fs10637-016-0409-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1007%2Fs10637-016-0409-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-016-0409-9%26sid%3Dliteratum%253Aachs%26aulast%3DCleary%26aufirst%3DJ.%2BM.%26aulast%3DRosen%26aufirst%3DL.%2BS.%26aulast%3DYoshida%26aufirst%3DK.%26aulast%3DRasco%26aufirst%3DD.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DSun%26aufirst%3DW.%26atitle%3DA%2520Phase%25201%2520Study%2520of%2520the%2520Pharmacokinetics%2520of%2520Nucleoside%2520Analog%2520Trifluridine%2520and%2520Thymidine%2520Phosphorylase%2520Inhibitor%2520Tipiracil%2520%2528Components%2520of%2520TAS-102%2529%2520Vs%2520Trifluridine%2520Alone%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2017%26volume%3D35%26issue%3D2%26spage%3D189%26epage%3D197%26doi%3D10.1007%2Fs10637-016-0409-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rios-Tamayo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Garcia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alarcon-Payer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Rodriguez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Guardia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia Collado, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez Morales, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurado Chacon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabeza Barrera, J.</span></span> <span> </span><span class="NLM_article-title">Pomalidomide in the Treatment of Multiple Myeloma: Design, Development and Place in Therapy</span>. <i>Drug Des. Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2399</span>â <span class="NLM_lpage">2408</span>, <span class="refDoi">Â DOI: 10.2147/DDDT.S115456</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.2147%2FDDDT.S115456" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=28860711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A280%3ADC%252BC1cbjs1SgtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&pages=2399-2408&author=R.+Rios-Tamayoauthor=A.+Martin-Garciaauthor=C.+Alarcon-Payerauthor=D.+Sanchez-Rodriguezauthor=A.+de+la+Guardiaauthor=C.+G.+Garcia+Colladoauthor=A.+Jimenez+Moralesauthor=M.+Jurado+Chaconauthor=J.+Cabeza+Barrera&title=Pomalidomide+in+the+Treatment+of+Multiple+Myeloma%3A+Design%2C+Development+and+Place+in+Therapy&doi=10.2147%2FDDDT.S115456"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy</span></div><div class="casAuthors">Rios-Tamayo Rafael; Sanchez-Rodriguez Dolores; Jurado Chacon Manuel; Rios-Tamayo Rafael; Jurado Chacon Manuel; Rios-Tamayo Rafael; Jurado Chacon Manuel; Rios-Tamayo Rafael; Jurado Chacon Manuel; Cabeza Barrera Jose; Martin-Garcia Agustin; Alarcon-Payer Carolina; de la Guardia Ana Maria Del Valle Diaz; Garcia Collado Carlos Gustavo; Jimenez Morales Alberto; Cabeza Barrera Jose; Martin-Garcia Agustin; Sanchez-Rodriguez Dolores</div><div class="citationInfo"><span class="NLM_cas:title">Drug design, development and therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2399-2408</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Multiple myeloma is a very heterogeneous disease with variable survival.  Despite recent progress and the widespread use of new agents, patients with relapsed and refractory disease have a poor outcome.  Immunomodulatory drugs play a key role in both the front-line and the relapsed/refractory setting.  The combination of pomalidomide (POM) and dexamethasone is safe and effective in relapsed and refractory patients, even in those with high-risk cytogenetic features.  Furthermore, it can be used in most patients without the need to adjust according to the degree of renal failure.  In order to further improve the results, POM-based triplet therapies are currently used.  This article highlights the most relevant issues of POM and POM-based combinations in the relapsed/refractory multiple myeloma setting, from a pharmacological and clinical point of view.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRAuKrO7n1L57GbPKh4T9eAfW6udTcc2eYuSNVMp8avqLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cbjs1SgtA%253D%253D&md5=75799abcbba614768174b4ab140c0d0c</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S115456&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S115456%26sid%3Dliteratum%253Aachs%26aulast%3DRios-Tamayo%26aufirst%3DR.%26aulast%3DMartin-Garcia%26aufirst%3DA.%26aulast%3DAlarcon-Payer%26aufirst%3DC.%26aulast%3DSanchez-Rodriguez%26aufirst%3DD.%26aulast%3Dde%2Bla%2BGuardia%26aufirst%3DA.%26aulast%3DGarcia%2BCollado%26aufirst%3DC.%2BG.%26aulast%3DJimenez%2BMorales%26aufirst%3DA.%26aulast%3DJurado%2BChacon%26aufirst%3DM.%26aulast%3DCabeza%2BBarrera%26aufirst%3DJ.%26atitle%3DPomalidomide%2520in%2520the%2520Treatment%2520of%2520Multiple%2520Myeloma%253A%2520Design%252C%2520Development%2520and%2520Place%2520in%2520Therapy%26jtitle%3DDrug%2520Des.%2520Dev.%2520Ther.%26date%3D2017%26volume%3D11%26spage%3D2399%26epage%3D2408%26doi%3D10.2147%2FDDDT.S115456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muller, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corral, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shire, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreira, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stirling, D. I.</span></span> <span> </span><span class="NLM_article-title">Structural Modifications of Thalidomide Produce Analogs with Enhanced Tumor Necrosis Factor Inhibitory Activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">3238</span>â <span class="NLM_lpage">3240</span>, <span class="refDoi">Â DOI: 10.1021/jm9603328</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9603328" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=3238-3240&issue=17&author=G.+W.+Mullerauthor=L.+G.+Corralauthor=M.+G.+Shireauthor=H.+Wangauthor=A.+Moreiraauthor=G.+Kaplanauthor=D.+I.+Stirling&title=Structural+Modifications+of+Thalidomide+Produce+Analogs+with+Enhanced+Tumor+Necrosis+Factor+Inhibitory+Activity&doi=10.1021%2Fjm9603328"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm9603328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9603328%26sid%3Dliteratum%253Aachs%26aulast%3DMuller%26aufirst%3DG.%2BW.%26aulast%3DCorral%26aufirst%3DL.%2BG.%26aulast%3DShire%26aufirst%3DM.%2BG.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DMoreira%26aufirst%3DA.%26aulast%3DKaplan%26aufirst%3DG.%26aulast%3DStirling%26aufirst%3DD.%2BI.%26atitle%3DStructural%2520Modifications%2520of%2520Thalidomide%2520Produce%2520Analogs%2520with%2520Enhanced%2520Tumor%2520Necrosis%2520Factor%2520Inhibitory%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26issue%3D17%26spage%3D3238%26epage%3D3240%26doi%3D10.1021%2Fjm9603328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DâAmato, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lentzsch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, M. S.</span></span> <span> </span><span class="NLM_article-title">Mechanism of Action of Thalidomide and 3-Aminothalidomide in Multiple Myeloma</span>. <i>Semin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">597</span>â <span class="NLM_lpage">601</span>, <span class="refDoi">Â DOI: 10.1053/sonc.2001.28601</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1053%2Fsonc.2001.28601" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=11740816" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BD38XjvVSmtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2001&pages=597-601&issue=6&author=R.+J.+D%E2%80%99Amatoauthor=S.+Lentzschauthor=K.+C.+Andersonauthor=M.+S.+Rogers&title=Mechanism+of+Action+of+Thalidomide+and+3-Aminothalidomide+in+Multiple+Myeloma&doi=10.1053%2Fsonc.2001.28601"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma</span></div><div class="casAuthors">D'Amato, Robert J.; Lentzsch, Suzanne; Anderson, Kenneth C.; Rogers, Michael S.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Oncology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">597-601</span>CODEN:
                <span class="NLM_cas:coden">SOLGAV</span>;
        ISSN:<span class="NLM_cas:issn">0093-7754</span>.
    
            (<span class="NLM_cas:orgname">W. B. Saunders Co.</span>)
        </div><div class="casAbstract">A review.  We have explored the mechanism of the antiangiogenic effects of thalidomide by structure-activity studies.  These investigations revealed that angiogenesis inhibition correlates with teratogenicity but not with tumor necrosis factor-alpha inhibition.  Addnl., one analog of thalidomide, 3-aminothalidomide, exhibited an unusual capacity to directly inhibit myeloma cell proliferation.  This activity did not correlate with TNF-Î± inhibition.  Thus 3-aminothalidomide was found to inhibit multiple myeloma through effects on both the tumor and vascular compartment.  The effects of an inhibitor of both the tumor and vascular compartments of a tumor on tumor growth may be synergistic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaR37NH2QpBLVg90H21EOLACvtfcHk0lhYnHSLA3GCjg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjvVSmtg%253D%253D&md5=30a6f07cb0152d98d0452f9b40c727cd</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1053%2Fsonc.2001.28601&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fsonc.2001.28601%26sid%3Dliteratum%253Aachs%26aulast%3DD%25E2%2580%2599Amato%26aufirst%3DR.%2BJ.%26aulast%3DLentzsch%26aufirst%3DS.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26aulast%3DRogers%26aufirst%3DM.%2BS.%26atitle%3DMechanism%2520of%2520Action%2520of%2520Thalidomide%2520and%25203-Aminothalidomide%2520in%2520Multiple%2520Myeloma%26jtitle%3DSemin.%2520Oncol.%26date%3D2001%26volume%3D28%26issue%3D6%26spage%3D597%26epage%3D601%26doi%3D10.1053%2Fsonc.2001.28601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, J. C.</span></span> <span> </span><span class="NLM_article-title">The Histamine H3 Receptor: From Discovery to Clinical Trials with Pitolisant</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>163</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">713</span>â <span class="NLM_lpage">721</span>, <span class="refDoi">Â DOI: 10.1111/j.1476-5381.2011.01286.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1111%2Fj.1476-5381.2011.01286.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=21615387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnsFOitr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2011&pages=713-721&issue=4&author=J.+C.+Schwartz&title=The+Histamine+H3+Receptor%3A+From+Discovery+to+Clinical+Trials+with+Pitolisant&doi=10.1111%2Fj.1476-5381.2011.01286.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">The histamine H3 receptor: from discovery to clinical trials with pitolisant</span></div><div class="casAuthors">Schwartz, Jean-Charles</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">713-721</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The third histamine receptor was discovered in 1983 by a traditional pharmacol. approach, consisting of assessing the inhibitory effect of histamine on its own release from depolarized rat brain slices.  The same in vitro test was used to design, in 1987, the first highly selective and potent H3-autoreceptor ligands, the antagonist thioperamide and the agonist alphamethylhistamine which enhances and inhibits, resp., the activity of histaminergic neurons in brain.  The use of these research tools was instrumental in establishing the main functions of cerebral histaminergic neurons, namely their role in maintenance of wakefulness, attention, learning and other cognitive processes.  In 1990, the cloning of the gene of the H3-receptor, a member of the superfamily of heptahelical receptors coupled to G proteins, paved the way to the demonstration of the high constitutive activity of the receptor, including its native form, and its participation in the tonic control of histamine release; it also facilitated the development of H3-receptor inverse agonist programs in many drug companies.  Pitolisant (BF2.649, 1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine, hydrochloride) is the first inverse agonist to be introduced in the clinics.  Its wake-promotion activity was evidenced in excessive diurnal sleepiness of patients with narcolepsy, Parkinson's disease or Obstructive Sleep Apnea/Hypopnea, in which this activity is characterized by a mean decrease of the Epworth Sleepiness Scale by about five units.  The procognitive activity of this novel class of drugs may also find therapeutic applications in dementias, schizophrenia or attention deficit hyperactivity disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHrkoL8T1XbbVg90H21EOLACvtfcHk0lhYnHSLA3GCjg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnsFOitr0%253D&md5=f8b1db02051f583d7ca6c179c29f0db2</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01286.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01286.x%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DJ.%2BC.%26atitle%3DThe%2520Histamine%2520H3%2520Receptor%253A%2520From%2520Discovery%2520to%2520Clinical%2520Trials%2520with%2520Pitolisant%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D163%26issue%3D4%26spage%3D713%26epage%3D721%26doi%3D10.1111%2Fj.1476-5381.2011.01286.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ropper, A. H.</span></span> <span> </span><span class="NLM_article-title">The âPoison Chairâ Treatment for Multiple Sclerosis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>367</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1149</span>â <span class="NLM_lpage">1150</span>, <span class="refDoi">Â DOI: 10.1056/NEJMe1209169</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1056%2FNEJMe1209169" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=22992079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVKkurrI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=1149-1150&issue=12&author=A.+H.+Ropper&title=The+%E2%80%9CPoison+Chair%E2%80%9D+Treatment+for+Multiple+Sclerosis&doi=10.1056%2FNEJMe1209169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">The "poison chair" treatment for multiple sclerosis</span></div><div class="casAuthors">Ropper, Allan H.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1149-1150</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocShrlNUh-8rVg90H21EOLACvtfcHk0lhy1TSxA_eTBQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVKkurrI&md5=4a5d46428fcb516083d5d0d780445a71</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1056%2FNEJMe1209169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMe1209169%26sid%3Dliteratum%253Aachs%26aulast%3DRopper%26aufirst%3DA.%2BH.%26atitle%3DThe%2520%25E2%2580%259CPoison%2520Chair%25E2%2580%259D%2520Treatment%2520for%2520Multiple%2520Sclerosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26issue%3D12%26spage%3D1149%26epage%3D1150%26doi%3D10.1056%2FNEJMe1209169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Held, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epp, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biaglow, J. E.</span></span> <span> </span><span class="NLM_article-title">Effect of Dimethyl Fumarate on the Radiation Sensitivity of Mammalian Cells in Vitro</span>. <i>Radiat. Res.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>115</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">495</span>â <span class="NLM_lpage">502</span>, <span class="refDoi">Â DOI: 10.2307/3577299</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.2307%2F3577299" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=3174933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADyaL1cXlsVGgtL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=1988&pages=495-502&issue=3&author=K.+D.+Heldauthor=E.+R.+Eppauthor=E.+P.+Clarkauthor=J.+E.+Biaglow&title=Effect+of+Dimethyl+Fumarate+on+the+Radiation+Sensitivity+of+Mammalian+Cells+in+Vitro&doi=10.2307%2F3577299"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of dimethylfumarate on the radiation sensitivity of mammalian cells in vitro</span></div><div class="casAuthors">Held, Kathryn D.; Epp, Edward R.; Clark, Edward P.; Biaglow, John E.</div><div class="citationInfo"><span class="NLM_cas:title">Radiation Research</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">495-202</span>CODEN:
                <span class="NLM_cas:coden">RAREAE</span>;
        ISSN:<span class="NLM_cas:issn">0033-7587</span>.
    </div><div class="casAbstract">Dimethylfumarate (DMF) depletes intracellular glutathione (GSH) by covalent bond formation in a reaction which may be mediated by GSH S-transferase.  In Chinese hamster ovary cells, this depletion is rapid; e.g., 0.5 mM DMF depletes GSH to <10% of control in 5 min at room temp.  DMF is a very effective hypoxic cell radiosensitizer, with an enhancement ratio (ER) of â¼3 obtained by a 5-min exposure of x-irradiated cells at room temp. to 5 mM DMF, without significant toxicity.  At this same concn. of drug, there is a small enhancement of aerobic cells (ER = 1.3), but the 5 mM DMF in hypoxia results in nearly a complete collapse of the hypoxic dose-response curve to the same level as seen in air with DMF.  It has been suggested previously that DMF sensitizes cells via electron affinic mechanisms.  However, this appears not to be the case in this study, as shown by the fact that cells pretreated with DMF and then washed free of the drug remained equally radiosensitive as cells irradiated in the presence of the drug.  This large enhancement of radiation sensitivity appears to be related to the drug's ability to deplete thiols; i.e., thiols appear to be a major factor responsible for radioresistance of hypoxic cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqz2kbR8UCOkrVg90H21EOLACvtfcHk0lhy1TSxA_eTBQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXlsVGgtL8%253D&md5=c3f6880556f978082aaebd491bc5f9f9</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.2307%2F3577299&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2307%252F3577299%26sid%3Dliteratum%253Aachs%26aulast%3DHeld%26aufirst%3DK.%2BD.%26aulast%3DEpp%26aufirst%3DE.%2BR.%26aulast%3DClark%26aufirst%3DE.%2BP.%26aulast%3DBiaglow%26aufirst%3DJ.%2BE.%26atitle%3DEffect%2520of%2520Dimethyl%2520Fumarate%2520on%2520the%2520Radiation%2520Sensitivity%2520of%2520Mammalian%2520Cells%2520in%2520Vitro%26jtitle%3DRadiat.%2520Res.%26date%3D1988%26volume%3D115%26issue%3D3%26spage%3D495%26epage%3D502%26doi%3D10.2307%2F3577299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schimrigk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brune, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellwig, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lukas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellenberg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rieks, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pohlau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Przuntek, H.</span></span> <span> </span><span class="NLM_article-title">Oral Fumaric Acid Esters for the Treatment of Active Multiple Sclerosis: An Open-Label, Baseline-Controlled Pilot Study</span>. <i>Eur. J. Neurol</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">604</span>â <span class="NLM_lpage">610</span>, <span class="refDoi">Â DOI: 10.1111/j.1468-1331.2006.01292.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1111%2Fj.1468-1331.2006.01292.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=16796584" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A280%3ADC%252BD28zotFagsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2006&pages=604-610&issue=6&author=S.+Schimrigkauthor=N.+Bruneauthor=K.+Hellwigauthor=C.+Lukasauthor=B.+Bellenbergauthor=M.+Rieksauthor=V.+Hoffmannauthor=D.+Pohlauauthor=H.+Przuntek&title=Oral+Fumaric+Acid+Esters+for+the+Treatment+of+Active+Multiple+Sclerosis%3A+An+Open-Label%2C+Baseline-Controlled+Pilot+Study&doi=10.1111%2Fj.1468-1331.2006.01292.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study</span></div><div class="casAuthors">Schimrigk S; Brune N; Hellwig K; Lukas C; Bellenberg B; Rieks M; Hoffmann V; Pohlau D; Przuntek H</div><div class="citationInfo"><span class="NLM_cas:title">European journal of neurology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">604-10</span>
        ISSN:<span class="NLM_cas:issn">1351-5101</span>.
    </div><div class="casAbstract">An exploratory, prospective, open-label study of fumaric acid esters (FAE, Fumaderm(R)) was conducted in patients with relapsing-remitting multiple sclerosis (RRMS).  The study consisted of the following four phases: 6-week baseline, 18-week treatment (target dose of 720 mg/day), 4-week washout, and a second 48-week treatment phase (target dose of 360 mg/day).  Ten patients with an Expanded Disability Status Scale (EDSS) score of 2.0-6.0 and at least one gadolinium-enhancing (Gd+) lesion on T1-weighted magnetic resonance imaging (MRI) brain scans participated in the study.  Safety was assessed by adverse events (AEs), blood chemistry/hematology, electrocardiogram, and urinalysis.  The primary efficacy outcomes were number and volume of Gd+ lesions.  Other clinical outcomes included EDSS score, ambulation index (AI), and nine-hole peg test (9-HPT).  Effects of FAE on intracellular cytokine profiles, T-cell apoptosis, and soluble adhesion molecules were also assessed.  Three patients withdrew during the first 3 weeks of the study because of side effects, non-compliance, and follow-up loss.  The most common AEs were gastrointestinal symptoms and flushing; all AEs were reported as mild and reversible.  FAE produced significant reductions from baseline in number (P < 0.05) and volume (P < 0.01) of Gd+ lesions after 18 weeks of treatment; this effect persisted during the second treatment phase at half the target dose after the 4-week washout period.  EDSS scores, AI, and 9-HPT remained stable or slightly improved from baseline in all patients.  Measures of T-cell function demonstrated alterations in cytokines and circulating tumor necrosis factor.  The results of this exploratory study suggest that further studies of FAE in patients with MS are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcThsEMDj3lPaEPI-fCgwosgfW6udTcc2eZLkdjwSpIchrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28zotFagsw%253D%253D&md5=c6bcbc1fb04d0b3bedebfbe53b6e1fff</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1111%2Fj.1468-1331.2006.01292.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1468-1331.2006.01292.x%26sid%3Dliteratum%253Aachs%26aulast%3DSchimrigk%26aufirst%3DS.%26aulast%3DBrune%26aufirst%3DN.%26aulast%3DHellwig%26aufirst%3DK.%26aulast%3DLukas%26aufirst%3DC.%26aulast%3DBellenberg%26aufirst%3DB.%26aulast%3DRieks%26aufirst%3DM.%26aulast%3DHoffmann%26aufirst%3DV.%26aulast%3DPohlau%26aufirst%3DD.%26aulast%3DPrzuntek%26aufirst%3DH.%26atitle%3DOral%2520Fumaric%2520Acid%2520Esters%2520for%2520the%2520Treatment%2520of%2520Active%2520Multiple%2520Sclerosis%253A%2520An%2520Open-Label%252C%2520Baseline-Controlled%2520Pilot%2520Study%26jtitle%3DEur.%2520J.%2520Neurol%26date%3D2006%26volume%3D13%26issue%3D6%26spage%3D604%26epage%3D610%26doi%3D10.1111%2Fj.1468-1331.2006.01292.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gold, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kappos, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bar-Or, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giovannoni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selmaj, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tornatore, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweetser, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheikh, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, K. T.</span></span> <span> </span><span class="NLM_article-title">Investigators, D. S. Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>367</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1098</span>â <span class="NLM_lpage">1107</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa1114287</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1056%2FNEJMoa1114287" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=22992073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVKkur3F" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=1098-1107&issue=12&author=R.+Goldauthor=L.+Kapposauthor=D.+L.+Arnoldauthor=A.+Bar-Orauthor=G.+Giovannoniauthor=K.+Selmajauthor=C.+Tornatoreauthor=M.+T.+Sweetserauthor=M.+Yangauthor=S.+I.+Sheikhauthor=K.+T.+Dawson&title=Investigators%2C+D.+S.+Placebo-Controlled+Phase+3+Study+of+Oral+BG-12+for+Relapsing+Multiple+Sclerosis&doi=10.1056%2FNEJMoa1114287"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis</span></div><div class="casAuthors">Gold, Ralf; Kappos, Ludwig; Arnold, Douglas L.; Bar-Or, Amit; Giovannoni, Gavin; Selmaj, Krzysztof; Tornatore, Carlo; Sweetser, Marianne T.; Yang, Minhua; Sheikh, Sarah I.; Dawson, Katherine T.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1098-1107</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: BG-12 (di-Me fumarate) was shown to have antiinflammatory and cytoprotective properties in preclin. expts. and to result in significant redns. in disease activity on magnetic resonance imaging (MRI) in a phase 2, placebo-controlled study involving patients with relapsing-remitting multiple sclerosis.  Methods: We conducted a randomized, double-blind, placebo-controlled phase 3 study involving patients with relapsing-remitting multiple sclerosis.  Patients were randomly assigned to receive oral BG-12 at a dose of 240 mg twice daily, BG-12 at a dose of 240 mg three times daily, or placebo.  The primary end point was the proportion of patients who had a relapse by 2 years.  Other end points included the annualized relapse rate, the time to confirmed progression of disability, and findings on MRI.  Results: The estd. proportion of patients who had a relapse was significantly lower in the two BG-12 groups than in the placebo group (27% with BG-12 twice daily and 26% with BG-12 thrice daily vs. 46% with placebo, P<0.001 for both comparisons).  The annualized relapse rate at 2 years was 0.17 in the twice-daily BG-12 group and 0.19 in the thrice-daily BG-12 group, as compared with 0.36 in the placebo group, representing relative redns. of 53% and 48% with the two BG-12 regimens, resp. (P<0.001 for the comparison of each BG-12 regimen with placebo).  The estd. proportion of patients with confirmed progression of disability was 16% in the twice-daily BG-12 group, 18% in the thrice-daily BG-12 group, and 27% in the placebo group, with significant relative risk redns. of 38% with BG-12 twice daily (P = 0.005) and 34% with BG-12 thrice daily (P = 0.01).  BG-12 also significantly reduced the no. of gadolinium-enhancing lesions and of new or enlarging T2-weighted hyperintense lesions (P<0.001 for the comparison of each BG-12 regimen with placebo).  Adverse events assocd. with BG-12 included flushing and gastrointestinal events, such as diarrhea, nausea, and upper abdominal pain, as well as decreased lymphocyte counts and elevated liver aminotransferase levels.  Conclusions: In patients with relapsing-remitting multiple sclerosis, both BG-12 regimens, as compared with placebo, significantly reduced the proportion of patients who had a relapse, the annualized relapse rate, the rate of disability progression, and the no. of lesions on MRI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNPrC6E7qh_rVg90H21EOLACvtfcHk0lgwETowADTmPA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVKkur3F&md5=5d10ff87768411553696da03ae888372</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1114287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1114287%26sid%3Dliteratum%253Aachs%26aulast%3DGold%26aufirst%3DR.%26aulast%3DKappos%26aufirst%3DL.%26aulast%3DArnold%26aufirst%3DD.%2BL.%26aulast%3DBar-Or%26aufirst%3DA.%26aulast%3DGiovannoni%26aufirst%3DG.%26aulast%3DSelmaj%26aufirst%3DK.%26aulast%3DTornatore%26aufirst%3DC.%26aulast%3DSweetser%26aufirst%3DM.%2BT.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DSheikh%26aufirst%3DS.%2BI.%26aulast%3DDawson%26aufirst%3DK.%2BT.%26atitle%3DInvestigators%252C%2520D.%2520S.%2520Placebo-Controlled%2520Phase%25203%2520Study%2520of%2520Oral%2520BG-12%2520for%2520Relapsing%2520Multiple%2520Sclerosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26issue%3D12%26spage%3D1098%26epage%3D1107%26doi%3D10.1056%2FNEJMoa1114287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGuire, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz-Zorrilla Diez, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emmerich, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strickson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritorto, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutavani, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houslay, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knebel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meakin, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phair, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashford, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trost, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arthur, J. S.</span></span> <span> </span><span class="NLM_article-title">Dimethyl Fumarate Blocks Pro-Inflammatory Cytokine Production Via Inhibition of TLR Induced M1 and K63 Ubiquitin Chain Formation</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">31159</span>, <span class="refDoi">Â DOI: 10.1038/srep31159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1038%2Fsrep31159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=27498693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlCisLbF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=31159&author=V.+A.+McGuireauthor=T.+Ruiz-Zorrilla+Diezauthor=C.+H.+Emmerichauthor=S.+Stricksonauthor=M.+S.+Ritortoauthor=R.+V.+Sutavaniauthor=A.+Weissauthor=K.+F.+Houslayauthor=A.+Knebelauthor=P.+J.+Meakinauthor=I.+R.+Phairauthor=M.+L.+Ashfordauthor=M.+Trostauthor=J.+S.+Arthur&title=Dimethyl+Fumarate+Blocks+Pro-Inflammatory+Cytokine+Production+Via+Inhibition+of+TLR+Induced+M1+and+K63+Ubiquitin+Chain+Formation&doi=10.1038%2Fsrep31159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Dimethyl fumarate blocks pro-inflammatory cytokine production via inhibition of TLR induced M1 and K63 ubiquitin chain formation</span></div><div class="casAuthors">McGuire, Victoria A.; Ruiz-Zorrilla Diez, Tamara; Emmerich, Christoph H.; Strickson, Sam; Ritorto, Maria Stella; Sutavani, Ruhcha V.; WeiÎ², Anne; Houslay, Kirsty F.; Knebel, Axel; Meakin, Paul J.; Phair, Iain R.; Ashford, Michael L. J.; Trost, Matthias; Arthur, J. Simon C.</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">31159</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Di-Me fumarate (DMF) possesses anti-inflammatory properties and is approved for the treatment of psoriasis and multiple sclerosis.  While clin. effective, its mol. target has remained elusive - although it is known to activate anti-oxidant pathways.  We find that DMF inhibits pro-inflammatory cytokine prodn. in response to TLR agonists independently of the Nrf2-Keap1 anti-oxidant pathway.  Instead we show that DMF can inhibit the E2 conjugating enzymes involved in K63 and M1 polyubiquitin chain formation both in vitro and in cells.  The formation of K63 and M1 chains is required to link TLR activation to downstream signaling, and consistent with the block in K63 and/or M1 chain formation, DMF inhibits NFÎºB and ERK1/2 activation, resulting in a loss of pro-inflammatory cytokine prodn.  Together these results reveal a new mol. target for DMF and show that a clin. approved drug inhibits M1 and K63 chain formation in TLR induced signaling complexes.  Selective targeting of E2s may therefore be a viable strategy for autoimmunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiuOzdY8UlbLVg90H21EOLACvtfcHk0lgwETowADTmPA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlCisLbF&md5=f185ac6db58eef6c7c61d1728f73a8d1</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fsrep31159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep31159%26sid%3Dliteratum%253Aachs%26aulast%3DMcGuire%26aufirst%3DV.%2BA.%26aulast%3DRuiz-Zorrilla%2BDiez%26aufirst%3DT.%26aulast%3DEmmerich%26aufirst%3DC.%2BH.%26aulast%3DStrickson%26aufirst%3DS.%26aulast%3DRitorto%26aufirst%3DM.%2BS.%26aulast%3DSutavani%26aufirst%3DR.%2BV.%26aulast%3DWeiss%26aufirst%3DA.%26aulast%3DHouslay%26aufirst%3DK.%2BF.%26aulast%3DKnebel%26aufirst%3DA.%26aulast%3DMeakin%26aufirst%3DP.%2BJ.%26aulast%3DPhair%26aufirst%3DI.%2BR.%26aulast%3DAshford%26aufirst%3DM.%2BL.%26aulast%3DTrost%26aufirst%3DM.%26aulast%3DArthur%26aufirst%3DJ.%2BS.%26atitle%3DDimethyl%2520Fumarate%2520Blocks%2520Pro-Inflammatory%2520Cytokine%2520Production%2520Via%2520Inhibition%2520of%2520TLR%2520Induced%2520M1%2520and%2520K63%2520Ubiquitin%2520Chain%2520Formation%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D31159%26doi%3D10.1038%2Fsrep31159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Susitaival, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winhoven, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lammintausta, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruvberger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimerson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruze, M.</span></span> <span> </span><span class="NLM_article-title">An Outbreak of Furniture Related Dermatitis (âSofa Dermatitisâ) in Finland and the UK: History and Clinical Cases</span>. <i>J. Eur. Acad. Dermatol. Venereol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">486</span>â <span class="NLM_lpage">489</span>, <span class="refDoi">Â DOI: 10.1111/j.1468-3083.2009.03429.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1111%2Fj.1468-3083.2009.03429.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=19796087" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A280%3ADC%252BC3czjtFyitA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2010&pages=486-489&issue=4&author=P.+Susitaivalauthor=S.+M.+Winhovenauthor=J.+Williamsauthor=K.+Lammintaustaauthor=T.+Hasanauthor=M.+H.+Beckauthor=B.+Gruvbergerauthor=E.+Zimersonauthor=M.+Bruze&title=An+Outbreak+of+Furniture+Related+Dermatitis+%28%E2%80%9CSofa+Dermatitis%E2%80%9D%29+in+Finland+and+the+UK%3A+History+and+Clinical+Cases&doi=10.1111%2Fj.1468-3083.2009.03429.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">An outbreak of furniture related dermatitis ('sofa dermatitis') in Finland and the UK: history and clinical cases</span></div><div class="casAuthors">Susitaival P; Winhoven S M; Williams J; Lammintausta K; Hasan T; Beck M H; Gruvberger B; Zimerson E; Bruze M</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the European Academy of Dermatology and Venereology : JEADV</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">486-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">In February 2007, an epidemic of severe dermatitis from Chinese recliner chairs and sofas started to unfold first in Finland and a few months later in the UK.  Some patients reacted in patch tests (PTs) strongly to the material of their furniture, either leather or fabric.  There have been hundreds of reports of chair or sofa dermatitis from Finland and the UK, with all cases linked to the same furniture factory in China.  Clinical findings in both countries were very similar and unlike any known dermatosis.  Many cases have been quite severe, resembling mycosis fungoides or septic infections, requiring hospitalization.  Commercial PTs did not reveal the cause but a fungicide was strongly suspected, although such use was denied by the factory.  The laboratory of Malmo University Dermatology Clinic has helped in the process by making thin layer chromatograms from sofa or chair materials and test substances of suspected chemicals.  Finally, sachets marked with 'mouldproof agent' were found in varying numbers and distribution in the sofas.  These contained dimethyl fumarate (DMF) which proved in skin tests to cause strong positive reactions with down to 0.01 dilution.  Reports from other countries (Belgium, France, Ireland, Sweden and Spain) have since appeared, and the EU has banned the use of DMF in consumer products.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTbOlNeOmwzHsAKB7Fa-xrUfW6udTcc2eadkJWaS-DrZbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3czjtFyitA%253D%253D&md5=859586397fcc3b73f7665dcca9e72dc6</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1111%2Fj.1468-3083.2009.03429.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1468-3083.2009.03429.x%26sid%3Dliteratum%253Aachs%26aulast%3DSusitaival%26aufirst%3DP.%26aulast%3DWinhoven%26aufirst%3DS.%2BM.%26aulast%3DWilliams%26aufirst%3DJ.%26aulast%3DLammintausta%26aufirst%3DK.%26aulast%3DHasan%26aufirst%3DT.%26aulast%3DBeck%26aufirst%3DM.%2BH.%26aulast%3DGruvberger%26aufirst%3DB.%26aulast%3DZimerson%26aufirst%3DE.%26aulast%3DBruze%26aufirst%3DM.%26atitle%3DAn%2520Outbreak%2520of%2520Furniture%2520Related%2520Dermatitis%2520%2528%25E2%2580%259CSofa%2520Dermatitis%25E2%2580%259D%2529%2520in%2520Finland%2520and%2520the%2520UK%253A%2520History%2520and%2520Clinical%2520Cases%26jtitle%3DJ.%2520Eur.%2520Acad.%2520Dermatol.%2520Venereol.%26date%3D2010%26volume%3D24%26issue%3D4%26spage%3D486%26epage%3D489%26doi%3D10.1111%2Fj.1468-3083.2009.03429.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miyake, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebata, M.</span></span> <span> </span><span class="NLM_article-title">Galactostatin, a New Beta-Galactosidase Inhibitor from Streptomyces Lydicus</span>. <i>J. Antibiot.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">122</span>â <span class="NLM_lpage">123</span>, <span class="refDoi">Â DOI: 10.7164/antibiotics.40.122</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.7164%2Fantibiotics.40.122" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1987&pages=122-123&issue=1&author=Y.+Miyakeauthor=M.+Ebata&title=Galactostatin%2C+a+New+Beta-Galactosidase+Inhibitor+from+Streptomyces+Lydicus&doi=10.7164%2Fantibiotics.40.122"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.7164%2Fantibiotics.40.122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7164%252Fantibiotics.40.122%26sid%3Dliteratum%253Aachs%26aulast%3DMiyake%26aufirst%3DY.%26aulast%3DEbata%26aufirst%3DM.%26atitle%3DGalactostatin%252C%2520a%2520New%2520Beta-Galactosidase%2520Inhibitor%2520from%2520Streptomyces%2520Lydicus%26jtitle%3DJ.%2520Antibiot.%26date%3D1987%26volume%3D40%26issue%3D1%26spage%3D122%26epage%3D123%26doi%3D10.7164%2Fantibiotics.40.122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Fernandez, E.
M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia Fernandez, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellet, C. O.</span></span> <span> </span><span class="NLM_article-title">Glycomimetic-Based Pharmacological Chaperones for Lysosomal Storage Disorders: Lessons from Gaucher, GM1-Gangliosidosis and Fabry Diseases</span>. <i>Chem. Commun. (Cambridge, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">32</span>),  <span class="NLM_fpage">5497</span>â <span class="NLM_lpage">5515</span>, <span class="refDoi">Â DOI: 10.1039/C6CC01564F</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1039%2FC6CC01564F" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=27043200" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC28XksFOht7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2016&pages=5497-5515&issue=32&author=E.%0AM.+Sanchez-Fernandezauthor=J.+M.+Garcia+Fernandezauthor=C.+O.+Mellet&title=Glycomimetic-Based+Pharmacological+Chaperones+for+Lysosomal+Storage+Disorders%3A+Lessons+from+Gaucher%2C+GM1-Gangliosidosis+and+Fabry+Diseases&doi=10.1039%2FC6CC01564F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Glycomimetic-based pharmacological chaperones for lysosomal storage disorders: lessons from Gaucher, GM1-gangliosidosis and Fabry diseases</span></div><div class="casAuthors">Sanchez-Fernandez, Elena M.; Garcia Fernandez, Jose M.; Mellet, Carmen Ortiz</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">5497-5515</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Lysosomal storage disorders (LSDs) are often caused by mutations that destabilize native folding and impair the trafficking of enzymes, leading to premature endoplasmic reticulum (ER)-assocd. degrdn., deficiencies of specific hydrolytic functions and aberrant storage of metabolites in the lysosomes.  Enzyme replacement therapy (ERT) and substrate redn. therapy (SRT) are available for a few of these conditions, but most remain orphan.  A main difficulty is that virtually all LSDs involve neurol. decline and neither proteins nor the current SRT drugs can cross the blood-brain barrier.  Twenty years ago a new therapeutic paradigm better suited for neuropathic LSDs was launched, namely pharmacol. chaperone (PC) therapy.  PCs are small mols. capable of binding to the mutant protein at the ER, inducing proper folding, restoring trafficking and increasing enzyme activity and substrate processing in the lysosome.  In many LSDs the mutated protein is a glycosidase and the accumulated substrate is an oligo- or polysaccharide or a glycoconjugate, e.g. a glycosphingolipid.  Although it might appear counterintuitive, substrate analogs (glycomimetics) behaving as competitive glycosidase inhibitors are good candidates to perform PC tasks.  The advancements in the knowledge of the mol. basis of LSDs, including enzyme structures, binding modes, trafficking pathways and substrate processing mechanisms, have been put forward to optimize PC selectivity and efficacy.  Moreover, the chem. versatility of glycomimetics and the variety of structures at hand allow simultaneous optimization of chaperone and pharmacokinetic properties.  In this Feature Article we review the advancements made in this field in the last few years and the future outlook through the lessons taught by three archetypical LSDs: Gaucher disease, GM1-gangliosidosis and Fabry disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBG6A7ONRboLVg90H21EOLACvtfcHk0ljse4uxpacVgw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XksFOht7w%253D&md5=c6f74ee25c03a3bc782813c39d30f851</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1039%2FC6CC01564F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6CC01564F%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez-Fernandez%26aufirst%3DE.%2BM.%26aulast%3DGarcia%2BFernandez%26aufirst%3DJ.%2BM.%26aulast%3DMellet%26aufirst%3DC.%2BO.%26atitle%3DGlycomimetic-Based%2520Pharmacological%2520Chaperones%2520for%2520Lysosomal%2520Storage%2520Disorders%253A%2520Lessons%2520from%2520Gaucher%252C%2520GM1-Gangliosidosis%2520and%2520Fabry%2520Diseases%26jtitle%3DChem.%2520Commun.%2520%2528Cambridge%252C%2520U.%2520K.%2529%26date%3D2016%26volume%3D52%26issue%3D32%26spage%3D5497%26epage%3D5515%26doi%3D10.1039%2FC6CC01564F" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khanna, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soska, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frascella, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brignol, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellegrino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sitaraman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desnick, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benjamin, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valenzano, K. J.</span></span> <span> </span><span class="NLM_article-title">The Pharmacological Chaperone 1-Deoxygalactonojirimycin Reduces Tissue Globotriaosylceramide Levels in a Mouse Model of Fabry Disease</span>. <i>Mol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">23</span>â <span class="NLM_lpage">33</span>, <span class="refDoi">Â DOI: 10.1038/mt.2009.220</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1038%2Fmt.2009.220" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=19773742" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFGrtrzN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=23-33&issue=1&author=R.+Khannaauthor=R.+Soskaauthor=Y.+Lunauthor=J.+Fengauthor=M.+Frascellaauthor=B.+Youngauthor=N.+Brignolauthor=L.+Pellegrinoauthor=S.+A.+Sitaramanauthor=R.+J.+Desnickauthor=E.+R.+Benjaminauthor=D.+J.+Lockhartauthor=K.+J.+Valenzano&title=The+Pharmacological+Chaperone+1-Deoxygalactonojirimycin+Reduces+Tissue+Globotriaosylceramide+Levels+in+a+Mouse+Model+of+Fabry+Disease&doi=10.1038%2Fmt.2009.220"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">The Pharmacological Chaperone 1-Deoxygalactonojirimycin Reduces Tissue Globotriaosylceramide Levels in a Mouse Model of Fabry Disease</span></div><div class="casAuthors">Khanna, Richie; Soska, Rebecca; Lun, Yi; Feng, Jessie; Frascella, Michelle; Young, Brandy; Brignol, Nastry; Pellegrino, Lee; Sitaraman, Sheela A.; Desnick, Robert J.; Benjamin, Elfrida R.; Lockhart, David J.; Valenzano, Kenneth J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Therapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">23-33</span>CODEN:
                <span class="NLM_cas:coden">MTOHCK</span>;
        ISSN:<span class="NLM_cas:issn">1525-0016</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Fabry disease is an X-linked lysosomal storage disorder caused by a deficiency in Î±-galactosidase A (Î±-Gal A) activity and subsequent accumulation of the substrate globotriaosylceramide (GL-3), which contributes to disease pathol.  The pharmacol. chaperone (PC) DGJ (1-deoxygalactonojirimycin) binds and stabilizes Î±-Gal A, increasing enzyme levels in cultured cells and in vivo.  The ability of DGJ to reduce GL-3 in vivo was investigated using transgenic (Tg) mice that express a mutant form of human Î±-Gal A (R301Q) on a knockout background (Tg/KO), which leads to GL-3 accumulation in disease-relevant tissues.  Four-week daily oral administration of DGJ to Tg/KO mice resulted in significant and dose-dependent increases in Î±-Gal A activity, with concomitant GL-3 redn. in skin, heart, kidney, brain, and plasma; 24-wk administration resulted in even greater redns.  Compared to daily administration, less frequent DGJ administration, including repeated cycles of 4 days with DGJ followed by 3 days without or every other day with DGJ, resulted in even greater GL-3 redns. that were comparable to those obtained with Fabrazyme.  Collectively, these data indicate that oral administration of DGJ increases mutant Î±-Gal A activity and reduces GL-3 in disease-relevant tissues in Tg/KO mice, and thus merits further evaluation as a treatment for Fabry disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobjW0bAkndtLVg90H21EOLACvtfcHk0ljse4uxpacVgw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFGrtrzN&md5=5b0cddd0c2f9e9246d73a935ab6c87d1</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fmt.2009.220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmt.2009.220%26sid%3Dliteratum%253Aachs%26aulast%3DKhanna%26aufirst%3DR.%26aulast%3DSoska%26aufirst%3DR.%26aulast%3DLun%26aufirst%3DY.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DFrascella%26aufirst%3DM.%26aulast%3DYoung%26aufirst%3DB.%26aulast%3DBrignol%26aufirst%3DN.%26aulast%3DPellegrino%26aufirst%3DL.%26aulast%3DSitaraman%26aufirst%3DS.%2BA.%26aulast%3DDesnick%26aufirst%3DR.%2BJ.%26aulast%3DBenjamin%26aufirst%3DE.%2BR.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DValenzano%26aufirst%3DK.%2BJ.%26atitle%3DThe%2520Pharmacological%2520Chaperone%25201-Deoxygalactonojirimycin%2520Reduces%2520Tissue%2520Globotriaosylceramide%2520Levels%2520in%2520a%2520Mouse%2520Model%2520of%2520Fabry%2520Disease%26jtitle%3DMol.%2520Ther.%26date%3D2010%26volume%3D18%26issue%3D1%26spage%3D23%26epage%3D33%26doi%3D10.1038%2Fmt.2009.220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benjamin, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schilling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pine, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wustman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desnick, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valenzano, K. J.</span></span> <span> </span><span class="NLM_article-title">The Pharmacological Chaperone 1-Deoxygalactonojirimycin Increases Alpha-Galactosidase a Levels in Fabry Patient Cell Lines</span>. <i>J. Inherited Metab. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">424</span>â <span class="NLM_lpage">440</span>, <span class="refDoi">Â DOI: 10.1007/s10545-009-1077-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1007%2Fs10545-009-1077-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmsFWrsbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2009&pages=424-440&issue=3&author=E.+R.+Benjaminauthor=J.+J.+Flanaganauthor=A.+Schillingauthor=H.+H.+Changauthor=L.+Agarwalauthor=E.+Katzauthor=X.+Wuauthor=C.+Pineauthor=B.+Wustmanauthor=R.+J.+Desnickauthor=D.+J.+Lockhartauthor=K.+J.+Valenzano&title=The+Pharmacological+Chaperone+1-Deoxygalactonojirimycin+Increases+Alpha-Galactosidase+a+Levels+in+Fabry+Patient+Cell+Lines&doi=10.1007%2Fs10545-009-1077-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">The pharmacological chaperone 1-deoxygalactonojirimycin increases Î±-galactosidase A levels in Fabry patient cell lines</span></div><div class="casAuthors">Benjamin, E. R.; Flanagan, J. J.; Schilling, A.; Chang, H. H.; Agarwal, L.; Katz, E.; Wu, X.; Pine, C.; Wustman, B.; Desnick, R. J.; Lockhart, D. J.; Valenzano, K. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Inherited Metabolic Disease</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">424-440</span>CODEN:
                <span class="NLM_cas:coden">JIMDDP</span>;
        ISSN:<span class="NLM_cas:issn">0141-8955</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Fabry disease is an X-linked lysosomal storage disorder caused by mutations in the gene encoding Î±-galactosidase A (Î±-Gal A), with consequent accumulation of its major glycosphingolipid substrate, globotriaosylceramide (GL-3).  Over 500 Fabry mutations have been reported; approx. 60% are missense.  The iminosugar 1-deoxygalactonojirimycin (DGJ, migalastat hydrochloride, AT1001) is a pharmacol. chaperone that selectively binds Î±-Gal A, increasing phys. stability, lysosomal trafficking, and cellular activity.  To identify DGJ-responsive mutant forms of Î±-Gal A, the effect of DGJ incubation on Î±-Gal A levels was assessed in cultured lymphoblasts from males with Fabry disease representing 75 different missense mutations, one insertion, and one splice-site mutation.  Baseline Î±-Gal A levels ranged from 0 to 52% of normal.  Increases in Î±-Gal A levels (1.5- to 28-fold) after continuous DGJ incubation for 5 days were seen for 49 different missense mutant forms with varying EC50 values (820 nmol/L to >1 mmol/L).  Amino acid substitutions in responsive forms were located throughout both structural domains of the enzyme.  Half of the missense mutant forms assocd. with classic (early-onset) Fabry disease and a majority (90%) assocd. with later-onset Fabry disease were responsive.  In cultured fibroblasts from males with Fabry disease, the responses to DGJ were comparable to those of lymphoblasts with the same mutation.  Importantly, elevated GL-3 levels in responsive Fabry fibroblasts were reduced after DGJ incubation, indicating that increased mutant Î±-Gal A levels can reduce accumulated substrate.  These data indicate that DGJ merits further evaluation as a treatment for patients with Fabry disease with various missense mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomhafQJSmJAbVg90H21EOLACvtfcHk0lgR9DTcSZbtrQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmsFWrsbo%253D&md5=b331b31de72efc3cfa4be43da28a2718</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1007%2Fs10545-009-1077-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10545-009-1077-0%26sid%3Dliteratum%253Aachs%26aulast%3DBenjamin%26aufirst%3DE.%2BR.%26aulast%3DFlanagan%26aufirst%3DJ.%2BJ.%26aulast%3DSchilling%26aufirst%3DA.%26aulast%3DChang%26aufirst%3DH.%2BH.%26aulast%3DAgarwal%26aufirst%3DL.%26aulast%3DKatz%26aufirst%3DE.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DPine%26aufirst%3DC.%26aulast%3DWustman%26aufirst%3DB.%26aulast%3DDesnick%26aufirst%3DR.%2BJ.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DValenzano%26aufirst%3DK.%2BJ.%26atitle%3DThe%2520Pharmacological%2520Chaperone%25201-Deoxygalactonojirimycin%2520Increases%2520Alpha-Galactosidase%2520a%2520Levels%2520in%2520Fabry%2520Patient%2520Cell%2520Lines%26jtitle%3DJ.%2520Inherited%2520Metab.%2520Dis.%26date%3D2009%26volume%3D32%26issue%3D3%26spage%3D424%26epage%3D440%26doi%3D10.1007%2Fs10545-009-1077-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abian, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfonso, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velazquez-Campoy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giraldo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pocovi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sancho, J.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Strategies for Gaucher Disease: Miglustat (NB-DNJ) as a Pharmacological Chaperone for Glucocerebrosidase and the Different Thermostability of Velaglucerase Alfa and Imiglucerase</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">2390</span>â <span class="NLM_lpage">2397</span>, <span class="refDoi">Â DOI: 10.1021/mp200313e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp200313e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVSit7vF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2011&pages=2390-2397&issue=6&author=O.+Abianauthor=P.+Alfonsoauthor=A.+Velazquez-Campoyauthor=P.+Giraldoauthor=M.+Pocoviauthor=J.+Sancho&title=Therapeutic+Strategies+for+Gaucher+Disease%3A+Miglustat+%28NB-DNJ%29+as+a+Pharmacological+Chaperone+for+Glucocerebrosidase+and+the+Different+Thermostability+of+Velaglucerase+Alfa+and+Imiglucerase&doi=10.1021%2Fmp200313e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Strategies for Gaucher Disease: Miglustat (NB-DNJ) as a Pharmacological Chaperone for Glucocerebrosidase and the Different Thermostability of Velaglucerase alfa and Imiglucerase</span></div><div class="casAuthors">Abian, Olga; Alfonso, Pilar; Velazquez- Campoy, Adrian; Giraldo, Pilar; Pocovi, Miguel; Sancho, Javier</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2390-2397</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Gaucher disease (GD) is a disorder of glycosphingolipid metab. caused by deficiency of lysosomal glucocerebrosidase (GlcCerase) activity, due to conformationally or functionally defective variants, resulting in progressive deposition of glycosylceramide in macrophages.  The glucose analog, N-butyldeoxynojirimycin (NB-DNJ, miglustat), is an inhibitor of the ceramide-specific glycosyltransferase, which catalyzes the first step of glycosphingolipid biosynthesis and is currently approved for the oral treatment of type 1 GD.  In a previous work, we found a GlcCerase activity increase in cell cultures in the presence of NB-DNJ, which could imply that this compd. is not only a substrate reducer but also a pharmacol. chaperone or inhibitor for GlcCerase degrdn.  In this work we compare imiglucerase (the enzyme currently used for replacement therapy) and velaglucerase alfa (a novel therapeutic enzyme form) in terms of conformational stability and enzymic activity, as well as the effect of NB-DNJ on them.  The interaction between these enzymes and NB-DNJ was studied by isothermal titrn. calorimetry.  Our results reveal that, although velaglucerase alfa and imiglucerase exhibit very similar activity profiles, velaglucerase alfa shows higher in vitro thermal stability and is less prone to aggregation/pptn., which could be advantageous for storage and clin. administration.  In addn., we show that at neutral pH NB-DNJ binds to and enhances the stability of both enzymes, while at mildly acidic lysosomal conditions it does not bind to them.  These results support the potential role of NB-DNJ as a pharmacol. chaperone, susceptible of being part of pharmaceutical formulation or combination therapy for GD in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtwLlY6fTnIbVg90H21EOLACvtfcHk0lgR9DTcSZbtrQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVSit7vF&md5=c16e8fc77ac3c4862c2a18546d8f43fd</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fmp200313e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp200313e%26sid%3Dliteratum%253Aachs%26aulast%3DAbian%26aufirst%3DO.%26aulast%3DAlfonso%26aufirst%3DP.%26aulast%3DVelazquez-Campoy%26aufirst%3DA.%26aulast%3DGiraldo%26aufirst%3DP.%26aulast%3DPocovi%26aufirst%3DM.%26aulast%3DSancho%26aufirst%3DJ.%26atitle%3DTherapeutic%2520Strategies%2520for%2520Gaucher%2520Disease%253A%2520Miglustat%2520%2528NB-DNJ%2529%2520as%2520a%2520Pharmacological%2520Chaperone%2520for%2520Glucocerebrosidase%2520and%2520the%2520Different%2520Thermostability%2520of%2520Velaglucerase%2520Alfa%2520and%2520Imiglucerase%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2011%26volume%3D8%26issue%3D6%26spage%3D2390%26epage%3D2397%26doi%3D10.1021%2Fmp200313e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schiffmann, R.</span></span> <span> </span><span class="NLM_article-title">Agalsidase Treatment for Fabry Disease: Uses and Rivalries</span>. <i>Genet. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">684</span>â <span class="NLM_lpage">685</span>, <span class="refDoi">Â DOI: 10.1097/GIM.0b013e3181f9a056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1097%2FGIM.0b013e3181f9a056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=20975568" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A280%3ADC%252BC3cbmt1WktA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2010&pages=684-685&issue=11&author=R.+Schiffmann&title=Agalsidase+Treatment+for+Fabry+Disease%3A+Uses+and+Rivalries&doi=10.1097%2FGIM.0b013e3181f9a056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Agalsidase treatment for Fabry disease: uses and rivalries</span></div><div class="casAuthors">Schiffmann Raphael</div><div class="citationInfo"><span class="NLM_cas:title">Genetics in medicine : official journal of the American College of Medical Genetics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">684-5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTAjxMNj4ga4T0O18WR3iAofW6udTcc2eZp55O8PEUOH7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cbmt1WktA%253D%253D&md5=b888aa3456f38ccd068b60d2596180d0</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1097%2FGIM.0b013e3181f9a056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FGIM.0b013e3181f9a056%26sid%3Dliteratum%253Aachs%26aulast%3DSchiffmann%26aufirst%3DR.%26atitle%3DAgalsidase%2520Treatment%2520for%2520Fabry%2520Disease%253A%2520Uses%2520and%2520Rivalries%26jtitle%3DGenet.%2520Med.%26date%3D2010%26volume%3D12%26issue%3D11%26spage%3D684%26epage%3D685%26doi%3D10.1097%2FGIM.0b013e3181f9a056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schiffmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reimschisel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castaneda, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lien, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastores, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kampmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ries, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, J. T.</span></span> <span> </span><span class="NLM_article-title">Four-Year Prospective Clinical Trial of Agalsidase Alfa in Children with Fabry Disease</span>. <i>J. Pediatr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>156</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">832</span>â <span class="NLM_lpage">837</span>, <span class="refDoi">Â DOI: 10.1016/j.jpeds.2009.11.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1016%2Fj.jpeds.2009.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=20097359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksFKgu74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2010&pages=832-837&issue=5&author=R.+Schiffmannauthor=R.+A.+Martinauthor=T.+Reimschiselauthor=K.+Johnsonauthor=V.+Castanedaauthor=Y.+H.+Lienauthor=G.+M.+Pastoresauthor=C.+Kampmannauthor=M.+Riesauthor=J.+T.+Clarke&title=Four-Year+Prospective+Clinical+Trial+of+Agalsidase+Alfa+in+Children+with+Fabry+Disease&doi=10.1016%2Fj.jpeds.2009.11.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Four-Year Prospective Clinical Trial of Agalsidase Alfa in Children with Fabry Disease</span></div><div class="casAuthors">Schiffmann, Raphael; Martin, Rick A.; Reimschisel, Tyler; Johnson, Karen; Castaneda, Victoria; Lien, Y. Howard; Pastores, Gregory M.; Kampmann, Christoph; Ries, Markus; Clarke, Joe T. R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pediatrics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">832-837, e832/1</span>CODEN:
                <span class="NLM_cas:coden">JOPDAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3476</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Objectives: To investigate a 4-yr prospective clin. trial of agalsidase alfa in children with Fabry disease, an X-linked metabolic disorder caused by a deficiency of the lysosomal enzyme Î±-galactosidase A. Study design: Seventeen (16 boys, 1 girl; age range, 7.3 to 18.4 years) of the 24 children who completed a 6-mo, open-label agalsidase alfa study enrolled in a 3.5-yr extension study that investigated the safety and potential efficacy of long-term treatment.  All 17 patients completed the initial 6-mo study, and 10 patients (9 boys) completed the extension study.  Results: Agalsidase alfa was well tolerated.  In treated boys, there were sustained, statistically-significant improvements in the clin. features of Fabry disease, including reduced plasma globotriaosylceramide levels, reduced pain severity assessed by the Brief Pain Index, and improved heart rate variability.  Mean urine globotriaosylceramide levels were reduced to normal range (P < .05 compared with baseline during 1.5 to 4 years).  Kidney function and left ventricular mass indexed to height remained stable throughout.  Conclusions: This clin. trial demonstrates that treatment with agalsidase alfa was well tolerated and assocd. with improvement of Fabry disease-related features.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMr7QFGBpwtbVg90H21EOLACvtfcHk0lgayq3pnKSBog"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksFKgu74%253D&md5=ca45db37d632e9d1e6342a9b4c0e7129</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.jpeds.2009.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpeds.2009.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DSchiffmann%26aufirst%3DR.%26aulast%3DMartin%26aufirst%3DR.%2BA.%26aulast%3DReimschisel%26aufirst%3DT.%26aulast%3DJohnson%26aufirst%3DK.%26aulast%3DCastaneda%26aufirst%3DV.%26aulast%3DLien%26aufirst%3DY.%2BH.%26aulast%3DPastores%26aufirst%3DG.%2BM.%26aulast%3DKampmann%26aufirst%3DC.%26aulast%3DRies%26aufirst%3DM.%26aulast%3DClarke%26aufirst%3DJ.%2BT.%26atitle%3DFour-Year%2520Prospective%2520Clinical%2520Trial%2520of%2520Agalsidase%2520Alfa%2520in%2520Children%2520with%2520Fabry%2520Disease%26jtitle%3DJ.%2520Pediatr.%26date%3D2010%26volume%3D156%26issue%3D5%26spage%3D832%26epage%3D837%26doi%3D10.1016%2Fj.jpeds.2009.11.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benjamin, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Della Valle, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pruthi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bond, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronfin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bichet, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Germain, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giugliani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiffmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilcox, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desnick, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlow, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valenzano, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castelli, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, D. J.</span></span> <span> </span><span class="NLM_article-title">The Validation of Pharmacogenetics for the Identification of Fabry Patients to Be Treated with Migalastat</span>. <i>Genet. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">430</span>â <span class="NLM_lpage">438</span>, <span class="refDoi">Â DOI: 10.1038/gim.2016.122</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1038%2Fgim.2016.122" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=27657681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlvVKktbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2017&pages=430-438&issue=4&author=E.+R.+Benjaminauthor=M.+C.+Della+Valleauthor=X.+Wuauthor=E.+Katzauthor=F.+Pruthiauthor=S.+Bondauthor=B.+Bronfinauthor=H.+Williamsauthor=J.+Yuauthor=D.+G.+Bichetauthor=D.+P.+Germainauthor=R.+Giuglianiauthor=D.+Hughesauthor=R.+Schiffmannauthor=W.+R.+Wilcoxauthor=R.+J.+Desnickauthor=J.+Kirkauthor=J.+Barthauthor=C.+Barlowauthor=K.+J.+Valenzanoauthor=J.+Castelliauthor=D.+J.+Lockhart&title=The+Validation+of+Pharmacogenetics+for+the+Identification+of+Fabry+Patients+to+Be+Treated+with+Migalastat&doi=10.1038%2Fgim.2016.122"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat</span></div><div class="casAuthors">Benjamin, Elfrida R.; Della Valle, Maria Cecilia; Wu, Xiaoyang; Katz, Evan; Pruthi, Farhana; Bond, Sarah; Bronfin, Benjamin; Williams, Hadis; Yu, Julie; Bichet, Daniel G.; Germain, Dominique P.; Giugliani, Roberto; Hughes, Derralynn; Schiffmann, Raphael; Wilcox, William R.; Desnick, Robert J.; Kirk, John; Barth, Jay; Barlow, Carrolee; Valenzano, Kenneth J.; Castelli, Jeff; Lockhart, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Genetics in Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">430-438</span>CODEN:
                <span class="NLM_cas:coden">GEMEF3</span>;
        ISSN:<span class="NLM_cas:issn">1098-3600</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Purpose: Fabry disease is an X-linked lysosomal storage disorder caused by mutations in the Î±-galactosidase A gene.  Migalastat, a pharmacol. chaperone, binds to specific mutant forms of Î±-galactosidase A to restore lysosomal activity.  Methods: A pharmacogenetic assay was used to identify the Î±-galactosidase A mutant forms amenable to migalastat.  Six hundred Fabry disease-causing mutations were expressed in HEK-293 (HEK) cells; increases in Î±-galactosidase A activity were measured by a good lab. practice (GLP)-validated assay (GLP HEK/Migalastat Amenability Assay).  The predictive value of the assay was assessed based on pharmacodynamic responses to migalastat in phase II and III clin. studies.  Results: Comparison of the GLP HEK assay results in in vivo white blood cell Î±-galactosidase A responses to migalastat in male patients showed high sensitivity, specificity, and pos. and neg. predictive values (â¥0.875).  GLP HEK assay results were also predictive of decreases in kidney globotriaosylceramide in males and plasma globotriaosylsphingosine in males and females.  The clin. study subset of amenable mutations (n = 51) was representative of all 268 amenable mutations identified by the GLP HEK assay.  Conclusion: The GLP HEK assay is a clin. validated method of identifying male and female Fabry patients for treatment with migalastat.  Genet Med19 4, 430-438.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSjYlljMKBIbVg90H21EOLACvtfcHk0lgayq3pnKSBog"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlvVKktbY%253D&md5=24f09332e08992a1632c681b0d8f9df5</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fgim.2016.122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fgim.2016.122%26sid%3Dliteratum%253Aachs%26aulast%3DBenjamin%26aufirst%3DE.%2BR.%26aulast%3DDella%2BValle%26aufirst%3DM.%2BC.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DKatz%26aufirst%3DE.%26aulast%3DPruthi%26aufirst%3DF.%26aulast%3DBond%26aufirst%3DS.%26aulast%3DBronfin%26aufirst%3DB.%26aulast%3DWilliams%26aufirst%3DH.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DBichet%26aufirst%3DD.%2BG.%26aulast%3DGermain%26aufirst%3DD.%2BP.%26aulast%3DGiugliani%26aufirst%3DR.%26aulast%3DHughes%26aufirst%3DD.%26aulast%3DSchiffmann%26aufirst%3DR.%26aulast%3DWilcox%26aufirst%3DW.%2BR.%26aulast%3DDesnick%26aufirst%3DR.%2BJ.%26aulast%3DKirk%26aufirst%3DJ.%26aulast%3DBarth%26aufirst%3DJ.%26aulast%3DBarlow%26aufirst%3DC.%26aulast%3DValenzano%26aufirst%3DK.%2BJ.%26aulast%3DCastelli%26aufirst%3DJ.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DThe%2520Validation%2520of%2520Pharmacogenetics%2520for%2520the%2520Identification%2520of%2520Fabry%2520Patients%2520to%2520Be%2520Treated%2520with%2520Migalastat%26jtitle%3DGenet.%2520Med.%26date%3D2017%26volume%3D19%26issue%3D4%26spage%3D430%26epage%3D438%26doi%3D10.1038%2Fgim.2016.122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antoniu, S. A.</span></span> <span> </span><span class="NLM_article-title">Pirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">823</span>â <span class="NLM_lpage">828</span>, <span class="refDoi">Â DOI: 10.1517/13543784.15.7.823</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1517%2F13543784.15.7.823" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2006&pages=823-828&issue=7&author=S.+A.+Antoniu&title=Pirfenidone+for+the+Treatment+of+Idiopathic+Pulmonary+Fibrosis&doi=10.1517%2F13543784.15.7.823"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1517%2F13543784.15.7.823&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.15.7.823%26sid%3Dliteratum%253Aachs%26aulast%3DAntoniu%26aufirst%3DS.%2BA.%26atitle%3DPirfenidone%2520for%2520the%2520Treatment%2520of%2520Idiopathic%2520Pulmonary%2520Fibrosis%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2006%26volume%3D15%26issue%3D7%26spage%3D823%26epage%3D828%26doi%3D10.1517%2F13543784.15.7.823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span>Genentech
Mission Critical. <a href="https://www.gene.com/stories/mission-critical" class="extLink">https://www.gene.com/stories/mission-critical</a> (accessed November 17, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Genentech%0AMission+Critical.+https%3A%2F%2Fwww.gene.com%2Fstories%2Fmission-critical+%28accessed+November+17%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albera, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradford, W. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costabel, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glaspole, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glassberg, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kardatzke, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daigl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirchgaessler, K.-U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lancaster, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lederer, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pereira, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swigris, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valeyre, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, P. W.</span></span> <span> </span><span class="NLM_article-title">Effect of Pirfenidone on Mortality: Pooled Analyses and Meta-Analyses of Clinical Trials in Idiopathic Pulmonary Fibrosis</span>. <i>Lancet Respir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">33</span>â <span class="NLM_lpage">41</span>, <span class="refDoi">Â DOI: 10.1016/S2213-2600(16)30326-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1016%2FS2213-2600%2816%2930326-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=27876247" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFCjtLbJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2017&pages=33-41&issue=1&author=S.+D.+Nathanauthor=C.+Alberaauthor=W.+Z.+Bradfordauthor=U.+Costabelauthor=I.+Glaspoleauthor=M.+K.+Glassbergauthor=D.+R.+Kardatzkeauthor=M.+Daiglauthor=K.-U.+Kirchgaesslerauthor=L.+H.+Lancasterauthor=D.+J.+Ledererauthor=C.+A.+Pereiraauthor=J.+J.+Swigrisauthor=D.+Valeyreauthor=P.+W.+Noble&title=Effect+of+Pirfenidone+on+Mortality%3A+Pooled+Analyses+and+Meta-Analyses+of+Clinical+Trials+in+Idiopathic+Pulmonary+Fibrosis&doi=10.1016%2FS2213-2600%2816%2930326-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Nathan, Steven D.; Albera, Carlo; Bradford, Williamson Z.; Costabel, Ulrich; Glaspole, Ian; Glassberg, Marilyn K.; Kardatzke, David R.; Daigl, Monica; Kirchgaessler, Klaus-Uwe; Lancaster, Lisa H.; Lederer, David J.; Pereira, Carlos A.; Swigris, Jeffrey J.; Valeyre, Dominique; Noble, Paul W.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Respiratory Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-41</span>CODEN:
                <span class="NLM_cas:coden">LRMAAU</span>;
        ISSN:<span class="NLM_cas:issn">2213-2600</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">In clin. trials of idiopathic pulmonary fibrosis, rates of all-cause mortality are low.  Thus prospective mortality trials are logistically very challenging, justifying the use of pooled analyses or meta-analyses.  We did pooled analyses and meta-analyses of clin. trials of pirfenidone vs. placebo to det. the effect of pirfenidone on mortality outcomes over 120 wk.  We did a pooled anal. of the combined patient populations of the three global randomised phase 3 trials of pirfenidone vs. placebo-Clin. Studies Assessing Pirfenidone in Idiopathic Pulmonary Fibrosis: Research of Efficacy and Safety Outcomes (CAPACITY 004 and 006; trial durations 72-120 wk) and Assessment of Pirfenidone to Confirm Efficacy and Safety in Idiopathic Pulmonary Fibrosis (ASCEND 016; 52 wk)-for all-cause mortality, treatment-emergent all-cause mortality, idiopathic-pulmonary-fibrosis-related mortality, and treatment-emergent idiopathic-pulmonary-fibrosis-related mortality at weeks 52, 72, and 120.  We also did meta-analyses of these data and data from two Japanese trials of pirfenidone vs. placebo-Shionogi Phase 2 (SP2) and Shionogi Phase 3 (SP3; trial durations 36-52 wk).  At week 52, the relative risk of death for all four mortality outcomes was significantly lower in the pirfenidone group than in the placebo group in the pooled population (all-cause mortality hazard ratio [HR] 0Â·52 [95% CI 0Â·31-0Â·87; p=0Â·0107]; treatment-emergent all-cause mortality 0Â·45 [0Â·24-0Â·83; 0Â·0094]; idiopathic-pulmonary-fibrosis-related mortality 0Â·35 [0Â·17-0Â·72; 0Â·0029]; treatment-emergent idiopathic-pulmonary-fibrosis-related mortality 0Â·32 [0Â·14-0Â·76; 0Â·0061]).  Consistent with the pooled anal., meta-analyses for all-cause mortality at week 52 also showed a clin. relevant and significant risk redn. in the pirfenidone group compared with the placebo group.  Over 120 wk, we noted significant differences in the pooled anal. favoring pirfenidone therapy compared with placebo for treatment-emergent all-cause mortality (p=0Â·0420), idiopathic-pulmonary-fibrosis-related mortality (0Â·0237), and treatment-emergent idiopathic-pulmonary-fibrosis-related (0Â·0132) mortality; similar results were shown by meta-analyses.  Several analytic approaches demonstrated that pirfenidone therapy is assocd. with a redn. in the relative risk of mortality compared with placebo over 120 wk.F Hoffmann-La Roche/Genentech.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoctc8zNsJE9rVg90H21EOLACvtfcHk0ljfY1AYQaxTSQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFCjtLbJ&md5=11d8dc8e0d2afee0ea69b9a05a14766d</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2FS2213-2600%2816%2930326-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2213-2600%252816%252930326-5%26sid%3Dliteratum%253Aachs%26aulast%3DNathan%26aufirst%3DS.%2BD.%26aulast%3DAlbera%26aufirst%3DC.%26aulast%3DBradford%26aufirst%3DW.%2BZ.%26aulast%3DCostabel%26aufirst%3DU.%26aulast%3DGlaspole%26aufirst%3DI.%26aulast%3DGlassberg%26aufirst%3DM.%2BK.%26aulast%3DKardatzke%26aufirst%3DD.%2BR.%26aulast%3DDaigl%26aufirst%3DM.%26aulast%3DKirchgaessler%26aufirst%3DK.-U.%26aulast%3DLancaster%26aufirst%3DL.%2BH.%26aulast%3DLederer%26aufirst%3DD.%2BJ.%26aulast%3DPereira%26aufirst%3DC.%2BA.%26aulast%3DSwigris%26aufirst%3DJ.%2BJ.%26aulast%3DValeyre%26aufirst%3DD.%26aulast%3DNoble%26aufirst%3DP.%2BW.%26atitle%3DEffect%2520of%2520Pirfenidone%2520on%2520Mortality%253A%2520Pooled%2520Analyses%2520and%2520Meta-Analyses%2520of%2520Clinical%2520Trials%2520in%2520Idiopathic%2520Pulmonary%2520Fibrosis%26jtitle%3DLancet%2520Respir.%2520Med.%26date%3D2017%26volume%3D5%26issue%3D1%26spage%3D33%26epage%3D41%26doi%3D10.1016%2FS2213-2600%2816%2930326-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noble, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albera, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradford, W. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costabel, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glassberg, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kardatzke, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lancaster, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahn, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szwarcberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valeyre, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">du Bois, R. M.</span></span> <span> </span><span class="NLM_article-title">Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (Capacity): Two Randomised Trials</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>377</i></span> (<span class="NLM_issue">9779</span>),  <span class="NLM_fpage">1760</span>â <span class="NLM_lpage">1769</span>, <span class="refDoi">Â DOI: 10.1016/S0140-6736(11)60405-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1016%2FS0140-6736%2811%2960405-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=21571362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtl2ktrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2011&pages=1760-1769&issue=9779&author=P.+W.+Nobleauthor=C.+Alberaauthor=W.+Z.+Bradfordauthor=U.+Costabelauthor=M.+K.+Glassbergauthor=D.+Kardatzkeauthor=T.+E.+Kingauthor=L.+Lancasterauthor=S.+A.+Sahnauthor=J.+Szwarcbergauthor=D.+Valeyreauthor=R.+M.+du+Bois&title=Pirfenidone+in+Patients+with+Idiopathic+Pulmonary+Fibrosis+%28Capacity%29%3A+Two+Randomised+Trials&doi=10.1016%2FS0140-6736%2811%2960405-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials</span></div><div class="casAuthors">Noble, Paul W.; Albera, Carlo; Bradford, Williamson Z.; Costabel, Ulrich; Glassberg, Marilyn K.; Kardatzke, David; King, Talmadge E., Jr.; Lancaster, Lisa; Sahn, Steven A.; Szwarcberg, Javier; Valeyre, Dominique; du Bois, Roland M.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">9779</span>),
    <span class="NLM_cas:pages">1760-1769</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Idiopathic pulmonary fibrosis is a progressive and fatal lung disease with inevitable loss of lung function.  The CAPACITY program (studies 004 and 006) was designed to confirm the results of a phase 2 study that suggested that pirfenidone, a novel antifibrotic and anti-inflammatory drug, reduces deterioration in lung function in patients with idiopathic pulmonary fibrosis.  In two concurrent trials (004 and 006), patients (aged 40-80 years) with idiopathic pulmonary fibrosis were randomly assigned to oral pirfenidone or placebo for a min. of 72 wk in 110 centers in Australia, Europe, and North America.  In study 004, patients were assigned in a 2:1:2 ratio to pirfenidone 2403 mg/day, pirfenidone 1197 mg/day, or placebo; in study 006, patients were assigned in a 1:1 ratio to pirfenidone 2403 mg/day or placebo.  The randomization code (permuted block design) was computer generated and stratified by region.  All study personnel were masked to treatment group assignment until after final database lock.  Treatments were administered orally, 801 mg or 399 mg three times a day.  The primary endpoint was change in percentage predicted forced vital capacity (FVC) at week 72.  Anal. was by intention to treat.  The studies are registered with ClinicalTrials.gov, nos. NCT00287729 and NCT00287716.  In study 004, 174 of 435 patients were assigned to pirfenidone 2403 mg/day, 87 to pirfenidone 1197 mg/day, and 174 to placebo.  In study 006, 171 of 344 patients were assigned to pirfenidone 2403 mg/day, and 173 to placebo.  All patients in both studies were analyzed.  In study 004, pirfenidone reduced decline in FVC (p = 0.001).  Mean FVC change at week 72 was -8.0% (SD 16.5) in the pirfenidone 2403 mg/day group and -12.4% (18.5) in the placebo group (difference 4.4%, 95% CI 0.7 to 9.1); 35 (20%) of 174 vs. 60 (35%) of 174 patients, resp., had a decline of at least 10%.  A significant treatment effect was noted at all timepoints from week 24 and in an anal. over all study timepoints (p = 0.0007).  Mean change in percentage FVC in the pirfenidone 1197 mg/day group was intermediate to that in the pirfenidone 2403 mg/day and placebo groups.  In study 006, the difference between groups in FVC change at week 72 was not significant (p = 0.501).  Mean change in FVC at week 72 was -9.0% (SD 19.6) in the pirfenidone group and -9.6% (19.1) in the placebo group, and the difference between groups in predicted FVC change at week 72 was not significant (0.6%, -3.5 to 4.7); however, a consistent pirfenidone effect was apparent until week 48 (p = 0.005) and in an anal. of all study timepoints (p = 0.007).  Patients in the pirfenidone 2403 mg/day group had higher incidences of nausea (125 [36%] of 345 vs 60 [17%] of 347), dyspepsia (66 [19%] vs 26 [7%]), vomiting (47 [14%] vs 15 [4%]), anorexia (37 [11%] vs 13 [4%]), photosensitivity (42 [12%] vs 6 [2%]), rash (111 [32%] vs 40 [12%]), and dizziness (63 [18%] vs 35 [10%]) than did those in the placebo group.  Fewer overall deaths (19 [6%] vs 29 [8%]) and fewer deaths related to idiopathic pulmonary fibrosis (12 [3%] vs 25 [7%]) occurred in the pirfenidone 2403 mg/day groups than in the placebo groups.  The data show pirfenidone has a favorable benefit risk profile and represents an appropriate treatment option for patients with idiopathic pulmonary fibrosis.  Funding: InterMune.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKu0rjQ2oNaLVg90H21EOLACvtfcHk0ljfY1AYQaxTSQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtl2ktrg%253D&md5=b32d8b1f0b3b1f8401d3744fc18c662a</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2811%2960405-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252811%252960405-4%26sid%3Dliteratum%253Aachs%26aulast%3DNoble%26aufirst%3DP.%2BW.%26aulast%3DAlbera%26aufirst%3DC.%26aulast%3DBradford%26aufirst%3DW.%2BZ.%26aulast%3DCostabel%26aufirst%3DU.%26aulast%3DGlassberg%26aufirst%3DM.%2BK.%26aulast%3DKardatzke%26aufirst%3DD.%26aulast%3DKing%26aufirst%3DT.%2BE.%26aulast%3DLancaster%26aufirst%3DL.%26aulast%3DSahn%26aufirst%3DS.%2BA.%26aulast%3DSzwarcberg%26aufirst%3DJ.%26aulast%3DValeyre%26aufirst%3DD.%26aulast%3Ddu%2BBois%26aufirst%3DR.%2BM.%26atitle%3DPirfenidone%2520in%2520Patients%2520with%2520Idiopathic%2520Pulmonary%2520Fibrosis%2520%2528Capacity%2529%253A%2520Two%2520Randomised%2520Trials%26jtitle%3DLancet%26date%3D2011%26volume%3D377%26issue%3D9779%26spage%3D1760%26epage%3D1769%26doi%3D10.1016%2FS0140-6736%2811%2960405-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Macias-Barragan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandoval-Rodriguez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro-Partida, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armendariz-Borunda, J.</span></span> <span> </span><span class="NLM_article-title">The Multifaceted Role of Pirfenidone and Its Novel Targets</span>. <i>Fibrog. Tissue Repair</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">16</span>, <span class="refDoi">Â DOI: 10.1186/1755-1536-3-16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1186%2F1755-1536-3-16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=20809935" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2010&pages=16&author=J.+Macias-Barraganauthor=A.+Sandoval-Rodriguezauthor=J.+Navarro-Partidaauthor=J.+Armendariz-Borunda&title=The+Multifaceted+Role+of+Pirfenidone+and+Its+Novel+Targets&doi=10.1186%2F1755-1536-3-16"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1186%2F1755-1536-3-16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1755-1536-3-16%26sid%3Dliteratum%253Aachs%26aulast%3DMacias-Barragan%26aufirst%3DJ.%26aulast%3DSandoval-Rodriguez%26aufirst%3DA.%26aulast%3DNavarro-Partida%26aufirst%3DJ.%26aulast%3DArmendariz-Borunda%26aufirst%3DJ.%26atitle%3DThe%2520Multifaceted%2520Role%2520of%2520Pirfenidone%2520and%2520Its%2520Novel%2520Targets%26jtitle%3DFibrog.%2520Tissue%2520Repair%26date%3D2010%26volume%3D3%26spage%3D16%26doi%3D10.1186%2F1755-1536-3-16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nanthakumar, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatley, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gauldie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, S. J.</span></span> <span> </span><span class="NLM_article-title">Dissecting Fibrosis: Therapeutic Insights from the Small-Molecule Toolbox</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">693</span>â <span class="NLM_lpage">720</span>, <span class="refDoi">Â DOI: 10.1038/nrd4592</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1038%2Fnrd4592" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=693-720&issue=10&author=C.+B.+Nanthakumarauthor=R.+J.+Hatleyauthor=S.+Lemmaauthor=J.+Gauldieauthor=R.+P.+Marshallauthor=S.+J.+Macdonald&title=Dissecting+Fibrosis%3A+Therapeutic+Insights+from+the+Small-Molecule+Toolbox&doi=10.1038%2Fnrd4592"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1038%2Fnrd4592&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4592%26sid%3Dliteratum%253Aachs%26aulast%3DNanthakumar%26aufirst%3DC.%2BB.%26aulast%3DHatley%26aufirst%3DR.%2BJ.%26aulast%3DLemma%26aufirst%3DS.%26aulast%3DGauldie%26aufirst%3DJ.%26aulast%3DMarshall%26aufirst%3DR.%2BP.%26aulast%3DMacdonald%26aufirst%3DS.%2BJ.%26atitle%3DDissecting%2520Fibrosis%253A%2520Therapeutic%2520Insights%2520from%2520the%2520Small-Molecule%2520Toolbox%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26issue%3D10%26spage%3D693%26epage%3D720%26doi%3D10.1038%2Fnrd4592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bertolini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aquino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biffi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">dâAtri, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Pierro, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrario, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mascagni, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somenzi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaliani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leoni, F.</span></span> <span> </span><span class="NLM_article-title">A New Rational Hypothesis for the Pharmacophore of the Active Metabolite of Leflunomide, a Potent Immunosuppressive Drug</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">2011</span>â <span class="NLM_lpage">2016</span>, <span class="refDoi">Â DOI: 10.1021/jm970039n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm970039n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1997&pages=2011-2016&issue=13&author=G.+Bertoliniauthor=M.+Aquinoauthor=M.+Biffiauthor=G.+d%E2%80%99Atriauthor=F.+Di+Pierroauthor=F.+Ferrarioauthor=P.+Mascagniauthor=F.+Somenziauthor=A.+Zalianiauthor=F.+Leoni&title=A+New+Rational+Hypothesis+for+the+Pharmacophore+of+the+Active+Metabolite+of+Leflunomide%2C+a+Potent+Immunosuppressive+Drug&doi=10.1021%2Fjm970039n"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fjm970039n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm970039n%26sid%3Dliteratum%253Aachs%26aulast%3DBertolini%26aufirst%3DG.%26aulast%3DAquino%26aufirst%3DM.%26aulast%3DBiffi%26aufirst%3DM.%26aulast%3Dd%25E2%2580%2599Atri%26aufirst%3DG.%26aulast%3DDi%2BPierro%26aufirst%3DF.%26aulast%3DFerrario%26aufirst%3DF.%26aulast%3DMascagni%26aufirst%3DP.%26aulast%3DSomenzi%26aufirst%3DF.%26aulast%3DZaliani%26aufirst%3DA.%26aulast%3DLeoni%26aufirst%3DF.%26atitle%3DA%2520New%2520Rational%2520Hypothesis%2520for%2520the%2520Pharmacophore%2520of%2520the%2520Active%2520Metabolite%2520of%2520Leflunomide%252C%2520a%2520Potent%2520Immunosuppressive%2520Drug%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1997%26volume%3D40%26issue%3D13%26spage%3D2011%26epage%3D2016%26doi%3D10.1021%2Fjm970039n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Munier-Lehmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vidalain, P. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tangy, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janin, Y. L.</span></span> <span> </span><span class="NLM_article-title">On Dihydroorotate Dehydrogenases and Their Inhibitors and Uses</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">3148</span>â <span class="NLM_lpage">3167</span>, <span class="refDoi">Â DOI: 10.1021/jm301848w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301848w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=3148-3167&issue=8&author=H.+Munier-Lehmannauthor=P.+O.+Vidalainauthor=F.+Tangyauthor=Y.+L.+Janin&title=On+Dihydroorotate+Dehydrogenases+and+Their+Inhibitors+and+Uses&doi=10.1021%2Fjm301848w"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Fjm301848w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301848w%26sid%3Dliteratum%253Aachs%26aulast%3DMunier-Lehmann%26aufirst%3DH.%26aulast%3DVidalain%26aufirst%3DP.%2BO.%26aulast%3DTangy%26aufirst%3DF.%26aulast%3DJanin%26aufirst%3DY.%2BL.%26atitle%3DOn%2520Dihydroorotate%2520Dehydrogenases%2520and%2520Their%2520Inhibitors%2520and%2520Uses%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D8%26spage%3D3148%26epage%3D3167%26doi%3D10.1021%2Fjm301848w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parada, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figueiredo, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alves, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freitas, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Learmonth, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunha, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrett, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soares-da-Silva, P.</span></span> <span> </span><span class="NLM_article-title">Anticonvulsant and Sodium Channel-Blocking Properties of Novel 10,11-Dihydro-5h-Dibenz[b,f]Azepine-5-Carboxamide Derivatives</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>42</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">2582</span>â <span class="NLM_lpage">2587</span>, <span class="refDoi">Â DOI: 10.1021/jm980627g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm980627g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=2582-2587&issue=14&author=J.+Benesauthor=A.+Paradaauthor=A.+A.+Figueiredoauthor=P.+C.+Alvesauthor=A.+P.+Freitasauthor=D.+A.+Learmonthauthor=R.+A.+Cunhaauthor=J.+Garrettauthor=P.+Soares-da-Silva&title=Anticonvulsant+and+Sodium+Channel-Blocking+Properties+of+Novel+10%2C11-Dihydro-5h-Dibenz%5Bb%2Cf%5DAzepine-5-Carboxamide+Derivatives&doi=10.1021%2Fjm980627g"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Fjm980627g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm980627g%26sid%3Dliteratum%253Aachs%26aulast%3DBenes%26aufirst%3DJ.%26aulast%3DParada%26aufirst%3DA.%26aulast%3DFigueiredo%26aufirst%3DA.%2BA.%26aulast%3DAlves%26aufirst%3DP.%2BC.%26aulast%3DFreitas%26aufirst%3DA.%2BP.%26aulast%3DLearmonth%26aufirst%3DD.%2BA.%26aulast%3DCunha%26aufirst%3DR.%2BA.%26aulast%3DGarrett%26aufirst%3DJ.%26aulast%3DSoares-da-Silva%26aufirst%3DP.%26atitle%3DAnticonvulsant%2520and%2520Sodium%2520Channel-Blocking%2520Properties%2520of%2520Novel%252010%252C11-Dihydro-5h-Dibenz%255Bb%252Cf%255DAzepine-5-Carboxamide%2520Derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26issue%3D14%26spage%3D2582%26epage%3D2587%26doi%3D10.1021%2Fjm980627g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="note"><p class="first last">Droxidopa, a prodrug, has six hydrogen bond donors, but the active entity, the neurotransmitter, norepinephrine has five and therefore is not an outlier to the rule-of-five concept.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Veber, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopple, K. D.</span></span> <span> </span><span class="NLM_article-title">Molecular Properties That Influence the Oral Bioavailability of Drug Candidates</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2615</span>â <span class="NLM_lpage">2623</span>, <span class="refDoi">Â DOI: 10.1021/jm020017n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020017n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BD38XjsFCmt7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=2615-2623&issue=12&author=D.+F.+Veberauthor=S.+R.+Johnsonauthor=H.+Y.+Chengauthor=B.+R.+Smithauthor=K.+W.+Wardauthor=K.+D.+Kopple&title=Molecular+Properties+That+Influence+the+Oral+Bioavailability+of+Drug+Candidates&doi=10.1021%2Fjm020017n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Properties That Influence the Oral Bioavailability of Drug Candidates</span></div><div class="casAuthors">Veber, Daniel F.; Johnson, Stephen R.; Cheng, Hung-Yuan; Smith, Brian R.; Ward, Keith W.; Kopple, Kenneth D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2615-2623</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Oral bioavailability measurements in rats for over 1100 drug candidates studied at Smith-Kline Beecham Pharmaceuticals (now Glaxo Smith-Kline) have allowed us to analyze the relative importance of mol. properties considered to influence that drug property.  Reduced mol. flexibility, as measured by the no. of rotatable bonds, and low polar surface area or total hydrogen bond count (sum of donors and acceptors) are found to be important predictors of good oral bioavailability, independent of mol. wt.  That on av. both the no. of rotatable bonds and polar surface area or hydrogen bond count tend to increase with mol. wt. may in part explain the success of the mol. wt. parameter in predicting oral bioavailability.  The commonly applied mol. wt. cutoff at 500 does not itself significantly sep. compds. with poor oral bioavailability from those with acceptable values in this extensive data set.  Our observations suggest that compds. which meet only the 2 criteria of (1) 10 or fewer rotatable bonds and (2) polar surface area â¤140 Ã2 (or 12 or fewer H-bond donors and acceptors) will have a high probability of good oral bioavailability in the rat.  Data sets for the artificial membrane permeation rate and for clearance in the rat were also examd.  Reduced polar surface area correlates better with increased permeation rate than does lipophilicity (C log P), and increased rotatable bond count has a neg. effect on the permeation rate.  A threshold permeation rate is a prerequisite of oral bioavailability.  The rotatable bond count does not correlate with the data examd. here for the in vivo clearance rate in the rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3JtJEkO7yVLVg90H21EOLACvtfcHk0lhAGvrAhRL0yA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjsFCmt7g%253D&md5=eaad26ed6a259de82ad65a8834fc397d</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Fjm020017n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020017n%26sid%3Dliteratum%253Aachs%26aulast%3DVeber%26aufirst%3DD.%2BF.%26aulast%3DJohnson%26aufirst%3DS.%2BR.%26aulast%3DCheng%26aufirst%3DH.%2BY.%26aulast%3DSmith%26aufirst%3DB.%2BR.%26aulast%3DWard%26aufirst%3DK.%2BW.%26aulast%3DKopple%26aufirst%3DK.%2BD.%26atitle%3DMolecular%2520Properties%2520That%2520Influence%2520the%2520Oral%2520Bioavailability%2520of%2520Drug%2520Candidates%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26issue%3D12%26spage%3D2615%26epage%3D2623%26doi%3D10.1021%2Fjm020017n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P.
D.</span></span> <span> </span><span class="NLM_article-title">Molecular Inflation, Attrition and the Rule of Five</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">22</span>â <span class="NLM_lpage">33</span>, <span class="refDoi">Â DOI: 10.1016/j.addr.2016.01.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1016%2Fj.addr.2016.01.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=26836397" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFCrt7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2016&pages=22-33&author=P.%0AD.+Leeson&title=Molecular+Inflation%2C+Attrition+and+the+Rule+of+Five&doi=10.1016%2Fj.addr.2016.01.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular inflation, attrition and the rule of five</span></div><div class="casAuthors">Leeson, Paul D.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">22-33</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Physicochem. properties underlie all aspects of drug action and are crit. for soly., permeability and successful formulation.  Specific physicochem. properties shown to be relevant to oral drugs are size, lipophilicity, ionisation, hydrogen bonding, polarity, aromaticity and shape.  The rule of 5 (Ro5) and subsequent studies have raised awareness of the importance of compd. quality amongst bioactive mols.  Lipophilicity, probably the most important phys. property of oral drugs, has on av. changed little over time in oral drugs, until increases in drugs published after 1990.  In contrast other mol. properties such as av. size have increased significantly.  Factors influencing property inflation include the targets pursued, where antivirals frequently violate the Ro5, risk/benefit considerations, and variable drug discovery practices.  The compds. published in patents from the pharmaceutical industry are on av. larger, more lipophilic and less complex than marketed oral drugs.  The variation between individual companies' patented compds. is due to different practices and not to the targets pursued.  Overall, there is demonstrable phys. property attrition in moving from patents to candidate drugs to marketed drugs.  The pharmaceutical industry's recent poor productivity has been due, in part, to progression of mols. that are unable to unambiguously test clin. efficacy, and attrition can therefore be improved by ensuring candidate drug quality is 'fit for purpose.' The combined ligand efficiency (LE) and lipophilic ligand efficiency (LLE) values of many marketed drugs are optimized relative to other mols. acting at the same target.  Application of LLE in optimization can help identify improved leads, even with challenging targets that seem to require lipophilic ligands.  Because of their targets, some projects may need to pursue 'beyond Ro5' physicochem. space; such projects will require non-std. lead generation and optimization and should not dominate in a well-balanced portfolio.  Compd. quality is controllable by lead selection and optimization and should not be a cause of clin. failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3YEbPW53-UbVg90H21EOLACvtfcHk0lhAGvrAhRL0yA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFCrt7k%253D&md5=7e31a4390c28a0f203f2254bcfb754af</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2016.01.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2016.01.018%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26atitle%3DMolecular%2520Inflation%252C%2520Attrition%2520and%2520the%2520Rule%2520of%2520Five%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2016%26volume%3D101%26spage%3D22%26epage%3D33%26doi%3D10.1016%2Fj.addr.2016.01.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groom, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alex, A.</span></span> <span> </span><span class="NLM_article-title">Ligand Efficiency: A Useful Metric for Lead Selection</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">430</span>â <span class="NLM_lpage">431</span>, <span class="refDoi">Â DOI: 10.1016/S1359-6446(04)03069-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1016%2FS1359-6446%2804%2903069-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=15109945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A280%3ADC%252BD2c3ht1ygtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=430-431&issue=10&author=A.+L.+Hopkinsauthor=C.+R.+Groomauthor=A.+Alex&title=Ligand+Efficiency%3A+A+Useful+Metric+for+Lead+Selection&doi=10.1016%2FS1359-6446%2804%2903069-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand efficiency: a useful metric for lead selection</span></div><div class="casAuthors">Hopkins Andrew L; Groom Colin R; Alex Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">430-1</span>
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSdMyKW_d6RPeIHSmpohpd0fW6udTcc2eYjhEtkXx9hGrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c3ht1ygtw%253D%253D&md5=eb19a1bca53247d0bd9adcb99d5817e6</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2804%2903069-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252804%252903069-7%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DGroom%26aufirst%3DC.%2BR.%26aulast%3DAlex%26aufirst%3DA.%26atitle%3DLigand%2520Efficiency%253A%2520A%2520Useful%2520Metric%2520for%2520Lead%2520Selection%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2004%26volume%3D9%26issue%3D10%26spage%3D430%26epage%3D431%26doi%3D10.1016%2FS1359-6446%2804%2903069-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keseru, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, C. H.</span></span> <span> </span><span class="NLM_article-title">The Role of Ligand Efficiency Metrics in Drug Discovery</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">105</span>â <span class="NLM_lpage">121</span>, <span class="refDoi">Â DOI: 10.1038/nrd4163</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1038%2Fnrd4163" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=24481311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1SmtLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=105-121&issue=2&author=A.+L.+Hopkinsauthor=G.+M.+Keseruauthor=P.+D.+Leesonauthor=D.+C.+Reesauthor=C.+H.+Reynolds&title=The+Role+of+Ligand+Efficiency+Metrics+in+Drug+Discovery&doi=10.1038%2Fnrd4163"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">The role of ligand efficiency metrics in drug discovery</span></div><div class="casAuthors">Hopkins, Andrew L.; Keserue, Gyoergy M.; Leeson, Paul D.; Rees, David C.; Reynolds, Charles H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">105-121</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The judicious application of ligand or binding efficiency metrics, which quantify the mol. properties required to obtain binding affinity for a drug target, is gaining traction in the selection and optimization of fragments, hits and leads.  Retrospective anal. of recently marketed oral drugs shows that they frequently have highly optimized ligand efficiency values for their targets.  Optimizing ligand efficiency metrics based on both mol. mass and lipophilicity, when set in the context of the specific target, has the potential to ameliorate the inflation of these properties that has been obsd. in current medicinal chem. practice, and to increase the quality of drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq96uhvE1OZ5LVg90H21EOLACvtfcHk0lhvzfBy0y_DbA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1SmtLk%253D&md5=344030e59f499180f79d311302a27532</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1038%2Fnrd4163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4163%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DKeseru%26aufirst%3DG.%2BM.%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DReynolds%26aufirst%3DC.%2BH.%26atitle%3DThe%2520Role%2520of%2520Ligand%2520Efficiency%2520Metrics%2520in%2520Drug%2520Discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26issue%3D2%26spage%3D105%26epage%3D121%26doi%3D10.1038%2Fnrd4163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Egan, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merz, K. M.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldwin, J. J.</span></span> <span> </span><span class="NLM_article-title">Prediction of Drug Absorption Using Multivariate Statistics</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>43</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">3867</span>â <span class="NLM_lpage">3877</span>, <span class="refDoi">Â DOI: 10.1021/jm000292e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm000292e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmsFeitLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=3867-3877&issue=21&author=W.+J.+Eganauthor=K.+M.+Merzauthor=J.+J.+Baldwin&title=Prediction+of+Drug+Absorption+Using+Multivariate+Statistics&doi=10.1021%2Fjm000292e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of Drug Absorption Using Multivariate Statistics</span></div><div class="casAuthors">Egan, William J.; Merz, Kenneth M. Jr.; Baldwin, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">3867-3877</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Literature data on compds. both well- and poorly-absorbed in humans were used to build a statistical pattern recognition model of passive intestinal absorption.  Robust outlier detection was utilized to analyze the well-absorbed compds., some of which were intermingled with the poorly-absorbed compds. in the model space.  Outliers were identified as being actively transported.  The descriptors chosen for inclusion in the model were PSA and AlogP98, based on consideration of the phys. processes involved in membrane permeability and the interrelationships and redundancies between available descriptors.  These descriptors are quite straightforward for a medicinal chemist to interpret, enhancing the utility of the model.  Mol. wt., while often used in passive absorption models, was shown to be superfluous, as it is already a component of both PSA and AlogP98.  Extensive validation of the model on hundreds of known orally delivered drugs, "drug-like" mols., and Pharmacopeia, Inc. compds., which had been assayed for Caco-2 cell permeability, demonstrated a good rate of successful predictions (74-92%, depending on the dataset and exact criterion used).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbZF9e_GNz8LVg90H21EOLACvtfcHk0lhvzfBy0y_DbA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmsFeitLk%253D&md5=44f909ad1fd6187840921e7f07497b4e</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Fjm000292e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000292e%26sid%3Dliteratum%253Aachs%26aulast%3DEgan%26aufirst%3DW.%2BJ.%26aulast%3DMerz%26aufirst%3DK.%2BM.%26aulast%3DBaldwin%26aufirst%3DJ.%2BJ.%26atitle%3DPrediction%2520of%2520Drug%2520Absorption%2520Using%2520Multivariate%2520Statistics%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26issue%3D21%26spage%3D3867%26epage%3D3877%26doi%3D10.1021%2Fjm000292e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chmielewska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamparczyk, H.</span></span> <span> </span><span class="NLM_article-title">Mass Versus Molar Doses, Similarities and Differences</span>. <i>Pharmazie</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">843</span>â <span class="NLM_lpage">848</span>, <span class="refDoi">Â DOI: 10.1691/ph.2008.8578</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1691%2Fph.2008.8578" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2008&pages=843-848&issue=11&author=A.+Chmielewskaauthor=H.+Lamparczyk&title=Mass+Versus+Molar+Doses%2C+Similarities+and+Differences&doi=10.1691%2Fph.2008.8578"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1691%2Fph.2008.8578&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1691%252Fph.2008.8578%26sid%3Dliteratum%253Aachs%26aulast%3DChmielewska%26aufirst%3DA.%26aulast%3DLamparczyk%26aufirst%3DH.%26atitle%3DMass%2520Versus%2520Molar%2520Doses%252C%2520Similarities%2520and%2520Differences%26jtitle%3DPharmazie%26date%3D2008%26volume%3D63%26issue%3D11%26spage%3D843%26epage%3D848%26doi%3D10.1691%2Fph.2008.8578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Varma, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steyn, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nkansah, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotter, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitney-Pickett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cram, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenner, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Kattan, A. F.</span></span> <span> </span><span class="NLM_article-title">Ph-Dependent Solubility and Permeability Criteria for Provisional Biopharmaceutics Classification (BCS and BDDCS) in Early Drug Discovery</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1199</span>â <span class="NLM_lpage">1212</span>, <span class="refDoi">Â DOI: 10.1021/mp2004912</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp2004912" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC38Xlt1Ont74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=1199-1212&issue=5&author=M.+V.+Varmaauthor=I.+Gardnerauthor=S.+J.+Steynauthor=P.+Nkansahauthor=C.+J.+Rotterauthor=C.+Whitney-Pickettauthor=H.+Zhangauthor=L.+Diauthor=M.+Cramauthor=K.+S.+Fennerauthor=A.+F.+El-Kattan&title=Ph-Dependent+Solubility+and+Permeability+Criteria+for+Provisional+Biopharmaceutics+Classification+%28BCS+and+BDDCS%29+in+Early+Drug+Discovery&doi=10.1021%2Fmp2004912"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery</span></div><div class="casAuthors">Varma, Manthena V.; Gardner, Iain; Steyn, Stefanus J.; Nkansah, Paul; Rotter, Charles J.; Whitney-Pickett, Carrie; Zhang, Hui; Di, Li; Cram, Michael; Fenner, Katherine S.; El-Kattan, Ayman F.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1199-1212</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The Biopharmaceutics Classification System (BCS) is a scientific framework that provides a basis for predicting the oral absorption of drugs.  These concepts have been extended in the Biopharmaceutics Drug Disposition Classification System (BDDCS) to explain the potential mechanism of drug clearance and understand the effects of uptake and efflux transporters on absorption, distribution, metab., and elimination.  The objective of present work is to establish criteria for provisional biopharmaceutics classification using pH-dependent passive permeability and aq. soly. data generated from high throughput screening methodologies in drug discovery settings.  The apparent permeability across monolayers of clonal cell line of Madin-Darby canine kidney cells, selected for low endogenous efflux transporter expression, was measured for a set of 105 drugs, with known BCS and BDDCS class.  The permeability at apical pH 6.5 for acidic drugs and at pH 7.4 for nonacidic drugs showed a good correlation with the fraction absorbed in human (Fa).  Receiver operating characteristic (ROC) curve anal. was utilized to define the permeability class boundary.  At permeability â¥5 Ã 10-6 cm/s, the accuracy of predicting Fa of â¥0.90 was 87%.  Also, this cutoff showed more than 80% sensitivity and specificity in predicting the literature permeability classes (BCS), and the metab. classes (BDDCS).  The equil. soly. of a subset of 49 drugs was measured in pH 1.2 medium, pH 6.5 phosphate buffer, and in FaSSIF medium (pH 6.5).  Although dose was not considered, good concordance of the measured soly. with BCS and BDDCS soly. class was achieved, when soly. at pH 1.2 was used for acidic compds. and FaSSIF soly. was used for basic, neutral, and zwitterionic compds.  Using a cutoff of 200 Î¼g/mL, the data set suggested a 93% sensitivity and 86% specificity in predicting both the BCS and BDDCS soly. classes.  In conclusion, this study identified pH-dependent permeability and soly. criteria that can be used to assign provisional biopharmaceutics class at early stage of the drug discovery process.  Addnl., such a classification system will enable discovery scientists to assess the potential limiting factors to oral absorption, as well as help predict the drug disposition mechanisms and potential drug-drug interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr84irw4TD15rVg90H21EOLACvtfcHk0lgCNj45B0EMHA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xlt1Ont74%253D&md5=2bcb29ea512d2e0665973292e4a4a0a3</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Fmp2004912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp2004912%26sid%3Dliteratum%253Aachs%26aulast%3DVarma%26aufirst%3DM.%2BV.%26aulast%3DGardner%26aufirst%3DI.%26aulast%3DSteyn%26aufirst%3DS.%2BJ.%26aulast%3DNkansah%26aufirst%3DP.%26aulast%3DRotter%26aufirst%3DC.%2BJ.%26aulast%3DWhitney-Pickett%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DDi%26aufirst%3DL.%26aulast%3DCram%26aufirst%3DM.%26aulast%3DFenner%26aufirst%3DK.%2BS.%26aulast%3DEl-Kattan%26aufirst%3DA.%2BF.%26atitle%3DPh-Dependent%2520Solubility%2520and%2520Permeability%2520Criteria%2520for%2520Provisional%2520Biopharmaceutics%2520Classification%2520%2528BCS%2520and%2520BDDCS%2529%2520in%2520Early%2520Drug%2520Discovery%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2012%26volume%3D9%26issue%3D5%26spage%3D1199%26epage%3D1212%26doi%3D10.1021%2Fmp2004912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huuskonen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Livingstone, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manallack, D. T.</span></span> <span> </span><span class="NLM_article-title">Prediction of Drug Solubility from Molecular Structure Using a Drug-Like Training Set</span>. <i>SAR QSAR Environ. Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">3â4</span>),  <span class="NLM_fpage">191</span>â <span class="NLM_lpage">212</span>, <span class="refDoi">Â DOI: 10.1080/10629360802083855</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1080%2F10629360802083855" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2008&pages=191-212&issue=3%E2%80%934&author=J.+Huuskonenauthor=D.+J.+Livingstoneauthor=D.+T.+Manallack&title=Prediction+of+Drug+Solubility+from+Molecular+Structure+Using+a+Drug-Like+Training+Set&doi=10.1080%2F10629360802083855"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1080%2F10629360802083855&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10629360802083855%26sid%3Dliteratum%253Aachs%26aulast%3DHuuskonen%26aufirst%3DJ.%26aulast%3DLivingstone%26aufirst%3DD.%2BJ.%26aulast%3DManallack%26aufirst%3DD.%2BT.%26atitle%3DPrediction%2520of%2520Drug%2520Solubility%2520from%2520Molecular%2520Structure%2520Using%2520a%2520Drug-Like%2520Training%2520Set%26jtitle%3DSAR%2520QSAR%2520Environ.%2520Res.%26date%3D2008%26volume%3D19%26issue%3D3%25E2%2580%25934%26spage%3D191%26epage%3D212%26doi%3D10.1080%2F10629360802083855" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yazdanian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glynn, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawi, A.</span></span> <span> </span><span class="NLM_article-title">Correlating Partitioning and Caco-2 Cell Permeability of Structurally Diverse Small Molecular Weight Compounds</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1490</span>â <span class="NLM_lpage">1494</span>, <span class="refDoi">Â DOI: 10.1023/A:1011930411574</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1023%2FA%3A1011930411574" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1998&pages=1490-1494&issue=9&author=M.+Yazdanianauthor=S.+L.+Glynnauthor=J.+L.+Wrightauthor=A.+Hawi&title=Correlating+Partitioning+and+Caco-2+Cell+Permeability+of+Structurally+Diverse+Small+Molecular+Weight+Compounds&doi=10.1023%2FA%3A1011930411574"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1023%2FA%3A1011930411574&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1011930411574%26sid%3Dliteratum%253Aachs%26aulast%3DYazdanian%26aufirst%3DM.%26aulast%3DGlynn%26aufirst%3DS.%2BL.%26aulast%3DWright%26aufirst%3DJ.%2BL.%26aulast%3DHawi%26aufirst%3DA.%26atitle%3DCorrelating%2520Partitioning%2520and%2520Caco-2%2520Cell%2520Permeability%2520of%2520Structurally%2520Diverse%2520Small%2520Molecular%2520Weight%2520Compounds%26jtitle%3DPharm.%2520Res.%26date%3D1998%26volume%3D15%26issue%3D9%26spage%3D1490%26epage%3D1494%26doi%3D10.1023%2FA%3A1011930411574" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Palm, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stenberg, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luthman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artursson, P.</span></span> <span> </span><span class="NLM_article-title">Polar Molecular Surface Properties Predict the Intestinal Absorption of Drugs in Humans</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">568</span>â <span class="NLM_lpage">571</span>, <span class="refDoi">Â DOI: 10.1023/A:1012188625088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1023%2FA%3A1012188625088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=9165525" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADyaK2sXjtlSksrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1997&pages=568-571&issue=5&author=K.+Palmauthor=P.+Stenbergauthor=K.+Luthmanauthor=P.+Artursson&title=Polar+Molecular+Surface+Properties+Predict+the+Intestinal+Absorption+of+Drugs+in+Humans&doi=10.1023%2FA%3A1012188625088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Polar molecular surface properties predict the intestinal absorption of drugs in humans</span></div><div class="casAuthors">Palm, Katrin; Stenberg, Patric; Luthman, Kristina; Artursson, Per</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">568-571</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Plenum</span>)
        </div><div class="casAbstract">A theor. method was devised for prediction of drug absorption after oral administration to humans.  Twenty structurally diverse model drugs, ranging from 0.3 to 100% absorbed, were investigated.  The compds. also displayed diversity in physicochem. properties such as lipophilicity, hydrogen bonding potential and mol. size.  The dynamic mol. surface properties of the compds. were calcd., taking into account their 3-dimensional shape and flexibility.  An excellent sigmoidal relationship was established between the absorbed fraction after oral administration to humans (FA) and the dynamic polar mol. surface area (PSAd) (r2 = 0.94).  The relationship was stronger than those obtained for more established predictors of drug absorption.  Drugs that are completely absorbed (FA > 90%) had a PSAd â¤ 60 Ã2 while drugs that are < 10% absorbed had a PSAd â¥ 140 Ã2.  PSAd can be used to differentiate poorly absorbed drugs at an early stage of the drug discovery process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPW66hupHIyLVg90H21EOLACvtfcHk0lgCNj45B0EMHA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjtlSksrk%253D&md5=1394f0d1059e7d99ee02be977b92da8b</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1023%2FA%3A1012188625088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1012188625088%26sid%3Dliteratum%253Aachs%26aulast%3DPalm%26aufirst%3DK.%26aulast%3DStenberg%26aufirst%3DP.%26aulast%3DLuthman%26aufirst%3DK.%26aulast%3DArtursson%26aufirst%3DP.%26atitle%3DPolar%2520Molecular%2520Surface%2520Properties%2520Predict%2520the%2520Intestinal%2520Absorption%2520of%2520Drugs%2520in%2520Humans%26jtitle%3DPharm.%2520Res.%26date%3D1997%26volume%3D14%26issue%3D5%26spage%3D568%26epage%3D571%26doi%3D10.1023%2FA%3A1012188625088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Artursson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ungell, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lofroth, J. E.</span></span> <span> </span><span class="NLM_article-title">Selective Paracellular Permeability in Two Models of Intestinal Absorption: Cultured Monolayers of Human Intestinal Epithelial Cells and Rat Intestinal Segments</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1123</span>â <span class="NLM_lpage">1129</span>, <span class="refDoi">Â DOI: 10.1023/A:1018903931777</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1023%2FA%3A1018903931777" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1993&pages=1123-1129&issue=8&author=P.+Arturssonauthor=A.+L.+Ungellauthor=J.+E.+Lofroth&title=Selective+Paracellular+Permeability+in+Two+Models+of+Intestinal+Absorption%3A+Cultured+Monolayers+of+Human+Intestinal+Epithelial+Cells+and+Rat+Intestinal+Segments&doi=10.1023%2FA%3A1018903931777"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1023%2FA%3A1018903931777&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1018903931777%26sid%3Dliteratum%253Aachs%26aulast%3DArtursson%26aufirst%3DP.%26aulast%3DUngell%26aufirst%3DA.%2BL.%26aulast%3DLofroth%26aufirst%3DJ.%2BE.%26atitle%3DSelective%2520Paracellular%2520Permeability%2520in%2520Two%2520Models%2520of%2520Intestinal%2520Absorption%253A%2520Cultured%2520Monolayers%2520of%2520Human%2520Intestinal%2520Epithelial%2520Cells%2520and%2520Rat%2520Intestinal%2520Segments%26jtitle%3DPharm.%2520Res.%26date%3D1993%26volume%3D10%26issue%3D8%26spage%3D1123%26epage%3D1129%26doi%3D10.1023%2FA%3A1018903931777" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dress, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M.</span></span> <span> </span><span class="NLM_article-title">Using the Golden Triangle to Optimize Clearance and Oral Absorption</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">5560</span>â <span class="NLM_lpage">5564</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2009.08.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1016%2Fj.bmcl.2009.08.045" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=5560-5564&issue=19&author=T.+W.+Johnsonauthor=K.+R.+Dressauthor=M.+Edwards&title=Using+the+Golden+Triangle+to+Optimize+Clearance+and+Oral+Absorption&doi=10.1016%2Fj.bmcl.2009.08.045"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.08.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.08.045%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DDress%26aufirst%3DK.%2BR.%26aulast%3DEdwards%26aufirst%3DM.%26atitle%3DUsing%2520the%2520Golden%2520Triangle%2520to%2520Optimize%2520Clearance%2520and%2520Oral%2520Absorption%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26issue%3D19%26spage%3D5560%26epage%3D5564%26doi%3D10.1016%2Fj.bmcl.2009.08.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">CNS Physicochemical Property Space Shaped by a Diverse Set of Molecules with Experimentally Determined Exposure in the Mouse Brain</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">5943</span>â <span class="NLM_lpage">5954</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.6b01469</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01469" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC2sXls1yqsbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5943-5954&issue=14&author=Z.+Rankovic&title=CNS+Physicochemical+Property+Space+Shaped+by+a+Diverse+Set+of+Molecules+with+Experimentally+Determined+Exposure+in+the+Mouse+Brain&doi=10.1021%2Facs.jmedchem.6b01469"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">CNS Physicochemical Property Space Shaped by a Diverse Set of Molecules with Experimentally Determined Exposure in the Mouse Brain</span></div><div class="casAuthors">Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5943-5954</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Understanding the "limits and boundaries" of the central nervous system (CNS) property space is a crit. aspect of modern CNS drug design.  Medicinal chemists are often guided by the physicochem. properties of marketed CNS drugs, which are heavily biased toward "traditional" aminergic targets and commonly described as small lipophilic amines.  This miniperspective describes the statistical anal. of the calcd. physicochem. properties for a diverse set of ligands for mostly "nontraditional" CNS targets and classified as either "brain penetrant" or "peripherally restricted" on the basis of the exptl. mouse brain exposure.  The results suggested that (a) the physicochem. property space conducive to brain exposure is larger than the one defined by the marketed CNS drugs and (b) the most crit. brain exposure determinants are descriptors of the mol. size and hydrogen bond capacity.  These findings led to a modified version of the CNS MPO scoring algorithm, termed CNS MPO.v2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4f3JpTCJ29rVg90H21EOLACvtfcHk0ljXnQGl557uRw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXls1yqsbk%253D&md5=bff2a3cd68c033d6cae235a7524cc528</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01469&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01469%26sid%3Dliteratum%253Aachs%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DCNS%2520Physicochemical%2520Property%2520Space%2520Shaped%2520by%2520a%2520Diverse%2520Set%2520of%2520Molecules%2520with%2520Experimentally%2520Determined%2520Exposure%2520in%2520the%2520Mouse%2520Brain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D14%26spage%3D5943%26epage%3D5954%26doi%3D10.1021%2Facs.jmedchem.6b01469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaumont, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span> <span> </span><span class="NLM_article-title">Volume of Distribution in Drug Design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">5691</span>â <span class="NLM_lpage">5698</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b00201</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00201" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC2MXltFSlsb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=5691-5698&issue=15&author=D.+A.+Smithauthor=K.+Beaumontauthor=T.+S.+Maurerauthor=L.+Di&title=Volume+of+Distribution+in+Drug+Design&doi=10.1021%2Facs.jmedchem.5b00201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Volume of Distribution in Drug Design</span></div><div class="casAuthors">Smith, Dennis A.; Beaumont, Kevin; Maurer, Tristan S.; Di, Li</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5691-5698</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Vol. of distribution is one of the most important pharmacokinetic properties of a drug candidate.  It is a major determinant of half-life and dosing frequency of a drug.  For a similar log P, a basic mol. will tend to exhibit higher vol. of distribution than a neutral mol.  Acids often exhibit low vols. of distribution.  Although a design strategy against vol. of distribution can be advantageous in achieving desirable dosing regimen, it must be well-directed in order to avoid detrimental effects to other important properties.  Strategies to increase vol. of distribution include adding lipophilicity and introducing basic functional groups in a way that does not increase metabolic clearance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP7QwgPahf4bVg90H21EOLACvtfcHk0ljXnQGl557uRw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXltFSlsb0%253D&md5=2c7289b3602a8edef2d9ef0e6a82e483</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00201%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DBeaumont%26aufirst%3DK.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DDi%26aufirst%3DL.%26atitle%3DVolume%2520of%2520Distribution%2520in%2520Drug%2520Design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D15%26spage%3D5691%26epage%3D5698%26doi%3D10.1021%2Facs.jmedchem.5b00201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaumont, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span> <span> </span><span class="NLM_article-title">Relevance of Half-Life in Drug Design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">4273</span>â <span class="NLM_lpage">4282</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.7b00969</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00969" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslOnsrnN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4273-4282&issue=10&author=D.+A.+Smithauthor=K.+Beaumontauthor=T.+S.+Maurerauthor=L.+Di&title=Relevance+of+Half-Life+in+Drug+Design&doi=10.1021%2Facs.jmedchem.7b00969"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Relevance of Half-Life in Drug Design</span></div><div class="casAuthors">Smith, Dennis A.; Beaumont, Kevin; Maurer, Tristan S.; Di, Li</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4273-4282</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Drug half-life has important implications for dosing regimen and peak-to-trough ratio at the steady state.  A half-life of 12-48 h is generally ideal for once daily dosing of oral drugs.  If the half-life is too short, it may require more frequent dosing in order to maintain desired exposures and avoid unnecessarily high peak concns.  This may pose challenges to achieving optimal efficacy, safety, and patient compliance.  If the half-life is too long, the time over which accumulation and subsequent elimination occur may be prolonged.  This may pose problems with managing adverse effects and the design of efficient clin. trials.  Half-life is a key parameter for optimization in research and development.  Structural modification to affect clearance, and to a lesser extent vol. of distribution, is the preferred means of modulating half-life.  An effective approach to half-life optimization requires an understanding of the many pitfalls assocd. with its estn. and interpretation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7kT9hNLRzb7Vg90H21EOLACvtfcHk0ljXnQGl557uRw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslOnsrnN&md5=ff748cbebc765f4fa3c3d7b3831f51c8</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00969%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DBeaumont%26aufirst%3DK.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DDi%26aufirst%3DL.%26atitle%3DRelevance%2520of%2520Half-Life%2520in%2520Drug%2520Design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D10%26spage%3D4273%26epage%3D4282%26doi%3D10.1021%2Facs.jmedchem.7b00969" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharifi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghafourian, T.</span></span> <span> </span><span class="NLM_article-title">Estimation of Biliary Excretion of Foreign Compounds Using Properties of Molecular Structure</span>. <i>AAPS J.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">65</span>â <span class="NLM_lpage">78</span>, <span class="refDoi">Â DOI: 10.1208/s12248-013-9541-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1208%2Fs12248-013-9541-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=24202722" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisFOkug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2014&pages=65-78&issue=1&author=M.+Sharifiauthor=T.+Ghafourian&title=Estimation+of+Biliary+Excretion+of+Foreign+Compounds+Using+Properties+of+Molecular+Structure&doi=10.1208%2Fs12248-013-9541-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Estimation of Biliary Excretion of Foreign Compounds Using Properties of Molecular Structure</span></div><div class="casAuthors">Sharifi, Mohsen; Ghafourian, Taravat</div><div class="citationInfo"><span class="NLM_cas:title">AAPS Journal</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">65-78</span>CODEN:
                <span class="NLM_cas:coden">AJAOB6</span>;
        ISSN:<span class="NLM_cas:issn">1550-7416</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Biliary excretion is one of the main elimination pathways for drugs and/or their metabolites.  Therefore, an insight into the structural profile of cholephilic compds. through accurate modeling of the biliary excretion is important for the estn. of clin. pharmacokinetics in early stages of drug discovery.  The aim of this study was to develop quant. structure-activity relationships as computational tools for the estn. of biliary excretion and identification of the mol. properties controlling this process.  The study used percentage of dose excreted intact into bile measured in vivo in rat for a diverse dataset of 217 compds.  Statistical techniques were multiple linear regression anal., regression trees, random forest and boosted trees.  A simple regression tree model generated using the CART algorithm was the most accurate in the estn. of the percentage of bile excretion of compds., and this outperformed the more sophisticated boosted trees and random forest techniques.  Anal. of the outliers indicated that the models perform best when lipophilicity is not too extreme (log P<5.35) and for compds. with mol. wt. above 280 Da.  Mol. descriptors selected by all these models including the top ten incorporated in boosted trees and random forest indicated a higher biliary excretion for relatively hydrophilic compds. esp. if they are anionic or cationic, and have a large mol. size.  A statistically validated mol. wt. threshold for potentially significant biliary excretion was above 348 Da.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq52DwTd6VS9bVg90H21EOLACvtfcHk0ljXnQGl557uRw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisFOkug%253D%253D&md5=05cb387d4ee81d805b96ea9398e3c0ba</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1208%2Fs12248-013-9541-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Fs12248-013-9541-z%26sid%3Dliteratum%253Aachs%26aulast%3DSharifi%26aufirst%3DM.%26aulast%3DGhafourian%26aufirst%3DT.%26atitle%3DEstimation%2520of%2520Biliary%2520Excretion%2520of%2520Foreign%2520Compounds%2520Using%2520Properties%2520of%2520Molecular%2520Structure%26jtitle%3DAAPS%2520J.%26date%3D2014%26volume%3D16%26issue%3D1%26spage%3D65%26epage%3D78%26doi%3D10.1208%2Fs12248-013-9541-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fleck, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braunlich, H.</span></span> <span> </span><span class="NLM_article-title">Factors Determining the Relationship between Renal and Hepatic Excretion of Xenobiotics</span>. <i>Arzneimittelforschung</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">942</span>â <span class="NLM_lpage">946</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1990&pages=942-946&issue=8&author=C.+Fleckauthor=H.+Braunlich&title=Factors+Determining+the+Relationship+between+Renal+and+Hepatic+Excretion+of+Xenobiotics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFleck%26aufirst%3DC.%26aulast%3DBraunlich%26aufirst%3DH.%26atitle%3DFactors%2520Determining%2520the%2520Relationship%2520between%2520Renal%2520and%2520Hepatic%2520Excretion%2520of%2520Xenobiotics%26jtitle%3DArzneimittelforschung%26date%3D1990%26volume%3D40%26issue%3D8%26spage%3D942%26epage%3D946" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Varma, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Kattan, A. F.</span></span> <span> </span><span class="NLM_article-title">Molecular Properties Associated with Transporter-Mediated Drug Disposition</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">92</span>â <span class="NLM_lpage">99</span>, <span class="refDoi">Â DOI: 10.1016/j.addr.2017.05.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1016%2Fj.addr.2017.05.014" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2017&pages=92-99&author=M.+V.+Varmaauthor=Y.+Laiauthor=A.+F.+El-Kattan&title=Molecular+Properties+Associated+with+Transporter-Mediated+Drug+Disposition&doi=10.1016%2Fj.addr.2017.05.014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2017.05.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2017.05.014%26sid%3Dliteratum%253Aachs%26aulast%3DVarma%26aufirst%3DM.%2BV.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DEl-Kattan%26aufirst%3DA.%2BF.%26atitle%3DMolecular%2520Properties%2520Associated%2520with%2520Transporter-Mediated%2520Drug%2520Disposition%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2017%26volume%3D116%26spage%3D92%26epage%3D99%26doi%3D10.1016%2Fj.addr.2017.05.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Improving Drug Design: An Update on Recent Applications of Efficiency Metrics, Strategies for Replacing Problematic Elements, and Compounds in Nontraditional Drug Space</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">564</span>â <span class="NLM_lpage">616</span>, <span class="refDoi">Â DOI: 10.1021/acs.chemrestox.6b00043</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.6b00043" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC28XktVCrs7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2016&pages=564-616&issue=4&author=N.+A.+Meanwell&title=Improving+Drug+Design%3A+An+Update+on+Recent+Applications+of+Efficiency+Metrics%2C+Strategies+for+Replacing+Problematic+Elements%2C+and+Compounds+in+Nontraditional+Drug+Space&doi=10.1021%2Facs.chemrestox.6b00043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Improving Drug Design: An Update on Recent Applications of Efficiency Metrics, Strategies for Replacing Problematic Elements, and Compounds in Nontraditional Drug Space</span></div><div class="casAuthors">Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">564-616</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Drug discovery and development is a complex and lengthy enterprise that suffers from high rates of candidate attrition at all stages of the process.  The phys., biol., and toxicol. properties of a drug candidate are inextricably linked to its structure, and once a mol. has been synthesized, all subsequent studies along the development path are focused only on assessing and understanding its properties in greater detail.  Unfortunately, a full prediction of the biol. properties of a mol. from an anal. of its 2- or 3-dimensional structure is currently beyond our expertise.  This backdrop mandates that considerable care be taken at the design stage if a mol. is to be successful in testing a mechanistic concept underlying a disease process and to progress into late stage clin. trials and, ultimately, marketing approval.  While there are multiple potential causes of candidate attrition, an introspective anal. of drug design practices over the past decade has focused attention on the perception that contemporary mols. are unnecessarily obese, burdened by high mol. wt. and excessive lipophilicity.  This practice is believed to have its roots in the singular pursuit of enhancing potency during lead optimization rather than adopting a more holistic approach to drug design that gives broader consideration to how structural features affect developability properties.  In an effort to provide the medicinal chem. community with practical guideposts to enhancing compd. quality in the drug design phase and which can readily be applied, a series of efficiency indexes have been proposed that attempt to define aspects of compd. quality in the context of a series of physicochem. parameters.  Of these metrics, lipophilic ligand efficiency (LLE or LipE), which provides an index of the dependence of the potency of a mol. on its intrinsic lipophilicity, has been characterized as the most robust metric that has potential for broad-based application.  In this review, after describing the background literature behind the derivation of efficiency metrics and approaches to assessing compd. aesthetics, synopses of some recent practical application in lead optimization campaigns are presented.  However, mols. that fall into space beyond that assocd. with traditional drug-like properties are an important part of the current and future landscape, exemplified by the summary of direct acting hepatitis C virus NS3 and NS5A inhibitors that have transformed clin. therapy for this chronic disease.  While drug development in nontraditional drug-like space is more challenging and the rules for compd. quality will be different with much still to be understood, careful and disciplined drug design practices will be an essential element of success.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpotJb_EhGoW7Vg90H21EOLACvtfcHk0lga6X539lGh2A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktVCrs7Y%253D&md5=aef48399fb698b5f958c1cc11e1d25aa</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.6b00043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.6b00043%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DImproving%2520Drug%2520Design%253A%2520An%2520Update%2520on%2520Recent%2520Applications%2520of%2520Efficiency%2520Metrics%252C%2520Strategies%2520for%2520Replacing%2520Problematic%2520Elements%252C%2520and%2520Compounds%2520in%2520Nontraditional%2520Drug%2520Space%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2016%26volume%3D29%26issue%3D4%26spage%3D564%26epage%3D616%26doi%3D10.1021%2Facs.chemrestox.6b00043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Struck, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruening, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaeger, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hossbach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preissner, R.</span></span> <span> </span><span class="NLM_article-title">Toxicity Versus Potency: Elucidation of Toxicity Properties Discriminating between Toxins, Drugs, and Natural Compounds</span>. <i>Genome Inform</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">231</span>â <span class="NLM_lpage">242</span>, <span class="refDoi">Â DOI: 10.1142/9781848163003_0020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1142%2F9781848163003_0020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=19425137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A280%3ADC%252BD1MzivFOisA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2008&pages=231-242&author=S.+Struckauthor=U.+Schmidtauthor=B.+Grueningauthor=I.+S.+Jaegerauthor=J.+Hossbachauthor=R.+Preissner&title=Toxicity+Versus+Potency%3A+Elucidation+of+Toxicity+Properties+Discriminating+between+Toxins%2C+Drugs%2C+and+Natural+Compounds&doi=10.1142%2F9781848163003_0020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Toxicity versus potency: elucidation of toxicity properties discriminating between toxins, drugs, and natural compounds</span></div><div class="casAuthors">Struck Swantje; Schmidt Ulrike; Gruening Bjoern; Jaeger Ines S; Hossbach Julia; Preissner Robert</div><div class="citationInfo"><span class="NLM_cas:title">Genome informatics. International Conference on Genome Informatics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">231-42</span>
        ISSN:<span class="NLM_cas:issn">0919-9454</span>.
    </div><div class="casAbstract">Within our everyday life we are confronted with a variety of toxic substances.  A number of these compounds are already used as lead structures for the development of new drugs, but the amount of toxic substances is still a rich resource of new bioactive compounds.  During the identification and development of new potential drugs, risk estimation of health hazards is an essential and topical subject in pharmaceutical industry.  To face this challenge, an extensive investigation of known toxic compounds is going to be helpful to estimate the toxicity of potential drugs. "Toxicity properties" found during those investigations will also function as a guideline for the toxicological classification of other unknown substances.  We have compiled a dataset of approximately 50,000 toxic compounds from literature and web sources.  All compounds were classified according to their toxicity.  During this study the collection of toxic compounds was investigated extensively regarding their chemical, functional, and structural properties and compared with a dataset of drugs and natural compounds.  We were able to identify differences in properties within the toxic compounds as well as in comparison to drugs and natural compounds.  These properties include molecular weight, hydrogen bond donors and acceptors, and functional groups which can be regarded as "toxicity properties", i.e. attributes defining toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT9d7GGDNKsmmx8TEN9K18QfW6udTcc2eZkvZSYvtCeYrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MzivFOisA%253D%253D&md5=a0319de47786e7a9b3b7e494e48a51e9</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1142%2F9781848163003_0020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1142%252F9781848163003_0020%26sid%3Dliteratum%253Aachs%26aulast%3DStruck%26aufirst%3DS.%26aulast%3DSchmidt%26aufirst%3DU.%26aulast%3DGruening%26aufirst%3DB.%26aulast%3DJaeger%26aufirst%3DI.%2BS.%26aulast%3DHossbach%26aufirst%3DJ.%26aulast%3DPreissner%26aufirst%3DR.%26atitle%3DToxicity%2520Versus%2520Potency%253A%2520Elucidation%2520of%2520Toxicity%2520Properties%2520Discriminating%2520between%2520Toxins%252C%2520Drugs%252C%2520and%2520Natural%2520Compounds%26jtitle%3DGenome%2520Inform%26date%3D2008%26volume%3D20%26spage%3D231%26epage%3D242%26doi%3D10.1142%2F9781848163003_0020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Price, D.</span>; <span class="NLM_string-name">Lee, K.</span></span> Unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Price%2C+D.%3B+Lee%2C+K.+Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DPrice%26aufirst%3DD." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zuegg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, M. A.</span></span> <span> </span><span class="NLM_article-title">Drug-likeness and Increased Hydrophobicity of Commercially Available Compound Libraries for Drug Screening</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">1500</span>â <span class="NLM_lpage">1513</span>, <span class="refDoi">Â DOI: 10.2174/156802612802652466</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.2174%2F156802612802652466" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=22827520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsV2iur7K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=1500-1513&issue=14&author=J.+Zueggauthor=M.+A.+Cooper&title=Drug-likeness+and+Increased+Hydrophobicity+of+Commercially+Available+Compound+Libraries+for+Drug+Screening&doi=10.2174%2F156802612802652466"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-likeness and increased hydrophobicity of commercially available compound libraries for drug screening</span></div><div class="casAuthors">Zuegg, Johannes; Cooper, Matthew A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1500-1513</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Most drug discovery programs today originate by selection of "hit" mols. resulting from assays against large compd. screening libraries.  The chem. space in which these hits reside has implications for its biol. activity in vivo and likelihood of progression to a drug candidate.  We have created a database of com. available screening compds. and natural products in order to analyze the drug- and lead-likeness of com. screening compds. and compare them with i) orally administered drugs, ii) non-orally administered drugs, and iii) compds. with significant biol. activity but unspecified or not yet detd. route of administration from the public databases DrugBank and ChEMBL.  The data set contained 15.5 million entries from 102 vendors, which resulted in just over 8 million unique chem. structures.  We review these data for current drug/lead-likeness, then utilize substructure-based filters for promiscuity and unwanted groups, and finally compare chem. properties for structures within the different sub-sets.  While the majority of the com. compds. satisfy various drug-likeness rules, they show a larger mol. wt. and higher hydrophobicity compared to orally available drugs, with generally higher aromaticity and lower soly.  This "right shift" of chem. properties has also been found in the majority of the compds. with significant biol. activity in ChEMBL, reflecting a common trend in current drug discovery, towards larger, more hydrophobic compds. and fewer drug-like compds.  In particular, successful drugs were found to possess much lower median logD values than those found for compd. collections.  In addn., com. compds. show a quite narrow distribution in mol. wt., with a median abs. deviation of only 78 Da around a median of 387 Da.  For high-throughput screening a highly stringent combination of several lead-likeness and substructure filters against unwanted groups could be applied, resulting in 2 million lead-like structures.  For fragment based screening approaches the rule of three (Ro3) would select around 400,000 structures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq04wKgd1oss7Vg90H21EOLACvtfcHk0liNu197xQsWoQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsV2iur7K&md5=aed253db97f077f79c748802cf4ec623</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.2174%2F156802612802652466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802612802652466%26sid%3Dliteratum%253Aachs%26aulast%3DZuegg%26aufirst%3DJ.%26aulast%3DCooper%26aufirst%3DM.%2BA.%26atitle%3DDrug-likeness%2520and%2520Increased%2520Hydrophobicity%2520of%2520Commercially%2520Available%2520Compound%2520Libraries%2520for%2520Drug%2520Screening%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2012%26volume%3D12%26issue%3D14%26spage%3D1500%26epage%3D1513%26doi%3D10.2174%2F156802612802652466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Kloe, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leurs, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Esch, I. J.</span></span> <span> </span><span class="NLM_article-title">Transforming Fragments into Candidates: Small Becomes Big in Medicinal Chemistry</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">13â14</span>),  <span class="NLM_fpage">630</span>â <span class="NLM_lpage">646</span>, <span class="refDoi">Â DOI: 10.1016/j.drudis.2009.03.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1016%2Fj.drudis.2009.03.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=19443265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A280%3ADC%252BD1MvmtFOquw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=630-646&issue=13%E2%80%9314&author=G.+E.+de%0AKloeauthor=D.+Baileyauthor=R.+Leursauthor=I.+J.+de+Esch&title=Transforming+Fragments+into+Candidates%3A+Small+Becomes+Big+in+Medicinal+Chemistry&doi=10.1016%2Fj.drudis.2009.03.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Transforming fragments into candidates: small becomes big in medicinal chemistry</span></div><div class="casAuthors">de Kloe Gerdien E; Bailey David; Leurs Rob; de Esch Iwan J P</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">13-14</span>),
    <span class="NLM_cas:pages">630-46</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Fragment-based drug discovery (FBDD) represents a logical and efficient approach to lead discovery and optimisation.  It can draw on structural, biophysical and biochemical data, incorporating a wide range of inputs, from precise mode-of-binding information on specific fragments to wider ranging pharmacophoric screening surveys using traditional HTS approaches.  It is truly an enabling technology for the imaginative medicinal chemist.  In this review, we analyse a representative set of 23 published FBDD studies that describe how low molecular weight fragments are being identified and efficiently transformed into higher molecular weight drug candidates.  FBDD is now becoming warmly endorsed by industry as well as academia and the focus on small interacting molecules is making a big scientific impact.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTPxy6qg7uE4oxhnOQkIHOxfW6udTcc2ebDZSgGJbV3dbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MvmtFOquw%253D%253D&md5=10ed9629dece190be12712f4862b3699</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2009.03.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2009.03.009%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BKloe%26aufirst%3DG.%2BE.%26aulast%3DBailey%26aufirst%3DD.%26aulast%3DLeurs%26aufirst%3DR.%26aulast%3Dde%2BEsch%26aufirst%3DI.%2BJ.%26atitle%3DTransforming%2520Fragments%2520into%2520Candidates%253A%2520Small%2520Becomes%2520Big%2520in%2520Medicinal%2520Chemistry%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2009%26volume%3D14%26issue%3D13%25E2%2580%259314%26spage%3D630%26epage%3D646%26doi%3D10.1016%2Fj.drudis.2009.03.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chessari, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodhead, A. J.</span></span> <span> </span><span class="NLM_article-title">From Fragment to Clinical Candidate--a Historical Perspective</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">13â14</span>),  <span class="NLM_fpage">668</span>â <span class="NLM_lpage">675</span>, <span class="refDoi">Â DOI: 10.1016/j.drudis.2009.04.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1016%2Fj.drudis.2009.04.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=19427404" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotFyktLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=668-675&issue=13%E2%80%9314&author=G.+Chessariauthor=A.+J.+Woodhead&title=From+Fragment+to+Clinical+Candidate%2D%2Da+Historical+Perspective&doi=10.1016%2Fj.drudis.2009.04.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">From fragment to clinical candidate-a historical perspective</span></div><div class="casAuthors">Chessari, Gianni; Woodhead, Andrew J.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">13/14</span>),
    <span class="NLM_cas:pages">668-675</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  As recently as ten years ago few scientists had heard of fragment screening, let alone considered low mol. wt. fragments (MW <300) with weak binding affinities to be attractive start points for drug discovery programs.  Today, however, there is widespread acceptance that these fragments can be progressed into lead series and on to become clin. candidates.  Consequently, over the past three to four years, fragment-based drug discovery has become firmly established within the biotechnol. and pharmaceutical industries as a complimentary strategy to high-throughput screening.  In this review, we give a historical perspective of how rapidly fragment-based drug discovery has developed and describe a no. of clin. compds. discovered using this approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIfibakR1lWLVg90H21EOLACvtfcHk0liNu197xQsWoQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotFyktLo%253D&md5=1bd47b7787b1b22681466ad220eb7cd1</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2009.04.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2009.04.007%26sid%3Dliteratum%253Aachs%26aulast%3DChessari%26aufirst%3DG.%26aulast%3DWoodhead%26aufirst%3DA.%2BJ.%26atitle%3DFrom%2520Fragment%2520to%2520Clinical%2520Candidate--a%2520Historical%2520Perspective%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2009%26volume%3D14%26issue%3D13%25E2%2580%259314%26spage%3D668%26epage%3D675%26doi%3D10.1016%2Fj.drudis.2009.04.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keseru, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erlanson, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferenczy, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hann, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickett, S. D.</span></span> <span> </span><span class="NLM_article-title">Design Principles for Fragment Libraries: Maximizing the Value of Learnings from Pharma Fragment-Based Drug Discovery (FBDD) Programs for Use in Academia</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">8189</span>â <span class="NLM_lpage">8206</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.6b00197</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00197" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC28XmvFSit7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8189-8206&issue=18&author=G.+M.+Keseruauthor=D.+A.+Erlansonauthor=G.+G.+Ferenczyauthor=M.+M.+Hannauthor=C.+W.+Murrayauthor=S.+D.+Pickett&title=Design+Principles+for+Fragment+Libraries%3A+Maximizing+the+Value+of+Learnings+from+Pharma+Fragment-Based+Drug+Discovery+%28FBDD%29+Programs+for+Use+in+Academia&doi=10.1021%2Facs.jmedchem.6b00197"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Design Principles for Fragment Libraries: Maximizing the Value of Learnings from Pharma Fragment-Based Drug Discovery (FBDD) Programs for Use in Academia</span></div><div class="casAuthors">Keseru, Gyorgy M.; Erlanson, Daniel A.; Ferenczy, Gyorgy G.; Hann, Michael M.; Murray, Christopher W.; Pickett, Stephen D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8189-8206</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Fragment-based drug discovery (FBDD) is well suited for discovering both drug leads and chem. probes of protein function; it can cover broad swaths of chem. space and allows the use of creative chem.  FBDD is widely implemented for lead discovery in industry but is sometimes used less systematically in academia.  Design principles and implementation approaches for fragment libraries are continually evolving, and the lack of up-to-date guidance may prevent more effective application of FBDD in academia.  This Perspective explores many of the theor., practical, and strategic considerations that occur within FBDD programs, including the optimal size, complexity, physicochem. profile, and shape profile of fragments in FBDD libraries, as well as compd. storage, evaluation, and screening technologies.  This compilation of industry experience in FBDD will hopefully be useful for those pursuing FBDD in academia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkrMUH3yVkGbVg90H21EOLACvtfcHk0liNu197xQsWoQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmvFSit7s%253D&md5=888fe2cf003c5564c2ec391cf54ea2ac</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00197%26sid%3Dliteratum%253Aachs%26aulast%3DKeseru%26aufirst%3DG.%2BM.%26aulast%3DErlanson%26aufirst%3DD.%2BA.%26aulast%3DFerenczy%26aufirst%3DG.%2BG.%26aulast%3DHann%26aufirst%3DM.%2BM.%26aulast%3DMurray%26aufirst%3DC.%2BW.%26aulast%3DPickett%26aufirst%3DS.%2BD.%26atitle%3DDesign%2520Principles%2520for%2520Fragment%2520Libraries%253A%2520Maximizing%2520the%2520Value%2520of%2520Learnings%2520from%2520Pharma%2520Fragment-Based%2520Drug%2520Discovery%2520%2528FBDD%2529%2520Programs%2520for%2520Use%2520in%2520Academia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D18%26spage%3D8189%26epage%3D8206%26doi%3D10.1021%2Facs.jmedchem.6b00197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parker, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galmozzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correia, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joslyn, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavallaro, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narvaiza, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span> <span> </span><span class="NLM_article-title">Ligand and Target Discovery by Fragment-Based Screening in Human Cells</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>168</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">527</span>â <span class="NLM_lpage">541</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2016.12.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1016%2Fj.cell.2016.12.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=28111073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVeiu7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=2017&pages=527-541&issue=3&author=C.+G.+Parkerauthor=A.+Galmozziauthor=Y.+Wangauthor=B.+E.+Correiaauthor=K.+Sasakiauthor=C.+M.+Joslynauthor=A.+S.+Kimauthor=C.+L.+Cavallaroauthor=R.+M.+Lawrenceauthor=S.+R.+Johnsonauthor=I.+Narvaizaauthor=E.+Saezauthor=B.+F.+Cravatt&title=Ligand+and+Target+Discovery+by+Fragment-Based+Screening+in+Human+Cells&doi=10.1016%2Fj.cell.2016.12.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand and Target Discovery by Fragment-Based Screening in Human Cells</span></div><div class="casAuthors">Parker, Christopher G.; Galmozzi, Andrea; Wang, Yujia; Correia, Bruno E.; Sasaki, Kenji; Joslyn, Christopher M.; Kim, Arthur S.; Cavallaro, Cullen L.; Lawrence, R. Michael; Johnson, Stephen R.; Narvaiza, Inigo; Saez, Enrique; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">168</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">527-541.e29</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Advances in the synthesis and screening of small-mol. libraries have accelerated the discovery of chem. probes for studying biol. processes.  Still, only a small fraction of the human proteome has chem. ligands.  Here, we describe a platform that marries fragment-based ligand discovery with quant. chem. proteomics to map thousands of reversible small mol.-protein interactions directly in human cells, many of which can be site-specifically detd.  We show that fragment hits can be advanced to furnish selective ligands that affect the activity of proteins heretofore lacking chem. probes.  We further combine fragment-based chem. proteomics with phenotypic screening to identify small mols. that promote adipocyte differentiation by engaging the poorly characterized membrane protein PGRMC2.  Fragment-based screening in human cells thus provides an extensive proteome-wide map of protein ligandability and facilitates the coordinated discovery of bioactive small mols. and their mol. targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPk-YJwFlDwbVg90H21EOLACvtfcHk0lhDFpOWm_CPPQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVeiu7Y%253D&md5=835264291015037ab9b7e446992caba3</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2016.12.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2016.12.029%26sid%3Dliteratum%253Aachs%26aulast%3DParker%26aufirst%3DC.%2BG.%26aulast%3DGalmozzi%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DCorreia%26aufirst%3DB.%2BE.%26aulast%3DSasaki%26aufirst%3DK.%26aulast%3DJoslyn%26aufirst%3DC.%2BM.%26aulast%3DKim%26aufirst%3DA.%2BS.%26aulast%3DCavallaro%26aufirst%3DC.%2BL.%26aulast%3DLawrence%26aufirst%3DR.%2BM.%26aulast%3DJohnson%26aufirst%3DS.%2BR.%26aulast%3DNarvaiza%26aufirst%3DI.%26aulast%3DSaez%26aufirst%3DE.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DLigand%2520and%2520Target%2520Discovery%2520by%2520Fragment-Based%2520Screening%2520in%2520Human%2520Cells%26jtitle%3DCell%26date%3D2017%26volume%3D168%26issue%3D3%26spage%3D527%26epage%3D541%26doi%3D10.1016%2Fj.cell.2016.12.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lajiness, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maggiora, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shanmugasundaram, V.</span></span> <span> </span><span class="NLM_article-title">Assessment of the Consistency of Medicinal Chemists in Reviewing Sets of Compounds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">4891</span>â <span class="NLM_lpage">4896</span>, <span class="refDoi">Â DOI: 10.1021/jm049740z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049740z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmvVejtL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=4891-4896&issue=20&author=M.+S.+Lajinessauthor=G.+M.+Maggioraauthor=V.+Shanmugasundaram&title=Assessment+of+the+Consistency+of+Medicinal+Chemists+in+Reviewing+Sets+of+Compounds&doi=10.1021%2Fjm049740z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Assessment of the Consistency of Medicinal Chemists in Reviewing Sets of Compounds</span></div><div class="casAuthors">Lajiness, Michael S.; Maggiora, Gerald M.; Shanmugasundaram, Veerabahu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">4891-4896</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Medicinal chemists are frequently asked to review lists of compds. to assess their drug- or lead-like nature and to evaluate the suitability of lead compds. based on their "attractiveness" and/or synthetic feasibility as a basis for launching a drug-discovery campaign.  It is often felt that one medicinal chemist's opinion is as good as any other, but is it.  In an attempt to answer this question, an expt. was performed in conjunction with a recent compd. acquisition program (CAP) conducted at Pharmacia.  Historically, the CAP included a review of many thousands of compds. by medicinal chemists who eliminate anything deemed undesirable for any reason.  In a review conducted in 2002, about 22 000 compds. requiring review by medicinal chemists were broken down into 11 lists of approx. 2000 compds. each.  Unknown to the medicinal chemists, a subset of 250 compds., previously rejected by a very experienced senior medicinal chemist, was added to each of the lists.  Most of the 13 medicinal chemists who participated in this process reviewed two lists, although some only reviewed a single list and one reviewed three lists.  Those compds. that were deemed unacceptable were recorded and tabulated in various ways to assess the consistency of the reviews.  It was found that medicinal chemists were not very consistent in the compds. they rejected as being undesirable.  The inconsistency arises from the subjective anal. that all humans utilize when considering "data sets" of any kind.  This has important implications for pharmaceutical project teams where individual medicinal chemists review lists of primary screening hits to identify those compds. suitable for follow-up.  Once a compd. is removed from a list, it and other structurally similar compds. are effectively removed from further consideration.  This can also have an impact on computational chemists who are developing models for assessing the desirability or attractiveness of different classes of compds. for lead discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZPYRvqjXJjLVg90H21EOLACvtfcHk0lhDFpOWm_CPPQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmvVejtL0%253D&md5=d5f8cbd4a56bb4c22782a3beccb3eefd</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1021%2Fjm049740z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049740z%26sid%3Dliteratum%253Aachs%26aulast%3DLajiness%26aufirst%3DM.%2BS.%26aulast%3DMaggiora%26aufirst%3DG.%2BM.%26aulast%3DShanmugasundaram%26aufirst%3DV.%26atitle%3DAssessment%2520of%2520the%2520Consistency%2520of%2520Medicinal%2520Chemists%2520in%2520Reviewing%2520Sets%2520of%2520Compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26issue%3D20%26spage%3D4891%26epage%3D4896%26doi%3D10.1021%2Fjm049740z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oleinikovas, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saladino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cossins, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gervasio, F. L.</span></span> <span> </span><span class="NLM_article-title">Understanding Cryptic Pocket Formation in Protein Targets by Enhanced Sampling Simulations</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>138</i></span> (<span class="NLM_issue">43</span>),  <span class="NLM_fpage">14257</span>â <span class="NLM_lpage">14263</span>, <span class="refDoi">Â DOI: 10.1021/jacs.6b05425</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.6b05425" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1CmtbnN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2016&pages=14257-14263&issue=43&author=V.+Oleinikovasauthor=G.+Saladinoauthor=B.+P.+Cossinsauthor=F.+L.+Gervasio&title=Understanding+Cryptic+Pocket+Formation+in+Protein+Targets+by+Enhanced+Sampling+Simulations&doi=10.1021%2Fjacs.6b05425"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding Cryptic Pocket Formation in Protein Targets by Enhanced Sampling Simulations</span></div><div class="casAuthors">Oleinikovas, Vladimiras; Saladino, Giorgio; Cossins, Benjamin P.; Gervasio, Francesco L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">14257-14263</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cryptic pockets, i.e. sites on protein targets that only become apparent when drugs bind, provide a promising alternative to classical binding sites for drug development.  Here the authors investigate the nature and dynamical properties of cryptic sites in four pharmacol. relevant targets, while comparing the efficacy of various simulation-based approaches in discovering them.  The authors find that the studied cryptic sites do not correspond to local min. in the computed conformational free energy landscape of the unliganded proteins.  They thus promptly close in all the mol. dynamics simulations performed, irresp. of the force-field used.  Temp.-based enhanced sampling approaches, such as Parallel Tempering, do not improve the situation, as the entropic term does not help in the opening of the sites.  The use of fragment probes helps, as in long simulations occasionally it leads to the opening and binding to the cryptic sites.  The obsd. mechanism of cryptic site formation is suggestive of an interplay between two classical mechanisms: induced-fit and conformational selection.  Employing this insight the authors developed a novel Hamiltonian Replica Exchange-based method "SWISH" (Sampling Water Interfaces through Scaled Hamiltonians), which combined with probes resulted in a promising general approach for cryptic site discovery.  The authors also addressed the issue of "false-positives" and propose a simple approach to distinguish them from druggable cryptic pockets.  The simulations, whose cumulative sampling time was more than 200 Î¼s, help clarifying the mol. mechanism of pocket formation, providing a solid basis for the choice of an efficient computational method.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowDhS6qnF6EbVg90H21EOLACvtfcHk0lhDFpOWm_CPPQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1CmtbnN&md5=9517e79e24851fa8c89b71b91123c34e</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1021%2Fjacs.6b05425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.6b05425%26sid%3Dliteratum%253Aachs%26aulast%3DOleinikovas%26aufirst%3DV.%26aulast%3DSaladino%26aufirst%3DG.%26aulast%3DCossins%26aufirst%3DB.%2BP.%26aulast%3DGervasio%26aufirst%3DF.%2BL.%26atitle%3DUnderstanding%2520Cryptic%2520Pocket%2520Formation%2520in%2520Protein%2520Targets%2520by%2520Enhanced%2520Sampling%2520Simulations%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2016%26volume%3D138%26issue%3D43%26spage%3D14257%26epage%3D14263%26doi%3D10.1021%2Fjacs.6b05425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ludlow, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verdonk, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saini, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tickle, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jhoti, H.</span></span> <span> </span><span class="NLM_article-title">Detection of Secondary Binding Sites in Proteins Using Fragment Screening</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>112</i></span> (<span class="NLM_issue">52</span>),  <span class="NLM_fpage">15910</span>â <span class="NLM_lpage">15915</span>, <span class="refDoi">Â DOI: 10.1073/pnas.1518946112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1073%2Fpnas.1518946112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=26655740" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2kt7zP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=15910-15915&issue=52&author=R.+F.+Ludlowauthor=M.+L.+Verdonkauthor=H.+K.+Sainiauthor=I.+J.+Tickleauthor=H.+Jhoti&title=Detection+of+Secondary+Binding+Sites+in+Proteins+Using+Fragment+Screening&doi=10.1073%2Fpnas.1518946112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Detection of secondary binding sites in proteins using fragment screening</span></div><div class="casAuthors">Ludlow, R. Frederick; Verdonk, Marcel L.; Saini, Harpreet K.; Tickle, Ian J.; Jhoti, Harren</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">52</span>),
    <span class="NLM_cas:pages">15910-15915</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Proteins need to be tightly regulated as they control biol. processes in most normal cellular functions.  The precise mechanisms of regulation are rarely completely understood but can involve binding of endogenous ligands and/or partner proteins at specific locations on a protein that can modulate function.  Often, these addnl. secondary binding sites appear sep. to the primary binding site, which, e.g., for an enzyme may bind a substrate.  In previous work, the authors uncovered several examples in which secondary binding sites were discovered on proteins using fragment screening approaches.  In each case, the authors were able to establish that the newly identified secondary binding site was biol. relevant as it was able to modulate function by the binding of a small mol.  Here, the authors investigated how often secondary binding sites are located on proteins by analyzing 24 protein targets for which they performed a fragment screen using x-ray crystallog.  The anal. showed that, surprisingly, the majority of proteins contained secondary binding sites based on their ability to bind fragments.  Furthermore, sequence anal. of these previously unknown sites indicated high conservation, which suggested that they may have a biol. function, perhaps via an allosteric mechanism.  Comparing the physicochem. properties of the secondary sites with known primary ligand-binding sites also showed broad similarities indicating that many of the secondary sites may be druggable in nature with small mols. that could provide new opportunities to modulate potential therapeutic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0ITF1w230fbVg90H21EOLACvtfcHk0lgAttkNd8GLJw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2kt7zP&md5=9e5f15595263dc049c713d5a3f5912a1</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1518946112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1518946112%26sid%3Dliteratum%253Aachs%26aulast%3DLudlow%26aufirst%3DR.%2BF.%26aulast%3DVerdonk%26aufirst%3DM.%2BL.%26aulast%3DSaini%26aufirst%3DH.%2BK.%26aulast%3DTickle%26aufirst%3DI.%2BJ.%26aulast%3DJhoti%26aufirst%3DH.%26atitle%3DDetection%2520of%2520Secondary%2520Binding%2520Sites%2520in%2520Proteins%2520Using%2520Fragment%2520Screening%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2015%26volume%3D112%26issue%3D52%26spage%3D15910%26epage%3D15915%26doi%3D10.1073%2Fpnas.1518946112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hart, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moeder, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, C. M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerman, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frederick, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, G. R.</span></span> <span> </span><span class="NLM_article-title">Designing Small Molecules to Target Cryptic Pockets Yields Both Positive and Negative Allosteric Modulators</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">e0178678</span>, <span class="refDoi">Â DOI: 10.1371/journal.pone.0178678</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1371%2Fjournal.pone.0178678" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=e0178678&issue=6&author=K.+M.+Hartauthor=K.+E.+Moederauthor=C.+M.+W.+Hoauthor=M.+I.+Zimmermanauthor=T.+E.+Frederickauthor=G.+R.+Bowman&title=Designing+Small+Molecules+to+Target+Cryptic+Pockets+Yields+Both+Positive+and+Negative+Allosteric+Modulators&doi=10.1371%2Fjournal.pone.0178678"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0178678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0178678%26sid%3Dliteratum%253Aachs%26aulast%3DHart%26aufirst%3DK.%2BM.%26aulast%3DMoeder%26aufirst%3DK.%2BE.%26aulast%3DHo%26aufirst%3DC.%2BM.%2BW.%26aulast%3DZimmerman%26aufirst%3DM.%2BI.%26aulast%3DFrederick%26aufirst%3DT.%2BE.%26aulast%3DBowman%26aufirst%3DG.%2BR.%26atitle%3DDesigning%2520Small%2520Molecules%2520to%2520Target%2520Cryptic%2520Pockets%2520Yields%2520Both%2520Positive%2520and%2520Negative%2520Allosteric%2520Modulators%26jtitle%3DPLoS%2520One%26date%3D2017%26volume%3D12%26issue%3D6%26spage%3De0178678%26doi%3D10.1371%2Fjournal.pone.0178678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span> <span> </span><span class="NLM_article-title">The Influence of Target Family and Functional Activity on the Physicochemical Properties of Pre-Clinical Compounds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2969</span>â <span class="NLM_lpage">2978</span>, <span class="refDoi">Â DOI: 10.1021/jm0512185</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0512185" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=2969-2978&issue=10&author=R.+Morphy&title=The+Influence+of+Target+Family+and+Functional+Activity+on+the+Physicochemical+Properties+of+Pre-Clinical+Compounds&doi=10.1021%2Fjm0512185"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1021%2Fjm0512185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0512185%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26atitle%3DThe%2520Influence%2520of%2520Target%2520Family%2520and%2520Functional%2520Activity%2520on%2520the%2520Physicochemical%2520Properties%2520of%2520Pre-Clinical%2520Compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26issue%3D10%26spage%3D2969%26epage%3D2978%26doi%3D10.1021%2Fjm0512185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waring, M.
J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrowsmith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandrell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pairaudeau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennie, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickett, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weir, A.</span></span> <span> </span><span class="NLM_article-title">An Analysis of the Attrition of Drug Candidates from Four Major Pharmaceutical Companies</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">475</span>â <span class="NLM_lpage">486</span>, <span class="refDoi">Â DOI: 10.1038/nrd4609</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1038%2Fnrd4609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=26091267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7jM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=475-486&issue=7&author=M.%0AJ.+Waringauthor=J.+Arrowsmithauthor=A.+R.+Leachauthor=P.+D.+Leesonauthor=S.+Mandrellauthor=R.+M.+Owenauthor=G.+Pairaudeauauthor=W.+D.+Pennieauthor=S.+D.+Pickettauthor=J.+Wangauthor=O.+Wallaceauthor=A.+Weir&title=An+Analysis+of+the+Attrition+of+Drug+Candidates+from+Four+Major+Pharmaceutical+Companies&doi=10.1038%2Fnrd4609"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">An analysis of the attrition of drug candidates from four major pharmaceutical companies</span></div><div class="casAuthors">Waring, Michael J.; Arrowsmith, John; Leach, Andrew R.; Leeson, Paul D.; Mandrell, Sam; Owen, Robert M.; Pairaudeau, Garry; Pennie, William D.; Pickett, Stephen D.; Wang, Jibo; Wallace, Owen; Weir, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">475-486</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The pharmaceutical industry remains under huge pressure to address the high attrition rates in drug development.  Attempts to reduce the no. of efficacy- and safety-related failures by analyzing possible links to the physicochem. properties of small-mol. drug candidates have been inconclusive because of the limited size of data sets from individual companies.  Here, we describe the compilation and anal. of combined data on the attrition of drug candidates from AstraZeneca, Eli Lilly and Company, GlaxoSmithKline and Pfizer.  The anal. reaffirms that control of physicochem. properties during compd. optimization is beneficial in identifying compds. of candidate drug quality and indicates for the first time a link between the physicochem. properties of compds. and clin. failure due to safety issues.  The results also suggest that further control of physicochem. properties is unlikely to have a significant effect on attrition rates and that addnl. work is required to address safety-related failures.  Further cross-company collaborations will be crucial to future progress in this area.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsLfBWrLC3ZLVg90H21EOLACvtfcHk0lgAttkNd8GLJw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7jM&md5=1fdc374d32816b1e91438152299dd1b1</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1038%2Fnrd4609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4609%26sid%3Dliteratum%253Aachs%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26aulast%3DArrowsmith%26aufirst%3DJ.%26aulast%3DLeach%26aufirst%3DA.%2BR.%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DMandrell%26aufirst%3DS.%26aulast%3DOwen%26aufirst%3DR.%2BM.%26aulast%3DPairaudeau%26aufirst%3DG.%26aulast%3DPennie%26aufirst%3DW.%2BD.%26aulast%3DPickett%26aufirst%3DS.%2BD.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWallace%26aufirst%3DO.%26aulast%3DWeir%26aufirst%3DA.%26atitle%3DAn%2520Analysis%2520of%2520the%2520Attrition%2520of%2520Drug%2520Candidates%2520from%2520Four%2520Major%2520Pharmaceutical%2520Companies%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26issue%3D7%26spage%3D475%26epage%3D486%26doi%3D10.1038%2Fnrd4609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soulard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caffrey, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salzberg, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, E. S.</span></span> <span> </span><span class="NLM_article-title">Structure-Based Maximal Affinity Model Predicts Small-Molecule Druggability</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">71</span>â <span class="NLM_lpage">75</span>, <span class="refDoi">Â DOI: 10.1038/nbt1273</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1038%2Fnbt1273" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=17211405" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BD2sXis1Grtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=71-75&issue=1&author=A.+C.+Chengauthor=R.+G.+Colemanauthor=K.+T.+Smythauthor=Q.+Caoauthor=P.+Soulardauthor=D.+R.+Caffreyauthor=A.+C.+Salzbergauthor=E.+S.+Huang&title=Structure-Based+Maximal+Affinity+Model+Predicts+Small-Molecule+Druggability&doi=10.1038%2Fnbt1273"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based maximal affinity model predicts small-molecule druggability</span></div><div class="casAuthors">Cheng, Alan C.; Coleman, Ryan G.; Smyth, Kathleen T.; Cao, Qing; Soulard, Patricia; Caffrey, Daniel R.; Salzberg, Anna C.; Huang, Enoch S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">71-75</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Lead generation is a major hurdle in small-mol. drug discovery, with an estd. 60% of projects failing from lack of lead matter or difficulty in optimizing leads for drug-like properties.  It would be valuable to identify these less-druggable targets before incurring substantial expenditure and effort.  Here we show that a model-based approach using basic biophys. principles yields good prediction of druggability based solely on the crystal structure of the target binding site.  We quant. est. the maximal affinity achievable by a drug-like mol., and we show that these calcd. values correlate with drug discovery outcomes.  We exptl. test two predictions using high-throughput screening of a diverse compd. collection.  The collective results highlight the utility of our approach as well as strategies for tackling difficult targets.  Both assays are simple, suitable for rapid screening of a large no. of medicinal libraries, and amenable for automation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomQJn2NNwCFLVg90H21EOLACvtfcHk0lizZBR79g3uuw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXis1Grtg%253D%253D&md5=e971faf87bf4b91602bf592b9296325b</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1038%2Fnbt1273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1273%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DA.%2BC.%26aulast%3DColeman%26aufirst%3DR.%2BG.%26aulast%3DSmyth%26aufirst%3DK.%2BT.%26aulast%3DCao%26aufirst%3DQ.%26aulast%3DSoulard%26aufirst%3DP.%26aulast%3DCaffrey%26aufirst%3DD.%2BR.%26aulast%3DSalzberg%26aufirst%3DA.%2BC.%26aulast%3DHuang%26aufirst%3DE.%2BS.%26atitle%3DStructure-Based%2520Maximal%2520Affinity%2520Model%2520Predicts%2520Small-Molecule%2520Druggability%26jtitle%3DNat.%2520Biotechnol.%26date%3D2007%26volume%3D25%26issue%3D1%26spage%3D71%26epage%3D75%26doi%3D10.1038%2Fnbt1273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Courtney, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hesterkamp, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, M.</span></span> <span> </span><span class="NLM_article-title">Fragment Screening by Biochemical Assay</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">225</span>â <span class="NLM_lpage">236</span>, <span class="refDoi">Â DOI: 10.1517/17460441.1.3.225</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1517%2F17460441.1.3.225" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2006&pages=225-236&issue=3&author=J.+Barkerauthor=S.+Courtneyauthor=T.+Hesterkampauthor=D.+Ullmannauthor=M.+Whittaker&title=Fragment+Screening+by+Biochemical+Assay&doi=10.1517%2F17460441.1.3.225"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1517%2F17460441.1.3.225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.1.3.225%26sid%3Dliteratum%253Aachs%26aulast%3DBarker%26aufirst%3DJ.%26aulast%3DCourtney%26aufirst%3DS.%26aulast%3DHesterkamp%26aufirst%3DT.%26aulast%3DUllmann%26aufirst%3DD.%26aulast%3DWhittaker%26aufirst%3DM.%26atitle%3DFragment%2520Screening%2520by%2520Biochemical%2520Assay%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2006%26volume%3D1%26issue%3D3%26spage%3D225%26epage%3D236%26doi%3D10.1517%2F17460441.1.3.225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boettcher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruedisser, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erbel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinzenz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiering, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassiepen, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rigollier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayr, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woelcke, J.</span></span> <span> </span><span class="NLM_article-title">Fragment-Based Screening by Biochemical Assays: Systematic Feasibility Studies with Trypsin and MMP12</span>. <i>J. Biomol. Screening</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1029</span>â <span class="NLM_lpage">1041</span>, <span class="refDoi">Â DOI: 10.1177/1087057110380455</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1177%2F1087057110380455" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=20855559" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVajsL3J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2010&pages=1029-1041&issue=9&author=A.+Boettcherauthor=S.+Ruedisserauthor=P.+Erbelauthor=D.+Vinzenzauthor=N.+Schieringauthor=U.+Hassiepenauthor=P.+Rigollierauthor=L.+M.+Mayrauthor=J.+Woelcke&title=Fragment-Based+Screening+by+Biochemical+Assays%3A+Systematic+Feasibility+Studies+with+Trypsin+and+MMP12&doi=10.1177%2F1087057110380455"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-based screening by biochemical assays: systematic feasibility studies with trypsin and MMP12</span></div><div class="casAuthors">Boettcher, Andreas; Ruedisser, Simon; Erbel, Paulus; Vinzenz, Daniela; Schiering, Nikolaus; Hassiepen, Ulrich; Rigollier, Pascal; Mayr, Lorenz M.; Woelcke, Julian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1029-1041</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Fragment-based screening (FBS) has gained acceptance in the pharmaceutical industry as an attractive approach for the identification of new chem. starting points for drug discovery programs in addn. to classical strategies such as high-throughput screening.  There is the concern that screening of fragments at high Î¼M concns. in biochem. assays results in increased false-pos. and false-neg. rates.  Here the authors systematically compare the data quality of FBS obtained by enzyme activity-based fluorescence intensity, fluorescence lifetime, and mobility shift assays with the data quality from surface plasmon resonance (SPR) and NMR methods.  The serine protease trypsin and the matrix metalloprotease MMP12 were selected as model systems.  For both studies, 352 fragments were selected each.  From the data generated, all 3 biochem. protease assay methods can be used for screening of fragments with low false-neg. and low false-pos. rates, comparable to those achieved with the SPR-based assays.  It can also be concluded that only fragments with a soly. higher than the screening concn. detd. by means of NMR should be used for FBS purposes.  Extrapolated to 10,000 fragments, the biochem. assays speed up the primary FBS process by approx. a factor of 10 and reduce the protease consumption by approx. 10,000-fold compared to NMR protein observation expts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_ivr2TNQFjrVg90H21EOLACvtfcHk0lizZBR79g3uuw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVajsL3J&md5=79b8d6d012e055adf8af3f0534ecafe0</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1177%2F1087057110380455&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057110380455%26sid%3Dliteratum%253Aachs%26aulast%3DBoettcher%26aufirst%3DA.%26aulast%3DRuedisser%26aufirst%3DS.%26aulast%3DErbel%26aufirst%3DP.%26aulast%3DVinzenz%26aufirst%3DD.%26aulast%3DSchiering%26aufirst%3DN.%26aulast%3DHassiepen%26aufirst%3DU.%26aulast%3DRigollier%26aufirst%3DP.%26aulast%3DMayr%26aufirst%3DL.%2BM.%26aulast%3DWoelcke%26aufirst%3DJ.%26atitle%3DFragment-Based%2520Screening%2520by%2520Biochemical%2520Assays%253A%2520Systematic%2520Feasibility%2520Studies%2520with%2520Trypsin%2520and%2520MMP12%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2010%26volume%3D15%26issue%3D9%26spage%3D1029%26epage%3D1041%26doi%3D10.1177%2F1087057110380455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erlanson, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, D. C.</span></span> <span> </span><span class="NLM_article-title">Fragment-to-Lead Medicinal Chemistry Publications in 2015</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">89</span>â <span class="NLM_lpage">99</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.6b01123</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01123" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=89-99&issue=1&author=C.+N.+Johnsonauthor=D.+A.+Erlansonauthor=C.+W.+Murrayauthor=D.+C.+Rees&title=Fragment-to-Lead+Medicinal+Chemistry+Publications+in+2015&doi=10.1021%2Facs.jmedchem.6b01123"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01123%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DC.%2BN.%26aulast%3DErlanson%26aufirst%3DD.%2BA.%26aulast%3DMurray%26aufirst%3DC.%2BW.%26aulast%3DRees%26aufirst%3DD.%2BC.%26atitle%3DFragment-to-Lead%2520Medicinal%2520Chemistry%2520Publications%2520in%25202015%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D1%26spage%3D89%26epage%3D99%26doi%3D10.1021%2Facs.jmedchem.6b01123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erlanson, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahnke, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortenson, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, D. C.</span></span> <span> </span><span class="NLM_article-title">Fragment-to-Lead Medicinal Chemistry Publications in 2016</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1774</span>â <span class="NLM_lpage">1784</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.7b01298</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01298" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1774-1784&issue=5&author=C.+N.+Johnsonauthor=D.+A.+Erlansonauthor=W.+Jahnkeauthor=P.+N.+Mortensonauthor=D.+C.+Rees&title=Fragment-to-Lead+Medicinal+Chemistry+Publications+in+2016&doi=10.1021%2Facs.jmedchem.7b01298"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01298%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DC.%2BN.%26aulast%3DErlanson%26aufirst%3DD.%2BA.%26aulast%3DJahnke%26aufirst%3DW.%26aulast%3DMortenson%26aufirst%3DP.%2BN.%26aulast%3DRees%26aufirst%3DD.%2BC.%26atitle%3DFragment-to-Lead%2520Medicinal%2520Chemistry%2520Publications%2520in%25202016%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D5%26spage%3D1774%26epage%3D1784%26doi%3D10.1021%2Facs.jmedchem.7b01298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':[],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 22 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Hongxiang Li, Wangyu Shi, Chang Wang, Hao Liu, Wei Wang, Yongjun Wu, <span class="NLM_string-name hlFld-ContribAuthor">Hongchao Guo</span>. </span><span class="cited-content_cbyCitation_article-title">Phosphine-Catalyzed Cascade Annulation of MBH Carbonates and Diazenes: Synthesis of Hexahydrocyclopenta[c]pyrazole Derivatives. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2021,</strong> <em>23 </em>
                                    (14)
                                     , 5571-5575. <a href="https://doi.org/10.1021/acs.orglett.1c01975" title="DOI URL">https://doi.org/10.1021/acs.orglett.1c01975</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.1c01975&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.1c01975%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DPhosphine-Catalyzed%252BCascade%252BAnnulation%252Bof%252BMBH%252BCarbonates%252Band%252BDiazenes%25253A%252BSynthesis%252Bof%252BHexahydrocyclopenta%25255Bc%25255Dpyrazole%252BDerivatives%26aulast%3DLi%26aufirst%3DHongxiang%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D14062021%26date%3D07072021%26volume%3D23%26issue%3D14%26spage%3D5571%26epage%3D5575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Paul D. Leeson, A. Patricia Bento, Anna Gaulton, Anne Hersey, Emma J. Manners, Chris J. Radoux, <span class="NLM_string-name hlFld-ContribAuthor">Andrew R. Leach</span>. </span><span class="cited-content_cbyCitation_article-title">Target-Based Evaluation of âDrug-Likeâ Properties and Ligand Efficiencies. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (11)
                                     , 7210-7230. <a href="https://doi.org/10.1021/acs.jmedchem.1c00416" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00416</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00416&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00416%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTarget-Based%252BEvaluation%252Bof%252B%2525E2%252580%25259CDrug-Like%2525E2%252580%25259D%252BProperties%252Band%252BLigand%252BEfficiencies%26aulast%3DLeeson%26aufirst%3DPaul%2BD.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D08032021%26date%3D13052021%26volume%3D64%26issue%3D11%26spage%3D7210%26epage%3D7230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Hao Zhang, Hao-Chi Hsu, Shoshanna C. Kahne, Ryoma Hara, Wenhu Zhan, Xiuju Jiang, Kristin Burns-Huang, Tierra Ouellette, Toshihiro Imaeda, Rei Okamoto, Masanori Kawasaki, Mayako Michino, Tzu-Tshin Wong, Akinori Toita, Takafumi Yukawa, Francesca Moraca, Jeremie Vendome, Priya Saha, Kenjiro Sato, Kazuyoshi Aso, John Ginn, Peter T. Meinke, Michael Foley, Carl F. Nathan, K. Heran Darwin, Huilin Li, <span class="NLM_string-name hlFld-ContribAuthor">Gang Lin</span>. </span><span class="cited-content_cbyCitation_article-title">Macrocyclic Peptides that Selectively Inhibit the Mycobacterium tuberculosis Proteasome. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (9)
                                     , 6262-6272. <a href="https://doi.org/10.1021/acs.jmedchem.1c00296" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00296</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00296&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00296%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMacrocyclic%252BPeptides%252Bthat%252BSelectively%252BInhibit%252Bthe%252BMycobacterium%252Btuberculosis%252BProteasome%26aulast%3DZhang%26aufirst%3DHao%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D15022021%26date%3D05052021%26volume%3D64%26issue%3D9%26spage%3D6262%26epage%3D6272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Marta Serafini, Sarah Cargnin, Alberto Massarotti, Gian Cesare Tron, Tracey Pirali, <span class="NLM_string-name hlFld-ContribAuthor">Armando A. Genazzani</span>. </span><span class="cited-content_cbyCitation_article-title">Whatâs in a Name? Drug Nomenclature and Medicinal Chemistry Trends using INN Publications. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (8)
                                     , 4410-4429. <a href="https://doi.org/10.1021/acs.jmedchem.1c00181" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00181</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00181&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00181%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DWhat%2525E2%252580%252599s%252Bin%252Ba%252BName%25253F%252BDrug%252BNomenclature%252Band%252BMedicinal%252BChemistry%252BTrends%252Busing%252BINN%252BPublications%26aulast%3DSerafini%26aufirst%3DMarta%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D01022021%26date%3D13042021%26volume%3D64%26issue%3D8%26spage%3D4410%26epage%3D4429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Pengfei Wang, Qijie Gong, Jiabao Hu, Xiang Li, <span class="NLM_string-name hlFld-ContribAuthor">Xiaojin Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Reactive Oxygen Species (ROS)-Responsive Prodrugs, Probes, and Theranostic Prodrugs: Applications in the ROS-Related Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (1)
                                     , 298-325. <a href="https://doi.org/10.1021/acs.jmedchem.0c01704" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01704</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01704%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DReactive%252BOxygen%252BSpecies%252B%252528ROS%252529-Responsive%252BProdrugs%25252C%252BProbes%25252C%252Band%252BTheranostic%252BProdrugs%25253A%252BApplications%252Bin%252Bthe%252BROS-Related%252BDiseases%26aulast%3DWang%26aufirst%3DPengfei%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D28092020%26date%3D23122020%26volume%3D64%26issue%3D1%26spage%3D298%26epage%3D325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Marco Tutone, Ivana Pibiri, Riccardo Perriera, Ambra Campofelice, Giulia Culletta, Raffaella Melfi, Andrea Pace, Anna Maria Almerico, <span class="NLM_string-name hlFld-ContribAuthor">Laura Lentini</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacophore-Based Design of New Chemical Scaffolds as Translational Readthrough-Inducing Drugs (TRIDs). </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (5)
                                     , 747-753. <a href="https://doi.org/10.1021/acsmedchemlett.9b00609" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00609</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00609%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DPharmacophore-Based%252BDesign%252Bof%252BNew%252BChemical%252BScaffolds%252Bas%252BTranslational%252BReadthrough-Inducing%252BDrugs%252B%252528TRIDs%252529%26aulast%3DTutone%26aufirst%3DMarco%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D16122019%26date%3D18022020%26date%3D20022020%26date%3D18022020%26volume%3D11%26issue%3D5%26spage%3D747%26epage%3D753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Gaochan Wu, Tong Zhao, Dongwei Kang, Jian Zhang, Yuning Song, Vigneshwaran Namasivayam, Jacob Kongsted, Christophe Pannecouque, Erik De Clercq, Vasanthanathan Poongavanam, Xinyong Liu, <span class="NLM_string-name hlFld-ContribAuthor">Peng Zhan</span>. </span><span class="cited-content_cbyCitation_article-title">Overview of Recent Strategic Advances in Medicinal Chemistry. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (21)
                                     , 9375-9414. <a href="https://doi.org/10.1021/acs.jmedchem.9b00359" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00359</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00359&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00359%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DOverview%252Bof%252BRecent%252BStrategic%252BAdvances%252Bin%252BMedicinal%252BChemistry%26aulast%3DWu%26aufirst%3DGaochan%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D26022019%26date%3D28052019%26date%3D03052019%26volume%3D62%26issue%3D21%26spage%3D9375%26epage%3D9414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Chang Wang, Yuehua Chen, Jingyu Li, Leijie Zhou, Bo Wang, Yumei Xiao, <span class="NLM_string-name hlFld-ContribAuthor">Hongchao Guo</span>. </span><span class="cited-content_cbyCitation_article-title">Phosphine-Catalyzed Asymmetric Cycloaddition Reaction of Diazenes: Enantioselective Synthesis of Chiral Dihydropyrazoles. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2019,</strong> <em>21 </em>
                                    (18)
                                     , 7519-7523. <a href="https://doi.org/10.1021/acs.orglett.9b02800" title="DOI URL">https://doi.org/10.1021/acs.orglett.9b02800</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.9b02800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.9b02800%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DPhosphine-Catalyzed%252BAsymmetric%252BCycloaddition%252BReaction%252Bof%252BDiazenes%25253A%252BEnantioselective%252BSynthesis%252Bof%252BChiral%252BDihydropyrazoles%26aulast%3DWang%26aufirst%3DChang%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D07082019%26date%3D04092019%26volume%3D21%26issue%3D18%26spage%3D7519%26epage%3D7523" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Marco Tutone, Ivana Pibiri, Laura Lentini, Andrea Pace, <span class="NLM_string-name hlFld-ContribAuthor">Anna Maria Almerico</span>. </span><span class="cited-content_cbyCitation_article-title">Deciphering the Nonsense Readthrough Mechanism of Action of Ataluren: An in Silico Compared Study. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>10 </em>
                                    (4)
                                     , 522-527. <a href="https://doi.org/10.1021/acsmedchemlett.8b00558" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.8b00558</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.8b00558&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.8b00558%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDeciphering%252Bthe%252BNonsense%252BReadthrough%252BMechanism%252Bof%252BAction%252Bof%252BAtaluren%25253A%252BAn%252Bin%252BSilico%252BCompared%252BStudy%26aulast%3DTutone%26aufirst%3DMarco%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D19112018%26date%3D07022019%26date%3D13022019%26date%3D07022019%26volume%3D10%26issue%3D4%26spage%3D522%26epage%3D527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hossein  Mousavi</span>. </span><span class="cited-content_cbyCitation_article-title">A comprehensive survey upon diverse and prolific applications of chitosan-based catalytic systems in one-pot multi-component synthesis of heterocyclic rings. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Biological Macromolecules</span><span> <strong>2021,</strong> <em>57 </em><a href="https://doi.org/10.1016/j.ijbiomac.2021.06.123" title="DOI URL">https://doi.org/10.1016/j.ijbiomac.2021.06.123</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ijbiomac.2021.06.123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ijbiomac.2021.06.123%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Biological%2520Macromolecules%26atitle%3DA%252Bcomprehensive%252Bsurvey%252Bupon%252Bdiverse%252Band%252Bprolific%252Bapplications%252Bof%252Bchitosan-based%252Bcatalytic%252Bsystems%252Bin%252Bone-pot%252Bmulti-component%252Bsynthesis%252Bof%252Bheterocyclic%252Brings%26aulast%3DMousavi%26aufirst%3DHossein%26date%3D2021%26volume%3D57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuo  Yuan</span>, <span class="hlFld-ContribAuthor ">Yong-Qiang  Luo</span>, <span class="hlFld-ContribAuthor ">Jia-Hui  Zuo</span>, <span class="hlFld-ContribAuthor ">Hui  Liu</span>, <span class="hlFld-ContribAuthor ">Fang  Li</span>, <span class="hlFld-ContribAuthor ">Bin  Yu</span>. </span><span class="cited-content_cbyCitation_article-title">New drug approvals for 2020: Synthesis and clinical applications. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>215 </em>, 113284. <a href="https://doi.org/10.1016/j.ejmech.2021.113284" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113284</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113284%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNew%252Bdrug%252Bapprovals%252Bfor%252B2020%25253A%252BSynthesis%252Band%252Bclinical%252Bapplications%26aulast%3DYuan%26aufirst%3DShuo%26date%3D2021%26volume%3D215%26spage%3D113284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hemant  Arya</span>, <span class="hlFld-ContribAuthor ">Mohane Selvaraj  Coumar</span>, <span class="hlFld-ContribAuthor ">Tarun Kumar  Bhatt</span>. </span><span class="cited-content_cbyCitation_article-title">Introduction of structural bioinformatics with respect to drug discovery. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 3-9. <a href="https://doi.org/10.1016/B978-0-12-821471-8.00001-5" title="DOI URL">https://doi.org/10.1016/B978-0-12-821471-8.00001-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-821471-8.00001-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-821471-8.00001-5%26sid%3Dliteratum%253Aachs%26atitle%3DIntroduction%252Bof%252Bstructural%252Bbioinformatics%252Bwith%252Brespect%252Bto%252Bdrug%252Bdiscovery%26aulast%3DArya%26aufirst%3DHemant%26date%3D2021%26spage%3D3%26epage%3D9%26pub%3DElsevier%26atitle%3DThe%252BDesign%252B%252526%252BDevelopment%252Bof%252BNovel%252BDrugs%252Band%252BVaccines%26date%3D2021%26volume%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hemant  Arya</span>, <span class="hlFld-ContribAuthor ">Mohane Selvaraj  Coumar</span>. </span><span class="cited-content_cbyCitation_article-title">Lead identification and optimization. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 31-63. <a href="https://doi.org/10.1016/B978-0-12-821471-8.00004-0" title="DOI URL">https://doi.org/10.1016/B978-0-12-821471-8.00004-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-821471-8.00004-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-821471-8.00004-0%26sid%3Dliteratum%253Aachs%26atitle%3DLead%252Bidentification%252Band%252Boptimization%26aulast%3DArya%26aufirst%3DHemant%26date%3D2021%26spage%3D31%26epage%3D63%26pub%3DElsevier%26atitle%3DThe%252BDesign%252B%252526%252BDevelopment%252Bof%252BNovel%252BDrugs%252Band%252BVaccines%26date%3D2021%26volume%3D61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maria  Kontoyianni</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-Based Virtual Screening: Theory, Challenges and Guidelines. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,<a href="https://doi.org/10.1016/B978-0-12-820472-6.00042-6" title="DOI URL">https://doi.org/10.1016/B978-0-12-820472-6.00042-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-820472-6.00042-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-820472-6.00042-6%26sid%3Dliteratum%253Aachs%26atitle%3DStructure-Based%252BVirtual%252BScreening%25253A%252BTheory%25252C%252BChallenges%252Band%252BGuidelines%26aulast%3DKontoyianni%26aufirst%3DMaria%26date%3D2021%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BBiomedical%252BSciences%26date%3D2021%26volume%3D3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuo  Yuan</span>, <span class="hlFld-ContribAuthor ">Bin  Yu</span>, <span class="hlFld-ContribAuthor ">Hong-Min  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">New drug approvals for 2019: Synthesis and clinical applications. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>205 </em>, 112667. <a href="https://doi.org/10.1016/j.ejmech.2020.112667" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112667</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112667&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112667%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNew%252Bdrug%252Bapprovals%252Bfor%252B2019%25253A%252BSynthesis%252Band%252Bclinical%252Bapplications%26aulast%3DYuan%26aufirst%3DShuo%26date%3D2020%26volume%3D205%26spage%3D112667" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peng  Wu</span>, <span class="hlFld-ContribAuthor ">Tai-Jin  Cheng</span>, <span class="hlFld-ContribAuthor ">Hai-Xia  Lin</span>, <span class="hlFld-ContribAuthor ">Hui  Xu</span>, <span class="hlFld-ContribAuthor ">Hui-Xiong  Dai</span>. </span><span class="cited-content_cbyCitation_article-title">Copper-mediated C H thiolation of (hetero)arenes using weakly coordinating directing group. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2020,</strong> <em>61 </em>
                                    (28)
                                     , 152062. <a href="https://doi.org/10.1016/j.tetlet.2020.152062" title="DOI URL">https://doi.org/10.1016/j.tetlet.2020.152062</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2020.152062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2020.152062%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DCopper-mediated%252BC%252BH%252Bthiolation%252Bof%252B%252528hetero%252529arenes%252Busing%252Bweakly%252Bcoordinating%252Bdirecting%252Bgroup%26aulast%3DWu%26aufirst%3DPeng%26date%3D2020%26volume%3D61%26issue%3D28%26spage%3D152062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">JinâFeng  Yu</span>, <span class="hlFld-ContribAuthor ">JianâJun  Li</span>, <span class="hlFld-ContribAuthor ">Peng  Wang</span>, <span class="hlFld-ContribAuthor ">JinâQuan  Yu</span>. </span><span class="cited-content_cbyCitation_article-title">CuâMediated Amination of (Hetero)Aryl CâH bonds with NH Azaheterocycles. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2019,</strong> <em>131 </em>
                                    (50)
                                     , 18309-18313. <a href="https://doi.org/10.1002/ange.201910395" title="DOI URL">https://doi.org/10.1002/ange.201910395</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.201910395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.201910395%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DCu%2525E2%252580%252590Mediated%252BAmination%252Bof%252B%252528Hetero%252529Aryl%252BC%2525E2%252588%252592H%252Bbonds%252Bwith%252BNH%252BAzaheterocycles%26aulast%3DYu%26aufirst%3DJin%25E2%2580%2590Feng%26date%3D2019%26date%3D2019%26volume%3D131%26issue%3D50%26spage%3D18309%26epage%3D18313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">JinâFeng  Yu</span>, <span class="hlFld-ContribAuthor ">JianâJun  Li</span>, <span class="hlFld-ContribAuthor ">Peng  Wang</span>, <span class="hlFld-ContribAuthor ">JinâQuan  Yu</span>. </span><span class="cited-content_cbyCitation_article-title">CuâMediated Amination of (Hetero)Aryl CâH bonds with NH Azaheterocycles. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2019,</strong> <em>58 </em>
                                    (50)
                                     , 18141-18145. <a href="https://doi.org/10.1002/anie.201910395" title="DOI URL">https://doi.org/10.1002/anie.201910395</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.201910395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.201910395%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DCu%2525E2%252580%252590Mediated%252BAmination%252Bof%252B%252528Hetero%252529Aryl%252BC%2525E2%252588%252592H%252Bbonds%252Bwith%252BNH%252BAzaheterocycles%26aulast%3DYu%26aufirst%3DJin%25E2%2580%2590Feng%26date%3D2019%26volume%3D58%26issue%3D50%26spage%3D18141%26epage%3D18145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Winai  Ieawsuwan</span>, <span class="hlFld-ContribAuthor ">Ratchanok  Pingaew</span>, <span class="hlFld-ContribAuthor ">Sukanya  Kunkaewom</span>, <span class="hlFld-ContribAuthor ">Poonsakdi  Ploypradith</span>, <span class="hlFld-ContribAuthor ">Somsak  Ruchirawat</span>. </span><span class="cited-content_cbyCitation_article-title">Scandium(III)âTriflateâCatalyzed PinacolâPinacolone Rearrangement and Cyclization of 1,2âDiarylâ1,2âEthanediol: A Versatile Synthesis of 1âArylâ2,3âDihydroâ1
              H
              â3âBenzazepines. </span><span class="cited-content_cbyCitation_journal-name">Asian Journal of Organic Chemistry</span><span> <strong>2019,</strong> <em>8 </em>
                                    (8)
                                     , 1441-1447. <a href="https://doi.org/10.1002/ajoc.201900318" title="DOI URL">https://doi.org/10.1002/ajoc.201900318</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ajoc.201900318&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fajoc.201900318%26sid%3Dliteratum%253Aachs%26jtitle%3DAsian%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DScandium%252528III%252529%2525E2%252580%252590Triflate%2525E2%252580%252590Catalyzed%252BPinacol%2525E2%252580%252590Pinacolone%252BRearrangement%252Band%252BCyclization%252Bof%252B1%25252C2%2525E2%252580%252590Diaryl%2525E2%252580%2525901%25252C2%2525E2%252580%252590Ethanediol%25253A%252BA%252BVersatile%252BSynthesis%252Bof%252B1%2525E2%252580%252590Aryl%2525E2%252580%2525902%25252C3%2525E2%252580%252590Dihydro%2525E2%252580%2525901%252BH%252B%2525E2%252580%2525903%2525E2%252580%252590Benzazepines%26aulast%3DIeawsuwan%26aufirst%3DWinai%26date%3D2019%26date%3D2019%26volume%3D8%26issue%3D8%26spage%3D1441%26epage%3D1447" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fernando  Fumagalli</span>, <span class="hlFld-ContribAuthor ">Shaiani Maria Gil  de Melo</span>, <span class="hlFld-ContribAuthor ">Camila MarÃ­ngolo  Ribeiro</span>, <span class="hlFld-ContribAuthor ">Mariana Cristina  Solcia</span>, <span class="hlFld-ContribAuthor ">Fernando RogÃ©rio  Pavan</span>, <span class="hlFld-ContribAuthor ">Flavio  da Silva Emery</span>. </span><span class="cited-content_cbyCitation_article-title">Exploiting the furo[2,3-b]pyridine core against multidrug-resistant Mycobacterium tuberculosis. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (8)
                                     , 974-977. <a href="https://doi.org/10.1016/j.bmcl.2019.02.019" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.02.019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.02.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.02.019%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DExploiting%252Bthe%252Bfuro%25255B2%25252C3-b%25255Dpyridine%252Bcore%252Bagainst%252Bmultidrug-resistant%252BMycobacterium%252Btuberculosis%26aulast%3DFumagalli%26aufirst%3DFernando%26date%3D2019%26volume%3D29%26issue%3D8%26spage%3D974%26epage%3D977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Collet  Dandara</span>, <span class="hlFld-ContribAuthor ">Collen  Masimirembwa</span>, <span class="hlFld-ContribAuthor ">Yosr Z.  Haffani</span>, <span class="hlFld-ContribAuthor ">Bernhards  Ogutu</span>, <span class="hlFld-ContribAuthor ">Jenniffer  Mabuka</span>, <span class="hlFld-ContribAuthor ">Eleni  Aklillu</span>, <span class="hlFld-ContribAuthor ">Oluseye  Bolaji</span>, . </span><span class="cited-content_cbyCitation_article-title">African Pharmacogenomics Consortium:Â Consolidating pharmacogenomics knowledge, capacity development and translation in Africa. </span><span class="cited-content_cbyCitation_journal-name">AAS Open Research</span><span> <strong>2019,</strong> <em>2 </em>, 19. <a href="https://doi.org/10.12688/aasopenres.12965.1" title="DOI URL">https://doi.org/10.12688/aasopenres.12965.1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.12688/aasopenres.12965.1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.12688%2Faasopenres.12965.1%26sid%3Dliteratum%253Aachs%26jtitle%3DAAS%2520Open%2520Research%26atitle%3DAfrican%252BPharmacogenomics%252BConsortium%25253A%2525C2%2525A0Consolidating%252Bpharmacogenomics%252Bknowledge%25252C%252Bcapacity%252Bdevelopment%252Band%252Btranslation%252Bin%252BAfrica%26aulast%3DDandara%26aufirst%3DCollet%26date%3D2019%26date%3D2019%26volume%3D2%26spage%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ivana  Pibiri</span>, <span class="hlFld-ContribAuthor ">Laura  Lentini</span>, <span class="hlFld-ContribAuthor ">Raffaella  Melfi</span>, <span class="hlFld-ContribAuthor ">Marco  Tutone</span>, <span class="hlFld-ContribAuthor ">Sara  Baldassano</span>, <span class="hlFld-ContribAuthor ">Paola  Ricco Galluzzo</span>, <span class="hlFld-ContribAuthor ">Aldo  Di Leonardo</span>, <span class="hlFld-ContribAuthor ">Andrea  Pace</span>. </span><span class="cited-content_cbyCitation_article-title">Rescuing the CFTR protein function: Introducing 1,3,4-oxadiazoles as translational readthrough inducing drugs. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>159 </em>, 126-142. <a href="https://doi.org/10.1016/j.ejmech.2018.09.057" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.09.057</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.09.057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.09.057%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRescuing%252Bthe%252BCFTR%252Bprotein%252Bfunction%25253A%252BIntroducing%252B1%25252C3%25252C4-oxadiazoles%252Bas%252Btranslational%252Breadthrough%252Binducing%252Bdrugs%26aulast%3DPibiri%26aufirst%3DIvana%26date%3D2018%26volume%3D159%26spage%3D126%26epage%3D142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b00407/20181207/images/medium/jm-2018-00407x_0004.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b00407/20181207/images/large/jm-2018-00407x_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00407&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b00407/20181207/images/medium/jm-2018-00407x_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b00407/20181207/images/large/jm-2018-00407x_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Number of new small molecule drug approvals and highly prescribed drugs, binned by molecular weight ranges: top 200 U.S. prescribed drugs in 2014 (red bars); drugs approved from 2011 to 2016 (blue bars); drugs approved in 2017 (green).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b00407/20181207/images/large/jm-2018-00407x_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00407&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b00407/20181207/images/medium/jm-2018-00407x_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b00407/20181207/images/large/jm-2018-00407x_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Counts of clogP, polar surface area (PSA), nitrogen and oxygen counts (NO), hydrogen bond donor counts (HBD), and rotational bonds for the approved (2011â2017) drugs that have MW â¤ 300.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b00407/20181207/images/large/jm-2018-00407x_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00407&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i35">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56874" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56874" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 95 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walters, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murcko, M. A.</span></span> <span> </span><span class="NLM_article-title">What Do Medicinal Chemists Actually Make? A 50-Year Retrospective</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">6405</span>â <span class="NLM_lpage">6416</span>, <span class="refDoi">Â DOI: 10.1021/jm200504p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200504p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFWjsr7O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6405-6416&issue=19&author=W.+P.+Waltersauthor=J.+Greenauthor=J.+R.+Weissauthor=M.+A.+Murcko&title=What+Do+Medicinal+Chemists+Actually+Make%3F+A+50-Year+Retrospective&doi=10.1021%2Fjm200504p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">What Do Medicinal Chemists Actually Make? A 50-Year Retrospective</span></div><div class="casAuthors">Walters, W. Patrick; Green, Jeremy; Weiss, Jonathan R.; Murcko, Mark A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6405-6416</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Despite the dramatically increasing costs of pharmaceutical R&D productivity, as measured by the no. of new drugs approved each year, has languished during the past decade.  Many different explanations have been proposed to account for this decline, such as increasing regulatory scrutiny, the inherent inefficiency of very large organizations, the pursuit of highly speculative targets identified from genomics, and more objective decision-making about advancing marginal compds. into latest age clin. trials.  Another factor often cited to help explain low pharmaceutical productivity is that, paradoxically, many compds. synthesized by medicinal chemists are not "druglike", at least as measured by various criteria.  The authors discuss the past, present and perspectives in the development of medicinal chem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqg5xuF4wHqKrVg90H21EOLACvtfcHk0ljw-5rbIVshNQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFWjsr7O&md5=33109f9d55967be0d34f377f433621e4</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1021%2Fjm200504p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200504p%26sid%3Dliteratum%253Aachs%26aulast%3DWalters%26aufirst%3DW.%2BP.%26aulast%3DGreen%26aufirst%3DJ.%26aulast%3DWeiss%26aufirst%3DJ.%2BR.%26aulast%3DMurcko%26aufirst%3DM.%2BA.%26atitle%3DWhat%2520Do%2520Medicinal%2520Chemists%2520Actually%2520Make%253F%2520A%252050-Year%2520Retrospective%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D19%26spage%3D6405%26epage%3D6416%26doi%3D10.1021%2Fjm200504p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lipinski, C. A.</span></span> <span> </span><span class="NLM_article-title">Lead- and Drug-Like Compounds: The Rule-of-Five Revolution</span>. <i>Drug Discovery Today: Technol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">337</span>â <span class="NLM_lpage">341</span>, <span class="refDoi">Â DOI: 10.1016/j.ddtec.2004.11.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1016%2Fj.ddtec.2004.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=24981612" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlSqsrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2004&pages=337-341&issue=4&author=C.+A.+Lipinski&title=Lead-+and+Drug-Like+Compounds%3A+The+Rule-of-Five+Revolution&doi=10.1016%2Fj.ddtec.2004.11.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Lead- and drug-like compounds: the rule-of-five revolution</span></div><div class="casAuthors">Lipinski, Christopher A.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today: Technologies</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">337-341</span>CODEN:
                <span class="NLM_cas:coden">DDTTB5</span>;
        ISSN:<span class="NLM_cas:issn">1740-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Citations in CAS SciFinder to the rule-of-five (RO5) publication will exceed 1000 by year-end 2004.  Trends in the RO5 literature explosion that can be discerned are the further definitions of drug-like.  This topic is explored in terms of drug-like physicochem. features, drug-like structural features, a comparison of drug-like and non-drug-like in drug discovery and a discussion of how drug-like features relate to clin. success.  Physicochem. features of CNS drugs and features related to CNS blood-brain transporter affinity are briefly reviewed.  Recent literature on features of non-oral drugs is reviewed and how features of lead-like compds. differ from those of drug-like compds. is discussed.  Most recently, partly driven by NIH roadmap initiatives, considerations have arisen as to what tool-like means in the search for chem. tools to probe biol. space.  All these topics frame the scope of this short review/perspective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnjiyP3CY7lLVg90H21EOLACvtfcHk0ljw-5rbIVshNQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlSqsrg%253D&md5=952c29b47003b884116d790ae9e4721f</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.ddtec.2004.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ddtec.2004.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26atitle%3DLead-%2520and%2520Drug-Like%2520Compounds%253A%2520The%2520Rule-of-Five%2520Revolution%26jtitle%3DDrug%2520Discovery%2520Today%253A%2520Technol.%26date%3D2004%26volume%3D1%26issue%3D4%26spage%3D337%26epage%3D341%26doi%3D10.1016%2Fj.ddtec.2004.11.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Congreve, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jhoti, H.</span></span> <span> </span><span class="NLM_article-title">A âRule of Threeâ for Fragment-Based Lead Discovery?</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">876</span>â <span class="NLM_lpage">877</span>, <span class="refDoi">Â DOI: 10.1016/S1359-6446(03)02831-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1016%2FS1359-6446%2803%2902831-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=14554012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A280%3ADC%252BD3svns1Cnsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2003&pages=876-877&issue=19&author=M.+Congreveauthor=R.+Carrauthor=C.+Murrayauthor=H.+Jhoti&title=A+%E2%80%98Rule+of+Three%E2%80%99+for+Fragment-Based+Lead+Discovery%3F&doi=10.1016%2FS1359-6446%2803%2902831-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">A 'rule of three' for fragment-based lead discovery?</span></div><div class="casAuthors">Congreve Miles; Carr Robin; Murray Chris; Jhoti Harren</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">876-7</span>
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRfFswFSn5vb43yKPtYViAGfW6udTcc2ebBCwM0cHWMV7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3svns1Cnsw%253D%253D&md5=137886dbb2062f7a3ad39277dd888df3</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2803%2902831-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252803%252902831-9%26sid%3Dliteratum%253Aachs%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DCarr%26aufirst%3DR.%26aulast%3DMurray%26aufirst%3DC.%26aulast%3DJhoti%26aufirst%3DH.%26atitle%3DA%2520%25E2%2580%2598Rule%2520of%2520Three%25E2%2580%2599%2520for%2520Fragment-Based%2520Lead%2520Discovery%253F%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2003%26volume%3D8%26issue%3D19%26spage%3D876%26epage%3D877%26doi%3D10.1016%2FS1359-6446%2803%2902831-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quinton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charruault, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nevers, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volland, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dognon, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creminon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taran, F.</span></span> <span> </span><span class="NLM_article-title">Toward the Limits of Sandwich Immunoassay of Very Low Molecular Weight Molecules</span>. <i>Anal. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>82</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">2536</span>â <span class="NLM_lpage">2540</span>, <span class="refDoi">Â DOI: 10.1021/ac100058f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ac100058f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2010&pages=2536-2540&issue=6&author=J.+Quintonauthor=L.+Charruaultauthor=M.+C.+Neversauthor=H.+Vollandauthor=J.+P.+Dognonauthor=C.+Creminonauthor=F.+Taran&title=Toward+the+Limits+of+Sandwich+Immunoassay+of+Very+Low+Molecular+Weight+Molecules&doi=10.1021%2Fac100058f"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fac100058f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fac100058f%26sid%3Dliteratum%253Aachs%26aulast%3DQuinton%26aufirst%3DJ.%26aulast%3DCharruault%26aufirst%3DL.%26aulast%3DNevers%26aufirst%3DM.%2BC.%26aulast%3DVolland%26aufirst%3DH.%26aulast%3DDognon%26aufirst%3DJ.%2BP.%26aulast%3DCreminon%26aufirst%3DC.%26aulast%3DTaran%26aufirst%3DF.%26atitle%3DToward%2520the%2520Limits%2520of%2520Sandwich%2520Immunoassay%2520of%2520Very%2520Low%2520Molecular%2520Weight%2520Molecules%26jtitle%3DAnal.%2520Chem.%26date%3D2010%26volume%3D82%26issue%3D6%26spage%3D2536%26epage%3D2540%26doi%3D10.1021%2Fac100058f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span>The Top
200 of 2017. <a href="http://clincalc.com/DrugStats/Top200Drugs.aspx" class="extLink">http://clincalc.com/DrugStats/Top200Drugs.aspx</a> (accessed November
17, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=The+Top%0A200+of+2017.+http%3A%2F%2Fclincalc.com%2FDrugStats%2FTop200Drugs.aspx+%28accessed+November%0A17%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverett, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyne, R. E.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâDonnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2014 New Drugs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1937</span>â <span class="NLM_lpage">1980</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2016.03.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1016%2Fj.bmc.2016.03.004" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=1937-1980&issue=9&author=A.+C.+Flickauthor=H.+X.+Dingauthor=C.+A.+Leverettauthor=R.+E.+Kyneauthor=K.+K.+Liuauthor=S.+J.+Finkauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+the+2014+New+Drugs&doi=10.1016%2Fj.bmc.2016.03.004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.03.004%26sid%3Dliteratum%253Aachs%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLeverett%26aufirst%3DC.%2BA.%26aulast%3DKyne%26aufirst%3DR.%2BE.%26aulast%3DLiu%26aufirst%3DK.%2BK.%26aulast%3DFink%26aufirst%3DS.%2BJ.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202014%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26issue%3D9%26spage%3D1937%26epage%3D1980%26doi%3D10.1016%2Fj.bmc.2016.03.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Elewski, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aly, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldwin, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez
Soto, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rich, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisfeld, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiltz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zane, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollak, R.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of Tavaborole Topical Solution, 5%, a Novel Boron-Based Antifungal Agent, for the Treatment of Toenail Onychomycosis: Results from 2 Randomized Phase-III Studies</span>. <i>J. Am. Acad. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>73</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">62</span>â <span class="NLM_lpage">69</span>, <span class="refDoi">Â DOI: 10.1016/j.jaad.2015.04.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1016%2Fj.jaad.2015.04.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=25956661" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnvFSqtrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2015&pages=62-69&issue=1&author=B.+E.+Elewskiauthor=R.+Alyauthor=S.+L.+Baldwinauthor=R.+F.+Gonzalez%0ASotoauthor=P.+Richauthor=M.+Weisfeldauthor=H.+Wiltzauthor=L.+T.+Zaneauthor=R.+Pollak&title=Efficacy+and+Safety+of+Tavaborole+Topical+Solution%2C+5%25%2C+a+Novel+Boron-Based+Antifungal+Agent%2C+for+the+Treatment+of+Toenail+Onychomycosis%3A+Results+from+2+Randomized+Phase-III+Studies&doi=10.1016%2Fj.jaad.2015.04.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: Results from 2 randomized phase-III studies</span></div><div class="casAuthors">Elewski, Boni E.; Aly, Raza; Baldwin, Sheryl L.; Gonzalez Soto, Remigio F.; Rich, Phoebe; Weisfeld, Max; Wiltz, Hector; Zane, Lee T.; Pollak, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Academy of Dermatology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">62-69</span>CODEN:
                <span class="NLM_cas:coden">JAADDB</span>;
        ISSN:<span class="NLM_cas:issn">0190-9622</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Onychomycosis, a fungal nail infection, can impact quality of life.  We sought to evaluate the efficacy and safety of tavaborole topical soln., 5% for treatment of toenail onychomycosis.  In 2 phase-III trials, adults with distal subungual onychomycosis affecting 20% to 60% of a target great toenail were randomized 2:1 to tavaborole or vehicle once daily for 48 wk.  The primary end point was complete cure of the target great toenail (completely clear nail with neg. mycol.) at week 52.  Secondary end points included completely or almost clear nail, neg. mycol., completely or almost clear nail plus neg. mycol., and safety.  Rates of neg. mycol. (31.1%-35.9% vs 7.2%-12.2%) and complete cure (6.5% and 9.1% vs 0.5% and 1.5%) significantly favored tavaborole vs. vehicle (P â¤ .001).  Completely or almost clear nail rates also significantly favored tavaborole vs. vehicle (26.1%-27.5% vs 9.3%-14.6%; P < .001).  Rates of completely or almost clear nail plus neg. mycol. (15.3%-17.9% vs 1.5%-3.9%) were significantly greater for tavaborole vs. vehicle (P < .001).  Application-site reactions with tavaborole included exfoliation (2.7%), erythema (1.6%), and dermatitis (1.3%).  Duration of follow-up is a limitation.  Tavaborole demonstrates a favorable benefit-risk profile in treatment of toenail onychomycosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq57HESc8Cdt7Vg90H21EOLACvtfcHk0lgoervhWif7EA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnvFSqtrs%253D&md5=ce2bd25a222bec52157508b38f9971f9</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.jaad.2015.04.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaad.2015.04.010%26sid%3Dliteratum%253Aachs%26aulast%3DElewski%26aufirst%3DB.%2BE.%26aulast%3DAly%26aufirst%3DR.%26aulast%3DBaldwin%26aufirst%3DS.%2BL.%26aulast%3DGonzalez%2BSoto%26aufirst%3DR.%2BF.%26aulast%3DRich%26aufirst%3DP.%26aulast%3DWeisfeld%26aufirst%3DM.%26aulast%3DWiltz%26aufirst%3DH.%26aulast%3DZane%26aufirst%3DL.%2BT.%26aulast%3DPollak%26aufirst%3DR.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Tavaborole%2520Topical%2520Solution%252C%25205%2525%252C%2520a%2520Novel%2520Boron-Based%2520Antifungal%2520Agent%252C%2520for%2520the%2520Treatment%2520of%2520Toenail%2520Onychomycosis%253A%2520Results%2520from%25202%2520Randomized%2520Phase-III%2520Studies%26jtitle%3DJ.%2520Am.%2520Acad.%2520Dermatol.%26date%3D2015%26volume%3D73%26issue%3D1%26spage%3D62%26epage%3D69%26doi%3D10.1016%2Fj.jaad.2015.04.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benkovic, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alley, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baboval, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajagopalan, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahng, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavassoli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, L.</span></span> <span> </span><span class="NLM_article-title">Identification of Borinic Esters as Inhibitors of Bacterial Cell Growth and Bacterial Methyltransferases, Ccrm and Menh</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">7468</span>â <span class="NLM_lpage">7476</span>, <span class="refDoi">Â DOI: 10.1021/jm050676a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm050676a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=7468-7476&issue=23&author=S.+J.+Benkovicauthor=S.+J.+Bakerauthor=M.+R.+Alleyauthor=Y.+H.+Wooauthor=Y.+K.+Zhangauthor=T.+Akamaauthor=W.+Maoauthor=J.+Babovalauthor=P.+T.+Rajagopalanauthor=M.+Wallauthor=L.+S.+Kahngauthor=A.+Tavassoliauthor=L.+Shapiro&title=Identification+of+Borinic+Esters+as+Inhibitors+of+Bacterial+Cell+Growth+and+Bacterial+Methyltransferases%2C+Ccrm+and+Menh&doi=10.1021%2Fjm050676a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Fjm050676a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050676a%26sid%3Dliteratum%253Aachs%26aulast%3DBenkovic%26aufirst%3DS.%2BJ.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DAlley%26aufirst%3DM.%2BR.%26aulast%3DWoo%26aufirst%3DY.%2BH.%26aulast%3DZhang%26aufirst%3DY.%2BK.%26aulast%3DAkama%26aufirst%3DT.%26aulast%3DMao%26aufirst%3DW.%26aulast%3DBaboval%26aufirst%3DJ.%26aulast%3DRajagopalan%26aufirst%3DP.%2BT.%26aulast%3DWall%26aufirst%3DM.%26aulast%3DKahng%26aufirst%3DL.%2BS.%26aulast%3DTavassoli%26aufirst%3DA.%26aulast%3DShapiro%26aufirst%3DL.%26atitle%3DIdentification%2520of%2520Borinic%2520Esters%2520as%2520Inhibitors%2520of%2520Bacterial%2520Cell%2520Growth%2520and%2520Bacterial%2520Methyltransferases%252C%2520Ccrm%2520and%2520Menh%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26issue%3D23%26spage%3D7468%26epage%3D7476%26doi%3D10.1021%2Fjm050676a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alley, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanders, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plattner, J. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of a New Boron-Containing Antifungal Agent, 5-Fluoro-1,3-Dihydro-1-Hydroxy-2,1- Benzoxaborole (AN2690), for the Potential Treatment of Onychomycosis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">4447</span>â <span class="NLM_lpage">4450</span>, <span class="refDoi">Â DOI: 10.1021/jm0603724</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0603724" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BD28Xmt12lsro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=4447-4450&issue=15&author=S.+J.+Bakerauthor=Y.+K.+Zhangauthor=T.+Akamaauthor=A.+Lauauthor=H.+Zhouauthor=V.+Hernandezauthor=W.+Maoauthor=M.+R.+Alleyauthor=V.+Sandersauthor=J.+J.+Plattner&title=Discovery+of+a+New+Boron-Containing+Antifungal+Agent%2C+5-Fluoro-1%2C3-Dihydro-1-Hydroxy-2%2C1-+Benzoxaborole+%28AN2690%29%2C+for+the+Potential+Treatment+of+Onychomycosis&doi=10.1021%2Fjm0603724"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a New Boron-Containing Antifungal Agent, 5-Fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole (AN2690), for the Potential Treatment of Onychomycosis</span></div><div class="casAuthors">Baker, Stephen J.; Zhang, Yong-Kang; Akama, Tsutomu; Lau, Agnes; Zhou, Huchen; Hernandez, Vincent; Mao, Weimin; Alley, M. R. K.; Sanders, Virginia; Plattner, Jacob J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4447-4450</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A structure-activity relationship investigation for a more efficacious therapy to treat onychomycosis, a fungal infection of the toe and fingernails, led to the discovery of a boron-contg. small mol., AN2690 (I), which is currently in clin. trials for onychomycosis topical treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQCA9knQ5nc7Vg90H21EOLACvtfcHk0ljKOz21jo6mXA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xmt12lsro%253D&md5=c21119d24d45861fefe07d802d9a786e</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fjm0603724&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0603724%26sid%3Dliteratum%253Aachs%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DZhang%26aufirst%3DY.%2BK.%26aulast%3DAkama%26aufirst%3DT.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DHernandez%26aufirst%3DV.%26aulast%3DMao%26aufirst%3DW.%26aulast%3DAlley%26aufirst%3DM.%2BR.%26aulast%3DSanders%26aufirst%3DV.%26aulast%3DPlattner%26aufirst%3DJ.%2BJ.%26atitle%3DDiscovery%2520of%2520a%2520New%2520Boron-Containing%2520Antifungal%2520Agent%252C%25205-Fluoro-1%252C3-Dihydro-1-Hydroxy-2%252C1-%2520Benzoxaborole%2520%2528AN2690%2529%252C%2520for%2520the%2520Potential%2520Treatment%2520of%2520Onychomycosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26issue%3D15%26spage%3D4447%26epage%3D4450%26doi%3D10.1021%2Fjm0603724" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paton, D. M.</span></span> <span> </span><span class="NLM_article-title">Crisaborole: Phosphodiesterase Inhibitor for Treatment of Atopic Dermatitis</span>. <i>Drugs Today</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">239</span>â <span class="NLM_lpage">245</span>, <span class="refDoi">Â DOI: 10.1358/dot.2017.53.4.2604174</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1358%2Fdot.2017.53.4.2604174" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A280%3ADC%252BC1crmtVykug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2017&pages=239-245&issue=4&author=D.+M.+Paton&title=Crisaborole%3A+Phosphodiesterase+Inhibitor+for+Treatment+of+Atopic+Dermatitis&doi=10.1358%2Fdot.2017.53.4.2604174"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Crisaborole: Phosphodiesterase inhibitor for treatment of atopic dermatitis</span></div><div class="casAuthors">Paton D M</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of today (Barcelona, Spain : 1998)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">239-245</span>
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    </div><div class="casAbstract">Atopic dermatitis (AD) is an extremely common condition affecting as many as 10-20% of children and 2-10% of adults.  A particularly distressing symptom of AD is pruritus.  One of the important aspects of AD is inflammation associated with increased activity of phosphodiesterase 4 (PDE4), resulting in decreased intracellular levels of cyclic adenosine monophosphate, which in turn causes increased production of inflammatory cytokines.  Crisaborole was developed as a small-molecule, boron-based, selective PDE4 inhibitor that can be used topically.  Clinical trials have demonstrated its efficacy in treating patients with mild to moderate AD, resulting in significant relief of pruritus.  Unlike PDE4 inhibitors that act systemically, crisaborole does not cause significant gastrointestinal adverse effects.  The most common adverse effect has been temporary stinging and burning in about 4% of patients upon application of the 2% ointment.  To date there is no evidence of atrophy, telangiectasia or hypopigmentation resulting from its use.  Crisaborole is the first topically applied PDE4 inhibitor to be approved by the FDA for use in AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTC3c4rt0Hyh4qdXsLcGTEUfW6udTcc2eaq1vXvN0Xc4Lntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crmtVykug%253D%253D&md5=a854efec1d46127283db4e443c22221f</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1358%2Fdot.2017.53.4.2604174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2017.53.4.2604174%26sid%3Dliteratum%253Aachs%26aulast%3DPaton%26aufirst%3DD.%2BM.%26atitle%3DCrisaborole%253A%2520Phosphodiesterase%2520Inhibitor%2520for%2520Treatment%2520of%2520Atopic%2520Dermatitis%26jtitle%3DDrugs%2520Today%26date%3D2017%26volume%3D53%26issue%3D4%26spage%3D239%26epage%3D245%26doi%3D10.1358%2Fdot.2017.53.4.2604174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pibiri, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lentini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melfi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallucci, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pace, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinello, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barone, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Leonardo, A.</span></span> <span> </span><span class="NLM_article-title">Enhancement of Premature Stop Codon Readthrough in the Cftr Gene by Ataluren (PTC124) Derivatives</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">236</span>â <span class="NLM_lpage">244</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2015.06.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1016%2Fj.ejmech.2015.06.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=26142488" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlCqsbvO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2015&pages=236-244&author=I.+Pibiriauthor=L.+Lentiniauthor=R.+Melfiauthor=G.+Gallucciauthor=A.+Paceauthor=A.+Spinelloauthor=G.+Baroneauthor=A.+Di+Leonardo&title=Enhancement+of+Premature+Stop+Codon+Readthrough+in+the+Cftr+Gene+by+Ataluren+%28PTC124%29+Derivatives&doi=10.1016%2Fj.ejmech.2015.06.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Enhancement of premature stop codon readthrough in the CFTR gene by Ataluren (PTC124) derivatives</span></div><div class="casAuthors">Pibiri, Ivana; Lentini, Laura; Melfi, Raffaella; Gallucci, Giulia; Pace, Andrea; Spinello, Angelo; Barone, Giampaolo; Di Leonardo, Aldo</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">236-244</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Premature stop codons are the result of nonsense mutations occurring within the coding sequence of a gene.  These mutations lead to the synthesis of a truncated protein and are responsible for several genetic diseases.  A potential pharmacol. approach to treat these diseases is to promote the translational readthrough of premature stop codons by small mols. aiming to restore the full-length protein.  The compd. PTC124 (Ataluren) was reported to promote the readthrough of the premature UGA stop codon, although its activity was questioned.  The potential interaction of PTC124 with mutated mRNA was recently suggested by mol. dynamics (MD) studies highlighting the importance of H-bonding and stacking Ï-Ï interactions.  To improve the readthrough activity we changed the fluorine no. and position in the PTC124 fluoroaryl moiety.  The readthrough ability of these PTC124 derivs. was tested in human cells harboring reporter plasmids with premature stop codons in H2BGFP and FLuc genes as well as in cystic fibrosis (CF) IB3.1 cells with a nonsense mutation.  Maintaining low toxicity, three of these mols. showed higher efficacy than PTC124 in the readthrough of the UGA premature stop codon and in recovering the expression of the CFTR protein in IB3.1 cells from cystic fibrosis patient.  Mol. dynamics simulations performed with mutated CFTR mRNA fragments and active or inactive derivs. are in agreement with the suggested interaction of PTC124 with mRNA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQCRNDatyIrbVg90H21EOLACvtfcHk0ljKOz21jo6mXA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlCqsbvO&md5=98faa152347759ad8d442d2acb0a24b1</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.06.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.06.038%26sid%3Dliteratum%253Aachs%26aulast%3DPibiri%26aufirst%3DI.%26aulast%3DLentini%26aufirst%3DL.%26aulast%3DMelfi%26aufirst%3DR.%26aulast%3DGallucci%26aufirst%3DG.%26aulast%3DPace%26aufirst%3DA.%26aulast%3DSpinello%26aufirst%3DA.%26aulast%3DBarone%26aufirst%3DG.%26aulast%3DDi%2BLeonardo%26aufirst%3DA.%26atitle%3DEnhancement%2520of%2520Premature%2520Stop%2520Codon%2520Readthrough%2520in%2520the%2520Cftr%2520Gene%2520by%2520Ataluren%2520%2528PTC124%2529%2520Derivatives%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D101%26spage%3D236%26epage%3D244%26doi%3D10.1016%2Fj.ejmech.2015.06.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lentini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melfi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Leonardo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinello, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barone, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pace, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palumbo
Piccionello, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pibiri, I.</span></span> <span> </span><span class="NLM_article-title">Toward a Rationale for the Ptc124 (Ataluren) Promoted Readthrough of Premature Stop Codons: A Computational Approach and GFP-Reporter Cell-Based Assay</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">653</span>â <span class="NLM_lpage">664</span>, <span class="refDoi">Â DOI: 10.1021/mp400230s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp400230s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsF2mtrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2014&pages=653-664&issue=3&author=L.+Lentiniauthor=R.+Melfiauthor=A.+Di+Leonardoauthor=A.+Spinelloauthor=G.+Baroneauthor=A.+Paceauthor=A.+Palumbo%0APiccionelloauthor=I.+Pibiri&title=Toward+a+Rationale+for+the+Ptc124+%28Ataluren%29+Promoted+Readthrough+of+Premature+Stop+Codons%3A+A+Computational+Approach+and+GFP-Reporter+Cell-Based+Assay&doi=10.1021%2Fmp400230s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Toward a rationale for the PTC124 (Ataluren) promoted readthrough of premature stop codons: a computational approach and GFP-reporter cell-based assay</span></div><div class="casAuthors">Lentini, Laura; Melfi, Raffaella; Di Leonardo, Aldo; Spinello, Angelo; Barone, Giampaolo; Pace, Andrea; Palumbo Piccionello, Antonio; Pibiri, Ivana</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">653-664</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The presence in the mRNA of premature stop codons (PTCs) results in protein truncation responsible for several inherited (genetic) diseases.  A well-known example of these diseases is cystic fibrosis (CF), where approx. 10% (worldwide) of patients have nonsense mutations in the CF transmembrane regulator (CFTR) gene.  PTC124 (3-(5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl)-benzoic acid), also known as Ataluren, is a small mol. that has been suggested to allow PTC readthrough even though its target has yet to be identified.  In the lack of a general consensus about its mechanism of action, we exptl. tested the ability of PTC124 to promote the readthrough of premature termination codons by using a new reporter.  The reporter vector was based on a plasmid harboring the H2B histone coding sequence fused in frame with the green fluorescent protein (GFP) cDNA, and a TGA stop codon was introduced in the H2B-GFP gene by site-directed mutagenesis.  Addnl., an unprecedented computational study on the putative supramol. interaction between PTC124 and an 11-codon (33-nucleotides) sequence corresponding to a CFTR mRNA fragment contg. a central UGA nonsense mutation showed a specific interaction between PTC124 and the UGA codon.  Altogether, the H2B-GFP-opal based assay and the mol. dynamics (MD) simulation support the hypothesis that PTC124 is able to promote the specific readthrough of internal TGA premature stop codons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoMyq0NCLi-rVg90H21EOLACvtfcHk0lhEuEh45S4N6w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsF2mtrg%253D&md5=9db7ec531aa57c1e0c376d05612bfd2f</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fmp400230s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp400230s%26sid%3Dliteratum%253Aachs%26aulast%3DLentini%26aufirst%3DL.%26aulast%3DMelfi%26aufirst%3DR.%26aulast%3DDi%2BLeonardo%26aufirst%3DA.%26aulast%3DSpinello%26aufirst%3DA.%26aulast%3DBarone%26aufirst%3DG.%26aulast%3DPace%26aufirst%3DA.%26aulast%3DPalumbo%2BPiccionello%26aufirst%3DA.%26aulast%3DPibiri%26aufirst%3DI.%26atitle%3DToward%2520a%2520Rationale%2520for%2520the%2520Ptc124%2520%2528Ataluren%2529%2520Promoted%2520Readthrough%2520of%2520Premature%2520Stop%2520Codons%253A%2520A%2520Computational%2520Approach%2520and%2520GFP-Reporter%2520Cell-Based%2520Assay%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2014%26volume%3D11%26issue%3D3%26spage%3D653%26epage%3D664%26doi%3D10.1021%2Fmp400230s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karp, G. M.</span>; <span class="NLM_string-name">Hwang, S.</span>; <span class="NLM_string-name">Chen, G.</span>; <span class="NLM_string-name">Almstead, N. G.</span>; <span class="NLM_string-name">Moon, Y.-C.</span></span> <span> </span><span class="NLM_article-title">1,2,4-Oxadiazole Benzoic Acid Compounds and Their Use for Nonsense Suppression and the Treatment of Disease</span>. <span class="NLM_patent">US6992096B2</span>, <span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=G.+M.+Karp&author=S.+Hwang&author=G.+Chen&author=N.+G.+Almstead&author=Y.-C.+Moon&title=1%2C2%2C4-Oxadiazole+Benzoic+Acid+Compounds+and+Their+Use+for+Nonsense+Suppression+and+the+Treatment+of+Disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKarp%26aufirst%3DG.%2BM.%26atitle%3D1%252C2%252C4-Oxadiazole%2520Benzoic%2520Acid%2520Compounds%2520and%2520Their%2520Use%2520for%2520Nonsense%2520Suppression%2520and%2520the%2520Treatment%2520of%2520Disease%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bang-Andersen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruhland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frederiksen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mork, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stensbol, T. B.</span></span> <span> </span><span class="NLM_article-title">Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)Phenyl]Piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">3206</span>â <span class="NLM_lpage">3221</span>, <span class="refDoi">Â DOI: 10.1021/jm101459g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101459g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC3MXksFGgtLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=3206-3221&issue=9&author=B.+Bang-Andersenauthor=T.+Ruhlandauthor=M.+Jorgensenauthor=G.+Smithauthor=K.+Frederiksenauthor=K.+G.+Jensenauthor=H.+Zhongauthor=S.+M.+Nielsenauthor=S.+Hoggauthor=A.+Morkauthor=T.+B.+Stensbol&title=Discovery+of+1-%5B2-%282%2C4-Dimethylphenylsulfanyl%29Phenyl%5DPiperazine+%28Lu+AA21004%29%3A+A+Novel+Multimodal+Compound+for+the+Treatment+of+Major+Depressive+Disorder&doi=10.1021%2Fjm101459g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder</span></div><div class="casAuthors">Bang-Andersen, Benny; Ruhland, Thomas; Jorgensen, Morten; Smith, Garrick; Frederiksen, Kristen; Jensen, Klaus Gjervig; Zhong, Huailing; Nielsen, Soren Moller; Hogg, Sandra; Mork, Arne; Stensbol, Tine Bryan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3206-3221</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis and structure-activity relationship of a novel series of compds. with combined effects on 5-HT3A and 5-HT1A receptors and on the serotonin (5-HT) transporter (SERT) are described.  Compd. 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004) was the lead compd., displaying high affinity for recombinant human 5-HT1A (Ki = 15 nM), 5-HT1B (Ki = 33 nM), 5-HT3A (Ki = 3.7 nM), 5-HT7 (Ki = 19 nM), and noradrenergic Î²1 (Ki = 46 nM) receptors, and SERT (Ki = 1.6 nM).  Lu AA21004 displayed antagonistic properties at 5-HT3A and 5-HT7 receptors, partial agonist properties at 5-HT1B receptors, agonistic properties at 5-HT1A receptors, and potent inhibition of SERT.  In conscious rats, Lu AA21004 significantly increased extracellular 5-HT levels in the brain after acute and 3 days of treatment.  Following the 3-day treatment (5 or 10 (mg/kg)/day) SERT occupancies were only 43% and 57%, resp.  These characteristics indicate that Lu AA21004 is a novel multimodal serotonergic compd., and is currently in clin. development for major depressive disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAspA4Bk8ro7Vg90H21EOLACvtfcHk0lhEuEh45S4N6w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXksFGgtLs%253D&md5=b9823f8a86f6d4d44d4a17cb510ea903</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm101459g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101459g%26sid%3Dliteratum%253Aachs%26aulast%3DBang-Andersen%26aufirst%3DB.%26aulast%3DRuhland%26aufirst%3DT.%26aulast%3DJorgensen%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DG.%26aulast%3DFrederiksen%26aufirst%3DK.%26aulast%3DJensen%26aufirst%3DK.%2BG.%26aulast%3DZhong%26aufirst%3DH.%26aulast%3DNielsen%26aufirst%3DS.%2BM.%26aulast%3DHogg%26aufirst%3DS.%26aulast%3DMork%26aufirst%3DA.%26aulast%3DStensbol%26aufirst%3DT.%2BB.%26atitle%3DDiscovery%2520of%25201-%255B2-%25282%252C4-Dimethylphenylsulfanyl%2529Phenyl%255DPiperazine%2520%2528Lu%2520AA21004%2529%253A%2520A%2520Novel%2520Multimodal%2520Compound%2520for%2520the%2520Treatment%2520of%2520Major%2520Depressive%2520Disorder%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D9%26spage%3D3206%26epage%3D3221%26doi%3D10.1021%2Fjm101459g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Edaravone
Acute Infarction Study Group.</span> <span> </span><span class="NLM_article-title">Effect of a Novel Free Radical Scavenger, Edaravone (MCI-186), on
Acute Brain Infarction. Randomized, Placebo-Controlled, Double-Blind
Study at Multicenters</span>. <i>Cerebrovasc. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">222</span>â <span class="NLM_lpage">229</span>, <span class="refDoi">Â DOI: 10.1159/000069318</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1159%2F000069318" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=12715790" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2003&pages=222-229&issue=3&author=Edaravone%0AAcute+Infarction+Study+Group.&title=Effect+of+a+Novel+Free+Radical+Scavenger%2C+Edaravone+%28MCI-186%29%2C+on%0AAcute+Brain+Infarction.+Randomized%2C+Placebo-Controlled%2C+Double-Blind%0AStudy+at+Multicenters&doi=10.1159%2F000069318"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1159%2F000069318&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000069318%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DEffect%2520of%2520a%2520Novel%2520Free%2520Radical%2520Scavenger%252C%2520Edaravone%2520%2528MCI-186%2529%252C%2520on%250AAcute%2520Brain%2520Infarction.%2520Randomized%252C%2520Placebo-Controlled%252C%2520Double-Blind%250AStudy%2520at%2520Multicenters%26jtitle%3DCerebrovasc.%2520Dis.%26date%3D2003%26volume%3D15%26issue%3D3%26spage%3D222%26epage%3D229%26doi%3D10.1159%2F000069318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kogure, K.</span></span> <span> </span><span class="NLM_article-title">Strong Attenuation of Ischemic and Postischemic Brain Edema in Rats by a Novel Free Radical Scavenger</span>. <i>Stroke</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">480</span>â <span class="NLM_lpage">485</span>, <span class="refDoi">Â DOI: 10.1161/01.STR.19.4.480</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1161%2F01.STR.19.4.480" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=1988&pages=480-485&issue=4&author=K.+Abeauthor=S.+Yukiauthor=K.+Kogure&title=Strong+Attenuation+of+Ischemic+and+Postischemic+Brain+Edema+in+Rats+by+a+Novel+Free+Radical+Scavenger&doi=10.1161%2F01.STR.19.4.480"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1161%2F01.STR.19.4.480&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.STR.19.4.480%26sid%3Dliteratum%253Aachs%26aulast%3DAbe%26aufirst%3DK.%26aulast%3DYuki%26aufirst%3DS.%26aulast%3DKogure%26aufirst%3DK.%26atitle%3DStrong%2520Attenuation%2520of%2520Ischemic%2520and%2520Postischemic%2520Brain%2520Edema%2520in%2520Rats%2520by%2520a%2520Novel%2520Free%2520Radical%2520Scavenger%26jtitle%3DStroke%26date%3D1988%26volume%3D19%26issue%3D4%26spage%3D480%26epage%3D485%26doi%3D10.1161%2F01.STR.19.4.480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brune, K.</span></span> <span> </span><span class="NLM_article-title">The Early History of Non-Opioid Analgesics</span>. <i>Acute Pain</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">33</span>â <span class="NLM_lpage">40</span>, <span class="refDoi">Â DOI: 10.1016/S1366-0071(97)80033-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1016%2FS1366-0071%2897%2980033-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADyaK1MXns1Srt7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1997&pages=33-40&issue=1&author=K.+Brune&title=The+Early+History+of+Non-Opioid+Analgesics&doi=10.1016%2FS1366-0071%2897%2980033-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">The early history of non-opioid analgesics</span></div><div class="casAuthors">Brune, Kay</div><div class="citationInfo"><span class="NLM_cas:title">Acute Pain</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-40</span>CODEN:
                <span class="NLM_cas:coden">ACPAFS</span>;
        ISSN:<span class="NLM_cas:issn">1366-0071</span>.
    
            (<span class="NLM_cas:orgname">Saldatore Ltd.</span>)
        </div><div class="casAbstract">A review with 14 refs.  The late 19th century gave rise to the discovery of the three prototypes of modern non-opioid antipyretic analgesics: acetaminophen (acetanilide), aspirin and salicylic acid, and phenazone.  At three different sites at almost the same time in Germany the zest for finding substitutes for quinine, ie antipyretic drugs, led to synthetic efforts culminating at Erlangen in the synthesis of phenazone (antipyrine), at Strasbourg of acetanilide (antifebrin), and at Wuppertal of aspirin (acetylsalicylic acid).  The rationales for synthesizing these drugs were not stringent, but proved, nonetheless, successful.  Thereafter chemists concd. their attempts merely on modifying the drugs discovered with the help of the rapidly expanding and improving org. chem.  Although no new principles were discovered, the 'relatives' of the originals, namely aspirin and its modifications, acetaminophen and propyphenazone, as well as dipyrone, still make up for about 50% of the market of the antipyretic analgesics worldwide.  Some of these compds. have attracted new interest recently.  This is particularly the case with dipyrone (metamizole, Novalgin).  After more than 50 yr of clin. use (without major research efforts) state of the art investigation was commenced, and at its 75th birthday this compd. is now thoroughly investigated.  The side effect profile and risks, as well as the pharmacokinetic parameters, are defined and the mode of action has been elucidated.  Although several clin. studies show effectiveness, probably due to the 75 yr-long worldwide experience, modern therapy orientated studies proving usefulness in specific indications, claimed by many physicians and patients (eg after bone marrow transplantation, against migraine, and in osteoarthrosis), are still unavailable.  In this respect, further research efforts and extension of knowledge is required, since this drug lacks gastrointestinal and renal toxicity, blood coagulation is only marginally influenced, and the widely discussed agranulocytosis is extremely rare and nearly never fatal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1yyVaqKrcBLVg90H21EOLACvtfcHk0lg8V1oKMgLzZg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXns1Srt7Y%253D&md5=35f2b06edf0b20306808ae2d8c173379</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2FS1366-0071%2897%2980033-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1366-0071%252897%252980033-2%26sid%3Dliteratum%253Aachs%26aulast%3DBrune%26aufirst%3DK.%26atitle%3DThe%2520Early%2520History%2520of%2520Non-Opioid%2520Analgesics%26jtitle%3DAcute%2520Pain%26date%3D1997%26volume%3D1%26issue%3D1%26spage%3D33%26epage%3D40%26doi%3D10.1016%2FS1366-0071%2897%2980033-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hardeland, R.</span></span> <span> </span><span class="NLM_article-title">Investigational Melatonin Receptor Agonists</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">747</span>â <span class="NLM_lpage">764</span>, <span class="refDoi">Â DOI: 10.1517/13543784.2010.482926</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1517%2F13543784.2010.482926" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2010&pages=747-764&issue=6&author=R.+Hardeland&title=Investigational+Melatonin+Receptor+Agonists&doi=10.1517%2F13543784.2010.482926"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1517%2F13543784.2010.482926&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2010.482926%26sid%3Dliteratum%253Aachs%26aulast%3DHardeland%26aufirst%3DR.%26atitle%3DInvestigational%2520Melatonin%2520Receptor%2520Agonists%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2010%26volume%3D19%26issue%3D6%26spage%3D747%26epage%3D764%26doi%3D10.1517%2F13543784.2010.482926" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vachharajani, N. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeleswaram, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulton, D. W.</span></span> <span> </span><span class="NLM_article-title">Preclinical Pharmacokinetics and Metabolism of BMS-214778, a Novel Melatonin Receptor Agonist</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>92</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">760</span>â <span class="NLM_lpage">772</span>, <span class="refDoi">Â DOI: 10.1002/jps.10348</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1002%2Fjps.10348" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2003&pages=760-772&issue=4&author=N.+N.+Vachharajaniauthor=K.+Yeleswaramauthor=D.+W.+Boulton&title=Preclinical+Pharmacokinetics+and+Metabolism+of+BMS-214778%2C+a+Novel+Melatonin+Receptor+Agonist&doi=10.1002%2Fjps.10348"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2Fjps.10348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.10348%26sid%3Dliteratum%253Aachs%26aulast%3DVachharajani%26aufirst%3DN.%2BN.%26aulast%3DYeleswaram%26aufirst%3DK.%26aulast%3DBoulton%26aufirst%3DD.%2BW.%26atitle%3DPreclinical%2520Pharmacokinetics%2520and%2520Metabolism%2520of%2520BMS-214778%252C%2520a%2520Novel%2520Melatonin%2520Receptor%2520Agonist%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2003%26volume%3D92%26issue%3D4%26spage%3D760%26epage%3D772%26doi%3D10.1002%2Fjps.10348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Halford, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrold, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawton, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blundell, J. E.</span></span> <span> </span><span class="NLM_article-title">Serotonin (5-HT) Drugs: Effects on Appetite Expression and Use for the Treatment of Obesity</span>. <i>Curr. Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">201</span>â <span class="NLM_lpage">213</span>, <span class="refDoi">Â DOI: 10.2174/1389450053174550</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.2174%2F1389450053174550" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=15777190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BD2MXisVSqu74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=201-213&issue=2&author=J.+C.+Halfordauthor=J.+A.+Harroldauthor=C.+L.+Lawtonauthor=J.+E.+Blundell&title=Serotonin+%285-HT%29+Drugs%3A+Effects+on+Appetite+Expression+and+Use+for+the+Treatment+of+Obesity&doi=10.2174%2F1389450053174550"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Serotonin (5-HT) drugs: effects on appetite expression and use for the treatment of obesity</span></div><div class="casAuthors">Halford, Jason C. G.; Harrold, Joanne A.; Lawton, Clare L.; Blundell, John E.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">201-213</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The pivotal role of 5-HT in the control of appetite was formally proposed nearly 30 years ago.  In particular endogenous hypothalamic 5-HT was implicated in the processes of within meal satiation and the end state of post meal satiety.  Of the numerous 5-HT receptor subtypes currently identified, 5-HT1B and 5-HT2C receptors are believed to mediate the 5-HT induced satiety.  5-HT drugs such as d-fenfluramine, selective serotoninergic reuptake inhibitor (SSRIs) and 5-HT2C receptor agonists have all been shown to significantly attenuate rodent body wt. gain, an effect strongly assocd. with marked hypophagia.  D-Fenfluramine, sibutramine, fluoxetine and the 5-HT2C receptor agonist mCPP have also all been shown to reduce caloric intake by modifying appetite in both lean and obese humans.  Specifically, 5-HT drugs reduce appetite prior to and after the consumption of fixed caloric loads, and reduce pre meal appetite and caloric intake at ad libitum meals.  Clin. significant wt. loss over a year or more can be produced by both d-fenfluramine and sibutramine treatment, but apparently not by the SSRI fluoxetine.  Treatment with the preferential 5-HT2C receptor agonist mCPP and the serotonin precursor 5-HTP was also shown to produce wt. loss in the obese.  Issues around the actual and possible side effects of these compds., and in the case of d-fenfluramine toxicity, have led to a search for drugs that act selectively on the CNS 5-HT receptors crit. to the satiety response.  Currently, a new generation of 5-HT2C selective agonists were developed (including Ro 60-0175, Org 12962, VER-3323, BVT-933 and YM348) and at least one, ADP356, is currently undergoing clin. trials.  Hopefully, such drugs will be as or even more effective at regulating appetite and controlling body wt., and will also be free of their predecessors' side effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMX0O68S7bxLVg90H21EOLACvtfcHk0lg8V1oKMgLzZg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXisVSqu74%253D&md5=ad765430cb2787564d02aad590309068</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.2174%2F1389450053174550&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389450053174550%26sid%3Dliteratum%253Aachs%26aulast%3DHalford%26aufirst%3DJ.%2BC.%26aulast%3DHarrold%26aufirst%3DJ.%2BA.%26aulast%3DLawton%26aufirst%3DC.%2BL.%26aulast%3DBlundell%26aufirst%3DJ.%2BE.%26atitle%3DSerotonin%2520%25285-HT%2529%2520Drugs%253A%2520Effects%2520on%2520Appetite%2520Expression%2520and%2520Use%2520for%2520the%2520Treatment%2520of%2520Obesity%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2005%26volume%3D6%26issue%3D2%26spage%3D201%26epage%3D213%26doi%3D10.2174%2F1389450053174550" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilson, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrada, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prieto, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallardo, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sengupta, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dosa, P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covel, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beeley, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espitia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saldana, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjenning, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whelan, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grottick, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menzaghi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomsen, W. J.</span></span> <span> </span><span class="NLM_article-title">Discovery and Structure-Activity Relationship of (1<i>R</i>)-8-Chloro-2,3,4,5-Tetrahydro-1-Methyl-1h-3-Benzazepine (Lorcaserin), a Selective Serotonin 5-HT2c Receptor Agonist for the Treatment of Obesity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">305</span>â <span class="NLM_lpage">313</span>, <span class="refDoi">Â DOI: 10.1021/jm0709034</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0709034" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=305-313&issue=2&author=B.+M.+Smithauthor=J.+M.+Smithauthor=J.+H.+Tsaiauthor=J.+A.+Schultzauthor=C.+A.+Gilsonauthor=S.+A.+Estradaauthor=R.+R.+Chenauthor=D.+M.+Parkauthor=E.+B.+Prietoauthor=C.+S.+Gallardoauthor=D.+Senguptaauthor=P.+I.+Dosaauthor=J.+A.+Covelauthor=A.+Renauthor=R.+R.+Webbauthor=N.+R.+Beeleyauthor=M.+Martinauthor=M.+Morganauthor=S.+Espitiaauthor=H.+R.+Saldanaauthor=C.+Bjenningauthor=K.+T.+Whelanauthor=A.+J.+Grottickauthor=F.+Menzaghiauthor=W.+J.+Thomsen&title=Discovery+and+Structure-Activity+Relationship+of+%281R%29-8-Chloro-2%2C3%2C4%2C5-Tetrahydro-1-Methyl-1h-3-Benzazepine+%28Lorcaserin%29%2C+a+Selective+Serotonin+5-HT2c+Receptor+Agonist+for+the+Treatment+of+Obesity&doi=10.1021%2Fjm0709034"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm0709034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0709034%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DB.%2BM.%26aulast%3DSmith%26aufirst%3DJ.%2BM.%26aulast%3DTsai%26aufirst%3DJ.%2BH.%26aulast%3DSchultz%26aufirst%3DJ.%2BA.%26aulast%3DGilson%26aufirst%3DC.%2BA.%26aulast%3DEstrada%26aufirst%3DS.%2BA.%26aulast%3DChen%26aufirst%3DR.%2BR.%26aulast%3DPark%26aufirst%3DD.%2BM.%26aulast%3DPrieto%26aufirst%3DE.%2BB.%26aulast%3DGallardo%26aufirst%3DC.%2BS.%26aulast%3DSengupta%26aufirst%3DD.%26aulast%3DDosa%26aufirst%3DP.%2BI.%26aulast%3DCovel%26aufirst%3DJ.%2BA.%26aulast%3DRen%26aufirst%3DA.%26aulast%3DWebb%26aufirst%3DR.%2BR.%26aulast%3DBeeley%26aufirst%3DN.%2BR.%26aulast%3DMartin%26aufirst%3DM.%26aulast%3DMorgan%26aufirst%3DM.%26aulast%3DEspitia%26aufirst%3DS.%26aulast%3DSaldana%26aufirst%3DH.%2BR.%26aulast%3DBjenning%26aufirst%3DC.%26aulast%3DWhelan%26aufirst%3DK.%2BT.%26aulast%3DGrottick%26aufirst%3DA.%2BJ.%26aulast%3DMenzaghi%26aufirst%3DF.%26aulast%3DThomsen%26aufirst%3DW.%2BJ.%26atitle%3DDiscovery%2520and%2520Structure-Activity%2520Relationship%2520of%2520%25281R%2529-8-Chloro-2%252C3%252C4%252C5-Tetrahydro-1-Methyl-1h-3-Benzazepine%2520%2528Lorcaserin%2529%252C%2520a%2520Selective%2520Serotonin%25205-HT2c%2520Receptor%2520Agonist%2520for%2520the%2520Treatment%2520of%2520Obesity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26issue%3D2%26spage%3D305%26epage%3D313%26doi%3D10.1021%2Fjm0709034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brashier, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahiya, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khadka, A.</span></span> <span> </span><span class="NLM_article-title">Lorcaserin: A Novel Antiobesity Drug</span>. <i>J. Pharmacol. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">175</span>â <span class="NLM_lpage">178</span>, <span class="refDoi">Â DOI: 10.4103/0976-500X.130158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.4103%2F0976-500X.130158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=24799830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A280%3ADC%252BC2cnpvVKqtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=175-178&issue=2&author=D.+B.+Brashierauthor=A.+K.+Sharmaauthor=N.+Dahiyaauthor=S.+K.+Singhauthor=A.+Khadka&title=Lorcaserin%3A+A+Novel+Antiobesity+Drug&doi=10.4103%2F0976-500X.130158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Lorcaserin: A novel antiobesity drug</span></div><div class="casAuthors">Brashier Dick B S; Sharma A K; Dahiya Navdeep; Singh S K; Khadka Anjan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of pharmacology & pharmacotherapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">175-8</span>
        ISSN:<span class="NLM_cas:issn">0976-500X</span>.
    </div><div class="casAbstract">Obesity is a major co-morbidity with hypertension and diabetes mellitus.  There are few drugs for treatment of obesity like orlistat and recentlty approved drug lorcaserin.  Lorcaserin has serotonergic properties and acts as an anorectic.  It may cause serious side effects, including serotonin syndrome, particularly when taken with certain medicines that increase serotonin levels or activate serotonin receptors.  Although, mainstay and first line of approach of treatment will always remain in having low calorie diet and increase in physical activity.  Lorcaserin has come as a new hope to achieve success in treating obese patients but still a long road with further extensive research to be undertaken in the treatment of obesity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSGtAc-AGMp0Kx48Rj5GnGofW6udTcc2eb0Q2uHRE06Trntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cnpvVKqtw%253D%253D&md5=7ec58017a635b51869935df70adb0f97</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.4103%2F0976-500X.130158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F0976-500X.130158%26sid%3Dliteratum%253Aachs%26aulast%3DBrashier%26aufirst%3DD.%2BB.%26aulast%3DSharma%26aufirst%3DA.%2BK.%26aulast%3DDahiya%26aufirst%3DN.%26aulast%3DSingh%26aufirst%3DS.%2BK.%26aulast%3DKhadka%26aufirst%3DA.%26atitle%3DLorcaserin%253A%2520A%2520Novel%2520Antiobesity%2520Drug%26jtitle%3DJ.%2520Pharmacol.%2520Pharmacother.%26date%3D2014%26volume%3D5%26issue%3D2%26spage%3D175%26epage%3D178%26doi%3D10.4103%2F0976-500X.130158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rogawski, M. A.</span></span> <span> </span><span class="NLM_article-title">Brivaracetam: A Rational Drug Discovery Success Story</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>154</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1555</span>â <span class="NLM_lpage">1557</span>, <span class="refDoi">Â DOI: 10.1038/bjp.2008.221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1038%2Fbjp.2008.221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=18552880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BD1cXps1Gru7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2008&pages=1555-1557&issue=8&author=M.+A.+Rogawski&title=Brivaracetam%3A+A+Rational+Drug+Discovery+Success+Story&doi=10.1038%2Fbjp.2008.221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Brivaracetam: a rational drug discovery success story</span></div><div class="casAuthors">Rogawski, M. A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1555-1557</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Levetiracetam, the Î±-Et analog of the nootropic piracetam, is a widely used antiepileptic drug (AED) that provides protection against partial seizures and is also effective in the treatment of primary generalized seizure syndromes including juvenile myoclonic epilepsy.  Levetiracetam was discovered in 1992 through screening in audiogenic seizure susceptible mice and, 3 years later, was reported to exhibit saturable, stereospecific binding in brain to a â¼90 kDa protein, later identified as the ubiquitous synaptic vesicle glycoprotein SV2A.  A large-scale screening effort to optimize binding affinity identified the 4-Pr analog, brivaracetam, as having greater potency and a broadened spectrum of activity in animal seizure models.  Recent phase II clin. trials demonstrating that brivaracetam is efficacious and well tolerated in the treatment of partial onset seizures have validated the strategy of the discovery program.  Brivaracetam is among the first clin. effective AEDs to be discovered by optimization of pharmacodynamic activity at a mol. target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqH0YRbNA1z7Vg90H21EOLACvtfcHk0lh9ESEReEctNA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXps1Gru7Y%253D&md5=2747db868571f4e48024d6688126f0ce</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fbjp.2008.221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjp.2008.221%26sid%3Dliteratum%253Aachs%26aulast%3DRogawski%26aufirst%3DM.%2BA.%26atitle%3DBrivaracetam%253A%2520A%2520Rational%2520Drug%2520Discovery%2520Success%2520Story%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2008%26volume%3D154%26issue%3D8%26spage%3D1555%26epage%3D1557%26doi%3D10.1038%2Fbjp.2008.221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klitgaard, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matagne, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolas, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamberty, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Ryck, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaminski, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leclercq, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niespodziany, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolff, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannestad, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kervyn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenda, B.</span></span> <span> </span><span class="NLM_article-title">Brivaracetam: Rationale for Discovery and Preclinical Profile of a Selective SV2A Ligand for Epilepsy Treatment</span>. <i>Epilepsia</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">538</span>â <span class="NLM_lpage">548</span>, <span class="refDoi">Â DOI: 10.1111/epi.13340</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1111%2Fepi.13340" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2016&pages=538-548&issue=4&author=H.+Klitgaardauthor=A.+Matagneauthor=J.+M.+Nicolasauthor=M.+Gillardauthor=Y.+Lambertyauthor=M.+De+Ryckauthor=R.+M.+Kaminskiauthor=K.+Leclercqauthor=I.+Niespodzianyauthor=C.+Wolffauthor=M.+Woodauthor=J.+Hannestadauthor=S.+Kervynauthor=B.+Kenda&title=Brivaracetam%3A+Rationale+for+Discovery+and+Preclinical+Profile+of+a+Selective+SV2A+Ligand+for+Epilepsy+Treatment&doi=10.1111%2Fepi.13340"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1111%2Fepi.13340&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fepi.13340%26sid%3Dliteratum%253Aachs%26aulast%3DKlitgaard%26aufirst%3DH.%26aulast%3DMatagne%26aufirst%3DA.%26aulast%3DNicolas%26aufirst%3DJ.%2BM.%26aulast%3DGillard%26aufirst%3DM.%26aulast%3DLamberty%26aufirst%3DY.%26aulast%3DDe%2BRyck%26aufirst%3DM.%26aulast%3DKaminski%26aufirst%3DR.%2BM.%26aulast%3DLeclercq%26aufirst%3DK.%26aulast%3DNiespodziany%26aufirst%3DI.%26aulast%3DWolff%26aufirst%3DC.%26aulast%3DWood%26aufirst%3DM.%26aulast%3DHannestad%26aufirst%3DJ.%26aulast%3DKervyn%26aufirst%3DS.%26aulast%3DKenda%26aufirst%3DB.%26atitle%3DBrivaracetam%253A%2520Rationale%2520for%2520Discovery%2520and%2520Preclinical%2520Profile%2520of%2520a%2520Selective%2520SV2A%2520Ligand%2520for%2520Epilepsy%2520Treatment%26jtitle%3DEpilepsia%26date%3D2016%26volume%3D57%26issue%3D4%26spage%3D538%26epage%3D548%26doi%3D10.1111%2Fepi.13340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Russo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Citraro, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mula, M.</span></span> <span> </span><span class="NLM_article-title">The Preclinical Discovery and Development of Brivaracetam for the Treatment of Focal Epilepsy</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1169</span>â <span class="NLM_lpage">1178</span>, <span class="refDoi">Â DOI: 10.1080/17460441.2017.1366985</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1080%2F17460441.2017.1366985" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=1169-1178&issue=11&author=E.+Russoauthor=R.+Citraroauthor=M.+Mula&title=The+Preclinical+Discovery+and+Development+of+Brivaracetam+for+the+Treatment+of+Focal+Epilepsy&doi=10.1080%2F17460441.2017.1366985"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1080%2F17460441.2017.1366985&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17460441.2017.1366985%26sid%3Dliteratum%253Aachs%26aulast%3DRusso%26aufirst%3DE.%26aulast%3DCitraro%26aufirst%3DR.%26aulast%3DMula%26aufirst%3DM.%26atitle%3DThe%2520Preclinical%2520Discovery%2520and%2520Development%2520of%2520Brivaracetam%2520for%2520the%2520Treatment%2520of%2520Focal%2520Epilepsy%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2017%26volume%3D12%26issue%3D11%26spage%3D1169%26epage%3D1178%26doi%3D10.1080%2F17460441.2017.1366985" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salem, M. E.</span></span> <span> </span><span class="NLM_article-title">Trifluridine/Tipiracil and Regorafenib: New Weapons in the War against Metastatic Colorectal Cancer</span>. <i>Clin Adv. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">630</span>â <span class="NLM_lpage">638</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=27487107" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A280%3ADC%252BC2s3nsFGjsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&pages=630-638&issue=8&author=B.+A.+Weinbergauthor=J.+L.+Marshallauthor=M.+E.+Salem&title=Trifluridine%2FTipiracil+and+Regorafenib%3A+New+Weapons+in+the+War+against+Metastatic+Colorectal+Cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Trifluridine/tipiracil and regorafenib: new weapons in the war against metastatic colorectal cancer</span></div><div class="casAuthors">Weinberg Benjamin A; Marshall John L; Salem Mohamed E</div><div class="citationInfo"><span class="NLM_cas:title">Clinical advances in hematology & oncology : H&O</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">630-8</span>
        ISSN:<span class="NLM_cas:issn">1543-0790</span>.
    </div><div class="casAbstract">Colorectal cancer (CRC) is the second leading cause of cancer-related death in the United States.  Approximately 20% of patients have metastatic disease at diagnosis, and a vast number of these patients die within 5 years.  The advent of modern chemotherapeutics has improved median overall survival for these patients; nonetheless, we must keep striving for better outcomes.  Trifluridine/tipiracil (TAS-102) and regorafenib are agents newly approved by the US Food and Drug Administration that show promise in the treatment of metastatic colorectal cancer.  These drugs have the benefit of being formulated for oral administration and have different side effect profiles.  These differences are important in the selection of the best therapy for each patient, especially if the patient is prone to a side effect that is unique to just one of the treatments.  In this review, we discuss the mechanism of action, side effect profile, and clinical efficacy of trifluridine/tipiracil, and compare them with those of regorafenib.  Future trials will evaluate the use of these drugs in earlier lines of therapy, alone and in combination with other agents.  We now have 2 more agents in the arsenal against metastatic colorectal cancer and the future is looking brighter for patients, although we still have a long way to go.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSZ0YmuRJN9jIqdXsLcGTEUfW6udTcc2eZJZ8tMQVIuOLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s3nsFGjsA%253D%253D&md5=42869ab762519154b8def8023a512f79</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWeinberg%26aufirst%3DB.%2BA.%26aulast%3DMarshall%26aufirst%3DJ.%2BL.%26aulast%3DSalem%26aufirst%3DM.%2BE.%26atitle%3DTrifluridine%252FTipiracil%2520and%2520Regorafenib%253A%2520New%2520Weapons%2520in%2520the%2520War%2520against%2520Metastatic%2520Colorectal%2520Cancer%26jtitle%3DClin%2520Adv.%2520Hematol.%2520Oncol.%26date%3D2016%26volume%3D14%26issue%3D8%26spage%3D630%26epage%3D638" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fukushima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazuno, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asao, T.</span></span> <span> </span><span class="NLM_article-title">Structure and Activity of Specific Inhibitors of Thymidine Phosphorylase to Potentiate the Function of Antitumor 2â²-Deoxyribonucleosides</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1227</span>â <span class="NLM_lpage">1236</span>, <span class="refDoi">Â DOI: 10.1016/S0006-2952(00)00253-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1016%2FS0006-2952%2800%2900253-7" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2000&pages=1227-1236&issue=10&author=M.+Fukushimaauthor=N.+Suzukiauthor=T.+Emuraauthor=S.+Yanoauthor=H.+Kazunoauthor=Y.+Tadaauthor=Y.+Yamadaauthor=T.+Asao&title=Structure+and+Activity+of+Specific+Inhibitors+of+Thymidine+Phosphorylase+to+Potentiate+the+Function+of+Antitumor+2%E2%80%B2-Deoxyribonucleosides&doi=10.1016%2FS0006-2952%2800%2900253-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2FS0006-2952%2800%2900253-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-2952%252800%252900253-7%26sid%3Dliteratum%253Aachs%26aulast%3DFukushima%26aufirst%3DM.%26aulast%3DSuzuki%26aufirst%3DN.%26aulast%3DEmura%26aufirst%3DT.%26aulast%3DYano%26aufirst%3DS.%26aulast%3DKazuno%26aufirst%3DH.%26aulast%3DTada%26aufirst%3DY.%26aulast%3DYamada%26aufirst%3DY.%26aulast%3DAsao%26aufirst%3DT.%26atitle%3DStructure%2520and%2520Activity%2520of%2520Specific%2520Inhibitors%2520of%2520Thymidine%2520Phosphorylase%2520to%2520Potentiate%2520the%2520Function%2520of%2520Antitumor%25202%25E2%2580%25B2-Deoxyribonucleosides%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2000%26volume%3D59%26issue%3D10%26spage%3D1227%26epage%3D1236%26doi%3D10.1016%2FS0006-2952%2800%2900253-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peters, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Bruin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukushima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Triest, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoekman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinedo, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ackland, S. P.</span></span> <span> </span><span class="NLM_article-title">Thymidine Phosphorylase in Angiogenesis and Drug Resistance. Homology with Platelet-Derived Endothelial Cell Growth Factor</span>. <i>Adv. Exp. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>486</i></span>,  <span class="NLM_fpage">291</span>â <span class="NLM_lpage">294</span>, <span class="refDoi">Â DOI: 10.1007/0-306-46843-3_57</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1007%2F0-306-46843-3_57" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=486&publication_year=2000&pages=291-294&author=G.+J.+Petersauthor=M.+De+Bruinauthor=M.+Fukushimaauthor=B.+Van+Triestauthor=K.+Hoekmanauthor=H.+M.+Pinedoauthor=S.+P.+Ackland&title=Thymidine+Phosphorylase+in+Angiogenesis+and+Drug+Resistance.+Homology+with+Platelet-Derived+Endothelial+Cell+Growth+Factor&doi=10.1007%2F0-306-46843-3_57"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1007%2F0-306-46843-3_57&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F0-306-46843-3_57%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DG.%2BJ.%26aulast%3DDe%2BBruin%26aufirst%3DM.%26aulast%3DFukushima%26aufirst%3DM.%26aulast%3DVan%2BTriest%26aufirst%3DB.%26aulast%3DHoekman%26aufirst%3DK.%26aulast%3DPinedo%26aufirst%3DH.%2BM.%26aulast%3DAckland%26aufirst%3DS.%2BP.%26atitle%3DThymidine%2520Phosphorylase%2520in%2520Angiogenesis%2520and%2520Drug%2520Resistance.%2520Homology%2520with%2520Platelet-Derived%2520Endothelial%2520Cell%2520Growth%2520Factor%26jtitle%3DAdv.%2520Exp.%2520Med.%2520Biol.%26date%3D2000%26volume%3D486%26spage%3D291%26epage%3D294%26doi%3D10.1007%2F0-306-46843-3_57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akiyama, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakajo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitazono, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natsugoe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyadera, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukushima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aikou, T.</span></span> <span> </span><span class="NLM_article-title">Suppression of Metastasis by Thymidine Phosphorylase Inhibitor</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">5345</span>â <span class="NLM_lpage">5348</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2000&pages=5345-5348&issue=19&author=S.+Takaoauthor=S.+I.+Akiyamaauthor=A.+Nakajoauthor=H.+Yohauthor=M.+Kitazonoauthor=S.+Natsugoeauthor=K.+Miyaderaauthor=M.+Fukushimaauthor=Y.+Yamadaauthor=T.+Aikou&title=Suppression+of+Metastasis+by+Thymidine+Phosphorylase+Inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTakao%26aufirst%3DS.%26aulast%3DAkiyama%26aufirst%3DS.%2BI.%26aulast%3DNakajo%26aufirst%3DA.%26aulast%3DYoh%26aufirst%3DH.%26aulast%3DKitazono%26aufirst%3DM.%26aulast%3DNatsugoe%26aufirst%3DS.%26aulast%3DMiyadera%26aufirst%3DK.%26aulast%3DFukushima%26aufirst%3DM.%26aulast%3DYamada%26aufirst%3DY.%26aulast%3DAikou%26aufirst%3DT.%26atitle%3DSuppression%2520of%2520Metastasis%2520by%2520Thymidine%2520Phosphorylase%2520Inhibitor%26jtitle%3DCancer%2520Res.%26date%3D2000%26volume%3D60%26issue%3D19%26spage%3D5345%26epage%3D5348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cleary, J.
M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasco, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, W.</span></span> <span> </span><span class="NLM_article-title">A Phase 1 Study of the Pharmacokinetics of Nucleoside Analog Trifluridine and Thymidine Phosphorylase Inhibitor Tipiracil (Components of TAS-102) Vs Trifluridine Alone</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">189</span>â <span class="NLM_lpage">197</span>, <span class="refDoi">Â DOI: 10.1007/s10637-016-0409-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1007%2Fs10637-016-0409-9" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=189-197&issue=2&author=J.%0AM.+Clearyauthor=L.+S.+Rosenauthor=K.+Yoshidaauthor=D.+Rascoauthor=G.+I.+Shapiroauthor=W.+Sun&title=A+Phase+1+Study+of+the+Pharmacokinetics+of+Nucleoside+Analog+Trifluridine+and+Thymidine+Phosphorylase+Inhibitor+Tipiracil+%28Components+of+TAS-102%29+Vs+Trifluridine+Alone&doi=10.1007%2Fs10637-016-0409-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1007%2Fs10637-016-0409-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-016-0409-9%26sid%3Dliteratum%253Aachs%26aulast%3DCleary%26aufirst%3DJ.%2BM.%26aulast%3DRosen%26aufirst%3DL.%2BS.%26aulast%3DYoshida%26aufirst%3DK.%26aulast%3DRasco%26aufirst%3DD.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DSun%26aufirst%3DW.%26atitle%3DA%2520Phase%25201%2520Study%2520of%2520the%2520Pharmacokinetics%2520of%2520Nucleoside%2520Analog%2520Trifluridine%2520and%2520Thymidine%2520Phosphorylase%2520Inhibitor%2520Tipiracil%2520%2528Components%2520of%2520TAS-102%2529%2520Vs%2520Trifluridine%2520Alone%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2017%26volume%3D35%26issue%3D2%26spage%3D189%26epage%3D197%26doi%3D10.1007%2Fs10637-016-0409-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rios-Tamayo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Garcia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alarcon-Payer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Rodriguez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Guardia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia Collado, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez Morales, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurado Chacon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabeza Barrera, J.</span></span> <span> </span><span class="NLM_article-title">Pomalidomide in the Treatment of Multiple Myeloma: Design, Development and Place in Therapy</span>. <i>Drug Des. Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2399</span>â <span class="NLM_lpage">2408</span>, <span class="refDoi">Â DOI: 10.2147/DDDT.S115456</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.2147%2FDDDT.S115456" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=28860711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A280%3ADC%252BC1cbjs1SgtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&pages=2399-2408&author=R.+Rios-Tamayoauthor=A.+Martin-Garciaauthor=C.+Alarcon-Payerauthor=D.+Sanchez-Rodriguezauthor=A.+de+la+Guardiaauthor=C.+G.+Garcia+Colladoauthor=A.+Jimenez+Moralesauthor=M.+Jurado+Chaconauthor=J.+Cabeza+Barrera&title=Pomalidomide+in+the+Treatment+of+Multiple+Myeloma%3A+Design%2C+Development+and+Place+in+Therapy&doi=10.2147%2FDDDT.S115456"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy</span></div><div class="casAuthors">Rios-Tamayo Rafael; Sanchez-Rodriguez Dolores; Jurado Chacon Manuel; Rios-Tamayo Rafael; Jurado Chacon Manuel; Rios-Tamayo Rafael; Jurado Chacon Manuel; Rios-Tamayo Rafael; Jurado Chacon Manuel; Cabeza Barrera Jose; Martin-Garcia Agustin; Alarcon-Payer Carolina; de la Guardia Ana Maria Del Valle Diaz; Garcia Collado Carlos Gustavo; Jimenez Morales Alberto; Cabeza Barrera Jose; Martin-Garcia Agustin; Sanchez-Rodriguez Dolores</div><div class="citationInfo"><span class="NLM_cas:title">Drug design, development and therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2399-2408</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Multiple myeloma is a very heterogeneous disease with variable survival.  Despite recent progress and the widespread use of new agents, patients with relapsed and refractory disease have a poor outcome.  Immunomodulatory drugs play a key role in both the front-line and the relapsed/refractory setting.  The combination of pomalidomide (POM) and dexamethasone is safe and effective in relapsed and refractory patients, even in those with high-risk cytogenetic features.  Furthermore, it can be used in most patients without the need to adjust according to the degree of renal failure.  In order to further improve the results, POM-based triplet therapies are currently used.  This article highlights the most relevant issues of POM and POM-based combinations in the relapsed/refractory multiple myeloma setting, from a pharmacological and clinical point of view.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRAuKrO7n1L57GbPKh4T9eAfW6udTcc2ebiKfzQGpYm-Lntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cbjs1SgtA%253D%253D&md5=75799abcbba614768174b4ab140c0d0c</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S115456&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S115456%26sid%3Dliteratum%253Aachs%26aulast%3DRios-Tamayo%26aufirst%3DR.%26aulast%3DMartin-Garcia%26aufirst%3DA.%26aulast%3DAlarcon-Payer%26aufirst%3DC.%26aulast%3DSanchez-Rodriguez%26aufirst%3DD.%26aulast%3Dde%2Bla%2BGuardia%26aufirst%3DA.%26aulast%3DGarcia%2BCollado%26aufirst%3DC.%2BG.%26aulast%3DJimenez%2BMorales%26aufirst%3DA.%26aulast%3DJurado%2BChacon%26aufirst%3DM.%26aulast%3DCabeza%2BBarrera%26aufirst%3DJ.%26atitle%3DPomalidomide%2520in%2520the%2520Treatment%2520of%2520Multiple%2520Myeloma%253A%2520Design%252C%2520Development%2520and%2520Place%2520in%2520Therapy%26jtitle%3DDrug%2520Des.%2520Dev.%2520Ther.%26date%3D2017%26volume%3D11%26spage%3D2399%26epage%3D2408%26doi%3D10.2147%2FDDDT.S115456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muller, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corral, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shire, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreira, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stirling, D. I.</span></span> <span> </span><span class="NLM_article-title">Structural Modifications of Thalidomide Produce Analogs with Enhanced Tumor Necrosis Factor Inhibitory Activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">3238</span>â <span class="NLM_lpage">3240</span>, <span class="refDoi">Â DOI: 10.1021/jm9603328</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9603328" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=3238-3240&issue=17&author=G.+W.+Mullerauthor=L.+G.+Corralauthor=M.+G.+Shireauthor=H.+Wangauthor=A.+Moreiraauthor=G.+Kaplanauthor=D.+I.+Stirling&title=Structural+Modifications+of+Thalidomide+Produce+Analogs+with+Enhanced+Tumor+Necrosis+Factor+Inhibitory+Activity&doi=10.1021%2Fjm9603328"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm9603328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9603328%26sid%3Dliteratum%253Aachs%26aulast%3DMuller%26aufirst%3DG.%2BW.%26aulast%3DCorral%26aufirst%3DL.%2BG.%26aulast%3DShire%26aufirst%3DM.%2BG.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DMoreira%26aufirst%3DA.%26aulast%3DKaplan%26aufirst%3DG.%26aulast%3DStirling%26aufirst%3DD.%2BI.%26atitle%3DStructural%2520Modifications%2520of%2520Thalidomide%2520Produce%2520Analogs%2520with%2520Enhanced%2520Tumor%2520Necrosis%2520Factor%2520Inhibitory%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26issue%3D17%26spage%3D3238%26epage%3D3240%26doi%3D10.1021%2Fjm9603328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DâAmato, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lentzsch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, M. S.</span></span> <span> </span><span class="NLM_article-title">Mechanism of Action of Thalidomide and 3-Aminothalidomide in Multiple Myeloma</span>. <i>Semin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">597</span>â <span class="NLM_lpage">601</span>, <span class="refDoi">Â DOI: 10.1053/sonc.2001.28601</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1053%2Fsonc.2001.28601" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=11740816" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BD38XjvVSmtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2001&pages=597-601&issue=6&author=R.+J.+D%E2%80%99Amatoauthor=S.+Lentzschauthor=K.+C.+Andersonauthor=M.+S.+Rogers&title=Mechanism+of+Action+of+Thalidomide+and+3-Aminothalidomide+in+Multiple+Myeloma&doi=10.1053%2Fsonc.2001.28601"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma</span></div><div class="casAuthors">D'Amato, Robert J.; Lentzsch, Suzanne; Anderson, Kenneth C.; Rogers, Michael S.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Oncology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">597-601</span>CODEN:
                <span class="NLM_cas:coden">SOLGAV</span>;
        ISSN:<span class="NLM_cas:issn">0093-7754</span>.
    
            (<span class="NLM_cas:orgname">W. B. Saunders Co.</span>)
        </div><div class="casAbstract">A review.  We have explored the mechanism of the antiangiogenic effects of thalidomide by structure-activity studies.  These investigations revealed that angiogenesis inhibition correlates with teratogenicity but not with tumor necrosis factor-alpha inhibition.  Addnl., one analog of thalidomide, 3-aminothalidomide, exhibited an unusual capacity to directly inhibit myeloma cell proliferation.  This activity did not correlate with TNF-Î± inhibition.  Thus 3-aminothalidomide was found to inhibit multiple myeloma through effects on both the tumor and vascular compartment.  The effects of an inhibitor of both the tumor and vascular compartments of a tumor on tumor growth may be synergistic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaR37NH2QpBLVg90H21EOLACvtfcHk0lhRDycXJHI5Rw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjvVSmtg%253D%253D&md5=30a6f07cb0152d98d0452f9b40c727cd</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1053%2Fsonc.2001.28601&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fsonc.2001.28601%26sid%3Dliteratum%253Aachs%26aulast%3DD%25E2%2580%2599Amato%26aufirst%3DR.%2BJ.%26aulast%3DLentzsch%26aufirst%3DS.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26aulast%3DRogers%26aufirst%3DM.%2BS.%26atitle%3DMechanism%2520of%2520Action%2520of%2520Thalidomide%2520and%25203-Aminothalidomide%2520in%2520Multiple%2520Myeloma%26jtitle%3DSemin.%2520Oncol.%26date%3D2001%26volume%3D28%26issue%3D6%26spage%3D597%26epage%3D601%26doi%3D10.1053%2Fsonc.2001.28601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, J. C.</span></span> <span> </span><span class="NLM_article-title">The Histamine H3 Receptor: From Discovery to Clinical Trials with Pitolisant</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>163</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">713</span>â <span class="NLM_lpage">721</span>, <span class="refDoi">Â DOI: 10.1111/j.1476-5381.2011.01286.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1111%2Fj.1476-5381.2011.01286.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=21615387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnsFOitr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2011&pages=713-721&issue=4&author=J.+C.+Schwartz&title=The+Histamine+H3+Receptor%3A+From+Discovery+to+Clinical+Trials+with+Pitolisant&doi=10.1111%2Fj.1476-5381.2011.01286.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">The histamine H3 receptor: from discovery to clinical trials with pitolisant</span></div><div class="casAuthors">Schwartz, Jean-Charles</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">713-721</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The third histamine receptor was discovered in 1983 by a traditional pharmacol. approach, consisting of assessing the inhibitory effect of histamine on its own release from depolarized rat brain slices.  The same in vitro test was used to design, in 1987, the first highly selective and potent H3-autoreceptor ligands, the antagonist thioperamide and the agonist alphamethylhistamine which enhances and inhibits, resp., the activity of histaminergic neurons in brain.  The use of these research tools was instrumental in establishing the main functions of cerebral histaminergic neurons, namely their role in maintenance of wakefulness, attention, learning and other cognitive processes.  In 1990, the cloning of the gene of the H3-receptor, a member of the superfamily of heptahelical receptors coupled to G proteins, paved the way to the demonstration of the high constitutive activity of the receptor, including its native form, and its participation in the tonic control of histamine release; it also facilitated the development of H3-receptor inverse agonist programs in many drug companies.  Pitolisant (BF2.649, 1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine, hydrochloride) is the first inverse agonist to be introduced in the clinics.  Its wake-promotion activity was evidenced in excessive diurnal sleepiness of patients with narcolepsy, Parkinson's disease or Obstructive Sleep Apnea/Hypopnea, in which this activity is characterized by a mean decrease of the Epworth Sleepiness Scale by about five units.  The procognitive activity of this novel class of drugs may also find therapeutic applications in dementias, schizophrenia or attention deficit hyperactivity disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHrkoL8T1XbbVg90H21EOLACvtfcHk0lhRDycXJHI5Rw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnsFOitr0%253D&md5=f8b1db02051f583d7ca6c179c29f0db2</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01286.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01286.x%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DJ.%2BC.%26atitle%3DThe%2520Histamine%2520H3%2520Receptor%253A%2520From%2520Discovery%2520to%2520Clinical%2520Trials%2520with%2520Pitolisant%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D163%26issue%3D4%26spage%3D713%26epage%3D721%26doi%3D10.1111%2Fj.1476-5381.2011.01286.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ropper, A. H.</span></span> <span> </span><span class="NLM_article-title">The âPoison Chairâ Treatment for Multiple Sclerosis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>367</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1149</span>â <span class="NLM_lpage">1150</span>, <span class="refDoi">Â DOI: 10.1056/NEJMe1209169</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1056%2FNEJMe1209169" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=22992079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVKkurrI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=1149-1150&issue=12&author=A.+H.+Ropper&title=The+%E2%80%9CPoison+Chair%E2%80%9D+Treatment+for+Multiple+Sclerosis&doi=10.1056%2FNEJMe1209169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">The "poison chair" treatment for multiple sclerosis</span></div><div class="casAuthors">Ropper, Allan H.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1149-1150</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocShrlNUh-8rVg90H21EOLACvtfcHk0lhRDycXJHI5Rw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVKkurrI&md5=4a5d46428fcb516083d5d0d780445a71</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1056%2FNEJMe1209169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMe1209169%26sid%3Dliteratum%253Aachs%26aulast%3DRopper%26aufirst%3DA.%2BH.%26atitle%3DThe%2520%25E2%2580%259CPoison%2520Chair%25E2%2580%259D%2520Treatment%2520for%2520Multiple%2520Sclerosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26issue%3D12%26spage%3D1149%26epage%3D1150%26doi%3D10.1056%2FNEJMe1209169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Held, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epp, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biaglow, J. E.</span></span> <span> </span><span class="NLM_article-title">Effect of Dimethyl Fumarate on the Radiation Sensitivity of Mammalian Cells in Vitro</span>. <i>Radiat. Res.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>115</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">495</span>â <span class="NLM_lpage">502</span>, <span class="refDoi">Â DOI: 10.2307/3577299</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.2307%2F3577299" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=3174933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADyaL1cXlsVGgtL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=1988&pages=495-502&issue=3&author=K.+D.+Heldauthor=E.+R.+Eppauthor=E.+P.+Clarkauthor=J.+E.+Biaglow&title=Effect+of+Dimethyl+Fumarate+on+the+Radiation+Sensitivity+of+Mammalian+Cells+in+Vitro&doi=10.2307%2F3577299"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of dimethylfumarate on the radiation sensitivity of mammalian cells in vitro</span></div><div class="casAuthors">Held, Kathryn D.; Epp, Edward R.; Clark, Edward P.; Biaglow, John E.</div><div class="citationInfo"><span class="NLM_cas:title">Radiation Research</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">495-202</span>CODEN:
                <span class="NLM_cas:coden">RAREAE</span>;
        ISSN:<span class="NLM_cas:issn">0033-7587</span>.
    </div><div class="casAbstract">Dimethylfumarate (DMF) depletes intracellular glutathione (GSH) by covalent bond formation in a reaction which may be mediated by GSH S-transferase.  In Chinese hamster ovary cells, this depletion is rapid; e.g., 0.5 mM DMF depletes GSH to <10% of control in 5 min at room temp.  DMF is a very effective hypoxic cell radiosensitizer, with an enhancement ratio (ER) of â¼3 obtained by a 5-min exposure of x-irradiated cells at room temp. to 5 mM DMF, without significant toxicity.  At this same concn. of drug, there is a small enhancement of aerobic cells (ER = 1.3), but the 5 mM DMF in hypoxia results in nearly a complete collapse of the hypoxic dose-response curve to the same level as seen in air with DMF.  It has been suggested previously that DMF sensitizes cells via electron affinic mechanisms.  However, this appears not to be the case in this study, as shown by the fact that cells pretreated with DMF and then washed free of the drug remained equally radiosensitive as cells irradiated in the presence of the drug.  This large enhancement of radiation sensitivity appears to be related to the drug's ability to deplete thiols; i.e., thiols appear to be a major factor responsible for radioresistance of hypoxic cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqz2kbR8UCOkrVg90H21EOLACvtfcHk0lh-J3RLQnjVhw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXlsVGgtL8%253D&md5=c3f6880556f978082aaebd491bc5f9f9</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.2307%2F3577299&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2307%252F3577299%26sid%3Dliteratum%253Aachs%26aulast%3DHeld%26aufirst%3DK.%2BD.%26aulast%3DEpp%26aufirst%3DE.%2BR.%26aulast%3DClark%26aufirst%3DE.%2BP.%26aulast%3DBiaglow%26aufirst%3DJ.%2BE.%26atitle%3DEffect%2520of%2520Dimethyl%2520Fumarate%2520on%2520the%2520Radiation%2520Sensitivity%2520of%2520Mammalian%2520Cells%2520in%2520Vitro%26jtitle%3DRadiat.%2520Res.%26date%3D1988%26volume%3D115%26issue%3D3%26spage%3D495%26epage%3D502%26doi%3D10.2307%2F3577299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schimrigk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brune, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellwig, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lukas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellenberg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rieks, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pohlau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Przuntek, H.</span></span> <span> </span><span class="NLM_article-title">Oral Fumaric Acid Esters for the Treatment of Active Multiple Sclerosis: An Open-Label, Baseline-Controlled Pilot Study</span>. <i>Eur. J. Neurol</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">604</span>â <span class="NLM_lpage">610</span>, <span class="refDoi">Â DOI: 10.1111/j.1468-1331.2006.01292.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1111%2Fj.1468-1331.2006.01292.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=16796584" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A280%3ADC%252BD28zotFagsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2006&pages=604-610&issue=6&author=S.+Schimrigkauthor=N.+Bruneauthor=K.+Hellwigauthor=C.+Lukasauthor=B.+Bellenbergauthor=M.+Rieksauthor=V.+Hoffmannauthor=D.+Pohlauauthor=H.+Przuntek&title=Oral+Fumaric+Acid+Esters+for+the+Treatment+of+Active+Multiple+Sclerosis%3A+An+Open-Label%2C+Baseline-Controlled+Pilot+Study&doi=10.1111%2Fj.1468-1331.2006.01292.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study</span></div><div class="casAuthors">Schimrigk S; Brune N; Hellwig K; Lukas C; Bellenberg B; Rieks M; Hoffmann V; Pohlau D; Przuntek H</div><div class="citationInfo"><span class="NLM_cas:title">European journal of neurology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">604-10</span>
        ISSN:<span class="NLM_cas:issn">1351-5101</span>.
    </div><div class="casAbstract">An exploratory, prospective, open-label study of fumaric acid esters (FAE, Fumaderm(R)) was conducted in patients with relapsing-remitting multiple sclerosis (RRMS).  The study consisted of the following four phases: 6-week baseline, 18-week treatment (target dose of 720 mg/day), 4-week washout, and a second 48-week treatment phase (target dose of 360 mg/day).  Ten patients with an Expanded Disability Status Scale (EDSS) score of 2.0-6.0 and at least one gadolinium-enhancing (Gd+) lesion on T1-weighted magnetic resonance imaging (MRI) brain scans participated in the study.  Safety was assessed by adverse events (AEs), blood chemistry/hematology, electrocardiogram, and urinalysis.  The primary efficacy outcomes were number and volume of Gd+ lesions.  Other clinical outcomes included EDSS score, ambulation index (AI), and nine-hole peg test (9-HPT).  Effects of FAE on intracellular cytokine profiles, T-cell apoptosis, and soluble adhesion molecules were also assessed.  Three patients withdrew during the first 3 weeks of the study because of side effects, non-compliance, and follow-up loss.  The most common AEs were gastrointestinal symptoms and flushing; all AEs were reported as mild and reversible.  FAE produced significant reductions from baseline in number (P < 0.05) and volume (P < 0.01) of Gd+ lesions after 18 weeks of treatment; this effect persisted during the second treatment phase at half the target dose after the 4-week washout period.  EDSS scores, AI, and 9-HPT remained stable or slightly improved from baseline in all patients.  Measures of T-cell function demonstrated alterations in cytokines and circulating tumor necrosis factor.  The results of this exploratory study suggest that further studies of FAE in patients with MS are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcThsEMDj3lPaEPI-fCgwosgfW6udTcc2eaGplwexKEsM7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28zotFagsw%253D%253D&md5=c6bcbc1fb04d0b3bedebfbe53b6e1fff</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1111%2Fj.1468-1331.2006.01292.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1468-1331.2006.01292.x%26sid%3Dliteratum%253Aachs%26aulast%3DSchimrigk%26aufirst%3DS.%26aulast%3DBrune%26aufirst%3DN.%26aulast%3DHellwig%26aufirst%3DK.%26aulast%3DLukas%26aufirst%3DC.%26aulast%3DBellenberg%26aufirst%3DB.%26aulast%3DRieks%26aufirst%3DM.%26aulast%3DHoffmann%26aufirst%3DV.%26aulast%3DPohlau%26aufirst%3DD.%26aulast%3DPrzuntek%26aufirst%3DH.%26atitle%3DOral%2520Fumaric%2520Acid%2520Esters%2520for%2520the%2520Treatment%2520of%2520Active%2520Multiple%2520Sclerosis%253A%2520An%2520Open-Label%252C%2520Baseline-Controlled%2520Pilot%2520Study%26jtitle%3DEur.%2520J.%2520Neurol%26date%3D2006%26volume%3D13%26issue%3D6%26spage%3D604%26epage%3D610%26doi%3D10.1111%2Fj.1468-1331.2006.01292.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gold, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kappos, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bar-Or, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giovannoni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selmaj, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tornatore, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweetser, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheikh, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, K. T.</span></span> <span> </span><span class="NLM_article-title">Investigators, D. S. Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>367</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1098</span>â <span class="NLM_lpage">1107</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa1114287</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1056%2FNEJMoa1114287" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=22992073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVKkur3F" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=1098-1107&issue=12&author=R.+Goldauthor=L.+Kapposauthor=D.+L.+Arnoldauthor=A.+Bar-Orauthor=G.+Giovannoniauthor=K.+Selmajauthor=C.+Tornatoreauthor=M.+T.+Sweetserauthor=M.+Yangauthor=S.+I.+Sheikhauthor=K.+T.+Dawson&title=Investigators%2C+D.+S.+Placebo-Controlled+Phase+3+Study+of+Oral+BG-12+for+Relapsing+Multiple+Sclerosis&doi=10.1056%2FNEJMoa1114287"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis</span></div><div class="casAuthors">Gold, Ralf; Kappos, Ludwig; Arnold, Douglas L.; Bar-Or, Amit; Giovannoni, Gavin; Selmaj, Krzysztof; Tornatore, Carlo; Sweetser, Marianne T.; Yang, Minhua; Sheikh, Sarah I.; Dawson, Katherine T.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1098-1107</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: BG-12 (di-Me fumarate) was shown to have antiinflammatory and cytoprotective properties in preclin. expts. and to result in significant redns. in disease activity on magnetic resonance imaging (MRI) in a phase 2, placebo-controlled study involving patients with relapsing-remitting multiple sclerosis.  Methods: We conducted a randomized, double-blind, placebo-controlled phase 3 study involving patients with relapsing-remitting multiple sclerosis.  Patients were randomly assigned to receive oral BG-12 at a dose of 240 mg twice daily, BG-12 at a dose of 240 mg three times daily, or placebo.  The primary end point was the proportion of patients who had a relapse by 2 years.  Other end points included the annualized relapse rate, the time to confirmed progression of disability, and findings on MRI.  Results: The estd. proportion of patients who had a relapse was significantly lower in the two BG-12 groups than in the placebo group (27% with BG-12 twice daily and 26% with BG-12 thrice daily vs. 46% with placebo, P<0.001 for both comparisons).  The annualized relapse rate at 2 years was 0.17 in the twice-daily BG-12 group and 0.19 in the thrice-daily BG-12 group, as compared with 0.36 in the placebo group, representing relative redns. of 53% and 48% with the two BG-12 regimens, resp. (P<0.001 for the comparison of each BG-12 regimen with placebo).  The estd. proportion of patients with confirmed progression of disability was 16% in the twice-daily BG-12 group, 18% in the thrice-daily BG-12 group, and 27% in the placebo group, with significant relative risk redns. of 38% with BG-12 twice daily (P = 0.005) and 34% with BG-12 thrice daily (P = 0.01).  BG-12 also significantly reduced the no. of gadolinium-enhancing lesions and of new or enlarging T2-weighted hyperintense lesions (P<0.001 for the comparison of each BG-12 regimen with placebo).  Adverse events assocd. with BG-12 included flushing and gastrointestinal events, such as diarrhea, nausea, and upper abdominal pain, as well as decreased lymphocyte counts and elevated liver aminotransferase levels.  Conclusions: In patients with relapsing-remitting multiple sclerosis, both BG-12 regimens, as compared with placebo, significantly reduced the proportion of patients who had a relapse, the annualized relapse rate, the rate of disability progression, and the no. of lesions on MRI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNPrC6E7qh_rVg90H21EOLACvtfcHk0lh-J3RLQnjVhw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVKkur3F&md5=5d10ff87768411553696da03ae888372</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1114287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1114287%26sid%3Dliteratum%253Aachs%26aulast%3DGold%26aufirst%3DR.%26aulast%3DKappos%26aufirst%3DL.%26aulast%3DArnold%26aufirst%3DD.%2BL.%26aulast%3DBar-Or%26aufirst%3DA.%26aulast%3DGiovannoni%26aufirst%3DG.%26aulast%3DSelmaj%26aufirst%3DK.%26aulast%3DTornatore%26aufirst%3DC.%26aulast%3DSweetser%26aufirst%3DM.%2BT.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DSheikh%26aufirst%3DS.%2BI.%26aulast%3DDawson%26aufirst%3DK.%2BT.%26atitle%3DInvestigators%252C%2520D.%2520S.%2520Placebo-Controlled%2520Phase%25203%2520Study%2520of%2520Oral%2520BG-12%2520for%2520Relapsing%2520Multiple%2520Sclerosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26issue%3D12%26spage%3D1098%26epage%3D1107%26doi%3D10.1056%2FNEJMoa1114287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGuire, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz-Zorrilla Diez, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emmerich, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strickson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritorto, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutavani, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houslay, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knebel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meakin, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phair, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashford, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trost, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arthur, J. S.</span></span> <span> </span><span class="NLM_article-title">Dimethyl Fumarate Blocks Pro-Inflammatory Cytokine Production Via Inhibition of TLR Induced M1 and K63 Ubiquitin Chain Formation</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">31159</span>, <span class="refDoi">Â DOI: 10.1038/srep31159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1038%2Fsrep31159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=27498693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlCisLbF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=31159&author=V.+A.+McGuireauthor=T.+Ruiz-Zorrilla+Diezauthor=C.+H.+Emmerichauthor=S.+Stricksonauthor=M.+S.+Ritortoauthor=R.+V.+Sutavaniauthor=A.+Weissauthor=K.+F.+Houslayauthor=A.+Knebelauthor=P.+J.+Meakinauthor=I.+R.+Phairauthor=M.+L.+Ashfordauthor=M.+Trostauthor=J.+S.+Arthur&title=Dimethyl+Fumarate+Blocks+Pro-Inflammatory+Cytokine+Production+Via+Inhibition+of+TLR+Induced+M1+and+K63+Ubiquitin+Chain+Formation&doi=10.1038%2Fsrep31159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Dimethyl fumarate blocks pro-inflammatory cytokine production via inhibition of TLR induced M1 and K63 ubiquitin chain formation</span></div><div class="casAuthors">McGuire, Victoria A.; Ruiz-Zorrilla Diez, Tamara; Emmerich, Christoph H.; Strickson, Sam; Ritorto, Maria Stella; Sutavani, Ruhcha V.; WeiÎ², Anne; Houslay, Kirsty F.; Knebel, Axel; Meakin, Paul J.; Phair, Iain R.; Ashford, Michael L. J.; Trost, Matthias; Arthur, J. Simon C.</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">31159</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Di-Me fumarate (DMF) possesses anti-inflammatory properties and is approved for the treatment of psoriasis and multiple sclerosis.  While clin. effective, its mol. target has remained elusive - although it is known to activate anti-oxidant pathways.  We find that DMF inhibits pro-inflammatory cytokine prodn. in response to TLR agonists independently of the Nrf2-Keap1 anti-oxidant pathway.  Instead we show that DMF can inhibit the E2 conjugating enzymes involved in K63 and M1 polyubiquitin chain formation both in vitro and in cells.  The formation of K63 and M1 chains is required to link TLR activation to downstream signaling, and consistent with the block in K63 and/or M1 chain formation, DMF inhibits NFÎºB and ERK1/2 activation, resulting in a loss of pro-inflammatory cytokine prodn.  Together these results reveal a new mol. target for DMF and show that a clin. approved drug inhibits M1 and K63 chain formation in TLR induced signaling complexes.  Selective targeting of E2s may therefore be a viable strategy for autoimmunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiuOzdY8UlbLVg90H21EOLACvtfcHk0lijPfticyTC0A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlCisLbF&md5=f185ac6db58eef6c7c61d1728f73a8d1</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fsrep31159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep31159%26sid%3Dliteratum%253Aachs%26aulast%3DMcGuire%26aufirst%3DV.%2BA.%26aulast%3DRuiz-Zorrilla%2BDiez%26aufirst%3DT.%26aulast%3DEmmerich%26aufirst%3DC.%2BH.%26aulast%3DStrickson%26aufirst%3DS.%26aulast%3DRitorto%26aufirst%3DM.%2BS.%26aulast%3DSutavani%26aufirst%3DR.%2BV.%26aulast%3DWeiss%26aufirst%3DA.%26aulast%3DHouslay%26aufirst%3DK.%2BF.%26aulast%3DKnebel%26aufirst%3DA.%26aulast%3DMeakin%26aufirst%3DP.%2BJ.%26aulast%3DPhair%26aufirst%3DI.%2BR.%26aulast%3DAshford%26aufirst%3DM.%2BL.%26aulast%3DTrost%26aufirst%3DM.%26aulast%3DArthur%26aufirst%3DJ.%2BS.%26atitle%3DDimethyl%2520Fumarate%2520Blocks%2520Pro-Inflammatory%2520Cytokine%2520Production%2520Via%2520Inhibition%2520of%2520TLR%2520Induced%2520M1%2520and%2520K63%2520Ubiquitin%2520Chain%2520Formation%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D31159%26doi%3D10.1038%2Fsrep31159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Susitaival, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winhoven, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lammintausta, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruvberger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimerson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruze, M.</span></span> <span> </span><span class="NLM_article-title">An Outbreak of Furniture Related Dermatitis (âSofa Dermatitisâ) in Finland and the UK: History and Clinical Cases</span>. <i>J. Eur. Acad. Dermatol. Venereol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">486</span>â <span class="NLM_lpage">489</span>, <span class="refDoi">Â DOI: 10.1111/j.1468-3083.2009.03429.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1111%2Fj.1468-3083.2009.03429.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=19796087" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A280%3ADC%252BC3czjtFyitA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2010&pages=486-489&issue=4&author=P.+Susitaivalauthor=S.+M.+Winhovenauthor=J.+Williamsauthor=K.+Lammintaustaauthor=T.+Hasanauthor=M.+H.+Beckauthor=B.+Gruvbergerauthor=E.+Zimersonauthor=M.+Bruze&title=An+Outbreak+of+Furniture+Related+Dermatitis+%28%E2%80%9CSofa+Dermatitis%E2%80%9D%29+in+Finland+and+the+UK%3A+History+and+Clinical+Cases&doi=10.1111%2Fj.1468-3083.2009.03429.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">An outbreak of furniture related dermatitis ('sofa dermatitis') in Finland and the UK: history and clinical cases</span></div><div class="casAuthors">Susitaival P; Winhoven S M; Williams J; Lammintausta K; Hasan T; Beck M H; Gruvberger B; Zimerson E; Bruze M</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the European Academy of Dermatology and Venereology : JEADV</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">486-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">In February 2007, an epidemic of severe dermatitis from Chinese recliner chairs and sofas started to unfold first in Finland and a few months later in the UK.  Some patients reacted in patch tests (PTs) strongly to the material of their furniture, either leather or fabric.  There have been hundreds of reports of chair or sofa dermatitis from Finland and the UK, with all cases linked to the same furniture factory in China.  Clinical findings in both countries were very similar and unlike any known dermatosis.  Many cases have been quite severe, resembling mycosis fungoides or septic infections, requiring hospitalization.  Commercial PTs did not reveal the cause but a fungicide was strongly suspected, although such use was denied by the factory.  The laboratory of Malmo University Dermatology Clinic has helped in the process by making thin layer chromatograms from sofa or chair materials and test substances of suspected chemicals.  Finally, sachets marked with 'mouldproof agent' were found in varying numbers and distribution in the sofas.  These contained dimethyl fumarate (DMF) which proved in skin tests to cause strong positive reactions with down to 0.01 dilution.  Reports from other countries (Belgium, France, Ireland, Sweden and Spain) have since appeared, and the EU has banned the use of DMF in consumer products.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTbOlNeOmwzHsAKB7Fa-xrUfW6udTcc2eY4kDLqeBkwyrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3czjtFyitA%253D%253D&md5=859586397fcc3b73f7665dcca9e72dc6</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1111%2Fj.1468-3083.2009.03429.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1468-3083.2009.03429.x%26sid%3Dliteratum%253Aachs%26aulast%3DSusitaival%26aufirst%3DP.%26aulast%3DWinhoven%26aufirst%3DS.%2BM.%26aulast%3DWilliams%26aufirst%3DJ.%26aulast%3DLammintausta%26aufirst%3DK.%26aulast%3DHasan%26aufirst%3DT.%26aulast%3DBeck%26aufirst%3DM.%2BH.%26aulast%3DGruvberger%26aufirst%3DB.%26aulast%3DZimerson%26aufirst%3DE.%26aulast%3DBruze%26aufirst%3DM.%26atitle%3DAn%2520Outbreak%2520of%2520Furniture%2520Related%2520Dermatitis%2520%2528%25E2%2580%259CSofa%2520Dermatitis%25E2%2580%259D%2529%2520in%2520Finland%2520and%2520the%2520UK%253A%2520History%2520and%2520Clinical%2520Cases%26jtitle%3DJ.%2520Eur.%2520Acad.%2520Dermatol.%2520Venereol.%26date%3D2010%26volume%3D24%26issue%3D4%26spage%3D486%26epage%3D489%26doi%3D10.1111%2Fj.1468-3083.2009.03429.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miyake, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebata, M.</span></span> <span> </span><span class="NLM_article-title">Galactostatin, a New Beta-Galactosidase Inhibitor from Streptomyces Lydicus</span>. <i>J. Antibiot.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">122</span>â <span class="NLM_lpage">123</span>, <span class="refDoi">Â DOI: 10.7164/antibiotics.40.122</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.7164%2Fantibiotics.40.122" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1987&pages=122-123&issue=1&author=Y.+Miyakeauthor=M.+Ebata&title=Galactostatin%2C+a+New+Beta-Galactosidase+Inhibitor+from+Streptomyces+Lydicus&doi=10.7164%2Fantibiotics.40.122"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.7164%2Fantibiotics.40.122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7164%252Fantibiotics.40.122%26sid%3Dliteratum%253Aachs%26aulast%3DMiyake%26aufirst%3DY.%26aulast%3DEbata%26aufirst%3DM.%26atitle%3DGalactostatin%252C%2520a%2520New%2520Beta-Galactosidase%2520Inhibitor%2520from%2520Streptomyces%2520Lydicus%26jtitle%3DJ.%2520Antibiot.%26date%3D1987%26volume%3D40%26issue%3D1%26spage%3D122%26epage%3D123%26doi%3D10.7164%2Fantibiotics.40.122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Fernandez, E.
M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia Fernandez, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellet, C. O.</span></span> <span> </span><span class="NLM_article-title">Glycomimetic-Based Pharmacological Chaperones for Lysosomal Storage Disorders: Lessons from Gaucher, GM1-Gangliosidosis and Fabry Diseases</span>. <i>Chem. Commun. (Cambridge, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">32</span>),  <span class="NLM_fpage">5497</span>â <span class="NLM_lpage">5515</span>, <span class="refDoi">Â DOI: 10.1039/C6CC01564F</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1039%2FC6CC01564F" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=27043200" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC28XksFOht7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2016&pages=5497-5515&issue=32&author=E.%0AM.+Sanchez-Fernandezauthor=J.+M.+Garcia+Fernandezauthor=C.+O.+Mellet&title=Glycomimetic-Based+Pharmacological+Chaperones+for+Lysosomal+Storage+Disorders%3A+Lessons+from+Gaucher%2C+GM1-Gangliosidosis+and+Fabry+Diseases&doi=10.1039%2FC6CC01564F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Glycomimetic-based pharmacological chaperones for lysosomal storage disorders: lessons from Gaucher, GM1-gangliosidosis and Fabry diseases</span></div><div class="casAuthors">Sanchez-Fernandez, Elena M.; Garcia Fernandez, Jose M.; Mellet, Carmen Ortiz</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">5497-5515</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Lysosomal storage disorders (LSDs) are often caused by mutations that destabilize native folding and impair the trafficking of enzymes, leading to premature endoplasmic reticulum (ER)-assocd. degrdn., deficiencies of specific hydrolytic functions and aberrant storage of metabolites in the lysosomes.  Enzyme replacement therapy (ERT) and substrate redn. therapy (SRT) are available for a few of these conditions, but most remain orphan.  A main difficulty is that virtually all LSDs involve neurol. decline and neither proteins nor the current SRT drugs can cross the blood-brain barrier.  Twenty years ago a new therapeutic paradigm better suited for neuropathic LSDs was launched, namely pharmacol. chaperone (PC) therapy.  PCs are small mols. capable of binding to the mutant protein at the ER, inducing proper folding, restoring trafficking and increasing enzyme activity and substrate processing in the lysosome.  In many LSDs the mutated protein is a glycosidase and the accumulated substrate is an oligo- or polysaccharide or a glycoconjugate, e.g. a glycosphingolipid.  Although it might appear counterintuitive, substrate analogs (glycomimetics) behaving as competitive glycosidase inhibitors are good candidates to perform PC tasks.  The advancements in the knowledge of the mol. basis of LSDs, including enzyme structures, binding modes, trafficking pathways and substrate processing mechanisms, have been put forward to optimize PC selectivity and efficacy.  Moreover, the chem. versatility of glycomimetics and the variety of structures at hand allow simultaneous optimization of chaperone and pharmacokinetic properties.  In this Feature Article we review the advancements made in this field in the last few years and the future outlook through the lessons taught by three archetypical LSDs: Gaucher disease, GM1-gangliosidosis and Fabry disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBG6A7ONRboLVg90H21EOLACvtfcHk0lijPfticyTC0A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XksFOht7w%253D&md5=c6f74ee25c03a3bc782813c39d30f851</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1039%2FC6CC01564F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6CC01564F%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez-Fernandez%26aufirst%3DE.%2BM.%26aulast%3DGarcia%2BFernandez%26aufirst%3DJ.%2BM.%26aulast%3DMellet%26aufirst%3DC.%2BO.%26atitle%3DGlycomimetic-Based%2520Pharmacological%2520Chaperones%2520for%2520Lysosomal%2520Storage%2520Disorders%253A%2520Lessons%2520from%2520Gaucher%252C%2520GM1-Gangliosidosis%2520and%2520Fabry%2520Diseases%26jtitle%3DChem.%2520Commun.%2520%2528Cambridge%252C%2520U.%2520K.%2529%26date%3D2016%26volume%3D52%26issue%3D32%26spage%3D5497%26epage%3D5515%26doi%3D10.1039%2FC6CC01564F" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khanna, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soska, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frascella, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brignol, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellegrino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sitaraman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desnick, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benjamin, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valenzano, K. J.</span></span> <span> </span><span class="NLM_article-title">The Pharmacological Chaperone 1-Deoxygalactonojirimycin Reduces Tissue Globotriaosylceramide Levels in a Mouse Model of Fabry Disease</span>. <i>Mol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">23</span>â <span class="NLM_lpage">33</span>, <span class="refDoi">Â DOI: 10.1038/mt.2009.220</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1038%2Fmt.2009.220" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=19773742" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFGrtrzN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=23-33&issue=1&author=R.+Khannaauthor=R.+Soskaauthor=Y.+Lunauthor=J.+Fengauthor=M.+Frascellaauthor=B.+Youngauthor=N.+Brignolauthor=L.+Pellegrinoauthor=S.+A.+Sitaramanauthor=R.+J.+Desnickauthor=E.+R.+Benjaminauthor=D.+J.+Lockhartauthor=K.+J.+Valenzano&title=The+Pharmacological+Chaperone+1-Deoxygalactonojirimycin+Reduces+Tissue+Globotriaosylceramide+Levels+in+a+Mouse+Model+of+Fabry+Disease&doi=10.1038%2Fmt.2009.220"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">The Pharmacological Chaperone 1-Deoxygalactonojirimycin Reduces Tissue Globotriaosylceramide Levels in a Mouse Model of Fabry Disease</span></div><div class="casAuthors">Khanna, Richie; Soska, Rebecca; Lun, Yi; Feng, Jessie; Frascella, Michelle; Young, Brandy; Brignol, Nastry; Pellegrino, Lee; Sitaraman, Sheela A.; Desnick, Robert J.; Benjamin, Elfrida R.; Lockhart, David J.; Valenzano, Kenneth J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Therapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">23-33</span>CODEN:
                <span class="NLM_cas:coden">MTOHCK</span>;
        ISSN:<span class="NLM_cas:issn">1525-0016</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Fabry disease is an X-linked lysosomal storage disorder caused by a deficiency in Î±-galactosidase A (Î±-Gal A) activity and subsequent accumulation of the substrate globotriaosylceramide (GL-3), which contributes to disease pathol.  The pharmacol. chaperone (PC) DGJ (1-deoxygalactonojirimycin) binds and stabilizes Î±-Gal A, increasing enzyme levels in cultured cells and in vivo.  The ability of DGJ to reduce GL-3 in vivo was investigated using transgenic (Tg) mice that express a mutant form of human Î±-Gal A (R301Q) on a knockout background (Tg/KO), which leads to GL-3 accumulation in disease-relevant tissues.  Four-week daily oral administration of DGJ to Tg/KO mice resulted in significant and dose-dependent increases in Î±-Gal A activity, with concomitant GL-3 redn. in skin, heart, kidney, brain, and plasma; 24-wk administration resulted in even greater redns.  Compared to daily administration, less frequent DGJ administration, including repeated cycles of 4 days with DGJ followed by 3 days without or every other day with DGJ, resulted in even greater GL-3 redns. that were comparable to those obtained with Fabrazyme.  Collectively, these data indicate that oral administration of DGJ increases mutant Î±-Gal A activity and reduces GL-3 in disease-relevant tissues in Tg/KO mice, and thus merits further evaluation as a treatment for Fabry disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobjW0bAkndtLVg90H21EOLACvtfcHk0lgbI6IW2gKu6A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFGrtrzN&md5=5b0cddd0c2f9e9246d73a935ab6c87d1</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fmt.2009.220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmt.2009.220%26sid%3Dliteratum%253Aachs%26aulast%3DKhanna%26aufirst%3DR.%26aulast%3DSoska%26aufirst%3DR.%26aulast%3DLun%26aufirst%3DY.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DFrascella%26aufirst%3DM.%26aulast%3DYoung%26aufirst%3DB.%26aulast%3DBrignol%26aufirst%3DN.%26aulast%3DPellegrino%26aufirst%3DL.%26aulast%3DSitaraman%26aufirst%3DS.%2BA.%26aulast%3DDesnick%26aufirst%3DR.%2BJ.%26aulast%3DBenjamin%26aufirst%3DE.%2BR.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DValenzano%26aufirst%3DK.%2BJ.%26atitle%3DThe%2520Pharmacological%2520Chaperone%25201-Deoxygalactonojirimycin%2520Reduces%2520Tissue%2520Globotriaosylceramide%2520Levels%2520in%2520a%2520Mouse%2520Model%2520of%2520Fabry%2520Disease%26jtitle%3DMol.%2520Ther.%26date%3D2010%26volume%3D18%26issue%3D1%26spage%3D23%26epage%3D33%26doi%3D10.1038%2Fmt.2009.220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benjamin, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schilling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pine, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wustman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desnick, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valenzano, K. J.</span></span> <span> </span><span class="NLM_article-title">The Pharmacological Chaperone 1-Deoxygalactonojirimycin Increases Alpha-Galactosidase a Levels in Fabry Patient Cell Lines</span>. <i>J. Inherited Metab. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">424</span>â <span class="NLM_lpage">440</span>, <span class="refDoi">Â DOI: 10.1007/s10545-009-1077-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1007%2Fs10545-009-1077-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmsFWrsbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2009&pages=424-440&issue=3&author=E.+R.+Benjaminauthor=J.+J.+Flanaganauthor=A.+Schillingauthor=H.+H.+Changauthor=L.+Agarwalauthor=E.+Katzauthor=X.+Wuauthor=C.+Pineauthor=B.+Wustmanauthor=R.+J.+Desnickauthor=D.+J.+Lockhartauthor=K.+J.+Valenzano&title=The+Pharmacological+Chaperone+1-Deoxygalactonojirimycin+Increases+Alpha-Galactosidase+a+Levels+in+Fabry+Patient+Cell+Lines&doi=10.1007%2Fs10545-009-1077-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">The pharmacological chaperone 1-deoxygalactonojirimycin increases Î±-galactosidase A levels in Fabry patient cell lines</span></div><div class="casAuthors">Benjamin, E. R.; Flanagan, J. J.; Schilling, A.; Chang, H. H.; Agarwal, L.; Katz, E.; Wu, X.; Pine, C.; Wustman, B.; Desnick, R. J.; Lockhart, D. J.; Valenzano, K. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Inherited Metabolic Disease</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">424-440</span>CODEN:
                <span class="NLM_cas:coden">JIMDDP</span>;
        ISSN:<span class="NLM_cas:issn">0141-8955</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Fabry disease is an X-linked lysosomal storage disorder caused by mutations in the gene encoding Î±-galactosidase A (Î±-Gal A), with consequent accumulation of its major glycosphingolipid substrate, globotriaosylceramide (GL-3).  Over 500 Fabry mutations have been reported; approx. 60% are missense.  The iminosugar 1-deoxygalactonojirimycin (DGJ, migalastat hydrochloride, AT1001) is a pharmacol. chaperone that selectively binds Î±-Gal A, increasing phys. stability, lysosomal trafficking, and cellular activity.  To identify DGJ-responsive mutant forms of Î±-Gal A, the effect of DGJ incubation on Î±-Gal A levels was assessed in cultured lymphoblasts from males with Fabry disease representing 75 different missense mutations, one insertion, and one splice-site mutation.  Baseline Î±-Gal A levels ranged from 0 to 52% of normal.  Increases in Î±-Gal A levels (1.5- to 28-fold) after continuous DGJ incubation for 5 days were seen for 49 different missense mutant forms with varying EC50 values (820 nmol/L to >1 mmol/L).  Amino acid substitutions in responsive forms were located throughout both structural domains of the enzyme.  Half of the missense mutant forms assocd. with classic (early-onset) Fabry disease and a majority (90%) assocd. with later-onset Fabry disease were responsive.  In cultured fibroblasts from males with Fabry disease, the responses to DGJ were comparable to those of lymphoblasts with the same mutation.  Importantly, elevated GL-3 levels in responsive Fabry fibroblasts were reduced after DGJ incubation, indicating that increased mutant Î±-Gal A levels can reduce accumulated substrate.  These data indicate that DGJ merits further evaluation as a treatment for patients with Fabry disease with various missense mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomhafQJSmJAbVg90H21EOLACvtfcHk0lgbI6IW2gKu6A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmsFWrsbo%253D&md5=b331b31de72efc3cfa4be43da28a2718</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1007%2Fs10545-009-1077-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10545-009-1077-0%26sid%3Dliteratum%253Aachs%26aulast%3DBenjamin%26aufirst%3DE.%2BR.%26aulast%3DFlanagan%26aufirst%3DJ.%2BJ.%26aulast%3DSchilling%26aufirst%3DA.%26aulast%3DChang%26aufirst%3DH.%2BH.%26aulast%3DAgarwal%26aufirst%3DL.%26aulast%3DKatz%26aufirst%3DE.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DPine%26aufirst%3DC.%26aulast%3DWustman%26aufirst%3DB.%26aulast%3DDesnick%26aufirst%3DR.%2BJ.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DValenzano%26aufirst%3DK.%2BJ.%26atitle%3DThe%2520Pharmacological%2520Chaperone%25201-Deoxygalactonojirimycin%2520Increases%2520Alpha-Galactosidase%2520a%2520Levels%2520in%2520Fabry%2520Patient%2520Cell%2520Lines%26jtitle%3DJ.%2520Inherited%2520Metab.%2520Dis.%26date%3D2009%26volume%3D32%26issue%3D3%26spage%3D424%26epage%3D440%26doi%3D10.1007%2Fs10545-009-1077-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abian, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfonso, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velazquez-Campoy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giraldo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pocovi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sancho, J.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Strategies for Gaucher Disease: Miglustat (NB-DNJ) as a Pharmacological Chaperone for Glucocerebrosidase and the Different Thermostability of Velaglucerase Alfa and Imiglucerase</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">2390</span>â <span class="NLM_lpage">2397</span>, <span class="refDoi">Â DOI: 10.1021/mp200313e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp200313e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVSit7vF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2011&pages=2390-2397&issue=6&author=O.+Abianauthor=P.+Alfonsoauthor=A.+Velazquez-Campoyauthor=P.+Giraldoauthor=M.+Pocoviauthor=J.+Sancho&title=Therapeutic+Strategies+for+Gaucher+Disease%3A+Miglustat+%28NB-DNJ%29+as+a+Pharmacological+Chaperone+for+Glucocerebrosidase+and+the+Different+Thermostability+of+Velaglucerase+Alfa+and+Imiglucerase&doi=10.1021%2Fmp200313e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Strategies for Gaucher Disease: Miglustat (NB-DNJ) as a Pharmacological Chaperone for Glucocerebrosidase and the Different Thermostability of Velaglucerase alfa and Imiglucerase</span></div><div class="casAuthors">Abian, Olga; Alfonso, Pilar; Velazquez- Campoy, Adrian; Giraldo, Pilar; Pocovi, Miguel; Sancho, Javier</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2390-2397</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Gaucher disease (GD) is a disorder of glycosphingolipid metab. caused by deficiency of lysosomal glucocerebrosidase (GlcCerase) activity, due to conformationally or functionally defective variants, resulting in progressive deposition of glycosylceramide in macrophages.  The glucose analog, N-butyldeoxynojirimycin (NB-DNJ, miglustat), is an inhibitor of the ceramide-specific glycosyltransferase, which catalyzes the first step of glycosphingolipid biosynthesis and is currently approved for the oral treatment of type 1 GD.  In a previous work, we found a GlcCerase activity increase in cell cultures in the presence of NB-DNJ, which could imply that this compd. is not only a substrate reducer but also a pharmacol. chaperone or inhibitor for GlcCerase degrdn.  In this work we compare imiglucerase (the enzyme currently used for replacement therapy) and velaglucerase alfa (a novel therapeutic enzyme form) in terms of conformational stability and enzymic activity, as well as the effect of NB-DNJ on them.  The interaction between these enzymes and NB-DNJ was studied by isothermal titrn. calorimetry.  Our results reveal that, although velaglucerase alfa and imiglucerase exhibit very similar activity profiles, velaglucerase alfa shows higher in vitro thermal stability and is less prone to aggregation/pptn., which could be advantageous for storage and clin. administration.  In addn., we show that at neutral pH NB-DNJ binds to and enhances the stability of both enzymes, while at mildly acidic lysosomal conditions it does not bind to them.  These results support the potential role of NB-DNJ as a pharmacol. chaperone, susceptible of being part of pharmaceutical formulation or combination therapy for GD in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtwLlY6fTnIbVg90H21EOLACvtfcHk0liQ48TbMPRpCA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVSit7vF&md5=c16e8fc77ac3c4862c2a18546d8f43fd</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fmp200313e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp200313e%26sid%3Dliteratum%253Aachs%26aulast%3DAbian%26aufirst%3DO.%26aulast%3DAlfonso%26aufirst%3DP.%26aulast%3DVelazquez-Campoy%26aufirst%3DA.%26aulast%3DGiraldo%26aufirst%3DP.%26aulast%3DPocovi%26aufirst%3DM.%26aulast%3DSancho%26aufirst%3DJ.%26atitle%3DTherapeutic%2520Strategies%2520for%2520Gaucher%2520Disease%253A%2520Miglustat%2520%2528NB-DNJ%2529%2520as%2520a%2520Pharmacological%2520Chaperone%2520for%2520Glucocerebrosidase%2520and%2520the%2520Different%2520Thermostability%2520of%2520Velaglucerase%2520Alfa%2520and%2520Imiglucerase%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2011%26volume%3D8%26issue%3D6%26spage%3D2390%26epage%3D2397%26doi%3D10.1021%2Fmp200313e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schiffmann, R.</span></span> <span> </span><span class="NLM_article-title">Agalsidase Treatment for Fabry Disease: Uses and Rivalries</span>. <i>Genet. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">684</span>â <span class="NLM_lpage">685</span>, <span class="refDoi">Â DOI: 10.1097/GIM.0b013e3181f9a056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1097%2FGIM.0b013e3181f9a056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=20975568" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A280%3ADC%252BC3cbmt1WktA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2010&pages=684-685&issue=11&author=R.+Schiffmann&title=Agalsidase+Treatment+for+Fabry+Disease%3A+Uses+and+Rivalries&doi=10.1097%2FGIM.0b013e3181f9a056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Agalsidase treatment for Fabry disease: uses and rivalries</span></div><div class="casAuthors">Schiffmann Raphael</div><div class="citationInfo"><span class="NLM_cas:title">Genetics in medicine : official journal of the American College of Medical Genetics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">684-5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTAjxMNj4ga4T0O18WR3iAofW6udTcc2eZSKqBAzhnCDrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cbmt1WktA%253D%253D&md5=b888aa3456f38ccd068b60d2596180d0</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1097%2FGIM.0b013e3181f9a056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FGIM.0b013e3181f9a056%26sid%3Dliteratum%253Aachs%26aulast%3DSchiffmann%26aufirst%3DR.%26atitle%3DAgalsidase%2520Treatment%2520for%2520Fabry%2520Disease%253A%2520Uses%2520and%2520Rivalries%26jtitle%3DGenet.%2520Med.%26date%3D2010%26volume%3D12%26issue%3D11%26spage%3D684%26epage%3D685%26doi%3D10.1097%2FGIM.0b013e3181f9a056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schiffmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reimschisel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castaneda, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lien, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastores, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kampmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ries, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, J. T.</span></span> <span> </span><span class="NLM_article-title">Four-Year Prospective Clinical Trial of Agalsidase Alfa in Children with Fabry Disease</span>. <i>J. Pediatr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>156</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">832</span>â <span class="NLM_lpage">837</span>, <span class="refDoi">Â DOI: 10.1016/j.jpeds.2009.11.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1016%2Fj.jpeds.2009.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=20097359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksFKgu74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2010&pages=832-837&issue=5&author=R.+Schiffmannauthor=R.+A.+Martinauthor=T.+Reimschiselauthor=K.+Johnsonauthor=V.+Castanedaauthor=Y.+H.+Lienauthor=G.+M.+Pastoresauthor=C.+Kampmannauthor=M.+Riesauthor=J.+T.+Clarke&title=Four-Year+Prospective+Clinical+Trial+of+Agalsidase+Alfa+in+Children+with+Fabry+Disease&doi=10.1016%2Fj.jpeds.2009.11.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Four-Year Prospective Clinical Trial of Agalsidase Alfa in Children with Fabry Disease</span></div><div class="casAuthors">Schiffmann, Raphael; Martin, Rick A.; Reimschisel, Tyler; Johnson, Karen; Castaneda, Victoria; Lien, Y. Howard; Pastores, Gregory M.; Kampmann, Christoph; Ries, Markus; Clarke, Joe T. R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pediatrics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">832-837, e832/1</span>CODEN:
                <span class="NLM_cas:coden">JOPDAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3476</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Objectives: To investigate a 4-yr prospective clin. trial of agalsidase alfa in children with Fabry disease, an X-linked metabolic disorder caused by a deficiency of the lysosomal enzyme Î±-galactosidase A. Study design: Seventeen (16 boys, 1 girl; age range, 7.3 to 18.4 years) of the 24 children who completed a 6-mo, open-label agalsidase alfa study enrolled in a 3.5-yr extension study that investigated the safety and potential efficacy of long-term treatment.  All 17 patients completed the initial 6-mo study, and 10 patients (9 boys) completed the extension study.  Results: Agalsidase alfa was well tolerated.  In treated boys, there were sustained, statistically-significant improvements in the clin. features of Fabry disease, including reduced plasma globotriaosylceramide levels, reduced pain severity assessed by the Brief Pain Index, and improved heart rate variability.  Mean urine globotriaosylceramide levels were reduced to normal range (P < .05 compared with baseline during 1.5 to 4 years).  Kidney function and left ventricular mass indexed to height remained stable throughout.  Conclusions: This clin. trial demonstrates that treatment with agalsidase alfa was well tolerated and assocd. with improvement of Fabry disease-related features.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMr7QFGBpwtbVg90H21EOLACvtfcHk0liQ48TbMPRpCA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksFKgu74%253D&md5=ca45db37d632e9d1e6342a9b4c0e7129</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.jpeds.2009.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpeds.2009.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DSchiffmann%26aufirst%3DR.%26aulast%3DMartin%26aufirst%3DR.%2BA.%26aulast%3DReimschisel%26aufirst%3DT.%26aulast%3DJohnson%26aufirst%3DK.%26aulast%3DCastaneda%26aufirst%3DV.%26aulast%3DLien%26aufirst%3DY.%2BH.%26aulast%3DPastores%26aufirst%3DG.%2BM.%26aulast%3DKampmann%26aufirst%3DC.%26aulast%3DRies%26aufirst%3DM.%26aulast%3DClarke%26aufirst%3DJ.%2BT.%26atitle%3DFour-Year%2520Prospective%2520Clinical%2520Trial%2520of%2520Agalsidase%2520Alfa%2520in%2520Children%2520with%2520Fabry%2520Disease%26jtitle%3DJ.%2520Pediatr.%26date%3D2010%26volume%3D156%26issue%3D5%26spage%3D832%26epage%3D837%26doi%3D10.1016%2Fj.jpeds.2009.11.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benjamin, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Della Valle, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pruthi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bond, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronfin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bichet, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Germain, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giugliani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiffmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilcox, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desnick, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlow, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valenzano, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castelli, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, D. J.</span></span> <span> </span><span class="NLM_article-title">The Validation of Pharmacogenetics for the Identification of Fabry Patients to Be Treated with Migalastat</span>. <i>Genet. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">430</span>â <span class="NLM_lpage">438</span>, <span class="refDoi">Â DOI: 10.1038/gim.2016.122</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1038%2Fgim.2016.122" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=27657681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlvVKktbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2017&pages=430-438&issue=4&author=E.+R.+Benjaminauthor=M.+C.+Della+Valleauthor=X.+Wuauthor=E.+Katzauthor=F.+Pruthiauthor=S.+Bondauthor=B.+Bronfinauthor=H.+Williamsauthor=J.+Yuauthor=D.+G.+Bichetauthor=D.+P.+Germainauthor=R.+Giuglianiauthor=D.+Hughesauthor=R.+Schiffmannauthor=W.+R.+Wilcoxauthor=R.+J.+Desnickauthor=J.+Kirkauthor=J.+Barthauthor=C.+Barlowauthor=K.+J.+Valenzanoauthor=J.+Castelliauthor=D.+J.+Lockhart&title=The+Validation+of+Pharmacogenetics+for+the+Identification+of+Fabry+Patients+to+Be+Treated+with+Migalastat&doi=10.1038%2Fgim.2016.122"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat</span></div><div class="casAuthors">Benjamin, Elfrida R.; Della Valle, Maria Cecilia; Wu, Xiaoyang; Katz, Evan; Pruthi, Farhana; Bond, Sarah; Bronfin, Benjamin; Williams, Hadis; Yu, Julie; Bichet, Daniel G.; Germain, Dominique P.; Giugliani, Roberto; Hughes, Derralynn; Schiffmann, Raphael; Wilcox, William R.; Desnick, Robert J.; Kirk, John; Barth, Jay; Barlow, Carrolee; Valenzano, Kenneth J.; Castelli, Jeff; Lockhart, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Genetics in Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">430-438</span>CODEN:
                <span class="NLM_cas:coden">GEMEF3</span>;
        ISSN:<span class="NLM_cas:issn">1098-3600</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Purpose: Fabry disease is an X-linked lysosomal storage disorder caused by mutations in the Î±-galactosidase A gene.  Migalastat, a pharmacol. chaperone, binds to specific mutant forms of Î±-galactosidase A to restore lysosomal activity.  Methods: A pharmacogenetic assay was used to identify the Î±-galactosidase A mutant forms amenable to migalastat.  Six hundred Fabry disease-causing mutations were expressed in HEK-293 (HEK) cells; increases in Î±-galactosidase A activity were measured by a good lab. practice (GLP)-validated assay (GLP HEK/Migalastat Amenability Assay).  The predictive value of the assay was assessed based on pharmacodynamic responses to migalastat in phase II and III clin. studies.  Results: Comparison of the GLP HEK assay results in in vivo white blood cell Î±-galactosidase A responses to migalastat in male patients showed high sensitivity, specificity, and pos. and neg. predictive values (â¥0.875).  GLP HEK assay results were also predictive of decreases in kidney globotriaosylceramide in males and plasma globotriaosylsphingosine in males and females.  The clin. study subset of amenable mutations (n = 51) was representative of all 268 amenable mutations identified by the GLP HEK assay.  Conclusion: The GLP HEK assay is a clin. validated method of identifying male and female Fabry patients for treatment with migalastat.  Genet Med19 4, 430-438.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSjYlljMKBIbVg90H21EOLACvtfcHk0liQ48TbMPRpCA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlvVKktbY%253D&md5=24f09332e08992a1632c681b0d8f9df5</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fgim.2016.122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fgim.2016.122%26sid%3Dliteratum%253Aachs%26aulast%3DBenjamin%26aufirst%3DE.%2BR.%26aulast%3DDella%2BValle%26aufirst%3DM.%2BC.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DKatz%26aufirst%3DE.%26aulast%3DPruthi%26aufirst%3DF.%26aulast%3DBond%26aufirst%3DS.%26aulast%3DBronfin%26aufirst%3DB.%26aulast%3DWilliams%26aufirst%3DH.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DBichet%26aufirst%3DD.%2BG.%26aulast%3DGermain%26aufirst%3DD.%2BP.%26aulast%3DGiugliani%26aufirst%3DR.%26aulast%3DHughes%26aufirst%3DD.%26aulast%3DSchiffmann%26aufirst%3DR.%26aulast%3DWilcox%26aufirst%3DW.%2BR.%26aulast%3DDesnick%26aufirst%3DR.%2BJ.%26aulast%3DKirk%26aufirst%3DJ.%26aulast%3DBarth%26aufirst%3DJ.%26aulast%3DBarlow%26aufirst%3DC.%26aulast%3DValenzano%26aufirst%3DK.%2BJ.%26aulast%3DCastelli%26aufirst%3DJ.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DThe%2520Validation%2520of%2520Pharmacogenetics%2520for%2520the%2520Identification%2520of%2520Fabry%2520Patients%2520to%2520Be%2520Treated%2520with%2520Migalastat%26jtitle%3DGenet.%2520Med.%26date%3D2017%26volume%3D19%26issue%3D4%26spage%3D430%26epage%3D438%26doi%3D10.1038%2Fgim.2016.122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antoniu, S. A.</span></span> <span> </span><span class="NLM_article-title">Pirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">823</span>â <span class="NLM_lpage">828</span>, <span class="refDoi">Â DOI: 10.1517/13543784.15.7.823</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1517%2F13543784.15.7.823" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2006&pages=823-828&issue=7&author=S.+A.+Antoniu&title=Pirfenidone+for+the+Treatment+of+Idiopathic+Pulmonary+Fibrosis&doi=10.1517%2F13543784.15.7.823"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1517%2F13543784.15.7.823&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.15.7.823%26sid%3Dliteratum%253Aachs%26aulast%3DAntoniu%26aufirst%3DS.%2BA.%26atitle%3DPirfenidone%2520for%2520the%2520Treatment%2520of%2520Idiopathic%2520Pulmonary%2520Fibrosis%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2006%26volume%3D15%26issue%3D7%26spage%3D823%26epage%3D828%26doi%3D10.1517%2F13543784.15.7.823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span>Genentech
Mission Critical. <a href="https://www.gene.com/stories/mission-critical" class="extLink">https://www.gene.com/stories/mission-critical</a> (accessed November 17, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Genentech%0AMission+Critical.+https%3A%2F%2Fwww.gene.com%2Fstories%2Fmission-critical+%28accessed+November+17%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albera, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradford, W. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costabel, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glaspole, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glassberg, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kardatzke, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daigl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirchgaessler, K.-U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lancaster, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lederer, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pereira, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swigris, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valeyre, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, P. W.</span></span> <span> </span><span class="NLM_article-title">Effect of Pirfenidone on Mortality: Pooled Analyses and Meta-Analyses of Clinical Trials in Idiopathic Pulmonary Fibrosis</span>. <i>Lancet Respir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">33</span>â <span class="NLM_lpage">41</span>, <span class="refDoi">Â DOI: 10.1016/S2213-2600(16)30326-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1016%2FS2213-2600%2816%2930326-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=27876247" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFCjtLbJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2017&pages=33-41&issue=1&author=S.+D.+Nathanauthor=C.+Alberaauthor=W.+Z.+Bradfordauthor=U.+Costabelauthor=I.+Glaspoleauthor=M.+K.+Glassbergauthor=D.+R.+Kardatzkeauthor=M.+Daiglauthor=K.-U.+Kirchgaesslerauthor=L.+H.+Lancasterauthor=D.+J.+Ledererauthor=C.+A.+Pereiraauthor=J.+J.+Swigrisauthor=D.+Valeyreauthor=P.+W.+Noble&title=Effect+of+Pirfenidone+on+Mortality%3A+Pooled+Analyses+and+Meta-Analyses+of+Clinical+Trials+in+Idiopathic+Pulmonary+Fibrosis&doi=10.1016%2FS2213-2600%2816%2930326-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Nathan, Steven D.; Albera, Carlo; Bradford, Williamson Z.; Costabel, Ulrich; Glaspole, Ian; Glassberg, Marilyn K.; Kardatzke, David R.; Daigl, Monica; Kirchgaessler, Klaus-Uwe; Lancaster, Lisa H.; Lederer, David J.; Pereira, Carlos A.; Swigris, Jeffrey J.; Valeyre, Dominique; Noble, Paul W.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Respiratory Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-41</span>CODEN:
                <span class="NLM_cas:coden">LRMAAU</span>;
        ISSN:<span class="NLM_cas:issn">2213-2600</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">In clin. trials of idiopathic pulmonary fibrosis, rates of all-cause mortality are low.  Thus prospective mortality trials are logistically very challenging, justifying the use of pooled analyses or meta-analyses.  We did pooled analyses and meta-analyses of clin. trials of pirfenidone vs. placebo to det. the effect of pirfenidone on mortality outcomes over 120 wk.  We did a pooled anal. of the combined patient populations of the three global randomised phase 3 trials of pirfenidone vs. placebo-Clin. Studies Assessing Pirfenidone in Idiopathic Pulmonary Fibrosis: Research of Efficacy and Safety Outcomes (CAPACITY 004 and 006; trial durations 72-120 wk) and Assessment of Pirfenidone to Confirm Efficacy and Safety in Idiopathic Pulmonary Fibrosis (ASCEND 016; 52 wk)-for all-cause mortality, treatment-emergent all-cause mortality, idiopathic-pulmonary-fibrosis-related mortality, and treatment-emergent idiopathic-pulmonary-fibrosis-related mortality at weeks 52, 72, and 120.  We also did meta-analyses of these data and data from two Japanese trials of pirfenidone vs. placebo-Shionogi Phase 2 (SP2) and Shionogi Phase 3 (SP3; trial durations 36-52 wk).  At week 52, the relative risk of death for all four mortality outcomes was significantly lower in the pirfenidone group than in the placebo group in the pooled population (all-cause mortality hazard ratio [HR] 0Â·52 [95% CI 0Â·31-0Â·87; p=0Â·0107]; treatment-emergent all-cause mortality 0Â·45 [0Â·24-0Â·83; 0Â·0094]; idiopathic-pulmonary-fibrosis-related mortality 0Â·35 [0Â·17-0Â·72; 0Â·0029]; treatment-emergent idiopathic-pulmonary-fibrosis-related mortality 0Â·32 [0Â·14-0Â·76; 0Â·0061]).  Consistent with the pooled anal., meta-analyses for all-cause mortality at week 52 also showed a clin. relevant and significant risk redn. in the pirfenidone group compared with the placebo group.  Over 120 wk, we noted significant differences in the pooled anal. favoring pirfenidone therapy compared with placebo for treatment-emergent all-cause mortality (p=0Â·0420), idiopathic-pulmonary-fibrosis-related mortality (0Â·0237), and treatment-emergent idiopathic-pulmonary-fibrosis-related (0Â·0132) mortality; similar results were shown by meta-analyses.  Several analytic approaches demonstrated that pirfenidone therapy is assocd. with a redn. in the relative risk of mortality compared with placebo over 120 wk.F Hoffmann-La Roche/Genentech.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoctc8zNsJE9rVg90H21EOLACvtfcHk0ljKwmayL8shGQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFCjtLbJ&md5=11d8dc8e0d2afee0ea69b9a05a14766d</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2FS2213-2600%2816%2930326-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2213-2600%252816%252930326-5%26sid%3Dliteratum%253Aachs%26aulast%3DNathan%26aufirst%3DS.%2BD.%26aulast%3DAlbera%26aufirst%3DC.%26aulast%3DBradford%26aufirst%3DW.%2BZ.%26aulast%3DCostabel%26aufirst%3DU.%26aulast%3DGlaspole%26aufirst%3DI.%26aulast%3DGlassberg%26aufirst%3DM.%2BK.%26aulast%3DKardatzke%26aufirst%3DD.%2BR.%26aulast%3DDaigl%26aufirst%3DM.%26aulast%3DKirchgaessler%26aufirst%3DK.-U.%26aulast%3DLancaster%26aufirst%3DL.%2BH.%26aulast%3DLederer%26aufirst%3DD.%2BJ.%26aulast%3DPereira%26aufirst%3DC.%2BA.%26aulast%3DSwigris%26aufirst%3DJ.%2BJ.%26aulast%3DValeyre%26aufirst%3DD.%26aulast%3DNoble%26aufirst%3DP.%2BW.%26atitle%3DEffect%2520of%2520Pirfenidone%2520on%2520Mortality%253A%2520Pooled%2520Analyses%2520and%2520Meta-Analyses%2520of%2520Clinical%2520Trials%2520in%2520Idiopathic%2520Pulmonary%2520Fibrosis%26jtitle%3DLancet%2520Respir.%2520Med.%26date%3D2017%26volume%3D5%26issue%3D1%26spage%3D33%26epage%3D41%26doi%3D10.1016%2FS2213-2600%2816%2930326-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noble, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albera, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradford, W. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costabel, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glassberg, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kardatzke, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lancaster, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahn, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szwarcberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valeyre, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">du Bois, R. M.</span></span> <span> </span><span class="NLM_article-title">Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (Capacity): Two Randomised Trials</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>377</i></span> (<span class="NLM_issue">9779</span>),  <span class="NLM_fpage">1760</span>â <span class="NLM_lpage">1769</span>, <span class="refDoi">Â DOI: 10.1016/S0140-6736(11)60405-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1016%2FS0140-6736%2811%2960405-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=21571362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtl2ktrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2011&pages=1760-1769&issue=9779&author=P.+W.+Nobleauthor=C.+Alberaauthor=W.+Z.+Bradfordauthor=U.+Costabelauthor=M.+K.+Glassbergauthor=D.+Kardatzkeauthor=T.+E.+Kingauthor=L.+Lancasterauthor=S.+A.+Sahnauthor=J.+Szwarcbergauthor=D.+Valeyreauthor=R.+M.+du+Bois&title=Pirfenidone+in+Patients+with+Idiopathic+Pulmonary+Fibrosis+%28Capacity%29%3A+Two+Randomised+Trials&doi=10.1016%2FS0140-6736%2811%2960405-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials</span></div><div class="casAuthors">Noble, Paul W.; Albera, Carlo; Bradford, Williamson Z.; Costabel, Ulrich; Glassberg, Marilyn K.; Kardatzke, David; King, Talmadge E., Jr.; Lancaster, Lisa; Sahn, Steven A.; Szwarcberg, Javier; Valeyre, Dominique; du Bois, Roland M.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">9779</span>),
    <span class="NLM_cas:pages">1760-1769</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Idiopathic pulmonary fibrosis is a progressive and fatal lung disease with inevitable loss of lung function.  The CAPACITY program (studies 004 and 006) was designed to confirm the results of a phase 2 study that suggested that pirfenidone, a novel antifibrotic and anti-inflammatory drug, reduces deterioration in lung function in patients with idiopathic pulmonary fibrosis.  In two concurrent trials (004 and 006), patients (aged 40-80 years) with idiopathic pulmonary fibrosis were randomly assigned to oral pirfenidone or placebo for a min. of 72 wk in 110 centers in Australia, Europe, and North America.  In study 004, patients were assigned in a 2:1:2 ratio to pirfenidone 2403 mg/day, pirfenidone 1197 mg/day, or placebo; in study 006, patients were assigned in a 1:1 ratio to pirfenidone 2403 mg/day or placebo.  The randomization code (permuted block design) was computer generated and stratified by region.  All study personnel were masked to treatment group assignment until after final database lock.  Treatments were administered orally, 801 mg or 399 mg three times a day.  The primary endpoint was change in percentage predicted forced vital capacity (FVC) at week 72.  Anal. was by intention to treat.  The studies are registered with ClinicalTrials.gov, nos. NCT00287729 and NCT00287716.  In study 004, 174 of 435 patients were assigned to pirfenidone 2403 mg/day, 87 to pirfenidone 1197 mg/day, and 174 to placebo.  In study 006, 171 of 344 patients were assigned to pirfenidone 2403 mg/day, and 173 to placebo.  All patients in both studies were analyzed.  In study 004, pirfenidone reduced decline in FVC (p = 0.001).  Mean FVC change at week 72 was -8.0% (SD 16.5) in the pirfenidone 2403 mg/day group and -12.4% (18.5) in the placebo group (difference 4.4%, 95% CI 0.7 to 9.1); 35 (20%) of 174 vs. 60 (35%) of 174 patients, resp., had a decline of at least 10%.  A significant treatment effect was noted at all timepoints from week 24 and in an anal. over all study timepoints (p = 0.0007).  Mean change in percentage FVC in the pirfenidone 1197 mg/day group was intermediate to that in the pirfenidone 2403 mg/day and placebo groups.  In study 006, the difference between groups in FVC change at week 72 was not significant (p = 0.501).  Mean change in FVC at week 72 was -9.0% (SD 19.6) in the pirfenidone group and -9.6% (19.1) in the placebo group, and the difference between groups in predicted FVC change at week 72 was not significant (0.6%, -3.5 to 4.7); however, a consistent pirfenidone effect was apparent until week 48 (p = 0.005) and in an anal. of all study timepoints (p = 0.007).  Patients in the pirfenidone 2403 mg/day group had higher incidences of nausea (125 [36%] of 345 vs 60 [17%] of 347), dyspepsia (66 [19%] vs 26 [7%]), vomiting (47 [14%] vs 15 [4%]), anorexia (37 [11%] vs 13 [4%]), photosensitivity (42 [12%] vs 6 [2%]), rash (111 [32%] vs 40 [12%]), and dizziness (63 [18%] vs 35 [10%]) than did those in the placebo group.  Fewer overall deaths (19 [6%] vs 29 [8%]) and fewer deaths related to idiopathic pulmonary fibrosis (12 [3%] vs 25 [7%]) occurred in the pirfenidone 2403 mg/day groups than in the placebo groups.  The data show pirfenidone has a favorable benefit risk profile and represents an appropriate treatment option for patients with idiopathic pulmonary fibrosis.  Funding: InterMune.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKu0rjQ2oNaLVg90H21EOLACvtfcHk0ljKwmayL8shGQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtl2ktrg%253D&md5=b32d8b1f0b3b1f8401d3744fc18c662a</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2811%2960405-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252811%252960405-4%26sid%3Dliteratum%253Aachs%26aulast%3DNoble%26aufirst%3DP.%2BW.%26aulast%3DAlbera%26aufirst%3DC.%26aulast%3DBradford%26aufirst%3DW.%2BZ.%26aulast%3DCostabel%26aufirst%3DU.%26aulast%3DGlassberg%26aufirst%3DM.%2BK.%26aulast%3DKardatzke%26aufirst%3DD.%26aulast%3DKing%26aufirst%3DT.%2BE.%26aulast%3DLancaster%26aufirst%3DL.%26aulast%3DSahn%26aufirst%3DS.%2BA.%26aulast%3DSzwarcberg%26aufirst%3DJ.%26aulast%3DValeyre%26aufirst%3DD.%26aulast%3Ddu%2BBois%26aufirst%3DR.%2BM.%26atitle%3DPirfenidone%2520in%2520Patients%2520with%2520Idiopathic%2520Pulmonary%2520Fibrosis%2520%2528Capacity%2529%253A%2520Two%2520Randomised%2520Trials%26jtitle%3DLancet%26date%3D2011%26volume%3D377%26issue%3D9779%26spage%3D1760%26epage%3D1769%26doi%3D10.1016%2FS0140-6736%2811%2960405-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Macias-Barragan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandoval-Rodriguez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro-Partida, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armendariz-Borunda, J.</span></span> <span> </span><span class="NLM_article-title">The Multifaceted Role of Pirfenidone and Its Novel Targets</span>. <i>Fibrog. Tissue Repair</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">16</span>, <span class="refDoi">Â DOI: 10.1186/1755-1536-3-16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1186%2F1755-1536-3-16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=20809935" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2010&pages=16&author=J.+Macias-Barraganauthor=A.+Sandoval-Rodriguezauthor=J.+Navarro-Partidaauthor=J.+Armendariz-Borunda&title=The+Multifaceted+Role+of+Pirfenidone+and+Its+Novel+Targets&doi=10.1186%2F1755-1536-3-16"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1186%2F1755-1536-3-16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1755-1536-3-16%26sid%3Dliteratum%253Aachs%26aulast%3DMacias-Barragan%26aufirst%3DJ.%26aulast%3DSandoval-Rodriguez%26aufirst%3DA.%26aulast%3DNavarro-Partida%26aufirst%3DJ.%26aulast%3DArmendariz-Borunda%26aufirst%3DJ.%26atitle%3DThe%2520Multifaceted%2520Role%2520of%2520Pirfenidone%2520and%2520Its%2520Novel%2520Targets%26jtitle%3DFibrog.%2520Tissue%2520Repair%26date%3D2010%26volume%3D3%26spage%3D16%26doi%3D10.1186%2F1755-1536-3-16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nanthakumar, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatley, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gauldie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, S. J.</span></span> <span> </span><span class="NLM_article-title">Dissecting Fibrosis: Therapeutic Insights from the Small-Molecule Toolbox</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">693</span>â <span class="NLM_lpage">720</span>, <span class="refDoi">Â DOI: 10.1038/nrd4592</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1038%2Fnrd4592" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=693-720&issue=10&author=C.+B.+Nanthakumarauthor=R.+J.+Hatleyauthor=S.+Lemmaauthor=J.+Gauldieauthor=R.+P.+Marshallauthor=S.+J.+Macdonald&title=Dissecting+Fibrosis%3A+Therapeutic+Insights+from+the+Small-Molecule+Toolbox&doi=10.1038%2Fnrd4592"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1038%2Fnrd4592&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4592%26sid%3Dliteratum%253Aachs%26aulast%3DNanthakumar%26aufirst%3DC.%2BB.%26aulast%3DHatley%26aufirst%3DR.%2BJ.%26aulast%3DLemma%26aufirst%3DS.%26aulast%3DGauldie%26aufirst%3DJ.%26aulast%3DMarshall%26aufirst%3DR.%2BP.%26aulast%3DMacdonald%26aufirst%3DS.%2BJ.%26atitle%3DDissecting%2520Fibrosis%253A%2520Therapeutic%2520Insights%2520from%2520the%2520Small-Molecule%2520Toolbox%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26issue%3D10%26spage%3D693%26epage%3D720%26doi%3D10.1038%2Fnrd4592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bertolini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aquino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biffi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">dâAtri, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Pierro, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrario, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mascagni, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somenzi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaliani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leoni, F.</span></span> <span> </span><span class="NLM_article-title">A New Rational Hypothesis for the Pharmacophore of the Active Metabolite of Leflunomide, a Potent Immunosuppressive Drug</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">2011</span>â <span class="NLM_lpage">2016</span>, <span class="refDoi">Â DOI: 10.1021/jm970039n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm970039n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1997&pages=2011-2016&issue=13&author=G.+Bertoliniauthor=M.+Aquinoauthor=M.+Biffiauthor=G.+d%E2%80%99Atriauthor=F.+Di+Pierroauthor=F.+Ferrarioauthor=P.+Mascagniauthor=F.+Somenziauthor=A.+Zalianiauthor=F.+Leoni&title=A+New+Rational+Hypothesis+for+the+Pharmacophore+of+the+Active+Metabolite+of+Leflunomide%2C+a+Potent+Immunosuppressive+Drug&doi=10.1021%2Fjm970039n"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fjm970039n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm970039n%26sid%3Dliteratum%253Aachs%26aulast%3DBertolini%26aufirst%3DG.%26aulast%3DAquino%26aufirst%3DM.%26aulast%3DBiffi%26aufirst%3DM.%26aulast%3Dd%25E2%2580%2599Atri%26aufirst%3DG.%26aulast%3DDi%2BPierro%26aufirst%3DF.%26aulast%3DFerrario%26aufirst%3DF.%26aulast%3DMascagni%26aufirst%3DP.%26aulast%3DSomenzi%26aufirst%3DF.%26aulast%3DZaliani%26aufirst%3DA.%26aulast%3DLeoni%26aufirst%3DF.%26atitle%3DA%2520New%2520Rational%2520Hypothesis%2520for%2520the%2520Pharmacophore%2520of%2520the%2520Active%2520Metabolite%2520of%2520Leflunomide%252C%2520a%2520Potent%2520Immunosuppressive%2520Drug%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1997%26volume%3D40%26issue%3D13%26spage%3D2011%26epage%3D2016%26doi%3D10.1021%2Fjm970039n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Munier-Lehmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vidalain, P. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tangy, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janin, Y. L.</span></span> <span> </span><span class="NLM_article-title">On Dihydroorotate Dehydrogenases and Their Inhibitors and Uses</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">3148</span>â <span class="NLM_lpage">3167</span>, <span class="refDoi">Â DOI: 10.1021/jm301848w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301848w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=3148-3167&issue=8&author=H.+Munier-Lehmannauthor=P.+O.+Vidalainauthor=F.+Tangyauthor=Y.+L.+Janin&title=On+Dihydroorotate+Dehydrogenases+and+Their+Inhibitors+and+Uses&doi=10.1021%2Fjm301848w"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Fjm301848w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301848w%26sid%3Dliteratum%253Aachs%26aulast%3DMunier-Lehmann%26aufirst%3DH.%26aulast%3DVidalain%26aufirst%3DP.%2BO.%26aulast%3DTangy%26aufirst%3DF.%26aulast%3DJanin%26aufirst%3DY.%2BL.%26atitle%3DOn%2520Dihydroorotate%2520Dehydrogenases%2520and%2520Their%2520Inhibitors%2520and%2520Uses%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D8%26spage%3D3148%26epage%3D3167%26doi%3D10.1021%2Fjm301848w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parada, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figueiredo, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alves, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freitas, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Learmonth, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunha, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrett, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soares-da-Silva, P.</span></span> <span> </span><span class="NLM_article-title">Anticonvulsant and Sodium Channel-Blocking Properties of Novel 10,11-Dihydro-5h-Dibenz[b,f]Azepine-5-Carboxamide Derivatives</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>42</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">2582</span>â <span class="NLM_lpage">2587</span>, <span class="refDoi">Â DOI: 10.1021/jm980627g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm980627g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=2582-2587&issue=14&author=J.+Benesauthor=A.+Paradaauthor=A.+A.+Figueiredoauthor=P.+C.+Alvesauthor=A.+P.+Freitasauthor=D.+A.+Learmonthauthor=R.+A.+Cunhaauthor=J.+Garrettauthor=P.+Soares-da-Silva&title=Anticonvulsant+and+Sodium+Channel-Blocking+Properties+of+Novel+10%2C11-Dihydro-5h-Dibenz%5Bb%2Cf%5DAzepine-5-Carboxamide+Derivatives&doi=10.1021%2Fjm980627g"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Fjm980627g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm980627g%26sid%3Dliteratum%253Aachs%26aulast%3DBenes%26aufirst%3DJ.%26aulast%3DParada%26aufirst%3DA.%26aulast%3DFigueiredo%26aufirst%3DA.%2BA.%26aulast%3DAlves%26aufirst%3DP.%2BC.%26aulast%3DFreitas%26aufirst%3DA.%2BP.%26aulast%3DLearmonth%26aufirst%3DD.%2BA.%26aulast%3DCunha%26aufirst%3DR.%2BA.%26aulast%3DGarrett%26aufirst%3DJ.%26aulast%3DSoares-da-Silva%26aufirst%3DP.%26atitle%3DAnticonvulsant%2520and%2520Sodium%2520Channel-Blocking%2520Properties%2520of%2520Novel%252010%252C11-Dihydro-5h-Dibenz%255Bb%252Cf%255DAzepine-5-Carboxamide%2520Derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26issue%3D14%26spage%3D2582%26epage%3D2587%26doi%3D10.1021%2Fjm980627g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="note"><p class="first last">Droxidopa, a prodrug, has six hydrogen bond donors, but the active entity, the neurotransmitter, norepinephrine has five and therefore is not an outlier to the rule-of-five concept.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Veber, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopple, K. D.</span></span> <span> </span><span class="NLM_article-title">Molecular Properties That Influence the Oral Bioavailability of Drug Candidates</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2615</span>â <span class="NLM_lpage">2623</span>, <span class="refDoi">Â DOI: 10.1021/jm020017n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020017n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BD38XjsFCmt7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=2615-2623&issue=12&author=D.+F.+Veberauthor=S.+R.+Johnsonauthor=H.+Y.+Chengauthor=B.+R.+Smithauthor=K.+W.+Wardauthor=K.+D.+Kopple&title=Molecular+Properties+That+Influence+the+Oral+Bioavailability+of+Drug+Candidates&doi=10.1021%2Fjm020017n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Properties That Influence the Oral Bioavailability of Drug Candidates</span></div><div class="casAuthors">Veber, Daniel F.; Johnson, Stephen R.; Cheng, Hung-Yuan; Smith, Brian R.; Ward, Keith W.; Kopple, Kenneth D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2615-2623</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Oral bioavailability measurements in rats for over 1100 drug candidates studied at Smith-Kline Beecham Pharmaceuticals (now Glaxo Smith-Kline) have allowed us to analyze the relative importance of mol. properties considered to influence that drug property.  Reduced mol. flexibility, as measured by the no. of rotatable bonds, and low polar surface area or total hydrogen bond count (sum of donors and acceptors) are found to be important predictors of good oral bioavailability, independent of mol. wt.  That on av. both the no. of rotatable bonds and polar surface area or hydrogen bond count tend to increase with mol. wt. may in part explain the success of the mol. wt. parameter in predicting oral bioavailability.  The commonly applied mol. wt. cutoff at 500 does not itself significantly sep. compds. with poor oral bioavailability from those with acceptable values in this extensive data set.  Our observations suggest that compds. which meet only the 2 criteria of (1) 10 or fewer rotatable bonds and (2) polar surface area â¤140 Ã2 (or 12 or fewer H-bond donors and acceptors) will have a high probability of good oral bioavailability in the rat.  Data sets for the artificial membrane permeation rate and for clearance in the rat were also examd.  Reduced polar surface area correlates better with increased permeation rate than does lipophilicity (C log P), and increased rotatable bond count has a neg. effect on the permeation rate.  A threshold permeation rate is a prerequisite of oral bioavailability.  The rotatable bond count does not correlate with the data examd. here for the in vivo clearance rate in the rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3JtJEkO7yVLVg90H21EOLACvtfcHk0lg-SrP3D45Gow"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjsFCmt7g%253D&md5=eaad26ed6a259de82ad65a8834fc397d</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Fjm020017n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020017n%26sid%3Dliteratum%253Aachs%26aulast%3DVeber%26aufirst%3DD.%2BF.%26aulast%3DJohnson%26aufirst%3DS.%2BR.%26aulast%3DCheng%26aufirst%3DH.%2BY.%26aulast%3DSmith%26aufirst%3DB.%2BR.%26aulast%3DWard%26aufirst%3DK.%2BW.%26aulast%3DKopple%26aufirst%3DK.%2BD.%26atitle%3DMolecular%2520Properties%2520That%2520Influence%2520the%2520Oral%2520Bioavailability%2520of%2520Drug%2520Candidates%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26issue%3D12%26spage%3D2615%26epage%3D2623%26doi%3D10.1021%2Fjm020017n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P.
D.</span></span> <span> </span><span class="NLM_article-title">Molecular Inflation, Attrition and the Rule of Five</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">22</span>â <span class="NLM_lpage">33</span>, <span class="refDoi">Â DOI: 10.1016/j.addr.2016.01.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1016%2Fj.addr.2016.01.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=26836397" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFCrt7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2016&pages=22-33&author=P.%0AD.+Leeson&title=Molecular+Inflation%2C+Attrition+and+the+Rule+of+Five&doi=10.1016%2Fj.addr.2016.01.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular inflation, attrition and the rule of five</span></div><div class="casAuthors">Leeson, Paul D.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">22-33</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Physicochem. properties underlie all aspects of drug action and are crit. for soly., permeability and successful formulation.  Specific physicochem. properties shown to be relevant to oral drugs are size, lipophilicity, ionisation, hydrogen bonding, polarity, aromaticity and shape.  The rule of 5 (Ro5) and subsequent studies have raised awareness of the importance of compd. quality amongst bioactive mols.  Lipophilicity, probably the most important phys. property of oral drugs, has on av. changed little over time in oral drugs, until increases in drugs published after 1990.  In contrast other mol. properties such as av. size have increased significantly.  Factors influencing property inflation include the targets pursued, where antivirals frequently violate the Ro5, risk/benefit considerations, and variable drug discovery practices.  The compds. published in patents from the pharmaceutical industry are on av. larger, more lipophilic and less complex than marketed oral drugs.  The variation between individual companies' patented compds. is due to different practices and not to the targets pursued.  Overall, there is demonstrable phys. property attrition in moving from patents to candidate drugs to marketed drugs.  The pharmaceutical industry's recent poor productivity has been due, in part, to progression of mols. that are unable to unambiguously test clin. efficacy, and attrition can therefore be improved by ensuring candidate drug quality is 'fit for purpose.' The combined ligand efficiency (LE) and lipophilic ligand efficiency (LLE) values of many marketed drugs are optimized relative to other mols. acting at the same target.  Application of LLE in optimization can help identify improved leads, even with challenging targets that seem to require lipophilic ligands.  Because of their targets, some projects may need to pursue 'beyond Ro5' physicochem. space; such projects will require non-std. lead generation and optimization and should not dominate in a well-balanced portfolio.  Compd. quality is controllable by lead selection and optimization and should not be a cause of clin. failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3YEbPW53-UbVg90H21EOLACvtfcHk0lg-SrP3D45Gow"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFCrt7k%253D&md5=7e31a4390c28a0f203f2254bcfb754af</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2016.01.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2016.01.018%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26atitle%3DMolecular%2520Inflation%252C%2520Attrition%2520and%2520the%2520Rule%2520of%2520Five%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2016%26volume%3D101%26spage%3D22%26epage%3D33%26doi%3D10.1016%2Fj.addr.2016.01.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groom, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alex, A.</span></span> <span> </span><span class="NLM_article-title">Ligand Efficiency: A Useful Metric for Lead Selection</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">430</span>â <span class="NLM_lpage">431</span>, <span class="refDoi">Â DOI: 10.1016/S1359-6446(04)03069-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1016%2FS1359-6446%2804%2903069-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=15109945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A280%3ADC%252BD2c3ht1ygtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=430-431&issue=10&author=A.+L.+Hopkinsauthor=C.+R.+Groomauthor=A.+Alex&title=Ligand+Efficiency%3A+A+Useful+Metric+for+Lead+Selection&doi=10.1016%2FS1359-6446%2804%2903069-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand efficiency: a useful metric for lead selection</span></div><div class="casAuthors">Hopkins Andrew L; Groom Colin R; Alex Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">430-1</span>
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSdMyKW_d6RPeIHSmpohpd0fW6udTcc2ebG2JBAazui9bntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c3ht1ygtw%253D%253D&md5=eb19a1bca53247d0bd9adcb99d5817e6</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2804%2903069-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252804%252903069-7%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DGroom%26aufirst%3DC.%2BR.%26aulast%3DAlex%26aufirst%3DA.%26atitle%3DLigand%2520Efficiency%253A%2520A%2520Useful%2520Metric%2520for%2520Lead%2520Selection%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2004%26volume%3D9%26issue%3D10%26spage%3D430%26epage%3D431%26doi%3D10.1016%2FS1359-6446%2804%2903069-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keseru, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, C. H.</span></span> <span> </span><span class="NLM_article-title">The Role of Ligand Efficiency Metrics in Drug Discovery</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">105</span>â <span class="NLM_lpage">121</span>, <span class="refDoi">Â DOI: 10.1038/nrd4163</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1038%2Fnrd4163" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=24481311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1SmtLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=105-121&issue=2&author=A.+L.+Hopkinsauthor=G.+M.+Keseruauthor=P.+D.+Leesonauthor=D.+C.+Reesauthor=C.+H.+Reynolds&title=The+Role+of+Ligand+Efficiency+Metrics+in+Drug+Discovery&doi=10.1038%2Fnrd4163"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">The role of ligand efficiency metrics in drug discovery</span></div><div class="casAuthors">Hopkins, Andrew L.; Keserue, Gyoergy M.; Leeson, Paul D.; Rees, David C.; Reynolds, Charles H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">105-121</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The judicious application of ligand or binding efficiency metrics, which quantify the mol. properties required to obtain binding affinity for a drug target, is gaining traction in the selection and optimization of fragments, hits and leads.  Retrospective anal. of recently marketed oral drugs shows that they frequently have highly optimized ligand efficiency values for their targets.  Optimizing ligand efficiency metrics based on both mol. mass and lipophilicity, when set in the context of the specific target, has the potential to ameliorate the inflation of these properties that has been obsd. in current medicinal chem. practice, and to increase the quality of drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq96uhvE1OZ5LVg90H21EOLACvtfcHk0lg-SrP3D45Gow"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1SmtLk%253D&md5=344030e59f499180f79d311302a27532</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1038%2Fnrd4163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4163%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DKeseru%26aufirst%3DG.%2BM.%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DReynolds%26aufirst%3DC.%2BH.%26atitle%3DThe%2520Role%2520of%2520Ligand%2520Efficiency%2520Metrics%2520in%2520Drug%2520Discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26issue%3D2%26spage%3D105%26epage%3D121%26doi%3D10.1038%2Fnrd4163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Egan, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merz, K. M.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldwin, J. J.</span></span> <span> </span><span class="NLM_article-title">Prediction of Drug Absorption Using Multivariate Statistics</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>43</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">3867</span>â <span class="NLM_lpage">3877</span>, <span class="refDoi">Â DOI: 10.1021/jm000292e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm000292e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmsFeitLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=3867-3877&issue=21&author=W.+J.+Eganauthor=K.+M.+Merzauthor=J.+J.+Baldwin&title=Prediction+of+Drug+Absorption+Using+Multivariate+Statistics&doi=10.1021%2Fjm000292e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of Drug Absorption Using Multivariate Statistics</span></div><div class="casAuthors">Egan, William J.; Merz, Kenneth M. Jr.; Baldwin, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">3867-3877</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Literature data on compds. both well- and poorly-absorbed in humans were used to build a statistical pattern recognition model of passive intestinal absorption.  Robust outlier detection was utilized to analyze the well-absorbed compds., some of which were intermingled with the poorly-absorbed compds. in the model space.  Outliers were identified as being actively transported.  The descriptors chosen for inclusion in the model were PSA and AlogP98, based on consideration of the phys. processes involved in membrane permeability and the interrelationships and redundancies between available descriptors.  These descriptors are quite straightforward for a medicinal chemist to interpret, enhancing the utility of the model.  Mol. wt., while often used in passive absorption models, was shown to be superfluous, as it is already a component of both PSA and AlogP98.  Extensive validation of the model on hundreds of known orally delivered drugs, "drug-like" mols., and Pharmacopeia, Inc. compds., which had been assayed for Caco-2 cell permeability, demonstrated a good rate of successful predictions (74-92%, depending on the dataset and exact criterion used).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbZF9e_GNz8LVg90H21EOLACvtfcHk0lhGtEABI0Grpg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmsFeitLk%253D&md5=44f909ad1fd6187840921e7f07497b4e</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Fjm000292e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000292e%26sid%3Dliteratum%253Aachs%26aulast%3DEgan%26aufirst%3DW.%2BJ.%26aulast%3DMerz%26aufirst%3DK.%2BM.%26aulast%3DBaldwin%26aufirst%3DJ.%2BJ.%26atitle%3DPrediction%2520of%2520Drug%2520Absorption%2520Using%2520Multivariate%2520Statistics%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26issue%3D21%26spage%3D3867%26epage%3D3877%26doi%3D10.1021%2Fjm000292e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chmielewska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamparczyk, H.</span></span> <span> </span><span class="NLM_article-title">Mass Versus Molar Doses, Similarities and Differences</span>. <i>Pharmazie</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">843</span>â <span class="NLM_lpage">848</span>, <span class="refDoi">Â DOI: 10.1691/ph.2008.8578</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1691%2Fph.2008.8578" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2008&pages=843-848&issue=11&author=A.+Chmielewskaauthor=H.+Lamparczyk&title=Mass+Versus+Molar+Doses%2C+Similarities+and+Differences&doi=10.1691%2Fph.2008.8578"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1691%2Fph.2008.8578&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1691%252Fph.2008.8578%26sid%3Dliteratum%253Aachs%26aulast%3DChmielewska%26aufirst%3DA.%26aulast%3DLamparczyk%26aufirst%3DH.%26atitle%3DMass%2520Versus%2520Molar%2520Doses%252C%2520Similarities%2520and%2520Differences%26jtitle%3DPharmazie%26date%3D2008%26volume%3D63%26issue%3D11%26spage%3D843%26epage%3D848%26doi%3D10.1691%2Fph.2008.8578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Varma, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steyn, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nkansah, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotter, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitney-Pickett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cram, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenner, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Kattan, A. F.</span></span> <span> </span><span class="NLM_article-title">Ph-Dependent Solubility and Permeability Criteria for Provisional Biopharmaceutics Classification (BCS and BDDCS) in Early Drug Discovery</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1199</span>â <span class="NLM_lpage">1212</span>, <span class="refDoi">Â DOI: 10.1021/mp2004912</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp2004912" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC38Xlt1Ont74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=1199-1212&issue=5&author=M.+V.+Varmaauthor=I.+Gardnerauthor=S.+J.+Steynauthor=P.+Nkansahauthor=C.+J.+Rotterauthor=C.+Whitney-Pickettauthor=H.+Zhangauthor=L.+Diauthor=M.+Cramauthor=K.+S.+Fennerauthor=A.+F.+El-Kattan&title=Ph-Dependent+Solubility+and+Permeability+Criteria+for+Provisional+Biopharmaceutics+Classification+%28BCS+and+BDDCS%29+in+Early+Drug+Discovery&doi=10.1021%2Fmp2004912"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery</span></div><div class="casAuthors">Varma, Manthena V.; Gardner, Iain; Steyn, Stefanus J.; Nkansah, Paul; Rotter, Charles J.; Whitney-Pickett, Carrie; Zhang, Hui; Di, Li; Cram, Michael; Fenner, Katherine S.; El-Kattan, Ayman F.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1199-1212</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The Biopharmaceutics Classification System (BCS) is a scientific framework that provides a basis for predicting the oral absorption of drugs.  These concepts have been extended in the Biopharmaceutics Drug Disposition Classification System (BDDCS) to explain the potential mechanism of drug clearance and understand the effects of uptake and efflux transporters on absorption, distribution, metab., and elimination.  The objective of present work is to establish criteria for provisional biopharmaceutics classification using pH-dependent passive permeability and aq. soly. data generated from high throughput screening methodologies in drug discovery settings.  The apparent permeability across monolayers of clonal cell line of Madin-Darby canine kidney cells, selected for low endogenous efflux transporter expression, was measured for a set of 105 drugs, with known BCS and BDDCS class.  The permeability at apical pH 6.5 for acidic drugs and at pH 7.4 for nonacidic drugs showed a good correlation with the fraction absorbed in human (Fa).  Receiver operating characteristic (ROC) curve anal. was utilized to define the permeability class boundary.  At permeability â¥5 Ã 10-6 cm/s, the accuracy of predicting Fa of â¥0.90 was 87%.  Also, this cutoff showed more than 80% sensitivity and specificity in predicting the literature permeability classes (BCS), and the metab. classes (BDDCS).  The equil. soly. of a subset of 49 drugs was measured in pH 1.2 medium, pH 6.5 phosphate buffer, and in FaSSIF medium (pH 6.5).  Although dose was not considered, good concordance of the measured soly. with BCS and BDDCS soly. class was achieved, when soly. at pH 1.2 was used for acidic compds. and FaSSIF soly. was used for basic, neutral, and zwitterionic compds.  Using a cutoff of 200 Î¼g/mL, the data set suggested a 93% sensitivity and 86% specificity in predicting both the BCS and BDDCS soly. classes.  In conclusion, this study identified pH-dependent permeability and soly. criteria that can be used to assign provisional biopharmaceutics class at early stage of the drug discovery process.  Addnl., such a classification system will enable discovery scientists to assess the potential limiting factors to oral absorption, as well as help predict the drug disposition mechanisms and potential drug-drug interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr84irw4TD15rVg90H21EOLACvtfcHk0lhGtEABI0Grpg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xlt1Ont74%253D&md5=2bcb29ea512d2e0665973292e4a4a0a3</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Fmp2004912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp2004912%26sid%3Dliteratum%253Aachs%26aulast%3DVarma%26aufirst%3DM.%2BV.%26aulast%3DGardner%26aufirst%3DI.%26aulast%3DSteyn%26aufirst%3DS.%2BJ.%26aulast%3DNkansah%26aufirst%3DP.%26aulast%3DRotter%26aufirst%3DC.%2BJ.%26aulast%3DWhitney-Pickett%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DDi%26aufirst%3DL.%26aulast%3DCram%26aufirst%3DM.%26aulast%3DFenner%26aufirst%3DK.%2BS.%26aulast%3DEl-Kattan%26aufirst%3DA.%2BF.%26atitle%3DPh-Dependent%2520Solubility%2520and%2520Permeability%2520Criteria%2520for%2520Provisional%2520Biopharmaceutics%2520Classification%2520%2528BCS%2520and%2520BDDCS%2529%2520in%2520Early%2520Drug%2520Discovery%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2012%26volume%3D9%26issue%3D5%26spage%3D1199%26epage%3D1212%26doi%3D10.1021%2Fmp2004912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huuskonen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Livingstone, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manallack, D. T.</span></span> <span> </span><span class="NLM_article-title">Prediction of Drug Solubility from Molecular Structure Using a Drug-Like Training Set</span>. <i>SAR QSAR Environ. Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">3â4</span>),  <span class="NLM_fpage">191</span>â <span class="NLM_lpage">212</span>, <span class="refDoi">Â DOI: 10.1080/10629360802083855</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1080%2F10629360802083855" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2008&pages=191-212&issue=3%E2%80%934&author=J.+Huuskonenauthor=D.+J.+Livingstoneauthor=D.+T.+Manallack&title=Prediction+of+Drug+Solubility+from+Molecular+Structure+Using+a+Drug-Like+Training+Set&doi=10.1080%2F10629360802083855"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1080%2F10629360802083855&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10629360802083855%26sid%3Dliteratum%253Aachs%26aulast%3DHuuskonen%26aufirst%3DJ.%26aulast%3DLivingstone%26aufirst%3DD.%2BJ.%26aulast%3DManallack%26aufirst%3DD.%2BT.%26atitle%3DPrediction%2520of%2520Drug%2520Solubility%2520from%2520Molecular%2520Structure%2520Using%2520a%2520Drug-Like%2520Training%2520Set%26jtitle%3DSAR%2520QSAR%2520Environ.%2520Res.%26date%3D2008%26volume%3D19%26issue%3D3%25E2%2580%25934%26spage%3D191%26epage%3D212%26doi%3D10.1080%2F10629360802083855" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yazdanian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glynn, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawi, A.</span></span> <span> </span><span class="NLM_article-title">Correlating Partitioning and Caco-2 Cell Permeability of Structurally Diverse Small Molecular Weight Compounds</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1490</span>â <span class="NLM_lpage">1494</span>, <span class="refDoi">Â DOI: 10.1023/A:1011930411574</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1023%2FA%3A1011930411574" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1998&pages=1490-1494&issue=9&author=M.+Yazdanianauthor=S.+L.+Glynnauthor=J.+L.+Wrightauthor=A.+Hawi&title=Correlating+Partitioning+and+Caco-2+Cell+Permeability+of+Structurally+Diverse+Small+Molecular+Weight+Compounds&doi=10.1023%2FA%3A1011930411574"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1023%2FA%3A1011930411574&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1011930411574%26sid%3Dliteratum%253Aachs%26aulast%3DYazdanian%26aufirst%3DM.%26aulast%3DGlynn%26aufirst%3DS.%2BL.%26aulast%3DWright%26aufirst%3DJ.%2BL.%26aulast%3DHawi%26aufirst%3DA.%26atitle%3DCorrelating%2520Partitioning%2520and%2520Caco-2%2520Cell%2520Permeability%2520of%2520Structurally%2520Diverse%2520Small%2520Molecular%2520Weight%2520Compounds%26jtitle%3DPharm.%2520Res.%26date%3D1998%26volume%3D15%26issue%3D9%26spage%3D1490%26epage%3D1494%26doi%3D10.1023%2FA%3A1011930411574" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Palm, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stenberg, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luthman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artursson, P.</span></span> <span> </span><span class="NLM_article-title">Polar Molecular Surface Properties Predict the Intestinal Absorption of Drugs in Humans</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">568</span>â <span class="NLM_lpage">571</span>, <span class="refDoi">Â DOI: 10.1023/A:1012188625088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1023%2FA%3A1012188625088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=9165525" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADyaK2sXjtlSksrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1997&pages=568-571&issue=5&author=K.+Palmauthor=P.+Stenbergauthor=K.+Luthmanauthor=P.+Artursson&title=Polar+Molecular+Surface+Properties+Predict+the+Intestinal+Absorption+of+Drugs+in+Humans&doi=10.1023%2FA%3A1012188625088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Polar molecular surface properties predict the intestinal absorption of drugs in humans</span></div><div class="casAuthors">Palm, Katrin; Stenberg, Patric; Luthman, Kristina; Artursson, Per</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">568-571</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Plenum</span>)
        </div><div class="casAbstract">A theor. method was devised for prediction of drug absorption after oral administration to humans.  Twenty structurally diverse model drugs, ranging from 0.3 to 100% absorbed, were investigated.  The compds. also displayed diversity in physicochem. properties such as lipophilicity, hydrogen bonding potential and mol. size.  The dynamic mol. surface properties of the compds. were calcd., taking into account their 3-dimensional shape and flexibility.  An excellent sigmoidal relationship was established between the absorbed fraction after oral administration to humans (FA) and the dynamic polar mol. surface area (PSAd) (r2 = 0.94).  The relationship was stronger than those obtained for more established predictors of drug absorption.  Drugs that are completely absorbed (FA > 90%) had a PSAd â¤ 60 Ã2 while drugs that are < 10% absorbed had a PSAd â¥ 140 Ã2.  PSAd can be used to differentiate poorly absorbed drugs at an early stage of the drug discovery process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPW66hupHIyLVg90H21EOLACvtfcHk0lhcCnj1Om1W8Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjtlSksrk%253D&md5=1394f0d1059e7d99ee02be977b92da8b</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1023%2FA%3A1012188625088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1012188625088%26sid%3Dliteratum%253Aachs%26aulast%3DPalm%26aufirst%3DK.%26aulast%3DStenberg%26aufirst%3DP.%26aulast%3DLuthman%26aufirst%3DK.%26aulast%3DArtursson%26aufirst%3DP.%26atitle%3DPolar%2520Molecular%2520Surface%2520Properties%2520Predict%2520the%2520Intestinal%2520Absorption%2520of%2520Drugs%2520in%2520Humans%26jtitle%3DPharm.%2520Res.%26date%3D1997%26volume%3D14%26issue%3D5%26spage%3D568%26epage%3D571%26doi%3D10.1023%2FA%3A1012188625088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Artursson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ungell, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lofroth, J. E.</span></span> <span> </span><span class="NLM_article-title">Selective Paracellular Permeability in Two Models of Intestinal Absorption: Cultured Monolayers of Human Intestinal Epithelial Cells and Rat Intestinal Segments</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1123</span>â <span class="NLM_lpage">1129</span>, <span class="refDoi">Â DOI: 10.1023/A:1018903931777</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1023%2FA%3A1018903931777" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1993&pages=1123-1129&issue=8&author=P.+Arturssonauthor=A.+L.+Ungellauthor=J.+E.+Lofroth&title=Selective+Paracellular+Permeability+in+Two+Models+of+Intestinal+Absorption%3A+Cultured+Monolayers+of+Human+Intestinal+Epithelial+Cells+and+Rat+Intestinal+Segments&doi=10.1023%2FA%3A1018903931777"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1023%2FA%3A1018903931777&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1018903931777%26sid%3Dliteratum%253Aachs%26aulast%3DArtursson%26aufirst%3DP.%26aulast%3DUngell%26aufirst%3DA.%2BL.%26aulast%3DLofroth%26aufirst%3DJ.%2BE.%26atitle%3DSelective%2520Paracellular%2520Permeability%2520in%2520Two%2520Models%2520of%2520Intestinal%2520Absorption%253A%2520Cultured%2520Monolayers%2520of%2520Human%2520Intestinal%2520Epithelial%2520Cells%2520and%2520Rat%2520Intestinal%2520Segments%26jtitle%3DPharm.%2520Res.%26date%3D1993%26volume%3D10%26issue%3D8%26spage%3D1123%26epage%3D1129%26doi%3D10.1023%2FA%3A1018903931777" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dress, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M.</span></span> <span> </span><span class="NLM_article-title">Using the Golden Triangle to Optimize Clearance and Oral Absorption</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">5560</span>â <span class="NLM_lpage">5564</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2009.08.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1016%2Fj.bmcl.2009.08.045" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=5560-5564&issue=19&author=T.+W.+Johnsonauthor=K.+R.+Dressauthor=M.+Edwards&title=Using+the+Golden+Triangle+to+Optimize+Clearance+and+Oral+Absorption&doi=10.1016%2Fj.bmcl.2009.08.045"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.08.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.08.045%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DDress%26aufirst%3DK.%2BR.%26aulast%3DEdwards%26aufirst%3DM.%26atitle%3DUsing%2520the%2520Golden%2520Triangle%2520to%2520Optimize%2520Clearance%2520and%2520Oral%2520Absorption%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26issue%3D19%26spage%3D5560%26epage%3D5564%26doi%3D10.1016%2Fj.bmcl.2009.08.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">CNS Physicochemical Property Space Shaped by a Diverse Set of Molecules with Experimentally Determined Exposure in the Mouse Brain</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">5943</span>â <span class="NLM_lpage">5954</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.6b01469</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01469" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC2sXls1yqsbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5943-5954&issue=14&author=Z.+Rankovic&title=CNS+Physicochemical+Property+Space+Shaped+by+a+Diverse+Set+of+Molecules+with+Experimentally+Determined+Exposure+in+the+Mouse+Brain&doi=10.1021%2Facs.jmedchem.6b01469"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">CNS Physicochemical Property Space Shaped by a Diverse Set of Molecules with Experimentally Determined Exposure in the Mouse Brain</span></div><div class="casAuthors">Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5943-5954</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Understanding the "limits and boundaries" of the central nervous system (CNS) property space is a crit. aspect of modern CNS drug design.  Medicinal chemists are often guided by the physicochem. properties of marketed CNS drugs, which are heavily biased toward "traditional" aminergic targets and commonly described as small lipophilic amines.  This miniperspective describes the statistical anal. of the calcd. physicochem. properties for a diverse set of ligands for mostly "nontraditional" CNS targets and classified as either "brain penetrant" or "peripherally restricted" on the basis of the exptl. mouse brain exposure.  The results suggested that (a) the physicochem. property space conducive to brain exposure is larger than the one defined by the marketed CNS drugs and (b) the most crit. brain exposure determinants are descriptors of the mol. size and hydrogen bond capacity.  These findings led to a modified version of the CNS MPO scoring algorithm, termed CNS MPO.v2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4f3JpTCJ29rVg90H21EOLACvtfcHk0lhcCnj1Om1W8Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXls1yqsbk%253D&md5=bff2a3cd68c033d6cae235a7524cc528</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01469&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01469%26sid%3Dliteratum%253Aachs%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DCNS%2520Physicochemical%2520Property%2520Space%2520Shaped%2520by%2520a%2520Diverse%2520Set%2520of%2520Molecules%2520with%2520Experimentally%2520Determined%2520Exposure%2520in%2520the%2520Mouse%2520Brain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D14%26spage%3D5943%26epage%3D5954%26doi%3D10.1021%2Facs.jmedchem.6b01469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaumont, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span> <span> </span><span class="NLM_article-title">Volume of Distribution in Drug Design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">5691</span>â <span class="NLM_lpage">5698</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b00201</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00201" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC2MXltFSlsb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=5691-5698&issue=15&author=D.+A.+Smithauthor=K.+Beaumontauthor=T.+S.+Maurerauthor=L.+Di&title=Volume+of+Distribution+in+Drug+Design&doi=10.1021%2Facs.jmedchem.5b00201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Volume of Distribution in Drug Design</span></div><div class="casAuthors">Smith, Dennis A.; Beaumont, Kevin; Maurer, Tristan S.; Di, Li</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5691-5698</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Vol. of distribution is one of the most important pharmacokinetic properties of a drug candidate.  It is a major determinant of half-life and dosing frequency of a drug.  For a similar log P, a basic mol. will tend to exhibit higher vol. of distribution than a neutral mol.  Acids often exhibit low vols. of distribution.  Although a design strategy against vol. of distribution can be advantageous in achieving desirable dosing regimen, it must be well-directed in order to avoid detrimental effects to other important properties.  Strategies to increase vol. of distribution include adding lipophilicity and introducing basic functional groups in a way that does not increase metabolic clearance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP7QwgPahf4bVg90H21EOLACvtfcHk0lhcCnj1Om1W8Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXltFSlsb0%253D&md5=2c7289b3602a8edef2d9ef0e6a82e483</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00201%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DBeaumont%26aufirst%3DK.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DDi%26aufirst%3DL.%26atitle%3DVolume%2520of%2520Distribution%2520in%2520Drug%2520Design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D15%26spage%3D5691%26epage%3D5698%26doi%3D10.1021%2Facs.jmedchem.5b00201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaumont, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span> <span> </span><span class="NLM_article-title">Relevance of Half-Life in Drug Design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">4273</span>â <span class="NLM_lpage">4282</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.7b00969</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00969" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslOnsrnN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4273-4282&issue=10&author=D.+A.+Smithauthor=K.+Beaumontauthor=T.+S.+Maurerauthor=L.+Di&title=Relevance+of+Half-Life+in+Drug+Design&doi=10.1021%2Facs.jmedchem.7b00969"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Relevance of Half-Life in Drug Design</span></div><div class="casAuthors">Smith, Dennis A.; Beaumont, Kevin; Maurer, Tristan S.; Di, Li</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4273-4282</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Drug half-life has important implications for dosing regimen and peak-to-trough ratio at the steady state.  A half-life of 12-48 h is generally ideal for once daily dosing of oral drugs.  If the half-life is too short, it may require more frequent dosing in order to maintain desired exposures and avoid unnecessarily high peak concns.  This may pose challenges to achieving optimal efficacy, safety, and patient compliance.  If the half-life is too long, the time over which accumulation and subsequent elimination occur may be prolonged.  This may pose problems with managing adverse effects and the design of efficient clin. trials.  Half-life is a key parameter for optimization in research and development.  Structural modification to affect clearance, and to a lesser extent vol. of distribution, is the preferred means of modulating half-life.  An effective approach to half-life optimization requires an understanding of the many pitfalls assocd. with its estn. and interpretation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7kT9hNLRzb7Vg90H21EOLACvtfcHk0lhPc3o98acXiQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslOnsrnN&md5=ff748cbebc765f4fa3c3d7b3831f51c8</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00969%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DBeaumont%26aufirst%3DK.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DDi%26aufirst%3DL.%26atitle%3DRelevance%2520of%2520Half-Life%2520in%2520Drug%2520Design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D10%26spage%3D4273%26epage%3D4282%26doi%3D10.1021%2Facs.jmedchem.7b00969" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharifi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghafourian, T.</span></span> <span> </span><span class="NLM_article-title">Estimation of Biliary Excretion of Foreign Compounds Using Properties of Molecular Structure</span>. <i>AAPS J.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">65</span>â <span class="NLM_lpage">78</span>, <span class="refDoi">Â DOI: 10.1208/s12248-013-9541-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1208%2Fs12248-013-9541-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=24202722" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisFOkug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2014&pages=65-78&issue=1&author=M.+Sharifiauthor=T.+Ghafourian&title=Estimation+of+Biliary+Excretion+of+Foreign+Compounds+Using+Properties+of+Molecular+Structure&doi=10.1208%2Fs12248-013-9541-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Estimation of Biliary Excretion of Foreign Compounds Using Properties of Molecular Structure</span></div><div class="casAuthors">Sharifi, Mohsen; Ghafourian, Taravat</div><div class="citationInfo"><span class="NLM_cas:title">AAPS Journal</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">65-78</span>CODEN:
                <span class="NLM_cas:coden">AJAOB6</span>;
        ISSN:<span class="NLM_cas:issn">1550-7416</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Biliary excretion is one of the main elimination pathways for drugs and/or their metabolites.  Therefore, an insight into the structural profile of cholephilic compds. through accurate modeling of the biliary excretion is important for the estn. of clin. pharmacokinetics in early stages of drug discovery.  The aim of this study was to develop quant. structure-activity relationships as computational tools for the estn. of biliary excretion and identification of the mol. properties controlling this process.  The study used percentage of dose excreted intact into bile measured in vivo in rat for a diverse dataset of 217 compds.  Statistical techniques were multiple linear regression anal., regression trees, random forest and boosted trees.  A simple regression tree model generated using the CART algorithm was the most accurate in the estn. of the percentage of bile excretion of compds., and this outperformed the more sophisticated boosted trees and random forest techniques.  Anal. of the outliers indicated that the models perform best when lipophilicity is not too extreme (log P<5.35) and for compds. with mol. wt. above 280 Da.  Mol. descriptors selected by all these models including the top ten incorporated in boosted trees and random forest indicated a higher biliary excretion for relatively hydrophilic compds. esp. if they are anionic or cationic, and have a large mol. size.  A statistically validated mol. wt. threshold for potentially significant biliary excretion was above 348 Da.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq52DwTd6VS9bVg90H21EOLACvtfcHk0lhPc3o98acXiQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisFOkug%253D%253D&md5=05cb387d4ee81d805b96ea9398e3c0ba</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1208%2Fs12248-013-9541-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Fs12248-013-9541-z%26sid%3Dliteratum%253Aachs%26aulast%3DSharifi%26aufirst%3DM.%26aulast%3DGhafourian%26aufirst%3DT.%26atitle%3DEstimation%2520of%2520Biliary%2520Excretion%2520of%2520Foreign%2520Compounds%2520Using%2520Properties%2520of%2520Molecular%2520Structure%26jtitle%3DAAPS%2520J.%26date%3D2014%26volume%3D16%26issue%3D1%26spage%3D65%26epage%3D78%26doi%3D10.1208%2Fs12248-013-9541-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fleck, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braunlich, H.</span></span> <span> </span><span class="NLM_article-title">Factors Determining the Relationship between Renal and Hepatic Excretion of Xenobiotics</span>. <i>Arzneimittelforschung</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">942</span>â <span class="NLM_lpage">946</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1990&pages=942-946&issue=8&author=C.+Fleckauthor=H.+Braunlich&title=Factors+Determining+the+Relationship+between+Renal+and+Hepatic+Excretion+of+Xenobiotics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFleck%26aufirst%3DC.%26aulast%3DBraunlich%26aufirst%3DH.%26atitle%3DFactors%2520Determining%2520the%2520Relationship%2520between%2520Renal%2520and%2520Hepatic%2520Excretion%2520of%2520Xenobiotics%26jtitle%3DArzneimittelforschung%26date%3D1990%26volume%3D40%26issue%3D8%26spage%3D942%26epage%3D946" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Varma, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Kattan, A. F.</span></span> <span> </span><span class="NLM_article-title">Molecular Properties Associated with Transporter-Mediated Drug Disposition</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">92</span>â <span class="NLM_lpage">99</span>, <span class="refDoi">Â DOI: 10.1016/j.addr.2017.05.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1016%2Fj.addr.2017.05.014" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2017&pages=92-99&author=M.+V.+Varmaauthor=Y.+Laiauthor=A.+F.+El-Kattan&title=Molecular+Properties+Associated+with+Transporter-Mediated+Drug+Disposition&doi=10.1016%2Fj.addr.2017.05.014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2017.05.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2017.05.014%26sid%3Dliteratum%253Aachs%26aulast%3DVarma%26aufirst%3DM.%2BV.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DEl-Kattan%26aufirst%3DA.%2BF.%26atitle%3DMolecular%2520Properties%2520Associated%2520with%2520Transporter-Mediated%2520Drug%2520Disposition%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2017%26volume%3D116%26spage%3D92%26epage%3D99%26doi%3D10.1016%2Fj.addr.2017.05.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Improving Drug Design: An Update on Recent Applications of Efficiency Metrics, Strategies for Replacing Problematic Elements, and Compounds in Nontraditional Drug Space</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">564</span>â <span class="NLM_lpage">616</span>, <span class="refDoi">Â DOI: 10.1021/acs.chemrestox.6b00043</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.6b00043" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC28XktVCrs7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2016&pages=564-616&issue=4&author=N.+A.+Meanwell&title=Improving+Drug+Design%3A+An+Update+on+Recent+Applications+of+Efficiency+Metrics%2C+Strategies+for+Replacing+Problematic+Elements%2C+and+Compounds+in+Nontraditional+Drug+Space&doi=10.1021%2Facs.chemrestox.6b00043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Improving Drug Design: An Update on Recent Applications of Efficiency Metrics, Strategies for Replacing Problematic Elements, and Compounds in Nontraditional Drug Space</span></div><div class="casAuthors">Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">564-616</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Drug discovery and development is a complex and lengthy enterprise that suffers from high rates of candidate attrition at all stages of the process.  The phys., biol., and toxicol. properties of a drug candidate are inextricably linked to its structure, and once a mol. has been synthesized, all subsequent studies along the development path are focused only on assessing and understanding its properties in greater detail.  Unfortunately, a full prediction of the biol. properties of a mol. from an anal. of its 2- or 3-dimensional structure is currently beyond our expertise.  This backdrop mandates that considerable care be taken at the design stage if a mol. is to be successful in testing a mechanistic concept underlying a disease process and to progress into late stage clin. trials and, ultimately, marketing approval.  While there are multiple potential causes of candidate attrition, an introspective anal. of drug design practices over the past decade has focused attention on the perception that contemporary mols. are unnecessarily obese, burdened by high mol. wt. and excessive lipophilicity.  This practice is believed to have its roots in the singular pursuit of enhancing potency during lead optimization rather than adopting a more holistic approach to drug design that gives broader consideration to how structural features affect developability properties.  In an effort to provide the medicinal chem. community with practical guideposts to enhancing compd. quality in the drug design phase and which can readily be applied, a series of efficiency indexes have been proposed that attempt to define aspects of compd. quality in the context of a series of physicochem. parameters.  Of these metrics, lipophilic ligand efficiency (LLE or LipE), which provides an index of the dependence of the potency of a mol. on its intrinsic lipophilicity, has been characterized as the most robust metric that has potential for broad-based application.  In this review, after describing the background literature behind the derivation of efficiency metrics and approaches to assessing compd. aesthetics, synopses of some recent practical application in lead optimization campaigns are presented.  However, mols. that fall into space beyond that assocd. with traditional drug-like properties are an important part of the current and future landscape, exemplified by the summary of direct acting hepatitis C virus NS3 and NS5A inhibitors that have transformed clin. therapy for this chronic disease.  While drug development in nontraditional drug-like space is more challenging and the rules for compd. quality will be different with much still to be understood, careful and disciplined drug design practices will be an essential element of success.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpotJb_EhGoW7Vg90H21EOLACvtfcHk0lg19skPi6kIHw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktVCrs7Y%253D&md5=aef48399fb698b5f958c1cc11e1d25aa</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.6b00043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.6b00043%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DImproving%2520Drug%2520Design%253A%2520An%2520Update%2520on%2520Recent%2520Applications%2520of%2520Efficiency%2520Metrics%252C%2520Strategies%2520for%2520Replacing%2520Problematic%2520Elements%252C%2520and%2520Compounds%2520in%2520Nontraditional%2520Drug%2520Space%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2016%26volume%3D29%26issue%3D4%26spage%3D564%26epage%3D616%26doi%3D10.1021%2Facs.chemrestox.6b00043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Struck, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruening, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaeger, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hossbach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preissner, R.</span></span> <span> </span><span class="NLM_article-title">Toxicity Versus Potency: Elucidation of Toxicity Properties Discriminating between Toxins, Drugs, and Natural Compounds</span>. <i>Genome Inform</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">231</span>â <span class="NLM_lpage">242</span>, <span class="refDoi">Â DOI: 10.1142/9781848163003_0020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1142%2F9781848163003_0020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=19425137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A280%3ADC%252BD1MzivFOisA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2008&pages=231-242&author=S.+Struckauthor=U.+Schmidtauthor=B.+Grueningauthor=I.+S.+Jaegerauthor=J.+Hossbachauthor=R.+Preissner&title=Toxicity+Versus+Potency%3A+Elucidation+of+Toxicity+Properties+Discriminating+between+Toxins%2C+Drugs%2C+and+Natural+Compounds&doi=10.1142%2F9781848163003_0020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Toxicity versus potency: elucidation of toxicity properties discriminating between toxins, drugs, and natural compounds</span></div><div class="casAuthors">Struck Swantje; Schmidt Ulrike; Gruening Bjoern; Jaeger Ines S; Hossbach Julia; Preissner Robert</div><div class="citationInfo"><span class="NLM_cas:title">Genome informatics. International Conference on Genome Informatics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">231-42</span>
        ISSN:<span class="NLM_cas:issn">0919-9454</span>.
    </div><div class="casAbstract">Within our everyday life we are confronted with a variety of toxic substances.  A number of these compounds are already used as lead structures for the development of new drugs, but the amount of toxic substances is still a rich resource of new bioactive compounds.  During the identification and development of new potential drugs, risk estimation of health hazards is an essential and topical subject in pharmaceutical industry.  To face this challenge, an extensive investigation of known toxic compounds is going to be helpful to estimate the toxicity of potential drugs. "Toxicity properties" found during those investigations will also function as a guideline for the toxicological classification of other unknown substances.  We have compiled a dataset of approximately 50,000 toxic compounds from literature and web sources.  All compounds were classified according to their toxicity.  During this study the collection of toxic compounds was investigated extensively regarding their chemical, functional, and structural properties and compared with a dataset of drugs and natural compounds.  We were able to identify differences in properties within the toxic compounds as well as in comparison to drugs and natural compounds.  These properties include molecular weight, hydrogen bond donors and acceptors, and functional groups which can be regarded as "toxicity properties", i.e. attributes defining toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT9d7GGDNKsmmx8TEN9K18QfW6udTcc2eZxN33d3oANI7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MzivFOisA%253D%253D&md5=a0319de47786e7a9b3b7e494e48a51e9</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1142%2F9781848163003_0020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1142%252F9781848163003_0020%26sid%3Dliteratum%253Aachs%26aulast%3DStruck%26aufirst%3DS.%26aulast%3DSchmidt%26aufirst%3DU.%26aulast%3DGruening%26aufirst%3DB.%26aulast%3DJaeger%26aufirst%3DI.%2BS.%26aulast%3DHossbach%26aufirst%3DJ.%26aulast%3DPreissner%26aufirst%3DR.%26atitle%3DToxicity%2520Versus%2520Potency%253A%2520Elucidation%2520of%2520Toxicity%2520Properties%2520Discriminating%2520between%2520Toxins%252C%2520Drugs%252C%2520and%2520Natural%2520Compounds%26jtitle%3DGenome%2520Inform%26date%3D2008%26volume%3D20%26spage%3D231%26epage%3D242%26doi%3D10.1142%2F9781848163003_0020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Price, D.</span>; <span class="NLM_string-name">Lee, K.</span></span> Unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Price%2C+D.%3B+Lee%2C+K.+Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DPrice%26aufirst%3DD." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zuegg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, M. A.</span></span> <span> </span><span class="NLM_article-title">Drug-likeness and Increased Hydrophobicity of Commercially Available Compound Libraries for Drug Screening</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">1500</span>â <span class="NLM_lpage">1513</span>, <span class="refDoi">Â DOI: 10.2174/156802612802652466</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.2174%2F156802612802652466" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=22827520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsV2iur7K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=1500-1513&issue=14&author=J.+Zueggauthor=M.+A.+Cooper&title=Drug-likeness+and+Increased+Hydrophobicity+of+Commercially+Available+Compound+Libraries+for+Drug+Screening&doi=10.2174%2F156802612802652466"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-likeness and increased hydrophobicity of commercially available compound libraries for drug screening</span></div><div class="casAuthors">Zuegg, Johannes; Cooper, Matthew A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1500-1513</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Most drug discovery programs today originate by selection of "hit" mols. resulting from assays against large compd. screening libraries.  The chem. space in which these hits reside has implications for its biol. activity in vivo and likelihood of progression to a drug candidate.  We have created a database of com. available screening compds. and natural products in order to analyze the drug- and lead-likeness of com. screening compds. and compare them with i) orally administered drugs, ii) non-orally administered drugs, and iii) compds. with significant biol. activity but unspecified or not yet detd. route of administration from the public databases DrugBank and ChEMBL.  The data set contained 15.5 million entries from 102 vendors, which resulted in just over 8 million unique chem. structures.  We review these data for current drug/lead-likeness, then utilize substructure-based filters for promiscuity and unwanted groups, and finally compare chem. properties for structures within the different sub-sets.  While the majority of the com. compds. satisfy various drug-likeness rules, they show a larger mol. wt. and higher hydrophobicity compared to orally available drugs, with generally higher aromaticity and lower soly.  This "right shift" of chem. properties has also been found in the majority of the compds. with significant biol. activity in ChEMBL, reflecting a common trend in current drug discovery, towards larger, more hydrophobic compds. and fewer drug-like compds.  In particular, successful drugs were found to possess much lower median logD values than those found for compd. collections.  In addn., com. compds. show a quite narrow distribution in mol. wt., with a median abs. deviation of only 78 Da around a median of 387 Da.  For high-throughput screening a highly stringent combination of several lead-likeness and substructure filters against unwanted groups could be applied, resulting in 2 million lead-like structures.  For fragment based screening approaches the rule of three (Ro3) would select around 400,000 structures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq04wKgd1oss7Vg90H21EOLACvtfcHk0lg19skPi6kIHw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsV2iur7K&md5=aed253db97f077f79c748802cf4ec623</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.2174%2F156802612802652466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802612802652466%26sid%3Dliteratum%253Aachs%26aulast%3DZuegg%26aufirst%3DJ.%26aulast%3DCooper%26aufirst%3DM.%2BA.%26atitle%3DDrug-likeness%2520and%2520Increased%2520Hydrophobicity%2520of%2520Commercially%2520Available%2520Compound%2520Libraries%2520for%2520Drug%2520Screening%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2012%26volume%3D12%26issue%3D14%26spage%3D1500%26epage%3D1513%26doi%3D10.2174%2F156802612802652466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Kloe, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leurs, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Esch, I. J.</span></span> <span> </span><span class="NLM_article-title">Transforming Fragments into Candidates: Small Becomes Big in Medicinal Chemistry</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">13â14</span>),  <span class="NLM_fpage">630</span>â <span class="NLM_lpage">646</span>, <span class="refDoi">Â DOI: 10.1016/j.drudis.2009.03.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1016%2Fj.drudis.2009.03.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=19443265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A280%3ADC%252BD1MvmtFOquw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=630-646&issue=13%E2%80%9314&author=G.+E.+de%0AKloeauthor=D.+Baileyauthor=R.+Leursauthor=I.+J.+de+Esch&title=Transforming+Fragments+into+Candidates%3A+Small+Becomes+Big+in+Medicinal+Chemistry&doi=10.1016%2Fj.drudis.2009.03.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Transforming fragments into candidates: small becomes big in medicinal chemistry</span></div><div class="casAuthors">de Kloe Gerdien E; Bailey David; Leurs Rob; de Esch Iwan J P</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">13-14</span>),
    <span class="NLM_cas:pages">630-46</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Fragment-based drug discovery (FBDD) represents a logical and efficient approach to lead discovery and optimisation.  It can draw on structural, biophysical and biochemical data, incorporating a wide range of inputs, from precise mode-of-binding information on specific fragments to wider ranging pharmacophoric screening surveys using traditional HTS approaches.  It is truly an enabling technology for the imaginative medicinal chemist.  In this review, we analyse a representative set of 23 published FBDD studies that describe how low molecular weight fragments are being identified and efficiently transformed into higher molecular weight drug candidates.  FBDD is now becoming warmly endorsed by industry as well as academia and the focus on small interacting molecules is making a big scientific impact.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTPxy6qg7uE4oxhnOQkIHOxfW6udTcc2ebOyrrYWy1pZLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MvmtFOquw%253D%253D&md5=10ed9629dece190be12712f4862b3699</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2009.03.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2009.03.009%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BKloe%26aufirst%3DG.%2BE.%26aulast%3DBailey%26aufirst%3DD.%26aulast%3DLeurs%26aufirst%3DR.%26aulast%3Dde%2BEsch%26aufirst%3DI.%2BJ.%26atitle%3DTransforming%2520Fragments%2520into%2520Candidates%253A%2520Small%2520Becomes%2520Big%2520in%2520Medicinal%2520Chemistry%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2009%26volume%3D14%26issue%3D13%25E2%2580%259314%26spage%3D630%26epage%3D646%26doi%3D10.1016%2Fj.drudis.2009.03.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chessari, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodhead, A. J.</span></span> <span> </span><span class="NLM_article-title">From Fragment to Clinical Candidate--a Historical Perspective</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">13â14</span>),  <span class="NLM_fpage">668</span>â <span class="NLM_lpage">675</span>, <span class="refDoi">Â DOI: 10.1016/j.drudis.2009.04.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1016%2Fj.drudis.2009.04.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=19427404" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotFyktLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=668-675&issue=13%E2%80%9314&author=G.+Chessariauthor=A.+J.+Woodhead&title=From+Fragment+to+Clinical+Candidate%2D%2Da+Historical+Perspective&doi=10.1016%2Fj.drudis.2009.04.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">From fragment to clinical candidate-a historical perspective</span></div><div class="casAuthors">Chessari, Gianni; Woodhead, Andrew J.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">13/14</span>),
    <span class="NLM_cas:pages">668-675</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  As recently as ten years ago few scientists had heard of fragment screening, let alone considered low mol. wt. fragments (MW <300) with weak binding affinities to be attractive start points for drug discovery programs.  Today, however, there is widespread acceptance that these fragments can be progressed into lead series and on to become clin. candidates.  Consequently, over the past three to four years, fragment-based drug discovery has become firmly established within the biotechnol. and pharmaceutical industries as a complimentary strategy to high-throughput screening.  In this review, we give a historical perspective of how rapidly fragment-based drug discovery has developed and describe a no. of clin. compds. discovered using this approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIfibakR1lWLVg90H21EOLACvtfcHk0li7j--Hmr5K0g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotFyktLo%253D&md5=1bd47b7787b1b22681466ad220eb7cd1</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2009.04.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2009.04.007%26sid%3Dliteratum%253Aachs%26aulast%3DChessari%26aufirst%3DG.%26aulast%3DWoodhead%26aufirst%3DA.%2BJ.%26atitle%3DFrom%2520Fragment%2520to%2520Clinical%2520Candidate--a%2520Historical%2520Perspective%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2009%26volume%3D14%26issue%3D13%25E2%2580%259314%26spage%3D668%26epage%3D675%26doi%3D10.1016%2Fj.drudis.2009.04.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keseru, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erlanson, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferenczy, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hann, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickett, S. D.</span></span> <span> </span><span class="NLM_article-title">Design Principles for Fragment Libraries: Maximizing the Value of Learnings from Pharma Fragment-Based Drug Discovery (FBDD) Programs for Use in Academia</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">8189</span>â <span class="NLM_lpage">8206</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.6b00197</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00197" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC28XmvFSit7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8189-8206&issue=18&author=G.+M.+Keseruauthor=D.+A.+Erlansonauthor=G.+G.+Ferenczyauthor=M.+M.+Hannauthor=C.+W.+Murrayauthor=S.+D.+Pickett&title=Design+Principles+for+Fragment+Libraries%3A+Maximizing+the+Value+of+Learnings+from+Pharma+Fragment-Based+Drug+Discovery+%28FBDD%29+Programs+for+Use+in+Academia&doi=10.1021%2Facs.jmedchem.6b00197"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Design Principles for Fragment Libraries: Maximizing the Value of Learnings from Pharma Fragment-Based Drug Discovery (FBDD) Programs for Use in Academia</span></div><div class="casAuthors">Keseru, Gyorgy M.; Erlanson, Daniel A.; Ferenczy, Gyorgy G.; Hann, Michael M.; Murray, Christopher W.; Pickett, Stephen D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8189-8206</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Fragment-based drug discovery (FBDD) is well suited for discovering both drug leads and chem. probes of protein function; it can cover broad swaths of chem. space and allows the use of creative chem.  FBDD is widely implemented for lead discovery in industry but is sometimes used less systematically in academia.  Design principles and implementation approaches for fragment libraries are continually evolving, and the lack of up-to-date guidance may prevent more effective application of FBDD in academia.  This Perspective explores many of the theor., practical, and strategic considerations that occur within FBDD programs, including the optimal size, complexity, physicochem. profile, and shape profile of fragments in FBDD libraries, as well as compd. storage, evaluation, and screening technologies.  This compilation of industry experience in FBDD will hopefully be useful for those pursuing FBDD in academia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkrMUH3yVkGbVg90H21EOLACvtfcHk0li7j--Hmr5K0g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmvFSit7s%253D&md5=888fe2cf003c5564c2ec391cf54ea2ac</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00197%26sid%3Dliteratum%253Aachs%26aulast%3DKeseru%26aufirst%3DG.%2BM.%26aulast%3DErlanson%26aufirst%3DD.%2BA.%26aulast%3DFerenczy%26aufirst%3DG.%2BG.%26aulast%3DHann%26aufirst%3DM.%2BM.%26aulast%3DMurray%26aufirst%3DC.%2BW.%26aulast%3DPickett%26aufirst%3DS.%2BD.%26atitle%3DDesign%2520Principles%2520for%2520Fragment%2520Libraries%253A%2520Maximizing%2520the%2520Value%2520of%2520Learnings%2520from%2520Pharma%2520Fragment-Based%2520Drug%2520Discovery%2520%2528FBDD%2529%2520Programs%2520for%2520Use%2520in%2520Academia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D18%26spage%3D8189%26epage%3D8206%26doi%3D10.1021%2Facs.jmedchem.6b00197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parker, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galmozzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correia, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joslyn, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavallaro, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narvaiza, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span> <span> </span><span class="NLM_article-title">Ligand and Target Discovery by Fragment-Based Screening in Human Cells</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>168</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">527</span>â <span class="NLM_lpage">541</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2016.12.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1016%2Fj.cell.2016.12.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=28111073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVeiu7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=2017&pages=527-541&issue=3&author=C.+G.+Parkerauthor=A.+Galmozziauthor=Y.+Wangauthor=B.+E.+Correiaauthor=K.+Sasakiauthor=C.+M.+Joslynauthor=A.+S.+Kimauthor=C.+L.+Cavallaroauthor=R.+M.+Lawrenceauthor=S.+R.+Johnsonauthor=I.+Narvaizaauthor=E.+Saezauthor=B.+F.+Cravatt&title=Ligand+and+Target+Discovery+by+Fragment-Based+Screening+in+Human+Cells&doi=10.1016%2Fj.cell.2016.12.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand and Target Discovery by Fragment-Based Screening in Human Cells</span></div><div class="casAuthors">Parker, Christopher G.; Galmozzi, Andrea; Wang, Yujia; Correia, Bruno E.; Sasaki, Kenji; Joslyn, Christopher M.; Kim, Arthur S.; Cavallaro, Cullen L.; Lawrence, R. Michael; Johnson, Stephen R.; Narvaiza, Inigo; Saez, Enrique; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">168</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">527-541.e29</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Advances in the synthesis and screening of small-mol. libraries have accelerated the discovery of chem. probes for studying biol. processes.  Still, only a small fraction of the human proteome has chem. ligands.  Here, we describe a platform that marries fragment-based ligand discovery with quant. chem. proteomics to map thousands of reversible small mol.-protein interactions directly in human cells, many of which can be site-specifically detd.  We show that fragment hits can be advanced to furnish selective ligands that affect the activity of proteins heretofore lacking chem. probes.  We further combine fragment-based chem. proteomics with phenotypic screening to identify small mols. that promote adipocyte differentiation by engaging the poorly characterized membrane protein PGRMC2.  Fragment-based screening in human cells thus provides an extensive proteome-wide map of protein ligandability and facilitates the coordinated discovery of bioactive small mols. and their mol. targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPk-YJwFlDwbVg90H21EOLACvtfcHk0lhejRt9613H3A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVeiu7Y%253D&md5=835264291015037ab9b7e446992caba3</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2016.12.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2016.12.029%26sid%3Dliteratum%253Aachs%26aulast%3DParker%26aufirst%3DC.%2BG.%26aulast%3DGalmozzi%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DCorreia%26aufirst%3DB.%2BE.%26aulast%3DSasaki%26aufirst%3DK.%26aulast%3DJoslyn%26aufirst%3DC.%2BM.%26aulast%3DKim%26aufirst%3DA.%2BS.%26aulast%3DCavallaro%26aufirst%3DC.%2BL.%26aulast%3DLawrence%26aufirst%3DR.%2BM.%26aulast%3DJohnson%26aufirst%3DS.%2BR.%26aulast%3DNarvaiza%26aufirst%3DI.%26aulast%3DSaez%26aufirst%3DE.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DLigand%2520and%2520Target%2520Discovery%2520by%2520Fragment-Based%2520Screening%2520in%2520Human%2520Cells%26jtitle%3DCell%26date%3D2017%26volume%3D168%26issue%3D3%26spage%3D527%26epage%3D541%26doi%3D10.1016%2Fj.cell.2016.12.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lajiness, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maggiora, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shanmugasundaram, V.</span></span> <span> </span><span class="NLM_article-title">Assessment of the Consistency of Medicinal Chemists in Reviewing Sets of Compounds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">4891</span>â <span class="NLM_lpage">4896</span>, <span class="refDoi">Â DOI: 10.1021/jm049740z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049740z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmvVejtL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=4891-4896&issue=20&author=M.+S.+Lajinessauthor=G.+M.+Maggioraauthor=V.+Shanmugasundaram&title=Assessment+of+the+Consistency+of+Medicinal+Chemists+in+Reviewing+Sets+of+Compounds&doi=10.1021%2Fjm049740z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Assessment of the Consistency of Medicinal Chemists in Reviewing Sets of Compounds</span></div><div class="casAuthors">Lajiness, Michael S.; Maggiora, Gerald M.; Shanmugasundaram, Veerabahu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">4891-4896</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Medicinal chemists are frequently asked to review lists of compds. to assess their drug- or lead-like nature and to evaluate the suitability of lead compds. based on their "attractiveness" and/or synthetic feasibility as a basis for launching a drug-discovery campaign.  It is often felt that one medicinal chemist's opinion is as good as any other, but is it.  In an attempt to answer this question, an expt. was performed in conjunction with a recent compd. acquisition program (CAP) conducted at Pharmacia.  Historically, the CAP included a review of many thousands of compds. by medicinal chemists who eliminate anything deemed undesirable for any reason.  In a review conducted in 2002, about 22 000 compds. requiring review by medicinal chemists were broken down into 11 lists of approx. 2000 compds. each.  Unknown to the medicinal chemists, a subset of 250 compds., previously rejected by a very experienced senior medicinal chemist, was added to each of the lists.  Most of the 13 medicinal chemists who participated in this process reviewed two lists, although some only reviewed a single list and one reviewed three lists.  Those compds. that were deemed unacceptable were recorded and tabulated in various ways to assess the consistency of the reviews.  It was found that medicinal chemists were not very consistent in the compds. they rejected as being undesirable.  The inconsistency arises from the subjective anal. that all humans utilize when considering "data sets" of any kind.  This has important implications for pharmaceutical project teams where individual medicinal chemists review lists of primary screening hits to identify those compds. suitable for follow-up.  Once a compd. is removed from a list, it and other structurally similar compds. are effectively removed from further consideration.  This can also have an impact on computational chemists who are developing models for assessing the desirability or attractiveness of different classes of compds. for lead discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZPYRvqjXJjLVg90H21EOLACvtfcHk0lhejRt9613H3A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmvVejtL0%253D&md5=d5f8cbd4a56bb4c22782a3beccb3eefd</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1021%2Fjm049740z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049740z%26sid%3Dliteratum%253Aachs%26aulast%3DLajiness%26aufirst%3DM.%2BS.%26aulast%3DMaggiora%26aufirst%3DG.%2BM.%26aulast%3DShanmugasundaram%26aufirst%3DV.%26atitle%3DAssessment%2520of%2520the%2520Consistency%2520of%2520Medicinal%2520Chemists%2520in%2520Reviewing%2520Sets%2520of%2520Compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26issue%3D20%26spage%3D4891%26epage%3D4896%26doi%3D10.1021%2Fjm049740z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oleinikovas, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saladino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cossins, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gervasio, F. L.</span></span> <span> </span><span class="NLM_article-title">Understanding Cryptic Pocket Formation in Protein Targets by Enhanced Sampling Simulations</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>138</i></span> (<span class="NLM_issue">43</span>),  <span class="NLM_fpage">14257</span>â <span class="NLM_lpage">14263</span>, <span class="refDoi">Â DOI: 10.1021/jacs.6b05425</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.6b05425" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1CmtbnN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2016&pages=14257-14263&issue=43&author=V.+Oleinikovasauthor=G.+Saladinoauthor=B.+P.+Cossinsauthor=F.+L.+Gervasio&title=Understanding+Cryptic+Pocket+Formation+in+Protein+Targets+by+Enhanced+Sampling+Simulations&doi=10.1021%2Fjacs.6b05425"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding Cryptic Pocket Formation in Protein Targets by Enhanced Sampling Simulations</span></div><div class="casAuthors">Oleinikovas, Vladimiras; Saladino, Giorgio; Cossins, Benjamin P.; Gervasio, Francesco L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">14257-14263</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cryptic pockets, i.e. sites on protein targets that only become apparent when drugs bind, provide a promising alternative to classical binding sites for drug development.  Here the authors investigate the nature and dynamical properties of cryptic sites in four pharmacol. relevant targets, while comparing the efficacy of various simulation-based approaches in discovering them.  The authors find that the studied cryptic sites do not correspond to local min. in the computed conformational free energy landscape of the unliganded proteins.  They thus promptly close in all the mol. dynamics simulations performed, irresp. of the force-field used.  Temp.-based enhanced sampling approaches, such as Parallel Tempering, do not improve the situation, as the entropic term does not help in the opening of the sites.  The use of fragment probes helps, as in long simulations occasionally it leads to the opening and binding to the cryptic sites.  The obsd. mechanism of cryptic site formation is suggestive of an interplay between two classical mechanisms: induced-fit and conformational selection.  Employing this insight the authors developed a novel Hamiltonian Replica Exchange-based method "SWISH" (Sampling Water Interfaces through Scaled Hamiltonians), which combined with probes resulted in a promising general approach for cryptic site discovery.  The authors also addressed the issue of "false-positives" and propose a simple approach to distinguish them from druggable cryptic pockets.  The simulations, whose cumulative sampling time was more than 200 Î¼s, help clarifying the mol. mechanism of pocket formation, providing a solid basis for the choice of an efficient computational method.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowDhS6qnF6EbVg90H21EOLACvtfcHk0lhejRt9613H3A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1CmtbnN&md5=9517e79e24851fa8c89b71b91123c34e</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1021%2Fjacs.6b05425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.6b05425%26sid%3Dliteratum%253Aachs%26aulast%3DOleinikovas%26aufirst%3DV.%26aulast%3DSaladino%26aufirst%3DG.%26aulast%3DCossins%26aufirst%3DB.%2BP.%26aulast%3DGervasio%26aufirst%3DF.%2BL.%26atitle%3DUnderstanding%2520Cryptic%2520Pocket%2520Formation%2520in%2520Protein%2520Targets%2520by%2520Enhanced%2520Sampling%2520Simulations%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2016%26volume%3D138%26issue%3D43%26spage%3D14257%26epage%3D14263%26doi%3D10.1021%2Fjacs.6b05425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ludlow, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verdonk, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saini, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tickle, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jhoti, H.</span></span> <span> </span><span class="NLM_article-title">Detection of Secondary Binding Sites in Proteins Using Fragment Screening</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>112</i></span> (<span class="NLM_issue">52</span>),  <span class="NLM_fpage">15910</span>â <span class="NLM_lpage">15915</span>, <span class="refDoi">Â DOI: 10.1073/pnas.1518946112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1073%2Fpnas.1518946112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=26655740" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2kt7zP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=15910-15915&issue=52&author=R.+F.+Ludlowauthor=M.+L.+Verdonkauthor=H.+K.+Sainiauthor=I.+J.+Tickleauthor=H.+Jhoti&title=Detection+of+Secondary+Binding+Sites+in+Proteins+Using+Fragment+Screening&doi=10.1073%2Fpnas.1518946112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Detection of secondary binding sites in proteins using fragment screening</span></div><div class="casAuthors">Ludlow, R. Frederick; Verdonk, Marcel L.; Saini, Harpreet K.; Tickle, Ian J.; Jhoti, Harren</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">52</span>),
    <span class="NLM_cas:pages">15910-15915</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Proteins need to be tightly regulated as they control biol. processes in most normal cellular functions.  The precise mechanisms of regulation are rarely completely understood but can involve binding of endogenous ligands and/or partner proteins at specific locations on a protein that can modulate function.  Often, these addnl. secondary binding sites appear sep. to the primary binding site, which, e.g., for an enzyme may bind a substrate.  In previous work, the authors uncovered several examples in which secondary binding sites were discovered on proteins using fragment screening approaches.  In each case, the authors were able to establish that the newly identified secondary binding site was biol. relevant as it was able to modulate function by the binding of a small mol.  Here, the authors investigated how often secondary binding sites are located on proteins by analyzing 24 protein targets for which they performed a fragment screen using x-ray crystallog.  The anal. showed that, surprisingly, the majority of proteins contained secondary binding sites based on their ability to bind fragments.  Furthermore, sequence anal. of these previously unknown sites indicated high conservation, which suggested that they may have a biol. function, perhaps via an allosteric mechanism.  Comparing the physicochem. properties of the secondary sites with known primary ligand-binding sites also showed broad similarities indicating that many of the secondary sites may be druggable in nature with small mols. that could provide new opportunities to modulate potential therapeutic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0ITF1w230fbVg90H21EOLACvtfcHk0lg4CHzIL6U-jw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2kt7zP&md5=9e5f15595263dc049c713d5a3f5912a1</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1518946112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1518946112%26sid%3Dliteratum%253Aachs%26aulast%3DLudlow%26aufirst%3DR.%2BF.%26aulast%3DVerdonk%26aufirst%3DM.%2BL.%26aulast%3DSaini%26aufirst%3DH.%2BK.%26aulast%3DTickle%26aufirst%3DI.%2BJ.%26aulast%3DJhoti%26aufirst%3DH.%26atitle%3DDetection%2520of%2520Secondary%2520Binding%2520Sites%2520in%2520Proteins%2520Using%2520Fragment%2520Screening%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2015%26volume%3D112%26issue%3D52%26spage%3D15910%26epage%3D15915%26doi%3D10.1073%2Fpnas.1518946112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hart, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moeder, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, C. M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerman, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frederick, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, G. R.</span></span> <span> </span><span class="NLM_article-title">Designing Small Molecules to Target Cryptic Pockets Yields Both Positive and Negative Allosteric Modulators</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">e0178678</span>, <span class="refDoi">Â DOI: 10.1371/journal.pone.0178678</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1371%2Fjournal.pone.0178678" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=e0178678&issue=6&author=K.+M.+Hartauthor=K.+E.+Moederauthor=C.+M.+W.+Hoauthor=M.+I.+Zimmermanauthor=T.+E.+Frederickauthor=G.+R.+Bowman&title=Designing+Small+Molecules+to+Target+Cryptic+Pockets+Yields+Both+Positive+and+Negative+Allosteric+Modulators&doi=10.1371%2Fjournal.pone.0178678"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0178678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0178678%26sid%3Dliteratum%253Aachs%26aulast%3DHart%26aufirst%3DK.%2BM.%26aulast%3DMoeder%26aufirst%3DK.%2BE.%26aulast%3DHo%26aufirst%3DC.%2BM.%2BW.%26aulast%3DZimmerman%26aufirst%3DM.%2BI.%26aulast%3DFrederick%26aufirst%3DT.%2BE.%26aulast%3DBowman%26aufirst%3DG.%2BR.%26atitle%3DDesigning%2520Small%2520Molecules%2520to%2520Target%2520Cryptic%2520Pockets%2520Yields%2520Both%2520Positive%2520and%2520Negative%2520Allosteric%2520Modulators%26jtitle%3DPLoS%2520One%26date%3D2017%26volume%3D12%26issue%3D6%26spage%3De0178678%26doi%3D10.1371%2Fjournal.pone.0178678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span> <span> </span><span class="NLM_article-title">The Influence of Target Family and Functional Activity on the Physicochemical Properties of Pre-Clinical Compounds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2969</span>â <span class="NLM_lpage">2978</span>, <span class="refDoi">Â DOI: 10.1021/jm0512185</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0512185" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=2969-2978&issue=10&author=R.+Morphy&title=The+Influence+of+Target+Family+and+Functional+Activity+on+the+Physicochemical+Properties+of+Pre-Clinical+Compounds&doi=10.1021%2Fjm0512185"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1021%2Fjm0512185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0512185%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26atitle%3DThe%2520Influence%2520of%2520Target%2520Family%2520and%2520Functional%2520Activity%2520on%2520the%2520Physicochemical%2520Properties%2520of%2520Pre-Clinical%2520Compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26issue%3D10%26spage%3D2969%26epage%3D2978%26doi%3D10.1021%2Fjm0512185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waring, M.
J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrowsmith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandrell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pairaudeau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennie, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickett, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weir, A.</span></span> <span> </span><span class="NLM_article-title">An Analysis of the Attrition of Drug Candidates from Four Major Pharmaceutical Companies</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">475</span>â <span class="NLM_lpage">486</span>, <span class="refDoi">Â DOI: 10.1038/nrd4609</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1038%2Fnrd4609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=26091267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7jM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=475-486&issue=7&author=M.%0AJ.+Waringauthor=J.+Arrowsmithauthor=A.+R.+Leachauthor=P.+D.+Leesonauthor=S.+Mandrellauthor=R.+M.+Owenauthor=G.+Pairaudeauauthor=W.+D.+Pennieauthor=S.+D.+Pickettauthor=J.+Wangauthor=O.+Wallaceauthor=A.+Weir&title=An+Analysis+of+the+Attrition+of+Drug+Candidates+from+Four+Major+Pharmaceutical+Companies&doi=10.1038%2Fnrd4609"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">An analysis of the attrition of drug candidates from four major pharmaceutical companies</span></div><div class="casAuthors">Waring, Michael J.; Arrowsmith, John; Leach, Andrew R.; Leeson, Paul D.; Mandrell, Sam; Owen, Robert M.; Pairaudeau, Garry; Pennie, William D.; Pickett, Stephen D.; Wang, Jibo; Wallace, Owen; Weir, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">475-486</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The pharmaceutical industry remains under huge pressure to address the high attrition rates in drug development.  Attempts to reduce the no. of efficacy- and safety-related failures by analyzing possible links to the physicochem. properties of small-mol. drug candidates have been inconclusive because of the limited size of data sets from individual companies.  Here, we describe the compilation and anal. of combined data on the attrition of drug candidates from AstraZeneca, Eli Lilly and Company, GlaxoSmithKline and Pfizer.  The anal. reaffirms that control of physicochem. properties during compd. optimization is beneficial in identifying compds. of candidate drug quality and indicates for the first time a link between the physicochem. properties of compds. and clin. failure due to safety issues.  The results also suggest that further control of physicochem. properties is unlikely to have a significant effect on attrition rates and that addnl. work is required to address safety-related failures.  Further cross-company collaborations will be crucial to future progress in this area.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsLfBWrLC3ZLVg90H21EOLACvtfcHk0lg4CHzIL6U-jw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7jM&md5=1fdc374d32816b1e91438152299dd1b1</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1038%2Fnrd4609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4609%26sid%3Dliteratum%253Aachs%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26aulast%3DArrowsmith%26aufirst%3DJ.%26aulast%3DLeach%26aufirst%3DA.%2BR.%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DMandrell%26aufirst%3DS.%26aulast%3DOwen%26aufirst%3DR.%2BM.%26aulast%3DPairaudeau%26aufirst%3DG.%26aulast%3DPennie%26aufirst%3DW.%2BD.%26aulast%3DPickett%26aufirst%3DS.%2BD.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWallace%26aufirst%3DO.%26aulast%3DWeir%26aufirst%3DA.%26atitle%3DAn%2520Analysis%2520of%2520the%2520Attrition%2520of%2520Drug%2520Candidates%2520from%2520Four%2520Major%2520Pharmaceutical%2520Companies%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26issue%3D7%26spage%3D475%26epage%3D486%26doi%3D10.1038%2Fnrd4609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soulard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caffrey, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salzberg, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, E. S.</span></span> <span> </span><span class="NLM_article-title">Structure-Based Maximal Affinity Model Predicts Small-Molecule Druggability</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">71</span>â <span class="NLM_lpage">75</span>, <span class="refDoi">Â DOI: 10.1038/nbt1273</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1038%2Fnbt1273" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=17211405" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BD2sXis1Grtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=71-75&issue=1&author=A.+C.+Chengauthor=R.+G.+Colemanauthor=K.+T.+Smythauthor=Q.+Caoauthor=P.+Soulardauthor=D.+R.+Caffreyauthor=A.+C.+Salzbergauthor=E.+S.+Huang&title=Structure-Based+Maximal+Affinity+Model+Predicts+Small-Molecule+Druggability&doi=10.1038%2Fnbt1273"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based maximal affinity model predicts small-molecule druggability</span></div><div class="casAuthors">Cheng, Alan C.; Coleman, Ryan G.; Smyth, Kathleen T.; Cao, Qing; Soulard, Patricia; Caffrey, Daniel R.; Salzberg, Anna C.; Huang, Enoch S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">71-75</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Lead generation is a major hurdle in small-mol. drug discovery, with an estd. 60% of projects failing from lack of lead matter or difficulty in optimizing leads for drug-like properties.  It would be valuable to identify these less-druggable targets before incurring substantial expenditure and effort.  Here we show that a model-based approach using basic biophys. principles yields good prediction of druggability based solely on the crystal structure of the target binding site.  We quant. est. the maximal affinity achievable by a drug-like mol., and we show that these calcd. values correlate with drug discovery outcomes.  We exptl. test two predictions using high-throughput screening of a diverse compd. collection.  The collective results highlight the utility of our approach as well as strategies for tackling difficult targets.  Both assays are simple, suitable for rapid screening of a large no. of medicinal libraries, and amenable for automation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomQJn2NNwCFLVg90H21EOLACvtfcHk0lg4CHzIL6U-jw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXis1Grtg%253D%253D&md5=e971faf87bf4b91602bf592b9296325b</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1038%2Fnbt1273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1273%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DA.%2BC.%26aulast%3DColeman%26aufirst%3DR.%2BG.%26aulast%3DSmyth%26aufirst%3DK.%2BT.%26aulast%3DCao%26aufirst%3DQ.%26aulast%3DSoulard%26aufirst%3DP.%26aulast%3DCaffrey%26aufirst%3DD.%2BR.%26aulast%3DSalzberg%26aufirst%3DA.%2BC.%26aulast%3DHuang%26aufirst%3DE.%2BS.%26atitle%3DStructure-Based%2520Maximal%2520Affinity%2520Model%2520Predicts%2520Small-Molecule%2520Druggability%26jtitle%3DNat.%2520Biotechnol.%26date%3D2007%26volume%3D25%26issue%3D1%26spage%3D71%26epage%3D75%26doi%3D10.1038%2Fnbt1273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Courtney, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hesterkamp, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, M.</span></span> <span> </span><span class="NLM_article-title">Fragment Screening by Biochemical Assay</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">225</span>â <span class="NLM_lpage">236</span>, <span class="refDoi">Â DOI: 10.1517/17460441.1.3.225</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1517%2F17460441.1.3.225" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2006&pages=225-236&issue=3&author=J.+Barkerauthor=S.+Courtneyauthor=T.+Hesterkampauthor=D.+Ullmannauthor=M.+Whittaker&title=Fragment+Screening+by+Biochemical+Assay&doi=10.1517%2F17460441.1.3.225"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1517%2F17460441.1.3.225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.1.3.225%26sid%3Dliteratum%253Aachs%26aulast%3DBarker%26aufirst%3DJ.%26aulast%3DCourtney%26aufirst%3DS.%26aulast%3DHesterkamp%26aufirst%3DT.%26aulast%3DUllmann%26aufirst%3DD.%26aulast%3DWhittaker%26aufirst%3DM.%26atitle%3DFragment%2520Screening%2520by%2520Biochemical%2520Assay%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2006%26volume%3D1%26issue%3D3%26spage%3D225%26epage%3D236%26doi%3D10.1517%2F17460441.1.3.225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boettcher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruedisser, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erbel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinzenz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiering, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassiepen, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rigollier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayr, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woelcke, J.</span></span> <span> </span><span class="NLM_article-title">Fragment-Based Screening by Biochemical Assays: Systematic Feasibility Studies with Trypsin and MMP12</span>. <i>J. Biomol. Screening</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1029</span>â <span class="NLM_lpage">1041</span>, <span class="refDoi">Â DOI: 10.1177/1087057110380455</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=10.1177%2F1087057110380455" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=20855559" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVajsL3J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2010&pages=1029-1041&issue=9&author=A.+Boettcherauthor=S.+Ruedisserauthor=P.+Erbelauthor=D.+Vinzenzauthor=N.+Schieringauthor=U.+Hassiepenauthor=P.+Rigollierauthor=L.+M.+Mayrauthor=J.+Woelcke&title=Fragment-Based+Screening+by+Biochemical+Assays%3A+Systematic+Feasibility+Studies+with+Trypsin+and+MMP12&doi=10.1177%2F1087057110380455"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-based screening by biochemical assays: systematic feasibility studies with trypsin and MMP12</span></div><div class="casAuthors">Boettcher, Andreas; Ruedisser, Simon; Erbel, Paulus; Vinzenz, Daniela; Schiering, Nikolaus; Hassiepen, Ulrich; Rigollier, Pascal; Mayr, Lorenz M.; Woelcke, Julian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1029-1041</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Fragment-based screening (FBS) has gained acceptance in the pharmaceutical industry as an attractive approach for the identification of new chem. starting points for drug discovery programs in addn. to classical strategies such as high-throughput screening.  There is the concern that screening of fragments at high Î¼M concns. in biochem. assays results in increased false-pos. and false-neg. rates.  Here the authors systematically compare the data quality of FBS obtained by enzyme activity-based fluorescence intensity, fluorescence lifetime, and mobility shift assays with the data quality from surface plasmon resonance (SPR) and NMR methods.  The serine protease trypsin and the matrix metalloprotease MMP12 were selected as model systems.  For both studies, 352 fragments were selected each.  From the data generated, all 3 biochem. protease assay methods can be used for screening of fragments with low false-neg. and low false-pos. rates, comparable to those achieved with the SPR-based assays.  It can also be concluded that only fragments with a soly. higher than the screening concn. detd. by means of NMR should be used for FBS purposes.  Extrapolated to 10,000 fragments, the biochem. assays speed up the primary FBS process by approx. a factor of 10 and reduce the protease consumption by approx. 10,000-fold compared to NMR protein observation expts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_ivr2TNQFjrVg90H21EOLACvtfcHk0lhO47oZxX5S1w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVajsL3J&md5=79b8d6d012e055adf8af3f0534ecafe0</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1177%2F1087057110380455&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057110380455%26sid%3Dliteratum%253Aachs%26aulast%3DBoettcher%26aufirst%3DA.%26aulast%3DRuedisser%26aufirst%3DS.%26aulast%3DErbel%26aufirst%3DP.%26aulast%3DVinzenz%26aufirst%3DD.%26aulast%3DSchiering%26aufirst%3DN.%26aulast%3DHassiepen%26aufirst%3DU.%26aulast%3DRigollier%26aufirst%3DP.%26aulast%3DMayr%26aufirst%3DL.%2BM.%26aulast%3DWoelcke%26aufirst%3DJ.%26atitle%3DFragment-Based%2520Screening%2520by%2520Biochemical%2520Assays%253A%2520Systematic%2520Feasibility%2520Studies%2520with%2520Trypsin%2520and%2520MMP12%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2010%26volume%3D15%26issue%3D9%26spage%3D1029%26epage%3D1041%26doi%3D10.1177%2F1087057110380455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erlanson, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, D. C.</span></span> <span> </span><span class="NLM_article-title">Fragment-to-Lead Medicinal Chemistry Publications in 2015</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">89</span>â <span class="NLM_lpage">99</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.6b01123</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01123" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=89-99&issue=1&author=C.+N.+Johnsonauthor=D.+A.+Erlansonauthor=C.+W.+Murrayauthor=D.+C.+Rees&title=Fragment-to-Lead+Medicinal+Chemistry+Publications+in+2015&doi=10.1021%2Facs.jmedchem.6b01123"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01123%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DC.%2BN.%26aulast%3DErlanson%26aufirst%3DD.%2BA.%26aulast%3DMurray%26aufirst%3DC.%2BW.%26aulast%3DRees%26aufirst%3DD.%2BC.%26atitle%3DFragment-to-Lead%2520Medicinal%2520Chemistry%2520Publications%2520in%25202015%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D1%26spage%3D89%26epage%3D99%26doi%3D10.1021%2Facs.jmedchem.6b01123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erlanson, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahnke, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortenson, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, D. C.</span></span> <span> </span><span class="NLM_article-title">Fragment-to-Lead Medicinal Chemistry Publications in 2016</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1774</span>â <span class="NLM_lpage">1784</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.7b01298</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01298" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1774-1784&issue=5&author=C.+N.+Johnsonauthor=D.+A.+Erlansonauthor=W.+Jahnkeauthor=P.+N.+Mortensonauthor=D.+C.+Rees&title=Fragment-to-Lead+Medicinal+Chemistry+Publications+in+2016&doi=10.1021%2Facs.jmedchem.7b01298"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01298%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DC.%2BN.%26aulast%3DErlanson%26aufirst%3DD.%2BA.%26aulast%3DJahnke%26aufirst%3DW.%26aulast%3DMortenson%26aufirst%3DP.%2BN.%26aulast%3DRees%26aufirst%3DD.%2BC.%26atitle%3DFragment-to-Lead%2520Medicinal%2520Chemistry%2520Publications%2520in%25202016%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D5%26spage%3D1774%26epage%3D1784%26doi%3D10.1021%2Facs.jmedchem.7b01298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i30"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00407">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_45630"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.8b00407">10.1021/acs.jmedchem.8b00407</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">List of FDA and EMA approved drugs from 2011 to 2017 with physicochemical properties and Smiles (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00407/suppl_file/jm8b00407_si_001.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00407/suppl_file/jm8b00407_si_001.csv">jm8b00407_si_001.csv (18.25 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b00407&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-23%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b00407%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b00407" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                1MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679a023ddc26d93e","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
